

Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of
malaria RDTs: round 7 (2015–2016)



Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of
malaria RDTs: round 7 (2015–2016)

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 7 (2015–2016). Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout: Bruno Duret

Editor: Elisabeth Heseltine

WHO does not warrant that: (1) the lists and figures are complete and/or error free and/or that (2) any products mentioned in the figures and tables are of acceptable quality, have obtained regulatory approval in any country or that their use is otherwise in accordance with the national laws and regulations of any country, including patent laws. Mention of any product in this report, particularly in any of the figures and tables on pp. 8 and 9, does not imply their approval by WHO (as this is the sole prerogative of national authorities).

The WHO Programme of Prequalification of Diagnostics and Medical Devices uses the results of the WHO Malaria RDT Product Testing Programme as the laboratory evaluation component of the prequalification process for malaria RDTs. Although WHO prequalification is not currently a requirement for WHO procurement, manufacturers are encouraged to apply for it. A regularly updated list of WHO-prequalified diagnostics, including malaria RDTs, is available at http://www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/.

WHO recommendations for procurement of malaria RDTs are currently based on the attainment of a set of minimum performance criteria in the WHO Malaria RDT Product Testing Programme. The recommendations were established by the WHO Malaria Policy Advisory Committee in 2012, are outlined in this report and are presented in full in a WHO information note (available at <http://www.who.int/malaria/publications/atoz/rdt-selection-criteria.pdf>). Products that do not meet the full set of minimum performance criteria are not eligible for procurement by WHO. As of 1 January 2018, WHO prequalification will become a requirement for procurement recommendation (<http://www.who.int/malaria/news/2016/rdt-procurement-criteria/en/>).

The lists of RDTs included in this report are not exhaustive but reflect those products that were submitted for evaluation in rounds 4–7 of the WHO Malaria RDT Product Testing Programme. Their mention indicates the extent to which these products, as manufactured by the listed companies, were – at the time of their evaluation – found to meet the above-mentioned set of minimum performance criteria. The evaluations indicated in the figures and tables apply only to the specific product listed with its unique product code or catalogue number and as manufactured by the listed company.

Improper storage, transport or handling of malaria RDTs may affect their performance.

The fact that certain products are not included in any of the lists and figures in this report indicates that they have not or not yet been submitted for evaluation to the WHO Malaria RDT Product Testing Programme or that their evaluation has not yet been completed and published or that they have been removed from summary reports due to noncompliance with compulsory resubmission requirements. It does not indicate anything in respect of such products' performance. The lists and figures are updated regularly, and malaria RDTs are added to the lists and figures as and when (following voluntary participation in the WHO Malaria RDT Product Testing Programme) their evaluation against the above-mentioned set of minimum performance criteria has been completed.

Although the malaria RDTs listed in the tables and figures are regularly re-evaluated, and updated evaluations are published by WHO, WHO cannot ensure that products on the lists and in figures will continue to meet the performance criteria in the same manner as indicated. WHO recommends therefore that, before procuring a malaria RDT, each lot of that product be tested at one of the two following lot-testing laboratories: the Institut Pasteur du Cambodge, Cambodia, or the Research Institute for Tropical Medicine, Philippines.

WHO disclaims any and all liability and responsibility whatsoever for any injury, death, loss, damage or other prejudice of any kind that may arise as a result of or in connection with the procurement, distribution and use of any product included in this report and the figures and tables listed on pages V–VIII.

This report may not be used by manufacturers and suppliers for commercial or promotional purposes.

Contents

ACKNOWLEDGEMENTS	IX
ABBREVIATIONS	X
1. SUMMARY OF PERFORMANCE OF RAPID DIAGNOSTIC TESTS FOR MALARIA: WHO PRODUCT TESTING ROUNDS 1–7	1
1.1. Introduction	1
1.2. The WHO product testing programme	1
1.3. Panel detection score and other results of the evaluation	2
1.4. Summary of outcomes	4
1.5. De-listing of products in summary report	5
1.6. How product testing results can inform RDT procurement and use	5
1.7. Product testing and WHO programme for prequalification of diagnostics and medical devices	6
2. EXECUTIVE SUMMARY	21
2.1. Introduction	21
2.2. The WHO product testing programme	21
2.3. Results of the evaluation	22
2.4. Use of the results	23
3. BACKGROUND	24
4. OBJECTIVE	24
5. MATERIALS AND METHODS	26
5.1. Test selection	26
5.2. The product testing protocol	28
5.3. Evaluation panels	28
5.4. Product registration	30
5.5. Specimen panel registration	30
5.6. Test phases	30
5.7. Performing rapid tests	32
5.8. Interpreting the results	32
5.9. Recording anomalies	32
6. DATA MANAGEMENT	32
7. QUALITY ASSURANCE	33
7.1. Quality of malaria RDTs and their use	33
7.2. Quality and objectivity of RDT readings	33
7.3. Quality of WHO specimen bank samples	33
7.4. Quality of the product testing site	33
8. ETHICAL CONSIDERATIONS	33
9. DATA ANALYSIS	34
9.1. Measures of parasite detection: panel detection score and positivity rates	34
9.2. False-positive results	34
9.2.1 Incorrect species identification	34
9.2.2 False-positive results for <i>Plasmodium</i> -negative samples	34
9.3. Band intensity	34
9.4. Lot agreement	35
9.5. Invalid tests	35
9.6. Heat (thermal) stability	35
9.7. Anomalies	35
9.8. Labelling and instructions for use	35

10. ASSOCIATION BETWEEN PARASITE DENSITY AND ANTIGEN CONCENTRATION	36
11. EVALUATION OF MALARIA RAPID DIAGNOSTIC TESTS IN THE LABORATORY AND IN THE FIELD	36
12. RESULTS	37
12.1. Summary	37
12.2. Phase 1: <i>P. falciparum</i> culture panel	43
12.3. Phase 2: wild -type <i>P. falciparum</i> and <i>P. vivax</i> - and <i>Plasmodium</i> spp.-negative samples.	43
12.3.1 <i>P. falciparum</i> detection	43
12.3.2 <i>P. vivax</i> detection	44
12.3.3 Combined detection of <i>P. falciparum</i> and <i>P. vivax</i>	45
12.3.4 <i>P. falciparum</i> and <i>P. vivax</i> positivity rate	45
12.3.5 Band intensity	45
12.3.6 False-positive rates	47
12.4. Performance of resubmitted products	50
13. HEAT STABILITY	52
13.1. Summary	52
13.2. <i>Plasmodium falciparum</i>	52
13.3. <i>Plasmodium vivax</i>	52
14. EASE OF USE, ANOMALIES, LABELLING AND INSTRUCTIONS FOR USE	60
14.1. Ease of use	60
14.2. Anomalies	60
14.3. Labelling and instructions for use	60
15. DISCUSSION OF KEY FINDINGS	73
15.1. Panel detection score and its relation to sensitivity	73
15.2. False-positive rate and specificity	74
15.3. Reactivity of combination HRP2 and pan-pLDH test lines against <i>P. falciparum</i> samples	74
15.4. Heat (thermal) stability	75
15.5. Ease-of-use description	75
15.6. Labelling and instructions for use	75
15.7. Anomalies in RDT production lots	76
15.8. Inter-lot variation	76
15.9. Selecting RDTs: target antigens, species and sensitivity	76
16. USING RESULTS TO ENSURE HIGH-QUALITY DIAGNOSIS IN THE FIELD	78
16.1. WHO prequalification	78
16.2. Beyond procurement	78
16.3. Post-market surveillance: lot verification	79
17. CONCLUSIONS	79
18. REFERENCES	80
ANNEXES	83
Annex S1: Characteristics of evaluation panels used in rounds 1–7 of WHO malaria RDT product testing, 2008–2016	84
Annex S2: Malaria RDT field assessment and anomalies	87
Annex S3: Selection of an appropriate RDT	90
Annex 1: Characteristics of RDTs evaluated in round 7	91
Annex 2: Malaria RDTs: guide to interpretation of results	93
Annex 3: Phase-1 results	108
Annex 4: Phase-2 results	112
Annex 5: Introducing RDT-based malaria diagnosis into national programmes	145

FIGURES

- Figure S1. Malaria RDT performance in phase 2 of rounds 4–7 against wild-type (clinical) samples containing *P. falciparum* at low (200) and high (2000) parasite density (parasites/μL) and clean-negative samples
- Figure S2. Malaria RDT performance in phase 2 of rounds 4–7 against wild-type (clinical) samples containing *P. vivax* at low (200) and high (2000) parasite density (parasites/μL) and clean-negative samples
- Figure S3. Panel detection score of malaria combination RDTs meeting WHO procurement criteria for false-positive and invalid rates, in phase 2 of rounds 4–7 against wild-type (clinical) samples containing *P. falciparum* and *P. vivax* at low parasite density (200 parasites/μL)
- Figure 1. Mode of action of antigen-detecting malaria RDTs
- Figure 2. Network of specimen collection, characterization and testing sites
- Figure 3. Overview of malaria RDT product testing
- Figure 4a. Origin of phase-2 *P. falciparum* wild-type (clinical) samples
- Figure 4b. Origin of phase-2 *P. vivax* wild-type (clinical) samples
- Figure 5. Testing procedure and calculation of panel detection score and band intensity for product A against a sample density of 200 parasites/μL
- Figure 6. Testing procedure and calculation of panel detection score and band intensity for product A against a sample density of 2000 parasites/μL
- Figure 7. Classification of incorrect species identification with combination malaria RDTs
- Figure 8. Explanation of lot agreement calculation
- Figure 9. Phase-1 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite density (parasites/μL)
- Figure 10. Phase-2 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite density (parasites/μL)
- Figure 11. Phase-2 *P. vivax* panel detection score of malaria RDTs at low (200) and high (2000) parasite density (parasites/μL)
- Figure 12. Phase-2 *P. falciparum* panel detection score and positivity rate at 200 parasites/μL
- Figure 13. Phase-2 *P. vivax* panel detection score and positivity rate at 200 parasites/μL
- Figure 14. Phase-2 *P. falciparum* (*P. falciparum* test line) false-positive rate against clean-negative samples
- Figure 15. Phase-2 *Plasmodium* spp. (pan or *P. vivax* test line) false-positive rate against clean-negative samples
- Figure 16. Phase-2 *P. falciparum* false-positive rate versus *P. falciparum* panel detection score at low parasite density (200 parasites/μL)
- Figure 17. Phase-2 *P. vivax* false-positive rate versus *P. vivax* panel detection score at low parasite density (200 parasites/μL)
- Figure 18. Phase-2 *P. falciparum* panel detection score at low parasite density (200 parasites/μL) during initial and subsequent testing of compulsorily and voluntarily resubmitted malaria RDTs
- Figure 19. Phase-2 *P. vivax* panel detection score at low parasite density (200 parasites/μL) during initial and subsequent testing of compulsorily and voluntarily resubmitted malaria RDTs
- Figure 20. Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a low-density *P. falciparum* sample (200 parasites/μL). Positivity rate at baseline and after 60 days' incubation
- Figure 21. Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a high-density *P. falciparum* sample (2000 parasites/μL). Positivity rate at baseline and after 60 days' incubation
- Figure 22. Heat stability of *P. falciparum*-specific test line in combination tests against a low-density *P. falciparum* sample (200 parasites/μL). Positivity rate at baseline and after 60 days' incubation
- Figure 23. Heat stability of *P. falciparum*-specific test line in combination tests against a high-density *P. falciparum* sample (2000 parasites/μL). Positivity rate at baseline and after 60 days' incubation
- Figure 24. Heat stability of pan line of combination tests against a low-density *P. falciparum* sample (200 parasites/μL). Positivity rate at baseline and after 60 days' incubation
- Figure 25. Heat stability of pan line of combination tests against a high-density *P. falciparum* sample (2000 parasites/μL). Positivity rate at baseline and after 60 days' incubation

- Figure 26. Heat stability of pan line of combination tests against a low-density *P. vivax* sample (200 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation
- Figure 27. Heat stability of pan line of combination tests against a high-density *P. vivax* sample (2000 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation
- Figure 28. Heat stability of *P. vivax*-specific test line in combination tests against a low-density *P. vivax* sample (200 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation
- Figure 29. Heat stability of *P. vivax*-specific test line in combination tests against a high-density *P. vivax* sample (2000 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation
- Figure 30. Percentage of RDTs with various anomalies observed in production lots
- Figure 31. Adherence to box labelling recommendations
- Figure 32. Adherence to cassette labelling recommendations
- Figure 33. Adherence to buffer bottle labelling recommendations
- Figure 34. Accessory labelling – use of internationally recognized symbols
- Figure 35. Completeness of information on accessory packaging – transfer device and lancet
- Figure 36. Completeness of information on accessory packaging – dessicant and alcohol swab
- Figure 37. Completeness of information included in the instructions for use: product information and intended use, precautions and limitations
- Figure 38. Completeness of information included in the instructions for use: procedure and performance specifications
- Figure AS1.1. Box-and-whisker plot of distribution of *P. falciparum* HRP2 concentration (ng/mL) in product testing phase 2 (wild-type) panels
- Figure AS1.2. Box-and-whisker plot of distribution of *P. falciparum* pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels
- Figure AS1.3. Box-and-whisker plot of distribution of *P. vivax* pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels
- Figure AS1.4. Box-and-whisker plot of distribution of *P. falciparum* aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels
- Figure AS1.5. Box-and-whisker plot of distribution of *P. vivax* aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels
- Figure AS2.1. Malaria RDT anomalies encountered in production lots
- Figure AS3.1. Selecting an appropriate RDT
- Figure A5.1. Example of malaria RDT implementation steps and timeline
- Figure A5.2. Components of the budget for a malaria diagnosis programme

TABLES

Table S1.	Product resubmissions: WHO malaria RDT product testing rounds 1–7
Table S2.	Malaria RDT phase-2 performance in rounds 4–6 against wild-type (clinical) samples containing <i>P. falciparum</i> and <i>P. vivax</i> at low (200) and high (2000) parasite density (parasites/μL) and clean-negative samples
Table S3.	Malaria RDT rounds 4–7 heat stability results on a cultured <i>P. falciparum</i> sample at low (200) and high (2000) parasite density (parasites/μL). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C
Table S4.	Products evaluated during rounds 1–7 that have been removed from summary results listings
Table 1a.	Manufacturers and products accepted into round 7 of WHO malaria RDT product testing programme
Table 1b.	Products due for compulsory resubmission in round 7
Table 2.	Characteristics of <i>Plasmodium</i> spp.-negative samples
Table 3.	Malaria antigen concentrations (ng/mL) in round 7 wild-type, low-density (200 parasites/μL) samples
Table 4.	Summary of phase-1 performance of 45 malaria RDTs against 20 cultured <i>P. falciparum</i> lines at low (200) and high (2000) parasite density (parasites/μL)
Table 5.	Summary of phase-2 performance of 46 malaria RDTs against wild-type (clinical) <i>P. falciparum</i> and <i>P. vivax</i> samples at low (200) and high (2000) parasite density (parasites/μL) and <i>Plasmodium</i> spp.-negative samples
Table 6a.	Heat stability testing results for 46 malaria RDTs on a cultured <i>P. falciparum</i> sample at low (200) and high (2000) parasite density (parasites/μL). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C
Table 6b.	Heat stability testing results for 27 malaria combination RDTs on a wild-type <i>P. vivax</i> sample at low (200) and high (2000) parasite density (parasites/μL). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C
Table 7.	Ease-of-use description of 46 malaria RDTs evaluated in round 7 of WHO malaria RDT product testing
Table 8.	Percentage distribution of anomalies observed by product in phase 2
Table AS1.1.	Statistics for <i>P. falciparum</i> HRP2 concentration (ng/mL) in product testing phase 2 (wild-type) panels
Table AS1.2.	Statistics for <i>P. falciparum</i> pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels
Table AS1.3.	Statistics for <i>P. vivax</i> pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels.
Table AS1.4.	Statistics for <i>P. falciparum</i> aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels
Table AS1.5.	Statistics for <i>P. vivax</i> aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels
Table AS2.1.	Field assessment of RDT packaging, safety and ease-of-use to guide product selection
Table A3.1.	Lot variation in positive results against phase-1 <i>P. falciparum</i> culture samples at low (200) and high (2000) parasite density (parasites/μL)
Table A3.2.	Distribution of test band intensity scores (0–4) against phase-1 <i>P. falciparum</i> cultured parasites at low (200) and high (2000) parasite density (parasites/μL)
Table A4.1.	Lot variation in positive results against phase-2 wild-type <i>P. falciparum</i> and <i>P. vivax</i> samples at low (200) and high (2000) parasite density (parasites/μL)
Table A4.2.	Distribution of test band intensity (0–4) scores against phase-2 wild-type <i>P. falciparum</i> samples at low (200) and high (2000) parasite density (parasites/μL)
Table A4.3.	Distribution of pan/ <i>P. vivax</i> test band intensity (0–4) scores for phase-2 wild-type <i>P. vivax</i> samples at low (200) and high (2000) parasite density (parasites/μL)
Table A4.4.	Phase-2 <i>P. falciparum</i> test line false-positive rates for wild-type <i>P. vivax</i> samples at low (200) and high (2000) parasite density (parasites/μL)
Table A4.5.	Phase-2 pan (or <i>P. vivax</i>) test line false-positive rate for non- <i>P. falciparum</i> infection on phase-2 wild-type <i>P. falciparum</i> samples at low (200) and high (2000) parasite density (parasites/μL)
Table A4.6.	Phase-2 false-positive rate for <i>P. falciparum</i> test line results on all malaria-negative samples
Table A4.7.	Phase-2 false-positive rate for <i>P. falciparum</i> in samples containing non-malarial infectious pathogens

Table A4.8.	Phase-2 false-positive rate for <i>P. falciparum</i> in samples containing potentially cross-reacting blood immunological factors
Table A4.9.	Phase-2 false-positive rate of pan or <i>P. vivax</i> test line results on all malaria-negative samples
Table A4.10.	Heat stability testing results for <i>P. falciparum</i> test line on a <i>P. falciparum</i> sample at low parasite density (200 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.10a.	Heat stability testing results for pan test line of combination RDTs on a <i>P. falciparum</i> sample at low parasite density (200 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.11.	Heat stability testing results for <i>P. falciparum</i> test line on a <i>P. falciparum</i> sample at high parasite density (2000 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.11a.	Heat stability testing results for pan test line of combination RDTs on a <i>P. falciparum</i> sample at high parasite density (2000 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.12.	Heat stability testing results for <i>P. falciparum</i> test line on parasite-negative samples. Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.12a.	Heat stability testing results for pan or <i>P. vivax</i> test line of combination RDTs on parasite-negative samples. Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.13.	Heat stability testing results for <i>P. falciparum</i> test line on <i>P. vivax</i> samples at low parasite density (200 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.14.	Heat stability testing results for <i>P. falciparum</i> test line on <i>P. vivax</i> samples at high parasite density (2000 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.15.	Heat stability testing results for <i>P. vivax</i> test line on <i>P. falciparum</i> samples at low parasite density (200 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.16.	Heat stability testing results for <i>P. vivax</i> test line on <i>P. falciparum</i> samples at high parasite density (2000 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.17.	Heat stability testing results for pan or <i>P. vivax</i> test line of combination tests on a <i>P. vivax</i> sample at low parasite density (200 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C
Table A4.18.	Heat stability testing results for pan or <i>P. vivax</i> test line of combination tests on a <i>P. vivax</i> sample at high parasite density (2000 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C

ACKNOWLEDGEMENTS

The evaluation reported here was a joint project of the WHO Global Malaria Programme, the Foundation for Innovative New Diagnostics (FIND) and the United States Centers for Disease Control and Prevention (CDC) within the WHO-FIND Malaria RDT Evaluation Programme. The project was financed by FIND through a grant from UNITAID. The project would not have been possible without the cooperation and support of the specimen collection sites and specimen characterization laboratories mentioned, and the authors acknowledge the technical advice from many malaria diagnostic manufacturers and developers. This report of round 7 of WHO malaria RDT product testing was compiled by Jane Cunningham (WHO, Global Malaria Programme, Switzerland), Michelle Gatton (Queensland University of Technology, University of Queensland, Australia), and Kate Kolaczinski (WHO, consultant).

The malaria RDT evaluation programme of WHO and FIND are grateful to all those who contributed to the evaluation and to the preparation of this report or previous versions:

Salim Abdullah	Ifakara Health Research and Development Centre, United Republic of Tanzania
Yong Ah	United States Centers for Disease Control and Prevention, National Center for Global Health, Division of Malaria and Parasitic Diseases, United States of America
Michael Aidoo	United States Centers for Disease Control and Prevention, National Center for Global Health, Division of Malaria and Parasitic Diseases, United States of America
Frederic Arieu	Institut Pasteur, Cambodia
John Barnwell	United States Centers for Disease Control and Prevention, National Center for Global Health, Division of Malaria and Parasitic Diseases, United States of America
David Bell	Foundation for Innovative New Diagnostics, Switzerland ¹
Andrea Bosman	WHO, Global Malaria Programme, Switzerland
Qin Cheng	Army Malaria Institute, Australia
Peter Chiodini	Hospital for Tropical Diseases, United Kingdom
Jane Cunningham	WHO, Global Malaria Programme, Switzerland
Djibrine Djalle	Institut Pasteur of Bangui, Central African Republic
Dany Doung	Institut Pasteur, Cambodia
Babacar Faye	Université Cheikh Anta Diop, Senegal
Dionicia Gamboa	Universidad Peruana Cayetano Heredia Instituto de Medicina Tropical, Peru
Michelle Gatton	Queensland University of Technology, Australia
Jeffrey Glenn	United States Centers for Disease Control and Prevention, National Center for Global Health, Division of Malaria and Parasitic Diseases, United States of America
Iveth Gonzalez	Foundation for Innovative New Diagnostics, Switzerland
Sandra Incardona	Foundation for Innovative New Diagnostics, Switzerland
Cara Kosack	Médecins sans Frontières, Netherlands
Myat Phone Kyaw	Department of Medical Research, Myanmar
Jennifer Luchavez	Research Institute of Tropical Medicine, Philippines
Christian Luna	Research Institute of Tropical Medicine, Philippines
James McCarthy	Queensland Institute of Medical Research, University of Queensland, Australia
Didier Menard	Institut Pasteur, Madagascar; Institut Pasteur, Cambodia
Rathana Meth	Institut Pasteur, Cambodia
Claribel Murillo	Centro Internacional de Entrenamiento e Investigaciones Médicas, Colombia
Sina Nhem	Institut Pasteur, National Malaria Centre, Cambodia
Bernhards Ogutu	Kenya Medical Research Institute, Kenya

¹ Currently affiliated with Global Health Technologies Global Good Fund (Intellectual Ventures Lab), United States

Pamela Onyor	Kenya Medical Research Institute, Kenya
Wellington Oyibo	University of Lagos, Nigeria
Roxanne Rees-Channer	Consultant, Foundation for Innovative New Diagnostics, Hospital for Tropical Diseases, United Kingdom
Muth Sinuon	National Malaria Centre, Cambodia
Johanna B. Sornillo	Research Institute of Tropical Medicine, Philippines
Scott Wilson	United States Centers for Disease Control and Prevention, National Center for Global Health, Division of Malaria and Parasitic Diseases, United States of America

ABBREVIATIONS

CDC	United States Centers for Disease Control and Prevention
ELISA	enzyme-linked immunosorbent assay
FIND	Foundation for Innovative New Diagnostics
HRP2	histidine-rich protein 2
ISO	International Organization for Standardization
PCR	polymerase chain reaction
PDS	panel detection score
pLDH	<i>Plasmodium</i> lactate dehydrogenase
RDT	rapid diagnostic test (for the purposes of this report, immunochromatographic lateral flow devices for the detection of malaria parasite antigens)
TDR	Special Programme for Research and Training in Tropical Diseases sponsored by UNICEF, UNDP, the World Bank and WHO

1. SUMMARY OF PERFORMANCE OF RAPID DIAGNOSTIC TESTS FOR MALARIA: WHO PRODUCT TESTING ROUNDS 1-7

1.1. Introduction

WHO estimates that 3.2 billion people are at risk for malaria. In 2015, there were an estimated 212 million new cases (with an uncertainty range of 148 million to 304 million) and an estimated 429 000 deaths (with an uncertainty range of 235 000 to 639 000). Approximately 90% of these deaths occurred in sub-Saharan Africa and just over 70% were of children under 5 years. Malaria remains endemic in 91 countries and territories and while parasite-based diagnosis is increasing, national surveys between 2013 and 2015 suggest approximately 31% of suspected malaria cases in sub-Saharan Africa were not confirmed with a diagnostic test, resulting in over-use of antimalarial drugs and poor disease monitoring (1).

WHO recommends that malaria case management be based on parasite diagnosis in all cases (2). The use of antigen-detecting rapid diagnostic tests (RDTs) is a vital part of this strategy, forming the basis for extending access to malaria diagnosis by providing parasite-based diagnosis in areas where good-quality microscopy cannot be maintained. The number of RDTs available and the scale of their use have increased rapidly over the past few years. However, limitations of field trials and the heterogeneous nature of malaria transmission have limited the availability of the good-quality data on performance that national malaria programmes require to make informed decisions on procurement and implementation, and it is difficult to extrapolate the results of field trials to different populations and times. Therefore, in 2006, the WHO Special Programme for Research and Training in Tropical Diseases (TDR) and the Foundation for Innovative New Diagnostics (FIND) launched a programme to systematically evaluate and compare the performance of commercially available malaria RDTs.

The results of WHO's malaria RDT product testing have been published annually since 2009 and form the basis of the procurement criteria of WHO, other United Nations agencies, the Global Fund to Fight AIDS, Tuberculosis and Malaria, national governments and non-governmental organizations. The data have guided procurement decisions, which, in turn, have shifted markets towards better-performing tests (1) and are driving overall improvements in the quality of manufacturing.

WHO's malaria RDT product testing constitutes the laboratory evaluation component of WHO malaria RDT prequalification, but meeting WHO prequalification criteria has not previously been a requirement for a WHO recommendation on

procurement. As of 1 January 2018, WHO prequalification, comprising a dossier and inspections of manufacturing sites as well as a laboratory evaluation, will determine the eligibility of malaria RDTs for procurement. Therefore, all manufacturers that submit products to Round 8 and future rounds will be required also to submit applications for WHO prequalification.

RDT sales increased from 46 million in 2008 (before implementation of the product testing programme) to 320 million in 2013 (according to manufacturer sales data). In 2014, the number of diagnostic tests provided (RDTs and microscopy combined) in Africa exceeded the total number of courses of artemisinin-based combination therapy administered in Africa for only the second time. Since 2013, decreasing RDT sales in Asia have led to an overall decrease in global sales (270 million were sold globally in 2015); however, sales in Africa have continued to rise each year since 2008. By 2014, it was confirmed that all 91 countries with ongoing malaria transmission had adopted the WHO policy of testing before administering treatment. Despite these achievements, a large number of cases remain undiagnosed, particularly in the private sector, indicating that some gains are still to be made (1).

This summary presents an overview of the results of rounds 4-7 of malaria RDT product testing and key concepts for understanding and using the results. It is published in conjunction with the release of the full report on round 7. With the exception of products that are no longer manufactured and/or are de-listed because of failure to comply with compulsory resubmission requirements, the results of all rounds of testing should be considered as a single data set. The separate, full reports of each round (3-8) should be consulted for further details of methods, product performance and interpretation of the results.

1.2. The WHO product testing programme

The RDT evaluations summarized here were performed in collaboration by WHO, TDR, FIND, the United States Centers for Disease Control and Prevention (CDC) and other partners¹. All companies that manufacture RDTs according to the ISO 13485:2003 quality system standard were invited to submit

¹ See full reports of rounds 1-7 for lists of collaborating partners.

products for evaluation. In each round of testing, products were evaluated against geographically diverse, cryopreserved *Plasmodium falciparum* and *P. vivax* clinical samples diluted to 200 and 2000 parasites/μL with consistently comparable concentration ranges of histidine-rich protein II (HRP2), *Plasmodium* lactate dehydrogenase (pLDH) and aldolase determined by quantitative enzyme-linked immunosorbent assay (ELISA) (Annex S1). In the first round of testing, 41 products from 21 manufacturers were evaluated against prepared blood panels of cultured *P. falciparum* parasites, while 29, 50, 48, 42, 41 and 46 products from 13, 23, 27, 34, 22 and 27 manufacturers were evaluated in rounds 2, 3, 4, 5, 6 and 7, respectively. Of these 297 products, 293 progressed to testing against panels of patient-derived *P. falciparum* and *P. vivax* parasites and a parasite-negative panel. Thermal stability was assessed after 2 months of storage at elevated temperature and humidity, and a rudimentary assessment of ease of use was made. In round 6 and 7, specific observations of RDT anomalies were also systematically recorded. Many manufacturers have decided voluntarily to submit products to one or more rounds of testing, and, in round 5, a requirement was instituted to resubmit products for re-evaluation within 5 years of original testing (Table S1). Of the 293 fully evaluated products in rounds 1–7, 31 have been evaluated twice, 21 have been evaluated three times, two evaluated four times and three evaluated five times. Of the 202 unique products tested in the programme, 65 detect *P. falciparum* alone, 143 detect and differentiate *P. falciparum* from non-*P. falciparum* malaria (either pan-specific or species-specific for *P. vivax* or *P. vivax*, *ovale* and *malariae*), 10 detect *P. falciparum* and non-*P. falciparum* malaria without distinguishing between them, and one product was designed to detect *P. vivax* only. Manufacturers submitted two lots of each product for evaluation. When the same products (9) were resubmitted in subsequent rounds of testing, the second set of results replaced those from the earlier round. Thus, the performance of some tests in the results below differs from that reported in rounds 1–6.

Of the 30 products due for compulsory retesting in round 7, five were submitted (Table S1). Round 3 products that were not resubmitted have been removed from the figures and tables in this summary performance document.

Product testing is part of a continuing programme of work to improve the quality of RDTs in use and to ensure reliable malaria diagnosis in areas where malaria is prevalent. The aim of the evaluation is to provide comparative data on the performance of the submitted production lots of each product. Since 2009, these data have guided procurement decisions by WHO, other United Nations agencies and national governments.

WHO product testing has constituted the laboratory evaluation component of the WHO prequalification process for malaria RDTs (10), which additionally includes a standardized dossier review and a manufacturing site inspection to ensure safety, quality and performance comprehensively. WHO prequalification of in vitro diagnostics, established in 2008, is used in all United Nations agencies to determine the eligibility for procurement of tests for HIV, hepatitis B and C and syphilis and by national authorities to complement

their national regulatory approvals. WHO prequalification will determine the eligibility of malaria RDTs for procurement as of 1 January 2018¹.

To facilitate this transition, manufacturers with products that currently meet procurement criteria and those submitting to future rounds of lab evaluations are required to submit applications to WHO prequalification. Only those products that meet WHO prequalification requirements by 31 December 2017 will be eligible for WHO procurement. An eighth round of product testing started in February 2017.

1.3. Panel detection score and other results of the evaluation

The results (summarized in Figs S1–S3 and Tables S2 and S3) provide comparative data on two lots of products against a panel of parasite samples diluted in blood to a low density (200 parasites/μL) and a higher density (2000 parasites/μL). The former is well below the mean parasite density found in many populations with endemic malaria and is considered close to the threshold that must be detected in order to reliably identify clinical malaria in many settings (11). For the purposes of this report, the main measure of performance is the panel detection score (PDS); for each RDT evaluated, the PDS is measured separately at the lower and the higher parasite densities. The summary figures also show the false-positive rates against blood samples containing no malaria parasites or known markers of other diseases and the rate of invalid results.


The PDS is the percentage of malaria samples in the panel that give a positive result in two RDTs per lot at the lower parasite density or by a single RDT per lot at the higher parasite density. As each sample is tested with RDTs from two lots, for a sample to be positive at the lower parasite density, it must show a positive result in four tests (two RDTs per lot for two lots); at the higher parasite density, it must show a positive result in two tests (one RDT per lot for two lots). Thus, the PDS is a combined measure of positivity rate incorporating inter-test and inter-lot consistency. As all tests performed on each sample must show a positive result for the sample to be considered positive, the PDS for a given RDT will usually be lower than a simple positivity rate per panel, measured by comparing the number of positive tests among all tests performed per panel. The PDS is also different from clinical sensitivity, which is the ability of the test to detect malaria infection in a given population of infected patients. Boxes 1 and 2 illustrate how the PDS is calculated and how it differs from a simple positivity rate for all samples tested and from clinical sensitivity in a population.

The PDS for a given RDT is different from the clinical sensitivity of that RDT (also called the true positive rate), which is a measure of the proportion of people known to have the disease who test positive for it. The sensitivity of malaria RDTs is highly dependent on local conditions, including the parasite density in the population; it therefore varies among populations with different levels of transmission, as their level

¹ <http://www.who.int/malaria/news/2016/rdt-procurement-criteria/en/>

Box 1: Example calculation of panel detection score and positivity rate for product A against a sample density of 200 parasites/μL

The first reading was at the minimum time specified by the manufacturer; the second reading was up to 30 min later^a. A sample is considered detected only if all first test readings, from both lots, are positive, i.e. readings a, b, c and d must be positive.



^a second reading results are for internal use only

<i>P. falciparum</i> sample	a	b	c	d	
1	+	-	+	+	Sample NOT detected
2	+	-	-	+	Sample NOT detected
3	+	+	+	+	Sample detected

In this example, only one of three samples was positive all four times it was tested; the PDS is therefore $1/3 = 33\%$.


The **positivity rate** is calculated as the percentage of all tests of a particular product that returned a positive test result at the manufacturers' recommended minimum reading time when tested against a *P. falciparum* or *P. vivax* sample.

In the above example, the positivity rate is: $9/12 = 75\%$.

The **positivity rate** is always greater than the PDS, except when the PDS and the positivity rate are both 100%.

Box 2: Performance measures in WHO product testing and in field settings: PDS versus clinical sensitivity
WHO Malaria RDT Product Testing

Primary performance measure: PDS indicates which products are likely to be more sensitive in the field, particularly in populations with low-density infections.



Reference panels: two fixed parasite densities allows discrimination in RDT performance.

Malaria endemic setting

Performance measure: sensitivity is the proportion of the population studied who have malaria for whom the test is positive.

- high, moderate, low transmission
- immune, non-immune
- vulnerable groups



Patients have varying parasite density. Most RDTs for *P. falciparum* and *P. vivax* perform well for a parasite density > 2000 parasites/μL, but clinically significant densities < 200 parasites/μL may be missed. The "overall" test performance will nevertheless be classified as very good in a field evaluation.

of immunity affects the parasite density at which they exhibit symptoms that warrant a diagnostic test. Where transmission rates are low, the parasite densities in people with symptoms of malaria are likely to be low, and tests will be less sensitive. Test performance at 200 parasites/μL is therefore particularly important. The results in this report show the comparative performance of RDTs and indicate which products are likely to be more sensitive in the field, particularly in populations with low-density infections.

In general, as countries reduce the prevalence of malaria and even move towards malaria elimination, detection of low parasite densities becomes increasingly important in case management. As the high PDS at 2000 parasites/μL indicates, the sensitivity of many of these products is similar in populations with higher parasite densities; therefore, it is not possible to discriminate RDTs with superior performance.

An important caveat to estimating field sensitivity from the PDS provided in this report is that the panels used include only parasites known to express the target antigens. While non-expression of the target antigens has not been recorded for aldolase or pLDH, it is known that parasites that infect people in some areas of South America (Peru, Colombia, Brazil), India and Africa (Eritrea, Ghana, Rwanda) do not express HRP2 (12–13, 33–34). In areas where HRP2-deleted parasites exist, tests for HRP2 will have greatly reduced sensitivity or be incapable of detecting *P. falciparum*. In such populations, only tests for pLDH or aldolase in *P. falciparum* parasites will be effective.

Heat stability (summarized in Table S3) is vital to maintaining the sensitivity of tests in the field. As a result, for procurement, careful consideration must be given to ensure that the products to be used in areas with high temperatures of transport and storage have demonstrated stability in the product testing programme. Requirements vary among countries; for example, if tests are to be deployed in areas where temperatures rarely rise above 30°C, less emphasis is needed on stability at high temperatures than on other aspects of quality.

Ease-of-use requirements depend on the extent of training and the work environment of the users. Particularly in primary health care settings, the simpler the test, the easier it will be to avoid errors in preparation and interpretation. Certain anomalies resulting from defects in production lots or RDT degradation may affect the running of the test or interpretation and may warrant a field safety notice and corrective action.

To encourage manufacturers to meet international standards and best practice in the packaging and labelling of malaria RDTs, with the goal of ensuring better, more consistent ease of use, WHO and partners have made recommendations for the instructions for use and labelling of malaria RDTs (14). Evaluation of adherence to the recommendations was introduced in round 7.

Detailed results can be found in the report of each evaluation (3–8) and at http://www.who.int/malaria/publications/diagnostic_testing/en/ (accessed 8 March 2017).

1.4. Summary of outcomes

Laboratory-based evaluation provides a comparative, standardized measure of RDT performance for distinguishing between well and poorly performing tests to serve as a basis for procurement decisions by malaria control programmes and to guide United Nations procurement policy.

In round 7, the proportion of tests that achieved a PDS $\geq$ 75% at a density of 200 parasites/μL is slightly lower than in round 6 for both *P. falciparum* (87.0%) and *P. vivax* (70.0%).

Several RDTs in the seven rounds of testing consistently detected malaria at a low parasite density (200 parasites/μL), had low false-positive rates, are stable at tropical temperatures, are relatively easy to use and can detect *P. falciparum* or *P. vivax* infections or both.

Although the performance of the products varied widely at low parasite density (200 parasites/μL) in round 7, all products had a high rate of detection of *P. falciparum* at 2000 parasites/μL (PDS of 100%), as did the majority of products for *P. vivax* at 2000 parasites/μL.

In all except two of the RDTs submitted to round 7, the HRP2 antigen was used to detect *P. falciparum*, either alone (41 products) or with Pf-pLDH (3 products). In the two exceptions, Pf-pLDH was used alone. Of the five products that detected Pf-pLDH, two combined Pf-pLDH with HRP2 in the same test line, one had dual test lines for detecting *P. falciparum* (one HRP2 and one Pf-pLDH test line), and two had only Pf-pLDH. While the dual test line product performed well overall, the line for detecting Pf-pLDH performed considerably less well than the HRP2-detecting test line at 200 μL, with a PDS of 38%. The PDS of the two products with Pf-pLDH alone for detecting *P. falciparum* at 200 parasites/μL were 75% and 73%. Thus, after seven rounds of testing, the choice of well-performing pLDH-based *P. falciparum* tests and of pan-only tests remains limited.

The test performance of lots in round 7 varied only slightly, with an average difference in positivity rates of 1.5 percentage point (range, 0–4.5%) and 1.0 percentage point (range, 0–3.5%) when tested against 200 parasites/μL wildtype *P. falciparum* and *P. vivax*, respectively (Tables A3.1 and A4.1), a pattern also seen in round 6. In previous rounds, however, wide variation was found, indicating the advisability of testing lots after purchase and before use in the field. The frequency of anomalies that can interfere with test interpretation was recorded for the first time in round 6. In round 7, one to five anomalies were found with 33 of the 46 products (Annex S2, Table 8, Fig. 30). Incomplete clearing and a red background were the most common anomalies, seen in 48% and 24% of products, respectively. The next most common anomalies were incomplete migration, failed migration and a red background obscuring the test lines, in 15%, 11% and 11% of products, respectively. Most products (44/46) had anomalies in < 1% of the tests; two products had anomalies in 1.4% of products (Table 8). Overall, fewer types and a lower frequency of anomalies were seen in round 7 than in round 6.

All except one of the RDTs evaluated in round 7 were in cassette format; the exception was in dipstick format.

Only 5 of the 30 RDTs due for compulsory resubmission were submitted for retesting. All met the WHO procurement criteria on initial testing. Two products (one for *P. falciparum* only and one combination RDT) scored higher in re-testing, with percentage point increases of 7 and 6, respectively, in the PDS at 200 µL against *P. falciparum* and an increase of 6 percentage points against *P. vivax* for the combination RDT. Three re-tested products (one *P. falciparum* only, two combination RDTs) scored lower than in their initial testing, with percentage point decreases of 7, 8 and 16 in the PDS at 200 µL against *P. falciparum* and a decrease of 91 percentage points (to a score of zero) in the PDS against *P. vivax* for the combination RDT. Of these three products with diminished performance, two no longer meet the criteria for procurement. Four products showed decreased false-positive rates on re-testing, whereas one had an increase from 0% to 5% at 200 µL.

1.5. De-listing of products in summary report

Products that are due for compulsory resubmission (every 5 years) but are not resubmitted are removed from the summary results listing (Tables S2 and S3) and the online interactive database (15) and are featured only in the full round-specific product testing report. They are also not eligible for WHO procurement. Furthermore, a product is de-listed if WHO is notified by the manufacturer that its production has been discontinued. To date, 72 products have been delisted (Table S4).

1.6. How product testing results can inform RDT procurement and use

Accurate diagnosis is vital to good malaria case management, whether based on microscopy or on RDTs. The results of this report should be used to make a short list of RDTs for procurement for use in settings where good microscopy is not available or appropriate. Box 3 lists WHO's minimum criteria for RDT selection, and Annex S3 provides a step-by-step approach to selecting an RDT, taking into consideration

local malaria transmission and illness where the tests will be used (e.g. *Plasmodium* spp., target antigen, parasite densities, climate) and other important considerations, including ease of use in the field (Annex S2), training or retraining requirements and lot testing.¹

The results in Table S2 indicate WHO prequalification status and are colour-coded to reflect achievement of WHO performance requirements for RDT procurement. A web-based tool that allows filtering of product testing results by various parameters to assist in selecting products with the performance characteristics most suitable for a country's health programme is available and is maintained by FIND (15). This online database has been updated to allow filtering of results by RDT procedural characteristics, such as blood volume requirements, number of buffer drops and time to a result. This will allow identification of products with similar procedures so that, when product replacement is required, another product can be selected with the same or a similar protocol. Use of similar products may reduce the need for user retraining and reduce user error.

The results in the product testing reports are presented by product, which are described by their name and "product code". The same RDT may be sold in a variety of product configurations, such as single or multi-kits, the number of tests per box, with or without certain accessories, and they are assigned a series of distinct product codes on this basis. The reports list the precise name and product code as provided by the manufacturer for testing. Procurers should contact the manufacturer for a list of product configurations before purchase.

Comprehensive guidance on several aspects of procurement can be found in *Recommended selection criteria for procurement of malaria rapid diagnostic tests* (16), published as a WHO information note in 2016² and *Good practices for selecting and procuring rapid diagnostic tests for malaria* (16). Guidance on implementation is provided in *Universal access to malaria diagnosis* (17).

¹ The WHO-FIND malaria RDT evaluation programme provides lot-testing capacity in two regional laboratories free of charge. Information on the programme and how to access it can be found at: <https://www.finddx.org/malaria-rdt-qa/> (accessed 8 March 2017).

² <http://www.who.int/malaria/publications/atoz/rdt-selection-criteria.pdf> (accessed 3 April)

Box 3: WHO selection criteria for the procurement of RDTs


Products should be selected in line with the following set of criteria, based on the results of the assessment of the WHO Malaria RDT Product Testing Programme:

- (A) For the detection of *Plasmodium falciparum* (Pf) in all transmission settings the panel detection score (PDS) against Pf samples should be at least 75% at 200 parasites/µL.
- (B) For the detection of *Plasmodium vivax* (Pv) in all transmission settings the panel detection score (PDS) against Pv samples should be at least 75% at 200 parasites/µL.
- (C) The false positive rate should be less than 10%.
- (D) The invalid rate should be less than 5%.

Only products meeting performance criteria outlined in A,B,C and D are recommended for procurement

As of 1 January, 2018 WHO procurement recommendations for malaria RDTs will change to require WHO prequalification designation¹.

Figure S1: Malaria RDT performance in phase 2 of rounds 4–7 against wild-type (clinical) samples containing *P. falciparum* at low (200) and high (2000) parasite density (parasites/μL) and clean-negative samples



^a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive.

^b Clean-negative - blood samples from healthy volunteers with no known current illness or blood abnormality.

* Indicates tests that also detect other non-*P. falciparum* parasites

1.7. Product testing and WHO programme for prequalification of diagnostics and medical devices

In the WHO programme for prequalification of diagnostics and medical devices, the results of product testing are used as the laboratory evaluation component of the prequalification process for malaria RDTs. These data are used to set priorities for dossier review and inspection. As of 1 January

2018, WHO prequalification will become a requirement for WHO procurement. Therefore, manufacturers are strongly encouraged to apply.¹ Prequalified RDTs are listed in summary tables and at http://www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/ (accessed 8 March 2017).

¹ <http://www.who.int/malaria/news/2016/rdt-procurement-criteria/en/>





Figure S2: Malaria RDT performance in phase 2 of rounds 4–7 against wild-type (clinical) samples containing *P. vivax* at low (200) and high (2000) parasite density (parasites/ μ L) and clean-negative samples



^a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive.

^b Clean-negative - blood samples from healthy volunteers with no known current illness or blood abnormality.





Figure S3: Panel detection score of malaria combination RDTs meeting WHO procurement criteria for false-positive and invalid rates, in phase 2 of rounds 4–7 against wild-type (clinical) samples containing *P. falciparum* and *P. vivax* at low parasite density (200 parasites/ μ L)



^a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive.

Table S1: Product resubmissions: WHO malaria RDT product testing rounds 1–7

Manufacturer	Product name	Product code*	Product resubmission Round	
			Voluntary	Compulsory
Access Bio, Inc.	CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-05072 ^a	2, 4, 7	
	CareStart™ Malaria HRP2/PLDH (Pf/VOM) COMBO	RMWM(U)-XXX7X ^b	2, 4	
	CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM(U)-XXX7X ^c	1	5
	CareStart™ Malaria HRP2/pLDH (Pf/PAN) Combo	RMRM(U)-XXX7X	1	5
	CareStart™ Malaria PAN (pLDH) Ag RDT	RMNM(U)-XXX7X ^c	1	5
	CareStart™ Malaria Pf (HRP2/pLDH) Ag RDT	RMPM(U)-XXX7X ^f	2	6
	CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071 ^g	3	7
	CareStart™ Malaria Screen RDT	RMAM-05071 ^h	3	7
Advy Chemical Pvt. Ltd. (Affiliate of Bharat Serums & Vaccines Ltd.)	EzDx™ Malaria Pan/Pf Rapid Test Detection Kit	RK MAL 001	4, 5, 6	
ARKRAY Healthcare Pvt. Ltd. ⁱ	ParaHIT® - f (Device) ^j	551C104-50	3	7
	ParaHIT® - f (Dipstick) ^k	551C103-50	3	7
ASAN Pharmaceutical Co., Ltd	Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	5, 7	
AZOG	Malaria pf (HRP II) / (PAN-LDH) Antigen Detection Test Device ^l	MFV-124R	1, 3	
	Malaria pf (pLDH) / PAN-pLDH Test Device	MFV-124	3, 5	
Bhat Bio-Tech India (P) Ltd.	Maleriscan® Malaria Pf/PAN (Pv, Pm, Po) 3 Line Antigen Test	MAT-PF/PAN-50	4, 5	
Bioland	NanoSign Malaria Pf/Pan Ag	RMAP10	3, 4	
Bionote, Inc.	BIONOTE MALARIA P.f. Ag Rapid Test Kit	RG19-11	3, 6	
	BIONOTE MALARIA P.f & Pan Ag Rapid Test Kit	RG19-08	3, 6	
Biosynex	IMMUNOQUICK® MALARIA falciparum	0502_K25	1	5
Bio Focus Co., Ltd.	BioTracer™ Malaria P.f/PAN Rapid Card	17012	5, 6, 7	
Blue Cross Bio-Medical (Beijing) Co., Ltd.	One Step Malaria Pf Test (cassette)	522352	2, 3, 4	
	One Step Malaria P.F/P.V Test (Cassette)	523352	4, 5	
	Onsite Pf Ag Rapid Test	R0114C	2, 3, 6	
CTK Biotech, Inc.	Onsite Malaria Pf/Pan Malaria Ag Rapid Test	R0113C	2, 3, 4, 5, 6	
	Onsite Malaria Pf/Pv Ag Rapid Test	R0112C	2, 3, 4, 6	
DiaMed - A Division of Bio-Rad	OptiMAL-IT	710024	1, 3	
Guangzhou Wondfo Biotech Co. Ltd.	Wondfo One Step Malaria Pf/Pan Whole Blood Test	W56-C	1, 3	
	One Step Malaria P.f/P.v Whole Blood Test	W056-C	5, 6, 7	
	One Step Malaria P.f Test ^m	W37-C	2, 3, 4, 6, 7	
Humasis Co., Ltd.	Humasis Malaria Pf/Pan Antigen Test	AMAL-7025	4, 5	
	ICT Malaria Combo Cassette Test	ML02	1, 3, 4	
ICT INTERNATIONAL	ICT Malaria Pf Cassette Test	ML01	1, 3	7
	ICT Malaria Dual Test	ML03	3, 5, 7	
InTec Products, Inc.	Advanced Quality™ One Step Malaria Pf Test	ITP11002TC1/TC40	1, 3, 7	5
	Advanced Quality™ One Step Malaria (Pf/Pv) Tri-line Test (whole blood)	ITP11003 TC40	3, 6, 7	
	Advantage Pan Malaria Card	IR013025	1	5
J.Mitra & Co. Pvt. Ltd.	Advantage Mal Card	IR221025	1	5
	Advantage P.f Malaria Card	IR016025	1	5
Lumiquick Diagnostics Inc.	QuickProfile™ Malaria Pf/Pv Antigen Test	71050	6, 7	
Orchid Biomedical Systems	Paracheck® Pf Device - Rapid test for P. falciparum Malaria (Ver. 3) ⁿ	30301025	1, 3, 4	
	Paracheck® Pf Dipstick - Rapid test for P. falciparum Malaria (Ver.3) ⁿ	30302025	1, 3, 4	
Premier Medical Corporation Ltd.	First Response® Malaria Ag Combo (pLDH/HRP2) ^o	I16FRC25	1, 2, 5	
	First Response Malaria Ag P. falciparum(HRP2) Card Test	I13FRC25	1	5
RapiGEN Inc.	BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C30RHA25	5, 6, 7	
SSA Diagnostics & Biotech Systems	diagnosticks- Malaria (Pf)Cassette WB	KMFC6001	2, 5	
Standard Diagnostics Inc.	SD BIOLINE Malaria Ag	05FK40	1, 3	
	SD BIOLINE Malaria Ag Pf/Pan	05FK60	1, 3, 5	
	SD BIOLINE Malaria Antigen	05FK50	1	5
	SD Bioline Malaria Ag P.f (HRP2/pLDH)	05FK90	3, 6	
	SD Bioline Malaria Ag P.f/P.v	05FK80	2	6
Unimed International Inc.	FirstSign™ - ParaView (Pan+Pf) Malaria Test	2101 CB-25	2, 4	
Vision Biotech (Pty) Ltd / Origenics (Alere Healthcare (Pty) Ltd subsidiaries)	Malaria Rapid Combo/Clearview® Malaria Combo	VB11 ^p	1, 3	
	Malaria Rapid Pf /Clearview® Malaria Pf	VB01	1, 3, 5	
	Malaria Rapid Dual/Clearview® Malaria Dual Test Device	VB20 ^p	1, 3, 5	
	Malascan™ Device - Rapid test for Malaria Pf/Pan	50402025	1, 3	
Zephyr Biomedical Systems	Parabank™ Device - Rapid test for Malaria Pan	50301025	1, 3	
	Parascreen™ Device -Rapid test for Malaria Pan/Pf	50310025; 503030025 (rd 6)	1, 3, 4, 5, 6	
	Falcivax Rapid Test for Malaria Pv/Pf (device)	50300025; 503010025 (rd 6)	2, 4, 6	

* The product code corresponds to a specific configuration of the RDT, kit components and accessories. Therefore, changes to this configuration including the quantity of tests, the contents or the manufacturing site are denoted by a different product code. Often this involves the end portion of the product code; however, the manufacturer should be contacted for full details.

^a Previously listed with product code G0161 for the Access Bio Inc product. Previously co-listed with G0161-ET, the equivalent Access Bio Ethiopia product. Access Bio Ethiopia products are now listed as separate products from separate manufacturers and not considered resubmissions.

^b Previously listed with product code G0171 for the Access Bio Inc product. Previously co-listed with G0171-ET, the equivalent Access Bio Ethiopia product. Access Bio Ethiopia products are now listed as separate products from separate manufacturers and not considered resubmissions.

^c Previously listed with product code G0141 for the Access Bio Inc product. Previously co-listed with G0141-ET, the equivalent Access Bio Ethiopia product. Access Bio Ethiopia products are now listed as separate products from separate manufacturers and not considered resubmissions.

^d Previously listed with product code G0131/G0131-ET

^e Previously listed with product code G0111

^f Previously listed with product code G0181/G0181-ET

^g Previously listed with product code G0121

^h Previously listed with product code G0231

ⁱ Arkay Healthcare Pvt. Ltd. was formerly Span Diagnostics Ltd.

^j New product codes have been in place since round 3, the previous code was 55IC102-10.

^k New product codes have been in place since round 3, the previous code was 55IC101-10.

^l Round 1 product name error : published - Malaria Pf (HRPII)/pv-LDH) Antigen Detection Test Device Code ; corrected product name: Malaria Pf (HRPII/PAN-LDH) Antigen Detection Test Device Code. No change in product code.

^m In round 2, product did not pass phase 1, therefore results do not feature in summary tables.

ⁿ Ver.3 was introduced after round 1

^o Error in WHO Malaria RDT product testing: round 1 report: product code (I16FRC30) should have been (I16FRC), as in round 2

^p New company acquisition (Alere™), therefore change in product branding and catalogue numbers; VB011 to VB11 and VB020 to VB20. Manufacturer confirmed compliance with product definition.

Table S2: Malaria RDT phase 2 performance in rounds 4–7 against wild type (clinical) samples containing *P. falciparum* and *P. vivax* at low (200) and high (2000) parasite density (parasites/ μ l) and clean–negative samples

Product	Product code	Manufacturer	Panel detection score ^a				False positive rates (%)						Total false positive rates ^b (%)		Round	Meets WHO procurement criteria	
			200 parasites/μl		2000 or 5000 parasites/μl		200 parasites/μl		2000 parasites/μl		Clean negative samples	Invalid rate (%) ^j					
			Pf samples ^e	Pv samples ^d	Pf samples ^e	Pv samples ^d	Pf samples	Pv samples	False positive non-Pf infection ^e	False positive Pf infection ^f			False positive non-Pf infection ^g	False positive Pf infection ^h			
Pf only																	
ABON™ Malaria Pf. Rapid Test Device (Whole Blood)	IMA-402	ABON Biopharm (Hangzhou) Co. Ltd	32.7	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.4	0.0	4	No		
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA1017	Adv Chemical Private Limited	80.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	7	Yes		
ADVANCED QUALITY™ ONE STEP Malaria (pf) Test ^j	ITP11002-TC25	Intec Products, Inc.	93.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.4	0.0	7	Yes		
Advantage Pf. Malaria Card	IR016025	J. Mitra & Co. Pvt. Ltd.	89.0	NA	99.0	NA	NA	0.7	NA	NA	0.0	0.0	0.0	5	Yes		
Aiere™ Malaria Ag Pf	05FK140-40-0	Standard Diagnostics, Inc.	98.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.9 (231)	0.1	7	Yes		
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	93.0	NA	100.0	NA	NA	0.7	NA	NA	0.0	1.3	0.0	7	Yes		
BIONOTE MALARIA Pf. Ag Rapid Test Kit	RG19-11	Bionote, Inc.	88.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.5	0.0	6	Yes		
BioTracer™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	97.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	7	Yes		
CareStart™ Malaria HRP2 (Pf)	RM0M(U)-XXX7X	Access Bio, Inc.	91.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.9	0.0	5	Yes ^m		
CareStart™ Malaria Pf (HRP2) Ag RDT	RM0M-03091	Access Bio Ethiopia	96.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.4	0.0	7	Yes		
CareStart™ Malaria Pf (HRP2)pLDH Ag RDT	RMPM(U)-XXX7X	Access Bio, Inc.	91.0	NA	99.0	NA	NA	0.7	NA	NA	0.0	0.0	0.0	6	Yes ^m		
CareStart™ Malaria Pf (HRP2)pLDH Ag Combo 3-Line ^k	RMSM-05071	Access Bio, Inc.	94.0 (94/38)	NA	99.0 (99/92)	NA	NA	2.1	NA	NA	1.4	0.4	0.0	7	Yes		
CareUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	94.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.9	0.0	7	Yes		
DIAQUICK Malaria Pf. Cassette	W06200	DIALAB	86.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	7	Yes		
Edx™ Malaria Pf Rapid Malaria antigen detection test	RK MAL 008	Adv Chemical Private Limited	71.0	NA	100.0	NA	NA	1.4	NA	NA	1.4	1.0	0.1	6	No		
First Response® Malaria Ag P. falciparum (HRP2) Card Test	I13RC25	Premier Medical Corporation Ltd.	95.0	NA	100.0	NA	NA	0.7	NA	NA	0.0	0.4	0.0	5	Yes ^m		
First Response® Malaria Ag P. falciparum (HRP2) Card Test	P113FRC	Premier Medical Corporation Ltd.	91.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	1.0	0.0	6	Yes		
FirstSign™ Malaria Pf	2100CB-25	Unimed International Inc.	94.9	NA	100.0	NA	NA	0.7	NA	NA	1.5	2.2 (231)	0.2	4	Yes		
Humasid Malaria Pf Antigen Test	ANMPF-7025	Humasid Co., Ltd.	87.0	NA	100.0	NA	NA	1.4	NA	NA	1.4	1.4	0.0	6	Yes		
ICT MALARIA PF. CASSETTE TEST ^j	ML01	ICT INTERNATIONAL	94.0	NA	100.0	NA	NA	5.0	NA	NA	1.4	1.7	0.0	7	Yes		
IMMUNOQUICK® MALARIA falciparum	0502_K25	Biosynex	72.0	NA	93.0	NA	NA	3.6	NA	NA	4.3	5.1 (234)	0.2	5	No		
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	85.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	7	Yes		
KHB® Malaria Ag Pf Rapid Test	KH-R-06-20	Shanghai Kehua Bio-engineering Co., Ltd.	79.0	NA	91.8 (98)	NA	NA	11.4	NA	NA	12.9	10.6 (235)	0.7	5	No		
Malaria Antigen Test-Pf	MAGO1040	Oscar Medicare Pvt. Ltd.	91.0	NA	100.0	NA	NA	1.4	NA	NA	1.4	1.0	0.0	6	Yes		
Malaria Pf Rapid Test	GCMAL(pF)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	89.0	NA	100.0	NA	NA	0.0 (139)	NA	NA	0.0	0.0	0.1	7	Yes		
Maleriscan® Malaria Pf Antigen Test	MAT-PF-50	Bhat Bio-Tech India (Pte.) Ltd.	83.7	NA	98.0	NA	NA	1.5	NA	NA	0.0	0.4	0.2	4	Yes		
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	86.0	NA	99.0	NA	NA	2.9	NA	NA	1.4	0.4 (231)	0.1	7	Yes		
One Step Malaria HRP2 (Pf) Test ^j	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	93.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	7	Yes		
One Step Malaria Pf Test (Cassette)	522352	Blue Cross Bio-Medical (Beijing) Co., Ltd.	94.9	NA	99.0	NA	NA	0	NA	NA	1.5	1.3	0.0	4	Yes		
One Step Test for Malaria PfHRP-II/AgMERISCREEN Malaria Pf HRP-II/Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	73.0	NA	99.0	NA	NA	0.7	NA	NA	0.0	0.0	0.0	7	No		
OnSite Malaria Pf Ag Rapid Test	R0114C	CTK Biotech, Inc.	75.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.2	6	Yes		
PALUTOP + pf®	5531	ALLDIAG SA	92.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	7	Yes		
Paracheck® Pf-Rapid Test for P.falciparum Malaria Device (Ver.3)	302030025	Orchid Biomedical Systems	95.9	NA	98.0	NA	NA	0.0	NA	NA	0.0	1.3	0.0	4	Yes		
Paracheck® Pf-Rapid Test for P.falciparum Malaria Dipstick (Ver.3)	302040025	Orchid Biomedical Systems	70.4	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.9	0.0	4	No		
Parahit® Ver 1.0 - Dipstick ^j	551C103-50	ARKRAY Healthcare Pvt Ltd ⁿ	74.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	7	No		
Parahit® F Ver 1.0 - Device ^j	551C104-50	ARKRAY Healthcare Pvt Ltd ⁿ	77.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	7	Yes ^m		
Rapid 1-2-3® Hema® Cassette Malaria Pf	MAL-PF-Q5J25 (100)	Hema Diagnostic Systems	93.0	NA	100.0	NA	NA	2.9 (139)	NA	NA	0.0	0.0	0.0	6	Yes		
RapiGEN BIO-CREDIT Malaria Ag Pf (HRPII)	C10RHA25	RapiGEN Inc.	88.0	NA	99.0	NA	NA	0.7	NA	NA	0.0	0.5 (207)	0.2	6	Yes		
RightSign® Malaria Pf. Rapid Test Cassette (Whole Blood)	IMPF-C51	Hangzhou Biotech Co., Ltd.	79.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	6	Yes		

Table S2 (continued)

Product	Product code	Manufacturer	Panel detection score ^a				False positive rates (%)						Total false positive rates ^b (%)		Invalid rate (%) ⁱ	Round	Meets WHO procurement criteria
			200 parasites/µl		2000 or 5000 parasites/µl		200 parasites/µl		2000 parasites/µl		Clean negative samples						
			Pf samples ^c	Pv samples ^d	Pf samples ^e	Pv samples ^d	Pf samples	Pv samples	Pf samples	Pv samples							
SD Bioline Malaria Ag P.f (HRP2/pLDH) ^k	05FK90	Standard Diagnostics, Inc.	88.0 (87/52)	NA	100.0 (100/97)	NA	NA	0.7	NA	0.0	0.0	0.0	0.0	0.0	6	Yes ^m	
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	90.0	NA	100.0	NA	NA	0.0	NA	0.0	0.0	0.0 (231)	0.1	0.0	7	Yes	
SD BIOLINE Malaria Ag Pf	05FK50	Standard Diagnostics, Inc.	95.0	NA	99.0	NA	NA	0.0	NA	2.9	0.0	0.0	0.0	0.0	5	Yes ^m	
Trusty™ Malaria Antigen P.f. test	A03-01-322	Artron Laboratories Inc.	88.8	NA	100.0	NA	NA	4.4 (135)	NA	2.9	0.0	5.2 (230)	0.7	0.0	4	Yes	
Pf and Pan																	
ABON™ Plus Malaria Pf/Pan Rapid Test Device (Whole Blood)	IMA-T402	ABON Biopharm (Hangzhou) Co. Ltd	85.7	5.9	100.0	97.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	4	No	
ACCUCARE ONE STEP MALARIA Pf/Pan Antigen Test	MAGC 25	LAB-CARE Diagnostics (India) PVT. LTD.	66.0	37.1	92.0	97.1	0.3	0.0 (139)	0.0 (199)	0.0	0.0	7.3 (234)	0.4	0.0	5	No	
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA016	Advx Chemical Private Limited	67.0	45.7	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7	No	
Advanced Quality™ Rapid Malaria Test (Pf/Pan)	ITP11005	InfTec Products, Inc.	88.0	60.0	100.0	97.1	0.3 (389)	6.7 (134)	0.0 (197)	1.4	0.0	8.7 (231)	2.1	0.0	5	No	
Advantage Mal Card	IR221025	J. Mitra & Co. Pvt. Ltd.	30.0	94.3	94.0	97.1	1.5	0.7	0.5	0.0	0.0	0.4	0.0	0.0	5	No	
Advantage Malaria Pan + Pf Card	IR231025	J. Mitra & Co. Pvt. Ltd.	84.0	100.0	100.0	100.0	3.5	0.0	0.0	0.0 (69)	0.0	0.0	0.2	0.0	5	Yes	
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-2/pLDH)	05FK60AL-40	Alere Medical Private Limited	85.0	91.4	98.0	100.0	1.3	0.0	1.0	0.0	0.0	0.0	0.0	0.0	7	Yes	
AllTest™ Malaria P.f/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	69.0	71.4	96.0	100.0	1.3	0.0	2.0	0.0	0.0	0.9	0.0	0.0	7	No	
Asan Easy Test® Malaria Pf/Pan Ag ^j	AM4650-K	ASAN Pharmaceutical Co., Ltd	88.0	100.0	98.0	100.0	0.5 (399)	0.0	1.0	0.0	0.0	1.3	0.1	0.0	7	Yes	
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	93.0	91.4	98.0	100.0	0.3 (399)	1.4 (138)	1.0	0.0	0.0	1.3 (231)	0.3	0.0	7	Yes	
ATOMORAPID™ MALARIA (PF/PAN)	MMAL01	Atomo Diagnostics PTY Limited	90.0	22.9	100.0	97.1	0.0 (399)	2.9	0.0	0.0	0.0	0.0 (207)	0.2	0.0	6	No	
AZOG Malaria pf (HRPII)/pf (LDH)/ (PAN-LDH) Antigen Detection Device ^k	MFV-124F	AZOG, INC.	62.2 (62/3.1)	0.0	98.0 (98/37.8)	88.2	0.0 (390)	5.2	0.0	0.0	0.0	1.7 (231)	0.3	0.0	4	No	
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) ^j	C32RHA25	RapiGEN Inc.	91.0	100.0	99.0	100.0	0.0	0.0	0.5	0.0	0.0	3.9	0.0	0.0	7	Yes	
BIONOTE MALARIA P.f & Pan Ag Rapid Test Kit	RG19-08	BioNote, Inc.	83.0	68.6	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	6	No	
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	85.0	85.7	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7	Yes	
BioTrace™ Malaria P.f/PAN Rapid Card ^j	17012	Bio Focus Co., Ltd.	96.0	97.1	99.0	94.3	0.8	0.7	0.5	2.9	0.0	0.9	0.0	0.0	7	Yes	
CareStart™ MALARIA Pf/PAN (pLDH) Ag RDT ^j	RMLM-05071	Access Bio, Inc.	73.0	0.0	100.0	71.4	0.0	0.7	0.0	0.0	0.0	1.7	0.0	0.0	7	No	
CareStart™ Malaria Pf/PAN (HRP2/pLDH) Ag COMBO RDT	RMRM(U)-XXX7X	Access Bio, Inc.	90.0	94.3	100.0	100.0	1.5	0.7	0.0	0.0	0.0	0.4	0.0	0.0	5	Yes ^m	
CareStart™ Malaria Screen RDT ^j	RMAM-05071	Access Bio, Inc.	93.0	94.3	99.0	97.1	1.3	0.0	0.5	0.0	0.0	0.0 (231)	0.1	0.0	7	Yes	
Core™ Malaria Pan Pf	MAL-190024	Core Diagnostics Ltd.	99.0	26.5	100.0	29.4	0.0	33.8	0.0	42.7	0.0	32.2 (230)	0.3	0.0	4	No	
DIAQUICK Malaria P.f/Pan Cassette	Z11200CE	DIALAB GmbH	90.0	82.9	100.0	97.1	0.3	2.9	0.0	0.0	1.5 (67)	2.1	0.2	0.0	5	Yes	
EzDx™ Malaria Pan/Pf Rapid test detection Kit	RK MAL 001	Advx Chemical Private Limited	78.0	88.6	100.0	100.0	0.3	0.0	0.0	0.0	0.0	1.4	0.0	0.0	6	Yes	
First Response® Malaria Ag. pLDH/HRP2 Combo Card Test	I16FRC	Premier Medical Corporation Ltd.	85.0	74.3	100.0	100.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5	No	
First Response® Malaria Ag. pLDH/HRP2 Combo Card Test	PI16FRC	Premier Medical Corporation Ltd.	82.0	91.4	100.0	100.0	1.5	0.0	0.0	0.0	0.0	1.9 (207)	0.1	0.0	6	Yes	
FirstSign™ ParaView (Pan+Pf)	2101CB-25	Unimed International Inc.	87.8	61.8	100.0	100.0	0.3	1.5	0.0	0.0	0.0	2.6	0.0	0.0	4	No	
GenBody™ Malaria Pf/Pan Ag	MALAG100	GenBody Inc.	84.0	54.3	100.0	97.1	0.0	0.0	0.0	0.0	0.0	0.0 (235)	0.2	0.0	5	No	
Genedia® Malaria P.f/Pan Ag Rapid Test	20-0146-01	Green Cross Medical Science Corp. (Korea)	67.0	17.1	96.0	88.6	0.0	13.6	0.0	7.1	0.0	10.6	0.1	0.0	5	No	
Humasis Malaria P.f/Pan Antigen Test	AMAL-7025	Humasis, Co., Ltd.	90.0	91.4	100.0	97.1	0.5 (396)	0.0 (138)	0.0 (199)	1.4	0.0	0.9 (235)	0.7	0.0	5	Yes	
Humasis Malaria P.f/Pan Antigen Test	ANMAL-7025	Humasis Co., Ltd.	89.0	62.9	99.0	97.1	0.0	0.7 (139)	0.0	1.4	0.0	0.5	0.1	0.0	6	No	
ICT MALARIA DUAL TEST ^j	MLO3	ICT INTERNATIONAL	85.0	31.4	98.0	100.0	0.3	0.0	1.0	0.0	0.0	1.3	0.0	0.0	7	No	
Is It... Malaria Pf/PAN	MPFPAN050	Medsourse Ozone Biomedicals Pvt. Ltd.	93.0	100.0	99.0	100.0	2.0	0.0	0.5	0.0	0.0	3.9	0.0	0.0	7	Yes	
Is It... Malaria Pf/Pv Device	AL030	Medsourse Ozone Biomedicals	88.0	91.4	99.0	100.0	0.5 (395)	0.0	0.0	0 (68)	0.0	1.0 (206)	0.8	0.0	6	Yes	
Malaria pf (HRP II)/PAN (pLDH) Antigen Detection Test Device	1-13-101-1	United Biotech, Inc.	63.3	2.9	100.0	85.3	0.0	0.0 (135)	0.0	0.0	0.0	0.0	0.1	0.0	4	No	
Malaria pf (pLDH) / PAN-pLDH Test Device	MFV-124	AZOG, Inc.	41.0	8.6	97.0	45.7	22.5	47.9	1.5	35.7	0.0	81.3 (235)	0.1	0.0	5	No	
Malaria Pf/Pan Antigen (MAL Pf/Pan) Test Kit	A03-18-322	Artron Laboratories Inc.	61.0	2.9	95.0	97.1	0.0 (398)	4.3	0.0 (199)	0.0	0.0	0.9	0.2	0.0	5	No	
Malaria Pf/PAN	GM004	Genomix Molecular Diagnostics Pvt.Ltd.	39.8	2.9	94.9	97.1	0.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	4	No	

(continued)

Table S2: Malaria RDT phase 2 performance in rounds 4–7 against wild type (clinical) samples containing *P. falciparum* and *P. vivax* at low (200) and high (2000) parasite density (parasites/μl) and clean-negative samples (continued)

Product	Product code	Manufacturer	Panel detection score ^a				False positive rates (%)						Total false positive rates ^b (%)		Invalid rate (%) ⁱ	Round	Meets WHO procurement criteria
			200 parasites/μl		2000 or 5000 parasites/μl		200 parasites/μl		2000 parasites/μl		Clean negative samples						
			Pf samples ^c	Pv samples ^d	Pf samples ^e	Pv samples ^d	Pf samples	False positive non-Pf infection ^e	Pv samples	False positive Pf infection ^f	False non-Pf infection ^g	False positive Pf infection ^h	False positive <i>Plasmodium</i> spp. Infection ⁱ				
Malaria Pf/Pan One Step Rapid Test	RT 20222	Zhejiang Orient Gene Biotech Co., Ltd.	89.0	91.4	100.0	100.0	0.0 (398)	0.7 (138)	0.0 (199)	0.0 (69)	0.4 (232)	1.0	5	Yes			
MeDiPro Malaria Ag HRP2/pLDH Combo	IR-0051K	Formosa Biomedical Technology Corp.	69.4	2.9	99.0	0.0	0.0 (391)	0.0	0.0	1.5	0.9	0.1	4	No			
Meriscan Malaria Pf/Pan Ag	MHLRPD-01	Meril Diagnostics Private Ltd.	77.0	71.4	100.0	100.0	1.3	0.0	0.0	0.0	0.5	0.0	6	No			
NanoSign Malaria pf/pan Ag 3.0	RMAP10	Bioland Ltd.	92.9	97.1	100.0	100.0	0.8	0.0	0.0	0.0	0.4	0.0	4	Yes			
NG-Test MALARIA Pf/Pan (pLDH)	NG-MAL-W23-001	SARL NG Biotech, Z.A.	90.0	65.7	100.0	94.3	0.5 (399)	9.3	0.0	4.3	15.3	0.1	5	No			
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	92.0	25.7	98.0	91.4	0.8 (399)	3.6 (139)	1.0	4.3	33.2	0.2	7	No			
One Step Malaria Pf/Pan Whole Blood Test	W62-C	Guangzhou Wondfo Biotech Co., Ltd.	77.0	14.3	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	6	No			
OnSite Malaria Pf/Pan Ag Rapid Test	R0113C	CTK Biotech, Inc.	78.0	85.7	99.0	97.1	0.0 (398)	0.0	0.5	1.4	0.0 (207)	0.2	6	Yes			
ParahIT – Total Ver. 1.0 (Device)	55(C204-10)	ARKRAY Healthcare Pvt. Ltd. ⁿ	84.7	82.4	99.0	91.2	0.3	0.0	0.5	3.0 (67)	0.0	0.1	4	Yes			
ParahIT – Total Ver. 1.0 (Dipstick)	55(C203-10)	ARKRAY Healthcare Pvt. Ltd. ⁿ	76.5	61.8	100.0	94.1	0.8	0.0	0.0	1.5	0.0	0.0	4	No			
Parascreen® – Rapid Test for Malaria Pan/Pf	503030025	Zephyr Biomedicals	79.0	97.1	100.0	100.0	2.3	0.0	0.0	0.0	0.0	0.0	6	Yes			
QuickProfile™ Malaria Pf/Pan Test	71063	Lumiquick Diagnostics, Inc.	79.0	91.4	99.0	100.0	6.5	1.4	0.5 (199)	0.0	7.2	0.1	6	Yes			
Rapid 1–2–3 HEMA® CASSETTE MALARIA PF/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	92.0	100.0	100.0	100.0	0.0	0.0	0.0	0.0	0.4	0.0	7	Yes			
RightSign™ Malaria Pf/Pan Rapid Test Cassette	IMPN-C52	Hangzhou Biotest Biotech Co. Ltd.	74.0	40.0	94.0	88.6	2.0	2.9	0.5	5.7	14.0	0.0	5	No			
SD BIOLINE Malaria Ag Pf/Pan	06FK60	Standard Diagnostics Inc.	94.0	91.4	99.0	97.1	0.8	0.7	0.5	1.4	0.0	0.0	5	Yes ^m			
Vikia® Malaria Ag Pf/Pan	412499	IMACCESS S.A.S	86.0	5.7	97.0	94.3	0.0	0.7 (139)	0.5 (199)	0.0 (69)	1.3 (235)	0.3	5	No			
Pf and Pv/Pvom																	
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test ^j	ITP11003-TC25	InTec Products, Inc.	92.0	97.1	98.0	100.0	1.0	0.0	1.0	1.4 (69)	0.4	0.1	7	Yes			
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	75.0	100.0	98.0	100.0	1.0 (399)	0.0 (139)	1.0 (199)	1.5 (68)	0.0 (230)	0.6	7	Yes			
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	85.0	91.4	99.0	100.0	0.0	0.0	0.0	0.0 (69)	0.0 (229)	0.3	7	Yes			
BioTracer™ Malaria Pf/Pv Rapid Card	17412	Bio Focus Co., Ltd.	91.0	94.3	100.0	100.0	0.0	0.0	0.0	0.0 (69)	0.0	0.1	6	Yes			
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	91.0	97.1	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	7	Yes			
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT ^j	RMVM-05072	Access Bio, Inc.	89.0	100.0	99.0	100.0	1.8	0.0	2.0	0.0	0.0 (231)	0.1	7	Yes ^m			
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	93.0	88.6	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	7	Yes			
Coretests® One Step Malaria Pf/Pv Ag Test Device	B42-21/B42-22	Core Technology Co., Ltd.	78.0	82.9	98.0	100.0	2.8 (399)	0.0 (138)	1.0	0.0	0.0 (207)	0.5	6	Yes			
EzDx™ Malaria Pv/Pf Rapid Malaria antigen detection test	RK MAL 003	Advy Chemical Private Limited	76.0	77.1	100.0	100.0	1.3	1.4	0.0	1.4	3.9	0.0	6	Yes			
FalciVax™ – Rapid Test for Malaria Pv/Pf	503010025	Zephyr Biomedicals	80.0	100.0	99.0	100.0	0.5	0.0	0.5	0.0	1.4	0.0	6	Yes			
First Response® Malaria Ag Pf/Pv Card Test	PI19FRC	Premier Medical Corporation Ltd.	85.0	71.4	100.0	100.0	0.0	0.0	0.0 (199)	0.0	0.5 (207)	0.2	6	No			
HiSens Malaria Ag Pf/Pv Combo Card	HR3123	HBI Co., Ltd.	89.8	79.4	100.0	94.1	0.3 (391)	0.0	0.5	0.0	0.4	0.1	4	Yes			
HiSens Malaria Ag Pf/VOM Combo Card	HR3323	HBI Co., Ltd.	89.8	76.5	100.0	91.2	0.0	0.0	0.5	0.0	0.0	0.0	4	Yes			
Humasis Malaria Pf/Pv Antigen Test	AMFV-7025	Humasis, Co., Ltd.	92.9	100.0	100.0	100.0	0.5	0.7	0.5	1.5	1.3	0.0	4	Yes			
Humasis Malaria Pf/Pv Antigen Test	ANMV-7025	Humasis Co., Ltd.	88.0	91.4	100.0	100.0	0.3	0.7	0.0	0.0	1.0 (207)	0.1	6	Yes			
KHB® Malaria Ag Pf/Pv Rapid Test	KH-R-07-50	Shanghai Kehua Bio-engineering Co., Ltd.	91.0	48.6	100.0	100.0	0.3	0.0	0.0	0.0	0.0	0.0	6	No			
Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device	1-13-101-3	United Biotech, Inc.	60.2	0.0	92.9	26.5	0.5	0.0 (135)	3.1 (195)	1.5	0.0 (230)	0.5	4	No			
Malaria Pf (HRPII) / PV (PLDH) Antigen Detection Test Device	GM006	Genomix Molecular Diagnostics Pvt. Ltd.	85.0	74.3	97.0	94.3	1.5 (391)	6.5 (138)	3.6 (195)	2.9	0.9 (232)	2.5	5	No			
Malaria Pf/Pv	GM002	Genomix Molecular Diagnostics Pvt. Ltd.	40.8	0.0	94.9	5.9	0.8	0.7	0.5	0.0	0.9	0.0	4	No			
Malaria Pf/Pv Rapid Test	GMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	89.0	57.1	99.0	100.0	0.0	0.0	0.5 (199)	0.0	0.0 (231)	0.3	7	No			
Malaria Pv/Pf (pLDH/HRP2) Antigen Test	Inf-72	Nantong Egens Biotechnology Co., Ltd.	90.0	51.4	100.0	97.1	0.0 (395)	0.0 (137)	0.5 (198)	0.0	0.0 (203)	1.3	6	No			
Malerscan® Malaria Pf/PAN (Pv, Pm, Po) 3 Line Antigen Test	MAT-PF/PAN-50	Bhat Bio-Tech India (P) Ltd.	84.0	62.9	100.0	100.0	27.3 (399)	5.8 (139)	87.4 (199)	4.3 (69)	0.0 (232)	0.7	5	No			

Table S2 (continued)

Product	Product code	Manufacturer	Panel detection score ^a				False positive rates (%)						Total false positive rates ^b (%)		Invalid rate (%) ⁱ	Round	Meets WHO procurement criteria
			200 parasites/µl		2000 or 5000 parasites/µl		200 parasites/µl		2000 parasites/µl		PF samples	Pv samples	PF samples	Pv samples			
			Pf samples ^d	Pv samples ^d	Pf samples ^c	Pv samples ^d	Pf samples	False positive non-Pf infection ^e	False positive non-Pf infection ^f	False positive non-Pf infection ^g							
One Step Malaria HRP2/pLDH (Pf/Pv) Test ^j	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	92.0	65.7	100.0	100.0	0.3	0.0	0.0	1.0	0.0	0.0	1.3	0.0	0.0	7	No
One- Step Malaria P/F/Pv Test (Cassette)	523352	Blue Cross Bio-Medical (Beijing) Co., Ltd.	92.0	100.0	100.0	100.0	21.5	53.6	9.0	9.0	34.3	0.0	77.1	0.0	0.0	5	No
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFRLPD-02	Meril Diagnostics Pvt. Ltd.	78.0	85.7	100.0	100.0	0.5	0.7	0.0	0.0	1.4	0.0	0.0	0.0	0.0	7	Yes
OnSite Malaria Pf/Pv Ag Rapid Test	R0112C	CTK Biotech, Inc.	74.0	80.0	98.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	6	No
ParaHit [®] /Rapid test for P. falciparum and P.vivax Malaria – Device	551C402-50	ARKRAY Healthcare Pvt. Ltd. ⁿ	63.0	37.1	91.0	85.7	2.0	3.99	5.7	0.5	2.9	0.0	6.4	0.1	0.1	5	No
QuickProfile [™] Malaria Pf/Pv Antigen Test ^j	71050	Lumipoint Diagnostics Inc.	79.0	88.6	99.0	100.0	39.8	0.0	0.0	27.5	0.0	0.0	22.9	0.1	0.1	7	No
RAPID 1-2-3 [®] HEMA CASSETTE MALARIA P/F/Pv TEST	MAL-PRV-CAS/25(100)	Hema Diagnostic Systems, LLC	92.9	79.4	100.0	100.0	0.0	0.7	0.0	0.0	1.5	0.0	4.3	0.0	0.0	4	Yes
RapiGEN BIO-CREDIT Malaria Ag P/F/Pv (HRP2/pLDH)	C40RHA25	RapiGEN Inc.	92.0	91.4	100.0	100.0	2.5	3.99	0.0	1.0	2.9	0.0	4.4	0.2	0.2	6	Yes
SD Bioline Malaria Ag P/F/Pv	05FK80	Standard Diagnostics, Inc.	92.0	94.3	100.0	100.0	0.5	0.7	0.0	0.0	0.0	0.0	1.9	0.0	0.0	6	Yes ^m
Rapid Test Kit for Malaria Ag P/F/Pv – Alere TrueLine Malaria Ag P/F/Pv	11108191040	Alere Medical Private Limited	85.0	88.6	98.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7	Yes
Trusty [™] Malaria Antigen P.f./p.v. test	A03-12-322	Artron Laboratories Inc.	88.8	38.2	99.0	100.0	13.3	27.4	135	160	194	19.4	32.0	0.5	0.5	4	No
Pf, Pf and Pv																	
SD Bioline Malaria Ag P.f/P.f/P.v ^k	05FK120	Standard Diagnostics, Inc.	85.0 (84/36)	91.4	100.0 (100/98)	100.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	6	Yes
Pf, Pv and Pan																	
PALUTOP +4 optima [®]	5499	ALLDIAG SA	91.0	82.9 ^p	99.0	100.0 ^p	1.3	0.7	0.5	0.5	0.0	0.0	0.0	0.0	0.0	7	Yes
Pan only																	
Advantage Pan Malaria Card	IR013025	J. Mitra & Co. Pvt. Ltd.	77.0	100.0	98.0	100.0	NA	NA	NA	NA	NA	NA	0.4	0.0	0.0	5	Yes
AZOG hCG Malaria Detection Test Device	MPT-124	AZOG, INC.	61.2	0.0	99.0	55.9	NA	NA	NA	NA	NA	NA	2.2	0.2	0.2	4	No
CareStart [™] Malaria PAN (pLDH) Ag RDT	RMNM(U)-XXX7X	Access Bio, Inc.	84.0	88.6	99.0	97.1	NA	NA	NA	NA	NA	NA	0.0	0.0	0.0	5	Yes ^m

NA, not applicable

^p *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species Pvom, *Plasmodium vivax*, ovale and *malariae*^a A sample is considered detected only if all RDTs from both lots read by the first technician; at minimum specified reading time, are positive^b The total number of times a positive result for malaria was generated when it should not have been^c Round 1, n=79; Round 2, n=100; Round 3, n=99; Round 4, n=98; Round 5, n=100; Round 6, n=100; Round 7, n=100^d Round 1, n=20; Round 2, n=40; Round 3, n=35; Round 4, n=34; Round 5, n=35; Round 6, n=35; Round 7, n=35^e For combination tests, pan or Pv line, only, positive indicates a false positive^f non *P. falciparum* infection (Round 1 n=316; Round 2, n=400; Round 3, n=396; Round 4, n=392; Round 5, n=400; Round 6, n=400; Round 7, n=400)^g Pf line positive indicates a false positive *P. falciparum* infection (Round 1, n=80; Round 2, n=160; Round 3, n=140; Round 4, n=136; Round 5, n=140; Round 6, n=140; Round 7, n=140)^h PDS presented in the table is based on a positive Pf test line (either HRP2 or Pf-pLDH). The results in brackets are the PDS based alone on HRP2 and Pf-pLDH test lines, respectively.ⁱ Round 1, n=954; Round 2, n=1240; Round 3, n=1204; Round 4, n=1192; Round 5, n=1214; Round 6, n=1210; Round 7, n=1210^j Product resubmission, results from most recent Round of testing replace previous results. Refer to Table S1.^k Round 1, n=168; Round 2, n=200; Round 3, n=232; Round 4, n=236; Round 5, n=236; Round 6, n=208; Round 7, n=220^l Round 1, n=188; Round 2, n=200; Round 3, n=200; Round 4, n=232; Round 5, n=236; Round 6, n=208; Round 7, n=220^m Indicates a WHO prequalified productⁿ ARKRAY Healthcare Pvt. Ltd. was formerly Span Diagnostics Ltd..^g For combination tests, pan or Pv line, only, positive indicates a false positive non-*P. falciparum* infection (Round 1, n=158; Round 2, n=200; Round 3, n=198; Round 4, n=196; Round 5, n=200; Round 6, n=200; Round 7, n=200)^h Pf line positive indicates a false positive *P. falciparum* infection (Round 1, n=40; Round 2, n=80; Round 3, n=70; Round 4, n=68; Round 5, n=70; Round 6, n=70; Round 7, n=70)ⁱ Round 1, n=168; Round 2, n=200; Round 3, n=232; Round 4, n=236; Round 5, n=236; Round 6, n=208; Round 7, n=220^j Product resubmission, results from most recent Round of testing replace previous results. Refer to Table S1.^k PDS presented in the table is based on a positive Pf test line (either HRP2 or Pf-pLDH). The results in brackets are the PDS based alone on HRP2 and Pf-pLDH test lines, respectively.^l Round 1, n=954; Round 2, n=1240; Round 3, n=1204; Round 4, n=1192; Round 5, n=1214; Round 6, n=1210; Round 7, n=1210^m Indicates a WHO prequalified productⁿ ARKRAY Healthcare Pvt. Ltd. was formerly Span Diagnostics Ltd..

Performance measure

Panel detection score for Pf and Pv 200/µl samples

False-positive rates against clean-negatives

Invalid rate

Recommended WHO procurement criteria

≥ 75%

< 10%

< 5% of tests conducted

Table S3: Malaria RDT rounds 4–7 heat stability results on a cultured *P. falciparum* sample at low (200) and high (2000) parasite density (parasites/μl). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Positive test results for <i>P. falciparum</i> (Pf line)				Positive test results for <i>P. falciparum</i> (Pf line)				Positive test results for <i>P. falciparum</i> (Pan line)				Round
			200 parasites/μl		45°C		2000 parasites/μl		45°C		200 parasites/μl		45°C		
			Baseline	35°C	45°C	Percentage of tests positive	Baseline	35°C	45°C	Percentage of tests positive	Baseline	35°C	45°C	Percentage of tests positive	
			Percentage of tests positive			Lots 1 and 2 combined	Percentage of tests positive			Lots 1 and 2 combined	Percentage of tests positive			Lots 1 and 2 combined	
			Lots 1 and 2 combined				Lots 1 and 2 combined				Lots 1 and 2 combined				
Pf only tests															
ABON™ Malaria Pf. Rapid Test Device (Whole Blood)	IMA-402	ABON Biopharm (Hangzhou) Co. Ltd	150	150	170	100.0	100.0	100.0	100.0	NA	NA	NA	NA	4	
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA1017	Adv Chemical Private Limited	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test ^a	ITP11002-TC25	InTec Products, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
Advantage Pf. Malaria Card	IR016025	J. Mitra & Co. Pvt. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	5	
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
BIONOTE MALARIA P.f. Ag Rapid Test Kit	RG19-11	Bionote, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
BioTracer™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
CareStart™ Malaria HRP2 (Pf)	RMOM(U)-XXX7X	Access Bio, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	5	
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
CareStart™ Malaria Pf (HRP2)pLDH) Ag RDT	RMPM(U)-XXX7X	Access Bio, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
CareStart™ Malaria Pf (HRP2)pLDH) Ag Combo 3-Line ^b	RMSM-05071	Access Bio, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
CareUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
DIAQUICK Malaria Pf. Cassette	W06200	DIALAB	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
Edx™ Malaria Pf Rapid Malaria antigen detection test	RK MAL 008	Adv Chemical Private Limited	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
First Response® Malaria Ag P. falciparum (HRP2) Card Test	I13FRC25	Premier Medical Corporation Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	5	
First Response® Malaria Ag P. falciparum (HRP2) Card Test	PI13FRC	Premier Medical Corporation Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
FirstSign™ Malaria Pf	2100CB-25	Unimed International Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	4	
Humasis Malaria Pf Antigen Test	ANMPF-7025	Humasis Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
ICT MALARIA P.F. CASSETTE TEST ^a	MI01	ICT INTERNATIONAL	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
IMMUNOQUICK® MALARIA falciparum	0502_K25	Biosynex	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	5	
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
KHB® Malaria Ag P.f Rapid Test	KH-R-06-20	Shanghai Kehua Bio-engineering Co. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	5	
Malaria Antigen Test-Pf	MAG01040	Oscar Medicare Pvt. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
Malaria Pf Rapid Test	GCWAL(pj)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
Maleriscan® Malaria Pf Antigen Test	MAT-PF-50	Bhat Bio-Tech India (Pte.) Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	4	
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
One Step Malaria HRP2 (Pf) Test ^a	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
One Step Malaria P.F Test (Cassette)	522352	Blue Cross Bio-Medical (Beijing) Co. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	4	
OneStepTest for Malaria PfHRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
OnSite Malaria Pf Ag Rapid Test	R0114C	CTK Biotech, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
PALUTOP + pf®	5531	ALLDIAG SA	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
Paracheck® Pf-Rapid Test for P.falciparum Malaria Device (Ver.3)	3020300025	Orchid Biomedical Systems	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	4	
Paracheck® Pf-Rapid Test for Pfalciparum Malaria Dipstick (Ver.3)	3020400025	Orchid Biomedical Systems	100.0	96.7	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	4	
Parahit® Ver 1.0 - Dipstick ^a	55IC103-50	ARKRAY Healthcare Pvt Ltd c	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
Parahit® f Ver 1.0 - Device ^a	55IC104-50	ARKRAY Healthcare Pvt Ltd c	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
Rapid 1-2-3® Hema® Cassette Malaria Pf	MAL-PF-CAS/25 (100)	Hema Diagnostic Systems	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
RapiGEN BIO-CREDIT Malaria Ag Pf (HRPII)	C10RHA25	RapiGEN Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
RightSign® Malaria P.F. Rapid Test Cassette (Whole Blood)	IMPF-C51	Hangzhou Biotech Biotech Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
SD BIOLINE Malaria Ag P.f. (HRP2)pLDH) ^b	05FK90	Standard Diagnostics Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	6	
SD BIOLINE Malaria Ag P.f. (HRP2)pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	7	
SD BIOLINE Malaria Ag Pf	05FK50	Standard Diagnostics, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	5	
Trusty™ Malaria Antigen P.f. test	A03-01-322	Artron Laboratories Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	4	

Table S3 (continued)

Product	Product code	Manufacturer	Positive test results for <i>P. falciparum</i> (Pf line)			Positive test results for <i>P. falciparum</i> (Pf line)			Positive test results for <i>P. falciparum</i> (Pan line)			Round
			200 parasites/µl			200 parasites/µl			200 parasites/µl			
			Baseline	35°C	45°C	Baseline	35°C	45°C	Baseline	35°C	45°C	
			Percentage of tests positive			Percentage of tests positive			Percentage of tests positive			
			Lots 1 and 2 combined			Lots 1 and 2 combined			Lots 1 and 2 combined			
Pf and Pan												
ABON™ Plus Malaria Pf/Pan Rapid Test Device (Whole Blood)	IMA-T402	ABON Biopharm (Hangzhou) Co. Ltd	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	0.0	4
ACCUCARE ONE STEP MALARIA Pf/Pan Antigen Test	MAGC 25	LAB-CARE Diagnostics (India) PVT. LTD.	83.3	73.3	10.0	100.0	100.0	100.0	3.3	10.0	0.0	5
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Adv Chemical Private Limited	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	100.0	7
Advanced Quality™ Rapid Malaria Test (Pf/Pan)	ITP11005	Inftec Products, Inc.	86.7	96.7	100.0	100.0	100.0	100.0	0.0	0.0	70.0	5
Advantage Mal Card	IR221025	J. Mitra & Co. Pvt. Ltd.	0.0	0.0	0.0	100.0	100.0	100.0	0.0	0.0	100.0	5
Advantage Malaria Pan + Pf Card	IR231025	J. Mitra & Co. Pvt. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	80.0	93.3	26.7	5
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60AL-40	Alere Medical Private Limited	100.0	100.0	100.0	100.0	100.0	100.0	46.7	70.0	33.3	7
AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	16.7	7
Asan Easy Test® Malaria Pf/Pan Ag ^a	AM4650-K	ASAN Pharmaceutical Co., Ltd	100.0	100.0	100.0	100.0	100.0	100.0	76.7	50.0	10.0	7
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	50.0	90.0	100.0	7
ATOMORAPID™ MALARIA (PF/PAN)	MMAL01	Atomo Diagnostics PTY Limited	100.0	100.0	100.0	100.0	100.0	100.0	0.0	16.7	0.0	6
AZOG Malaria pf (HRP II)/pf (LDH) / (PAN-LDH) Antigen Detection Device ^b	MFV-124F	AZOG, INC.	96.7	96.7	100.0	100.0	100.0	100.0	3.3	0.0	0.0	4
BIOCREDIT Malaria Ag Pf/Pan (HRP II/pLDH) ^a	C32RHA25	Rapigen Inc.	100.0	100.0	100.0	100.0	100.0	100.0	80.0	26.7	6.7	7
BIONOTE MALARIA Pf&E Pan Ag Rapid Test Kit ^a	RG19-08	Bionote, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	100.0	6
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	100.0	7
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	100.0	7
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT ^a	RMLM-05071	Access Bio, Inc.	100.0	96.7	93.3	100.0	100.0	100.0	0.0	6.7	0.0	7
CareStart™ Malaria Pf/PAN (HRP2/pLDH) Ag COMBO RDT	RMRM(U)-XXX7X	Access Bio, Inc.	100.0	100.0	96.7	100.0	100.0	100.0	93.3	86.7	53.3	5
CareStart™ Malaria Screen RDT ^a	RMAM-05071	Access Bio, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	7
Core Malaria Pan Pf	MAL-190024	Core Diagnostics Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	26.7	80.0	83.3	4
DIAQUICK Malaria Pf/Pan Cassette	Z11200CE	DIALAB GmbH	100.0	100.0	96.7	100.0	100.0	100.0	0.0	0.0	100.0	5
Edx™ Malaria Pan/Pf Rapid test detection Kit	RK MAL 001	Adv Chemical Private Limited	100.0	100.0	100.0	100.0	100.0	100.0	3.3	23.3	10.0	6
First Response® Malaria Ag, pLDH/HRP2 Combo Card Test	I16FRC	Premier Medical Corporation Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	10.0	0.0	5
First Response® Malaria Ag, pLDH/HRP2 Combo Card Test	P16FRC	Premier Medical Corporation Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	96.7	100.0	70.0	6
FirstSign™ ParaView (Pan+Pf)	2101CB-25	Unimed International Inc.	96.7	100.0	100.0	100.0	100.0	100.0	0.0	0.0	13.3	4
GenBody™ Malaria Pf/Pan Ag	MALAG100	GenBody Inc.	100.0	100.0	93.3	100.0	100.0	100.0	0.0	0.0	50.0	5
Genedia® Malaria Pf/Pan Ag Rapid Test	20-0146-01	Green Cross Medical Science Corp. (Korea)	100.0	100.0	43.3	100.0	100.0	100.0	3.3	0.0	13.3	5
Humasis Malaria Pf/Pan Antigen Test	AMAL-7025	Humasis, Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	100.0	5
Humasis Malaria Pf/Pan Antigen Test	ANMAL-7025	Humasis, Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	100.0	6
ICT MALARIA DUAL TEST ^a	MLO3	ICT INTERNATIONAL	100.0	100.0	100.0	100.0	100.0	100.0	3.3	3.3	13.3	7
Is It... Malaria Pf/PAN	MPPFAN050	Medsourse Ozone Biomedicals Pvt. Ltd.	100.0	93.3	100.0	100.0	100.0	100.0	93.3	93.3	93.3	7
Is It... Malaria Pf/Pv Device	AL030	Medsourse Ozone Biomedicals	100.0	100.0	96.7	100.0	100.0	100.0	93.1	96.6	36.7	6
Malaria pf (HRP II)/PAN (pLDH) Antigen Detection Test Device	1-13-101-1	United Biotech, Inc.	100.0	96.7	96.7	100.0	100.0	100.0	16.6	0.0	0.0	4
Malaria pf (pLDH) / PAN-pLDH Test Device	MFV-124	AZOG, Inc.	46.7	56.7	66.7	100.0	100.0	100.0	13.3	93.3	100.0	5
Malaria Pf/Pan Antigen (MAL Pf/Pan) Test Kit	A03-18-322	Artron Laboratories Inc.	10.0	6.7	0.0	100.0	100.0	100.0	10.0	3.3	0.0	5
Malaria Pf/PAN	GM004	Artron Laboratories Inc.	56.7	23.3	26.7	100.0	100.0	100.0	0.0	0.0	60.0	4
Malaria Pf/Pan One Step Rapid Test	RT 20222	Genomix Molecular Diagnostics Pvt.Ltd.	100.0	100.0	96.7	100.0	100.0	100.0	0.0	0.0	100.0	5
MeDiPro Malaria Ag HRP2/pLDH Combo	IR-0051K	Zhejiang Orient Gene Biotech Co., Ltd.	100.0	96.7	96.7	100.0	100.0	100.0	0.0	0.0	0.0	4
Meriscreen Malaria Pf/Pan Ag	MHLRPD-01	Formosa Biomedical Technology Corp.	100.0	100.0	100.0	100.0	100.0	100.0	46.7	56.7	0.0	6
NanoSign Malaria pf/pan Ag 3.0	RMAP10	Meril Diagnostics Private Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	100.0	4
NG-Test MALARIA Pf/Pan (pLDH)	NG-MAL-WP23-001	SARL NG Biotech, Z A	100.0	100.0	100.0	100.0	100.0	100.0	0.0	6.7	0.0	5

(continued)

Table S3: Malaria RDT rounds 4–7 heat stability results on a cultured *P. falciparum* sample at low (200) and high (2000) parasite density (parasites/ μ L). Positivity rate at baseline (room temperature) and after 60 days' incubation at 35°C and 45°C (continued)

Product	Product code	Manufacturer	Positive test results for <i>P. falciparum</i> (Pf line)			Positive test results for <i>P. falciparum</i> (Pf line)			Positive test results for <i>P. falciparum</i> (Pan line)			Round		
			200 parasites/μl			2000 parasites/μl			2000 parasites/μl					
			Baseline	35°C	45°C	Baseline	35°C	45°C	Baseline	35°C	45°C			
			Percentage of tests positive			Percentage of tests positive			Percentage of tests positive					
			Lots 1 and 2 combined			Lots 1 and 2 combined			Lots 1 and 2 combined					
Pf and Pv/PvOm	NG-Test MALARIA Pf/Pan (pLDH)	NG Biotech	100.0	100.0	100.0	100.0	100.0	100.0	53.3	86.7	66.7	100.0	100.0	7
	One Step Malaria Pf/Pan Whole Blood Test	Guangzhou Wondfo Biotech Co., Ltd.	100.0	100.0	96.7	100.0	100.0	100.0	0.0	0.0	0.0	90.0	100.0	70.0
	On-Site Malaria Pf/Pan Ag Rapid Test	CTK Biotech, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	6.7	0.0	100.0	100.0	100.0
	ParaHiT – Total Ver. 1.0 (Device)	Span Diagnostics Ltd. ^d	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	0.0	100.0	100.0	100.0
	ParaHiT – Total Ver. 1.0 (Dipstick)	Span Diagnostics Ltd. ^d	100.0	93.3	46.7	100.0	100.0	60.0	50.0	0.0	0.0	100.0	90.0	0.0
	Parascreen® – Rapid test for Malaria Pan/Pf	Zephyr Biomedicals	100.0	100.0	100.0	100.0	100.0	100.0	100.0	90.0	93.3	100.0	100.0	100.0
	QuickProfile™ Malaria Pf/Pan Test	Lumiquick Diagnostics, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	100.0	96.7	100.0	100.0	100.0	100.0
	Rapid 1–2–3 HEMA® CASSETTE MALARIA Pf/PAN	Hema Diagnostic Systems	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	33.3	100.0	100.0	100.0
	RightSign™ Malaria Pf/Pan Rapid Test Cassette	Hangzhou Biotech Co. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	20.0	100.0	100.0	60.0	100.0
	SD BIOLINE Malaria Ag Pf/Pan	Standard Diagnostics Inc.	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	0.0	100.0	100.0	100.0
	Vikia® Malaria Ag Pf/Pan	IMACCESS S.A.S	100.0	96.7	96.7	100.0	100.0	100.0	0.0	0.0	0.0	60.0	60.0	0.0
	ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test ^a	Intec Products, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	RapiGEN Inc.	93.3	86.7	58.6	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Biosynex® Malaria Pf/Pv	Biosynex	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	BioTracer™ Malaria Pf/Pv Rapid Card	Bio Focus Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	Access Bio Ethiopia	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT ^a	Access Bio, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	CareUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	WELLS BIO, INC	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Coretests® One Step Malaria Pf/Pv Ag Test Device	Core Technology Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	ExDx™ Malaria Pf/PF Rapid Malaria antigen detection test	Advy Chemical Private Limited	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	FalciVax™ – Rapid Test for Malaria Pf/PF	Zephyr Biomedicals	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	First Response® Malaria Ag Pf/Pv Card Test	Premier Medical Corporation Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	HiSens Malaria Ag Pf/Pv Combo Card	HBI Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	HiSens Malaria Ag Pf/VOM Combo Card	HBI Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Humasis Malaria Pf/Pv Antigen Test	Humasis, Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Humasis Malaria Pf/Pv Antigen Test	Humasis, Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	KHB® Malaria Ag Pf/Pv Rapid Test	Shanghai Kehua Bio-engineering Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device	United Biotech, Inc.	100.0	100.0	100.0	90.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Malaria Pf (HRP II) / PV (pLDH) Antigen Detection Test Device	Genomix Molecular Diagnostics Pvt. Ltd.	83.3	90.0	83.3	100.0	90.0	70.0	NA	NA	NA	NA	NA	NA
	Malaria Pf/Pv	Genomix Molecular Diagnostics Pvt.Ltd.	40.0	33.3	40.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Malaria Pf/Pv Rapid Test	Zhejiang Orient Gene Biotech Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Malaria Pf/PF (pLDH/HRP2) Antigen Test	Nantong Egens Biotechnology Co., Ltd.	100.0	100.0	96.6	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	Malariscan® Malaria Pf/PAN (Pv, Pm, Poi) 3 Line Antigen Test	Bhat Bio-Tech India (P) Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	One Step Malaria HRP2/pLDH (Pf/Pv) Test ^a	Guangzhou Wondfo Biotech Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	One Step Malaria Pf/Pv Test (Cassette)	Blue Cross Bio-Medical (Beijing) Co., Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	Meril Diagnostics Pvt. Ltd.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	On-Site Malaria Pf/Pv Ag Rapid Test	CTK Biotech, Inc.	100.0	100.0	90.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	ParaHiT®V Rapid test for P. falciparum and P.vivax Malaria - Device	Span Diagnostics Ltd. ^d	100.0	96.7	96.7	100.0	100.0	90.0	NA	NA	NA	NA	NA	NA
	QuickProfile™ Malaria Pf/Pv Antigen Test ^a	Lumiquick Diagnostics Inc.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	RAPID 1-2-3® HEMA CASSETTE MALARIA Pf/Pv TEST	Hema Diagnostic Systems, LLC	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	RapiGEN BIOCREDIT Malaria Ag Pf/Pv (HRP II/pLDH)	RapiGEN Inc.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA
	SD Bioline Malaria Ag Pf/Pv	Standard Diagnostics, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	NA	NA	NA

Table S3 (continued)

Product	Product code	Manufacturer	Positive test results for <i>P. falciparum</i> (Pf line)			Positive test results for <i>P. falciparum</i> (Pf line)			Positive test results for <i>P. falciparum</i> (Pan line)			Round
			200 parasites/µl		Percentage of tests positive	2000 parasites/µl		Percentage of tests positive	2000 parasites/µl		Percentage of tests positive	
			Baseline	35°C		Baseline	35°C		Baseline	35°C		
			Lots 1 and 2 combined			Lots 1 and 2 combined			Lots 1 and 2 combined			
Rapid Test Kit for Malaria Ag Pf/Pv – Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	7
Trusty™ Malaria Antigen P.f. (p.v. test	A03-12-322	Artron Laboratories Inc.	100.0	100.0	36.7	100.0	100.0	100.0	NA	NA	NA	4
Pf, Pf and Pv												
SD Bioline Malaria Ag P.f(Pf/Pv) ^b	05FK120	Standard Diagnostics, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	6
Pf, Pv and Pan												
PALUTOP +4 optima®	5499	ALLDIAG SA	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	7
Pan Only												
Advantage Pan Malaria Card	IR013025	J. Mitra & Co. Pvt. Ltd.	NA	NA	NA	NA	NA	NA	36.7	66.7	100.0	5
AZOG HCG Malaria Detection Test Device	MPT-124	AZOG, INC.	NA	NA	NA	NA	NA	NA	100.0	100.0	100.0	4
CareStart™ Malaria PAN (pLDH) Ag RDT	RMNM(U)-XXX7X	Access Bio, Inc.	NA	NA	NA	NA	NA	NA	100.0	100.0	100.0	5
NA, not applicable												
Pf, <i>Plasmodium falciparum</i>	Pv, <i>Plasmodium vivax</i>	pan, <i>Plasmodium vivax</i> , <i>ovale</i> and <i>malariae</i>										
Indicates results for those products that meet all WHO recommended procurement criteria												
^a Product resubmission, results from most recent round of testing replace previous results. Refer to Table S1.												
^b Results presented in the table are based on stability of a Pf test line (either HRP2 or Pf-pLDH). Results based on stability of individual test lines is presented in the following table:												
^c Arkay Healthcare Pvt. Ltd. was formerly Span Diagnostics Ltd.												
^d Span Diagnostics Ltd. is now Arkay Healthcare Pvt. Ltd.												
Product	Product code	Manufacturer	Positive test results for <i>P. falciparum</i> (Pf line)			Positive test results for <i>P. falciparum</i> (Pf line)			Positive test results for <i>P. falciparum</i> (pan line)			Round
			200 parasites/µl		Percentage of tests positive	2000 parasites/µl		Percentage of tests positive	200 parasites/µl		Percentage of tests positive	
			Baseline	35°C		Baseline	35°C		Baseline	35°C		
			Lots 1 and 2 combined			Lots 1 and 2 combined			Lots 1 and 2 combined			
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line – (Pf(HRP2) line)	RMSM-05071	Access Bio, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	7
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line – (Pf(pLDH) line)			100.0	50.0	50.0	100.0	50.0	50.0	NA	NA	NA	7
SD Bioline Malaria Ag P.f(Pf/Pv) – (Pf(HRP2) line)	05FK120	Standard Diagnostics, Inc.	100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	6
SD Bioline Malaria Ag P.f(Pf/Pv) – (Pf(pLDH) line)			30.0	30.0	30.0	100.0	100.0	100.0	NA	NA	NA	6
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) – (Pf(HRP2) line)			100.0	100.0	100.0	100.0	100.0	100.0	NA	NA	NA	6
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) – (Pf(pLDH) line)	05FK90	Standard Diagnostics Inc.	93.3	90.0	66.7	100.0	100.0	100.0	NA	NA	NA	6
AZOG Malaria pf (HRPII)/pf (LDH)/ (PAN-LDH) Antigen Detection Device – (Pf(HRP2) line)			96.7	96.7	100.0	100.0	100.0	100.0	3.3	0.0	0.0	4
AZOG Malaria pf (HRPII)/pf (LDH)/ (PAN-LDH) Antigen Detection Device – (Pf(pLDH) line)	MFV-124F	AZOG, INC.	13.3	3.3	6.7	50.0	10.0	50.0	3.3	0.0	0.0	4

Table S4: Products evaluated during rounds 1–7 that have been removed from summary results listings

Manufacturer	Product name	Product code
Amgenix International, Inc.	OnSight™ - Malaria Pf Test	511-25-DB
	OnSight™ - ParaQuick-2 (Pv,Pf) Malaria Test	537-25-DB
	OnSight™ - PanScreen (Pan) Malaria Test	539-25-DB
	OnSight™ - ParaQuick (Pan, Pf) Test	536-25DB
Abon Biopharm (Hangzhou) Co. Ltd. (Iverness Medical)	ABON Malaria Pan/P.f.Rapid Test Device (whole blood)	IMA-B402
Access Bio, Inc.	CareStart™ Malaria/Pregnancy (HRP2/pLDH/ HCG)	RRHM(U)-XXX7X ^a
Access Bio Ethiopia	ParaCare Malaria HRP2/pLDH (Pf/Pv) COMBO	G0161
	ParaCare Malaria HRP2/pLDH (Pf/VOM) COMBO	G0171
ACON Biotech (Hangzhou) Co. Ltd	Surestep™ Malaria Pf/Pan Rapid Test Device (Whole Blood)	IMA-T402
Acon Laboratories, Inc	Malaria Plasmodium falciparum Rapid Test Device (Whole Blood)	IMA-402
AZOG, Inc	Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device	MFV-124V
	Malaria pf (HRP II) / (PAN-LDH) Antigen Detection Test Device	MFV-124R
Bhat Bio-Tech India (P) Ltd	Maleriscan® Malaria Pf/Pv	MAT-50
Bioland, Ltd	Nano Sign Malaria Pf Ag	RMAF10
	NanoSign Malaria Pf/Pv Ag	RMAD10
BioNote, Inc.	BIONOTE MALARIA P.f&P.v Ag Rapid Test Kit	RG19-12
Biosynex	IMMUNOQUICK CONTACT falciparum	0519K25
	Immunoquick Malaria +4	0506_K25
	IMMUNOQUICK CONTACT Malaria +4	0525K25
Core Diagnostics	Core™ Malaria Pf	MAL-190020
	Core™ Malaria Pv/Pf	Mal-190022
	Core™ Malaria Pan/Pv/Pf	Mal-190026
CTK Biotech, Inc.	OnSite Pf Ag Rapid Test	R0114C
DiaMed - A Division of Bio-Rad	OptiMAL-IT	710024
Dima • Gesellschaft für Diagnostika mbH	Malaria Pan test	MAL-W23N-001
Diagnostics Automation/Cortez Diagnostics Inc.	Malaria P.F/Vivax	172110P-25
Guangzhou Wondfo Biotech Co. Ltd.	One Step Malaria P.f./Pan Whole Blood Test	W56-C
HBI Co., Ltd.	HiSens Malaria Ag P.f/P.v Card	HR2823
	HiSens Malaria Ag Pf/Pv (HRP2/pLDH) Card	HR2923
	HiSens Malaria Ag Pf HRP2 Card	HR3023
Human GmbH	Hexagon Malaria	58051
	Hexagon Malaria Combi	58024
ICT INTERNATIONAL	ICT Malaria Combo	ML02
	ICT MALARIA P.F.	ML04
IND Diagnostic Inc.	One Step Malaria Antigen Strip	820-1
	IND ONE STEP MALARIA ANTIGEN P.f/Pan TEST	535-10
	IND ONE STEP MALARIA ANTIGEN P.f	535-11
Innovatek Medical Inc.	Quickstick Malaria Antigen Test	
Inverness Medical Innovations, Inc.	Binax Now Malaria	IN660050
J. Mitra & Co. Pvt. Ltd.	Advantage Malaria Card	IR211025
Medical Diagnostech (Pty) Ltd	MD Malaria Pf/Pan(pLDH) test	MDMALLDH001
Medisensor, Inc.	Medisensor Malaria HRP2/pLDH (Pf/Pv) COMBO	M161
	Medisensor Malaria HRP2/pLDH (Pf/VOM) COMBO	M171
Orgenics Ltd. (Inverness Innovations)	Clearview® Malaria pLDH	70884025
Orgenics Ltd.(IS)	Clearview® Malaria Dual	VB20
Premier Medical Corporation Ltd.	First Response® Malaria Ag pLDH	I12FRC30
RapiGen inc.	BIOCREDIT Malaria pf(HRP II)	HR0100
Real World Diagnostics	Malaria Pf/PAN Test ^x	PROMALPFV001
	ParaHIT®-f Dipstick	551C010-50/25977
	ParaHIT®- f Device	551C102-50/25975
	ParaHIT - Total (Device)	551C202-10/25989
	ParaHIT Pan M (dipstick)	551C301-10
Span Diagnostics	ParaHIT total (dipstick)	551C201-10/25988
	diagnostics- Malaria (Pf) Cassette	KMFC6001
	diagnostics- Malaria (Pf) Dipstick	KMFD6007
	diagnostics- Malaria (Pv/Pf) Cassette	KMVFC6002
	diagnostics MALARIA (Pan) Cassette	MPNWBC1007.3
SSA Diagnostics & Biotech Systems	diagnostics MALARIA (Pan/Pf) Cassette	MPNFWBC1007.4
	diagnostics MALARIA (Pan/Pv/Pf) Cassette	MPNVFC1007.5
	SD BIOLINE Malaria Ag	05FK40
	SD BIOLINE Malaria Ag Pf/ Pf/ Pv	05FK100
	SD BIOLINE Malaria Ag Pf/ Pan	05FK66
Standard Diagnostics Inc.	SD BIOLINE Malaria Ag Pv	05FK70
	SD BIOLINE Malaria Ag P.f/Pan	05FK63 ^b
	SD BIOLINE Malaria Ag P.f/P.v	05FK83 ^c
	SD BIOLINE Malaria Ag Pf	05FK53 ^d
	FirstSign - Malaria Pf Card Test	-
Unimed International	FirstSign - ParaView-2 (Pv + Pf) Card Test	2102CB-25
	FirstSign™ - PanCheck (Pan) Malaria Test	2104 CB-25
	FirstSign™ - ParaView-3 (Pan+Pv+Pf) Malaria Test	2103 CB-25
	Vision Malaria Pf	VB01
Vision Biotech (Pty) Ltd	Clearview® Malaria Combo	VB11
Zephyr Biomedicals	Paramax-3 Rapid Test for Malaria Pan/Pv/Pf (device)	50320025

Pf, *P. falciparum* Pv, *P. vivax* Pvom, *P. vivax, ovale, malariae* HRP2, histidine-rich protein 2 pLDH, *Plasmodium* lactate dehydrogenase

^a Previously listed with product code G0221

^b Previously co-listed with 05FK60 (multi-use pack), but removed because single pack format (05FK63) not evaluated at CDC

^c Previously co-listed with 05FK80 (multi-use pack), but removed because single pack format (05FK83) not evaluated at CDC

^d Previously co-listed with 05FK50 (multi-use pack), but removed because single pack format (05FK53) not evaluated at CDC

2. EXECUTIVE SUMMARY

2.1. Introduction

WHO estimates that 3.2 billion people are at risk for malaria. In 2015, there were an estimated 212 million cases (with an uncertainty range of 148 million to 304 million) and an estimated 429 000 deaths (with an uncertainty range of 235 000 to 639 000). Approximately 90% of these deaths occurred in sub-Saharan Africa, and just over 70% were of children under 5 years. Malaria remains endemic in 91 countries and territories, and, while parasite-based diagnosis is increasing, national surveys between 2013 and 2015 suggest approximately 31% of suspected malaria cases in sub-Saharan Africa were not confirmed with a diagnostic test, resulting in over-use of antimalarial drugs and poor disease monitoring (1).

WHO recommends that malaria case management be based on parasite diagnosis in all cases (2). The use of antigen-detecting RDTs is a vital part of this strategy, forming the basis for extending access to malaria diagnosis by providing parasite-based diagnosis in areas where good-quality microscopy cannot be maintained. The data generated by the WHO and FIND programme to evaluate and compare the performance of commercially available malaria RDTs are guiding procurement decisions, which, in turn, have shifted markets towards better-performing tests and helped to improve the quality of manufacture. Since 2009, these data have guided procurement decisions by WHO, other United Nations agencies and national governments and have formed the laboratory evaluation component of the WHO prequalification process for malaria RDTs. Meeting WHO prequalification criteria has not previously been a requirement for WHO procurement; however, as of 1 January 2018, only those products that meet WHO prequalification requirements will be eligible for WHO procurement.¹ This report provides the results of round 7 of product testing, performed at the CDC during 2015–2016, with data on the performance of 46 products. This round adds to the evaluations of rounds 1–6 (3–8), which should be considered as a single evaluation, except that the results for products tested in previous rounds that were resubmitted for testing replace those reported previously. From round to round, the evaluation panels are essentially the same (Annex S1), and the same or slightly modified testing protocols are followed. This report extends the data from previous rounds and therefore increases the number of RDTs available for procurement for which detailed, comparative data are available on aspects of performance relevant to field use. The report provides updated data on the performance of products at least every 5 years, as a result of implementation of the compulsory resubmission policy.

2.2. The WHO product testing programme

Product testing is part of the WHO–FIND malaria RDT evaluation programme, which develops methods for evaluation and provides data on antigen-detecting malaria RDTs. The programme is a collaboration among many institutions in malaria-endemic and non-endemic countries, with a global specimen bank and testing performed at the CDC (Fig. 2).

All companies that manufacture according to ISO 13485:2003 quality system standards were invited to submit tests for evaluation in the programme. The 46 products from 26 manufacturers were evaluated with prepared blood panels of cultured *P. falciparum* parasites, patient-derived wild-type *P. falciparum* and *P. vivax* parasites and a parasite-negative panel. Observed anomalies were recorded. Thermal stability was assessed after 2 months of storage at elevated temperature and humidity, and a rudimentary assessment of ease of use was recorded. In round 7 a new assessment of compliance with good practices for product labelling and instructions for use was included. As in previous rounds, RDTs are grouped in the tables and figures into those designed to detect *P. falciparum* only, various combination tests and those that have a line only for pan-specific (or *P. vivax*-specific) malaria. Manufacturers submitted two lots of each product for evaluation. The 15 products that had been tested in previous rounds comprised five compulsory resubmissions and 10 voluntary resubmissions (Tables 1a,b).

The aim of the evaluation is to provide comparative data on the performance of the submitted production lots of each product against samples containing low (200 parasites/μL) and high densities (2000 parasites/μL) of *P. falciparum* or *P. vivax*. Because the concentration of target antigens in samples with the same parasite density is variable, the process for selecting the panel is adjusted to ensure that there is no statistically significant difference in mean or median concentrations of HRP2, aldolase and pLDH antigens between panels used in different rounds of testing (Annex S1, Table 3).

WHO product testing constitutes the laboratory evaluation component of the WHO prequalification process for malaria RDTs (10), which also includes a standardized dossier review and a manufacturing site inspection to ensure safety, quality and performance comprehensively. WHO prequalification of in vitro diagnostics, established in 2008, is used by all United Nations agencies to determine the eligibility of tests for HIV, hepatitis B and C and syphilis for procurement and by national authorities as a complement to their regulatory approvals. WHO prequalification will determine the eligibility of malaria RDTs for procurement as of 1 January 2018. The results of WHO product testing will continue to be used as the independent laboratory evaluation component of the prequalification process.

¹ <http://www.who.int/malaria/news/2016/rdt-procurement-criteria/en/> (accessed 8 March 2017)

Compulsory resubmission was introduced in round 5. Products that are due for resubmission (every 5 years) that are not submitted are removed from the summary results (Tables S2 and S3) and the online interactive database and appear only in the full round-specific product testing report. These products will not be eligible for WHO procurement. A product is also de-listed if WHO is notified by the manufacturer that its production has been discontinued.

2.3. Results of the evaluation

The results (summarized in Tables 4 and 5 and Figs 9, 10, 11, 14 and 15) provide a comparison of two lots of products against a panel of parasite samples diluted to a low parasite density (200 parasites/μL), considered to be close to the threshold that tests must detect in order to identify clinical malaria reliably in many settings (11), and a higher parasite density (2000 parasites/μL).

For the purposes of this report, the main measure of performance is the panel detection score (PDS), the percentage of malaria samples in a panel that give a positive result in two RDTs per lot at the lower parasite density and a single RDT per lot at the higher parasite density. Thus, it is not a measure of clinical sensitivity or of the positivity rate against the panel but rather a combined measure of positivity rate and inter-test and inter-lot consistency.

As for products evaluated in previous rounds of product testing, the PDS varied, although much less variation was seen for *P. falciparum*-only detecting RDTs in round 7. Generally, products with high performance in detecting parasites have low false-positive rates, good thermal stability and low rates of anomalies. Overall, there is no obvious trade-off between the PDS (or positivity rate) and the false-positive rate, which are surrogates for sensitivity and specificity in the field, respectively.

The basis for *P. falciparum* detection by combination RDTs, particularly in samples with low parasite density, is predominantly detection of HRP2 and not pLDH. In other words, it is mainly the HRP2 test band that reacts with *P. falciparum*-containing samples, probably reflecting poorer affinity of the monoclonal pLDH antibodies on the pLDH test band and not HRP2-persistent antigenaemia, as all samples are known to contain *P. falciparum* (and pLDH). Therefore, when using HRP2 and pan-pLDH (or Pf-pLDH) combination products in the field, it is important to remember that the presence of an HRP2 band combined with the absence of a pLDH band may reflect the lower sensitivity of the pLDH-detecting band in low-density samples and not persistent antigenaemia or successful treatment.

In round 7, the results for five products submitted for compulsory retesting showed an average PDS decrease of 3.5 percentage points as compared to the previous evaluation round, for detection of *P. falciparum* (range, -16 to +7; 2/5 had a better PDS). Only two of these tests also targeted *P. vivax* at 200 parasites/μL; the mean change in PDS was -42.9 percentage points (range, -91 to +5). The mean change in the false-positive rate of clean negatives

was -0.4 percentage points (range, -2.5 to +1.7%). Two of the five tests had improved false-positive rates (one showed no change, and two showed increases). Overall, most of the differences were decreases in PDS and improvements in false-positivity rates in comparison with previous testing. Among the voluntary resubmissions, 80% (8/10) and 75% (6/8) of products showed the same or better detection of *P. falciparum* and *P. vivax* at 200 parasites/μL, respectively. Specifically, in tests for *P. falciparum*, the mean change in PDS was +9.2 percentage points (range, -8 to +40; n = 10); 8/10 had improved PDS. For *P. vivax*, the mean change in PDS was +30.7 percentage points (range, -8.6 to +65.7; n = 8), and 6/8 had a better PDS. The mean change in the false-positive rate on clean negatives was 1.9 percentage points (range, -7.3 to +22.9%; n = 10), while 2/10 had a better false-positive rate.

In combination tests, no significant correlation was found between the changes in *P. falciparum* and *P. vivax* detection ($p = 0.7$), suggesting that the changes in the detection of the two parasite species were independent.

In round 7, none of the products had very high false-positive rates when tested against clean negatives, as in round 6. These are an improvement from the high rates observed in rounds 4 and 5. In contrast, more products reacted against blood samples containing specific immunological abnormalities (and against samples containing non-*Plasmodium* infectious agents), and these false-positive rates were higher than those seen in round 5 (Tables A4.6–A4.9). The number of samples evaluated was, however, small, and the clinical significance of these results is limited, although they may be important in certain populations with very low parasite prevalence.

There was no notable variation among lots in round 7 (Table A4.1); however, as previous rounds have shown variation in performance between the two lots evaluated, it is still recommended that products be lot-tested before field use.

The *P. falciparum* HRP2 test lines in the majority of products showed good heat (thermal) stability after 2 months' storage at 45°C and 75% humidity; however, Pf-pLDH test lines showed variable baseline performance and deterioration after incubation at 45°C. For many products, pan-pLDH performance at baseline and after heat stress for detection of the *P. falciparum* isolate was poor, and it was nearly universally poor against low-parasite-density samples, making it difficult to assess true stability. As in round 6, products were assessed for heat stability against a wild-type *P. vivax* sample. While most of the products performed well, with high positivity rates after 2 months' storage at 45°C and 75% humidity, others showed some drop in performance after storage, with little difference between pan-pLDH and *P. vivax* pLDH in test line stability.

The frequencies of anomalies that can interfere with test interpretation were recorded. In round 7, 33 of the 46 products had one to five different types of anomaly (Annex S2, Table 8, Fig. 30). Incomplete clearing and red background (not obscuring the test lines) were the most common anomalies, seen in 48% and 24% of products, respectively. Incomplete

migration, failed migration and a red background obscuring the test lines were the next most common anomalies, in 15%, 11% and 11% of products, respectively. Most of the products with anomalies (31/33) had anomalies in < 1% of the tests, while two products had anomalies in 1.4% of tests (Table 8). This rate is far lower than in round 6, in which all products had one to six anomalies, and approximately half had a frequency > 2%.

The clinical sensitivity of an RDT, i.e. the proportion of known cases of the disease with a positive test, is highly dependent on local conditions, including the parasite density in the target population; it therefore varies in populations with different levels of transmission. The comparative performance between RDTs shown in this report give an indication of which products are likely to be more sensitive in the field, particularly for populations with low-density infections. In general, as the malaria prevalence in countries falls and they even move towards malaria elimination, detection of low parasite densities will become increasingly important in case management. As the PDS at 2000 parasites/μL indicates, the sensitivity of many of these products will be similar in populations with higher parasite densities, although a subset of any population will include vulnerable individuals who may develop illness at low parasite densities (e.g. young children, pregnant women, people well protected by bed nets) and must always be taken into account when interpreting RDT results. For areas where significant non-expression of HRP2 is known, the results in this report for HRP2-detecting tests should not be considered to predict sensitivity in the field. Only tests targeting *P. falciparum* by detection of pLDH or aldolase should be considered.

Heat stability (summarized in Tables 6a and 6b) is vital to maintaining the sensitivity of a test in the field. For procurement, therefore, the stability results should be used to ensure that products to be used in areas with high temperatures during transport and storage have demonstrated good stability in the product testing programme. The requirements vary by country; for example, if tests are to be used in areas where the temperature rarely rises above 30°C, stability at high temperatures is less important.

The requirements for ease of use depend on the extent of training and the work environment of users. Particularly in primary health care settings, the simpler the test, the easier it should be to avoid errors in preparation and interpretation.

In round 7, for the first time, adherence to a list of recommendations on instructions for use and product labelling was assessed (Fig. 31–38). Products generally scored well in this assessment for labelling of the main device and labelling of the device packaging and of the primary product box, with some exceptions, especially in warnings and precautions. The scores for adherence to recommendations on labelling of buffer bottles and other accessories were lower. The instructions for use were highly variable, with some important omissions, particularly on laboratory safety, product performance and interpretation.

2.4. Use of the results

Box 3 lists WHO's current minimum criteria for selecting RDTs. With the upcoming transition to WHO prequalification as a requirement for malaria RDT procurement, the findings from dossiers and site inspections will also be considered; however, the performance requirements will remain the same. The results in Tables S2, S3 and 5 are colour-coded to reflect achievement of these requirements, as well as current WHO prequalification status (indicated in Table S2). A web-based tool maintained by FIND allows filtering of product testing results by various parameters to assist in selecting products with the performance characteristics most suitable for a country's health programme (15). This online database has been updated to allow filtering of results by RDT procedural characteristics, such as blood volume requirements, number of buffer drops and time to result. This grouping, also indicated in Annex 1, will allow use of the same or similar protocols to identify products, so that, when product replacement is required, another product with the same or similar protocol may be selected. Use of similar products may reduce the need for user retraining and also reduce user error.

The results of product testing are reported by product, with the product name and code. The same RDT may be sold in a variety of configurations, such as single or multi-kits, different numbers of tests per box, with or without certain accessories; and they are assigned a distinct product code on this basis. The reports give the precise name and product code provided by the manufacturer for testing. Procurers should contact the manufacturer for a list of product configurations prior to purchase.

Annex S3 outlines a step-by-step approach to selecting an RDT, taking into consideration local conditions of malaria transmission and illness (e.g. *Plasmodium* spp., target antigen, parasite density, climate) and other important considerations, such as ease of use in the field and lot testing. RDTs must not be procured without preparation for proper use, including supply chain management and training in test use and disposal and in patient management in response to results. Comprehensive guidance on several aspects of procurement can be found in *Recommended selection criteria for procurement of malaria rapid diagnostic tests* (16), published as a WHO information note in 2016,¹ and guidance on implementation in *Universal access to malaria diagnosis* (17).

¹ <http://www.who.int/malaria/publications/atoz/rdt-selection-criteria.pdf>

3. BACKGROUND

During the past decade, new opportunities for the control of malaria have emerged, including use of long-lasting insecticidal nets, indoor residual spraying of insecticides and artemisinin-based combination therapy. These have been shown to reduce the burden of malaria infection in countries where they are adequately implemented. Therefore, the proportion of febrile episodes attributable to malaria is likely to decrease substantially.

Despite WHO's recommendation for a parasitologically confirmed diagnosis of malaria infection before treatment in all cases (2), diagnoses are still often made on clinical grounds (11); however, in many endemic areas, malaria accounts for a minority of cases of "malaria-like" febrile illness. Microscopy has been the cornerstone of diagnosis and is recommended for malaria diagnosis when its quality can be maintained; however, the need for trained personnel and adequate reagents and equipment limits its availability and accessibility in malaria-endemic areas. Rapid, accurate, accessible diagnostic tools are increasingly required as programmes extend parasite-based diagnosis and the prevalence of malaria decreases. RDTs to detect *Plasmodium*-specific antigens (proteins) in whole blood of infected people are an attractive alternative to microscopy. The currently available RDTs come in various formats (dipstick, cassette or hybrids) and contain antibodies bound to specific antigens, such as HRP2 specific to *P. falciparum*, pan-specific and species-specific pLDH or aldolase specific to all the major *Plasmodium* species most relevant to human health (*P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale*) (Fig. 1).

To be widely useful, an RDT must be highly sensitive to ensure detection of all clinically significant malaria infections, highly specific to allow monitoring of low malaria prevalence and appropriate management of non-malarial fevers and highly stable to allow transport and storage in ambient conditions in malaria-endemic areas. Published field trials of RDTs show highly variable performance, probably due to poor manufacturing quality, incorrect storage and handling, poor preparation and interpretation, and sometimes poor study

methods, analysis and reporting (17–25). In general, diagnostic testing by microscopy or RDT to a level of 200 parasites/ μ L will reliably detect nearly all clinically relevant infections in malaria-endemic areas (11).


The number of RDTs available on the market grew rapidly after their introduction in the late 1990s; sales reported by 41 manufacturers showed a peak of 320 million tests sold in 2013. Since 2013, there has been a global decline, due to decreasing sales in Asia, although sales in Africa have risen every year since 2008 (1). Regulatory control of diagnostics is, however, often weak, and procurement agencies have had considerable difficulty in selecting appropriate RDTs and ensuring their quality. In view of the inconsistency in the results of field studies and the inherent difficulties in assessing large numbers of products in a standardized way in field trials, WHO and partners embarked on a programme in 2002 to evaluate RDTs for malaria, in order to ensure standardized assessment of performance and to guide procurement decisions and regulatory mechanisms. Between 2003 and mid-2012, the programme was managed by WHO and TDR in partnership with FIND. After TDR withdrew its involvement in 2012, the WHO Global Malaria Programme assumed a coordinating role. A steering committee oversees the development of and modifications to standard operating procedures (26, 27). A network of specimen collection sites has been established to provide specimens for a global bank at the CDC and to facilitate local quality control (Fig. 2).

The reports of the previous six rounds of product testing have been released annually since 2009 (3–8). This seventh report adds data on the performance of 29 new products and updated data on 17 resubmitted RDTs. Testing for round 7 was conducted against an evaluation panel with characteristics similar to those of previous panels in terms of overall antigen concentration, parasite origin and parasite-negative blood samples (Annex S1). Most panel samples were retained from previous rounds, with 19 of 100 *P. falciparum*, 5 of 35 *P. vivax* and 17 of 100 negative samples replaced (new) in round 7.

4. OBJECTIVE

The objective of the programme is to evaluate malaria RDTs for performance in order to guide procurement of RDTs for use in the field in malaria-endemic countries.

Figure 1: Mode of action of antigen-detecting malaria RDTs




Mode of action of common malaria RDT format:

(a) Dye-labelled antibody (Ab), specific for the target antigen, is present on the lower end of the nitrocellulose strip or in a well provided with the strip. Antibody, also specific for the target antigen, is bound to the strip in a thin (test) line, and either antibody specific for the labeled antibody, or antigen (Ag), is bound at the control line.

(b) Blood and buffer, which have been placed on the strip or in the well, are mixed with the labelled antibody and are drawn up the strip across the lines of bound antibody.

(c) If antigen is present, some labelled antibody will be trapped on the test line. Other labelled antibody is trapped on the control line.

Figure 2: Network of specimen collection, characterization and testing sites



CDC, Centers for Disease Control and Prevention (Atlanta, United States of America); CIDEIM, Centro Internacional de Entrenamiento y Investigaciones Médicas (Cali, Colombia); DMR, Experimental Medicine Research Division (Department of Medical Research, Yangon, Myanmar); EHNRI, Ethiopian Health and Nutrition Research Institute (Addis Ababa, Ethiopia); HTD, Hospital for Tropical Diseases (London, United Kingdom); IHRDC, Ifakara Health Research and Development Center (Bagamoyo, United Republic of Tanzania); IMT, Instituto de Medicina Tropical (Universidad Peruana Cayetano Heredia, Lima, Peru); IPB, Institut Pasteur de Bangui (Bangui, Central African Republic); IPC, Institut Pasteur du Cambodge (Phnom Penh, Cambodia); IPM, Institut Pasteur de Madagascar (Antananarivo, Madagascar); KEMRI, Kenya Medical Research Institute (Kisumu, Kenya); QIMR, Queensland Institute of Medical Research (Brisbane, Australia); RITM, Research Institute of Tropical Medicine (Manila, Philippines); UCAD, Université Cheikh Anta DIOP (Dakar, Senegal); UL, University of Lagos (Lagos, Nigeria).

5. MATERIALS AND METHODS

5.1. Test selection

In July 2015, the WHO-FIND malaria RDT evaluation programme issued a call for expressions of interest to manufacturers of malaria RDTs with information on the requirements for submission of a product to round 7 and the conditions for participation in the evaluation programme (29). Manufacturers of products that had not been retested since round 3 were informed they must resubmit these products; otherwise, the performance characteristics would be removed from the summary results document, which is a

compilation of the results of all previous rounds of testing. This rule was introduced in round 5 to ensure that all products were retested < 5 years after the primary submission. Other standard requirements included valid ISO 13485:2003 certification of all manufacturing sites, sufficient quantities of products (1100 tests from each of two lots¹), compliance with

¹ Manufacturers were requested to supply an additional 500 RDTs per lot voluntarily to support the WHO-FIND evaluation of malaria recombinant antigens.

Table 1a: Manufacturers and products accepted into round 7 of WHO malaria RDT product testing programme

Manufacturer	Product name	Product code ^a	Target antigen(s)
Access Bio, Inc.	CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT ^c	RMVM-05072	V(pLDH), HRP2
	CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line	RMSM-05071	F(pLDH), HRP2
	CareStart™ Malaria Screen RDT ^b	RMAM-05071	pan(pLDH), HRP2/F(pLDH)
	CareStart™ Malaria Pf/PAN (pLDH) Ag RDT ^b	RMLM-05071	pan(pLDH), F(pLDH)
Access Bio Ethiopia	CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	HRP2
	CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	V(pLDH), HRP2
Adv Chemical Private Limited	Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	pan(pLDH), HRP2
	Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	HRP2
Alere Medical Private Limited	Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60AI-40	pan(pLDH), HRP2
	Rapid Test Kit for Malaria Ag Pf/Pv- Alere Trueline Malaria Ag Pf/Pv	11108191040	V(pLDH), HRP2
ALLDIAG SA	PALUTOP +4 optima [®]	5499	pan(pLDH), V(pLDH), HRP2
	PALUTOP + pf [®]	5531	HRP2
ARKRAY Healthcare Pvt Ltd	Parahit [®] f Ver 1.0 - Device ^b	551C104-50	HRP2
	Parahit [®] f Ver 1.0 - Dipstick ^b	551C103-50	HRP2
ASAN Pharmaceutical Co., Ltd	Asan Easy Test [®] Malaria Pf/Pan Ag ^c	AM4650-K	pan(pLDH), HRP2
Aspen Laboratories Pvt. Ltd.	Aspen [®] Malaria Ag Pf/Pv	AS0060	V(pLDH), HRP2
	Aspen [®] Malaria Ag Pf	AS0015	HRP2
Bio Focus Co., Ltd.	BioTracer™ Malaria P.f Rapid Card	17912	HRP2
	BioTracer™ Malaria P.f/PAN Rapid Cardc	17012	pan(pLDH), HRP2
Biosynex	Biosynex [®] Malaria Pf/Pv	0581_K25	V(pLDH), HRP2
	Biosynex [®] Malaria Pf/Pan	0584_K25	pan(pLDH), HRP2
DIALAB	DIAQUICK Malaria P.f. Cassette	W06200	HRP2
Guangzhou Wondfo Biotech Co., Ltd.	One Step Malaria HRP2 (P.f) Test ^c	W37-C	HRP2
	One Step Malaria HRP2/pLDH (P.f/P.v) Test ^c	W056-C	V(pLDH), HRP2
Hangzhou AllTest Biotech Co. Ltd.	AllTest™ Malaria P.f/Pan Rapid Test Cassette	IMPN-402	Aldolase, HRP2
Hema Diagnostic Systems	Rapid 1-2-3 HEMA [®] CASSETTE MALARIA PF/PAN	MAL-PF/Pan-CAS/25	HRP2, pan(pLDH)
ICT INTERNATIONAL	ICT MALARIA DUAL TEST ^c	ML03	HRP2, pan(pLDH)
	ICT MALARIA P.F. CASSETTE TEST ^b	ML01	HRP2
InTec Products, Inc.	ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test ^c	ITP11002-TC25	HRP2
	ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test ^c	ITP11003-TC25	V(pLDH), HRP2
Lumiquick Diagnostics Inc.	QuickProfile™ Malaria Pf/Pv Antigen Test ^c	71050	V(pLDH), HRP2
Medical Diagnostech (Pty) Ltd	GMD Malaria Pf test	GMDMALPF001	HRP2
Real World Diagnostics	Malaria Pf/PAN Test	PROMALPFV001	HRP2, V(pLDH)
Medsources Ozone Biomedicals Pvt. Ltd.	Is It... Malaria Pf PAN	MPFPAN050	pan(pLDH), HRP2
Meril Diagnostics Pvt. Ltd.	One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	V(pLDH), HRP2
	One Step Test for Malaria Pf/HRP-II Ag MERISCREEN Malaria Pf/HRP-II Ag	MPHRPD-01	HRP2

Table 1a: (continued)

Manufacturer	Product name	Product code ^a	Target antigen(s)
NG Biotech	NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	HRP2, pan(pLDH)
RapiGEN Inc.	BIOCREDIT Malaria Ag Pf/Pan (HRP2/pLDH) ^c	C32RHA25	pan(pLDH), HRP2
	BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	V(pLDH), F(pLDH)
Shanghai Kehua Bio-engineering Co., Ltd.	KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	HRP2
Standard Diagnostics, Inc. ^d	SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	05FK130-40-0	HRP2/F(pLDH)
	Alere™ Malaria Ag P.f	05FK140-40-0	HRP2
WELLS BIO, INC	careUS™ Malaria Pf (HRP2) Ag	RM0-M05082	HRP2
	careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	V(pLDH), HRP2
Zhejiang Orient Gene Biotech Co., Ltd.	Malaria Pf Rapid Test	GCMAL(pf)-402a	HRP2
	Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	HRP2, V(pLDH)

pLDH, *Plasmodium* lactate dehydrogenase; HRP2, histidine rich protein 2; V, *P. vivax*; F, *P. falciparum*

^a The product code corresponds to a specific configuration of the RDT, kit components and accessories. Therefore, changes to this configuration including the quantity of tests, the contents or the manufacturing site are denoted by a different product code. Often this involves the end portion of the product code; however, the manufacturer should be contacted for full details.

^b Indicates previously submitted products which were submitted for compulsory retesting in round 7.

^c Indicates products which have previously been submitted and were voluntarily resubmitted in round 7.

^d An Alere company

Table 1b: Products due for compulsory resubmission in round 7

Manufacturer	Product name	Product Code	Participation in round 7 ^a
ABON Biopharm (Hangzhou) Co. Ltd	ABON Malaria Pan/P.f. Rapid Test Device (Whole Blood)	IMA-B402	No
Access Bio, Inc.	CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071 ^b	Yes
	CareStart™ Malaria/Pregnancy (HRP2/pLDH/ HCG)	RRHM(U)-XXX7X ^c	No
	CareStart™ Malaria Screen RDT	RMAM-05071 ^d	Yes
ACON Biotech (Hangzhou) Co. Ltd	Surestep™ Malaria Pf/Pan Rapid Test Device (Whole Blood)	IMA-T402	No
AZOG, Inc	Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device	MFV-124V	No
	Malaria pf (HRP II) / (PAN-LDH) Antigen Detection Test Device	MFV-124R	No
Bioland, Ltd	Nano Sign Malaria Pf Ag	RMAF10	No
	NanoSign Malaria Pf/Pv Ag	RMAD10	No
BioNote, Inc.	BIONOTE MALARIA P.f/P.v Ag Rapid Test Kit	RG19-12	No
Biosynex	IMMUNOQUICK CONTACT falciparum	0519K25	No
	IMMUNOQUICK CONTACT MALARIA +4	0525K25	No
Core Diagnostics	Core™ Malaria Pf	MAL-190020	No
	Core™ Malaria Pv/Pf	Mal-190022	No
	Core™ Malaria Pan/Pv/Pf	Mal-190026	No
CTK Biotech, Inc.	OnSite Pf Ag Rapid Test	R0114C	No
DiaMed – A Division of Bio-Rad	OptiMAL-IT	710024	No
Dima • Gesellschaft für Diagnostika mbH	Malaria Pan test	MAL-W23N-001	No
ICT International	ICT Diagnostics Malaria P.f	ML01	Yes
J. Mitra & Co. Pvt. Ltd.	Advantage Malaria Card	IR211025	No
Orgenics Ltd.	Clearview® Malaria pLDH	70884025	No
Standard Diagnostics Inc.	SD BIOLINE Malaria Ag	05FK40	No
Span Diagnostics Ltd. ^e	ParaHIT® - f (Device)	55IC102-10	Yes
	ParaHIT® - f (Dipstick)	55IC101-10	Yes
SSA Diagnostics & Biotech Systems	diagnosticks MALARIA (Pan) Cassette	MPNWBC1007.3	No
	diagnosticks MALARIA (Pan/Pf) Cassette	MPNFWBC1007.4	No
	diagnosticks MALARIA (Pan/Pv/Pf) Cassette	MPNVFC1007.5	No
Vision Biotech (Pty) Ltd.	Clearview® Malaria Combo	VB11	No
	Clearview® Malaria Pf	VB01	No
Guangzhou Wondfo Biotech Co. Ltd.	One Step Malaria P.f./Pan Whole Blood Test	W56-C	No

^a The results of the first testing of the products in this list that were not retested in round 7 have been removed from tables S2 and S3 and figs S1 and S2 and are listed in table S4.

^b Previously listed with product code G0121

^c Previously listed with product code G0221

^d Previously listed with product code G0231

^e Currently listed with product codes 55IC104-50 and 55IC103-50. Span Diagnostics is now ARKRAY Healthcare Pvt.Ltd.

the product definition¹, deadlines for document submission and payment of fees.

Twenty-seven manufacturers, proposing 45 products, responded to the call, and the products went forward for testing. A further product from one manufacturer was exceptionally accepted as a late entry, directly into phase 2, because of the urgent need for pf-pLDH-based RDTs in areas with a high prevalence of HRP2 deletions. Overall, 46 products from 27 manufacturers were tested in round 7 (Table 1a). Catalogue numbers and verification with manufacturers showed that 15 of the 46 products (33%) had been submitted previously to one or more rounds, including five (11%) scheduled for compulsory resubmission (Table 1b). All 45 products met the minimum performance requirements² in the initial evaluation against the *P. falciparum* culture-derived panel (phase 1) and were therefore evaluated fully in phase 2, with the additional product.

Of the 46 products that were fully evaluated, 19 are designed to detect *P. falciparum* alone, 13 to detect and differentiate *P. falciparum* from non-*P. falciparum* malaria, 13 to differentiate *P. falciparum* from *P. vivax* and one to detect and differentiate *P. falciparum*, *P. vivax* and other *Plasmodium* species. Of these products, five detected *P. falciparum* pLDH. Three products had separate Pf-pLDH detecting lines and two combined *P. falciparum* pLDH with HRP2 on the same line. Annexes 1 and 2 give a comprehensive overview of the product characteristics.

¹ A working definition of a product can be found in Annex 2 (<http://www.who.int/malaria/news/2015/EOI-letter-to-manufacturers-Rd7-annex-2jul2015.pdf?ua=1>, accessed 8 March 2017).

² PDS > 80% against high-density (2000 parasites/μL) *P. falciparum* in culture

5.2. The product testing protocol

The testing process is outlined in Fig. 3 and in the *Methods manual for product testing of malaria rapid diagnostic tests*, version 6 (28). In brief, RDTs from each of two lots of each product were evaluated against a panel of parasite-positive and parasite-negative cryopreserved blood samples. Both lots were also tested for heat (thermal) stability, evaluated after 2 months' storage at room temperature (21–24°C), 35°C and 45°C. A description of the ease of use of the products was completed on a standard form, and common anomalies were recorded. Evaluation of adherence to recommendations on instructions for use and labelling was introduced in round 7. Products were assessed against a list of preferred and required recommendations on the scope, format and terms used in the instructions for use and on the labelling of the box, the test device, its primary packaging, buffer bottle, other accessories.


The testing and all the results were monitored by the WHO–FIND steering committee, and manufacturers were given 30 days to comment on the results for individual products before publication.

5.3. Evaluation panels

RDTs were evaluated against three panels:

- *P. falciparum* culture lines (includes a subset, “manufacturer's panel”) at low (200 parasites/μL) and high parasite density (2000 parasites/μL);
- wild-type *Plasmodium* species (*P. falciparum*, *P. vivax*) from naturally infected humans diluted with parasite-negative samples to low (200 parasites/μL) and high

Figure 3: Overview of malaria RDT product testing



parasite density (2000¹ parasites/μL), all samples prepared from isolates that express HRP2; and

- a parasite-negative panel ("clean" samples and disease-specific or blood factor-specific samples).

An overview of sample collection and characterization is given in the methods manuals prepared for this purpose (27, 28). Characterization results for each round are available in the reports of previous rounds (3–8). Each panel specimen was characterized for:

- species, by duplicate microscopy (two microscopists) and confirmation of mono-species infection by nested polymerase chain reaction (PCR);
- antigen concentration, by quantitative ELISA for HRP2, pLDH and aldolase; and
- the absence of malaria parasites by nested PCR and confirmatory testing for other diseases in the case of parasite-negative samples.

Some of the *P. falciparum* samples in the global specimen bank were also characterized according to HRP2 sequence by PCR amplification and sequencing. This was not performed on samples collected after 2009, as accumulated evidence indicates that HRP2 variation has no significant effect on RDT sensitivity (30). The geographical origin of all samples was recorded.

Panel composition

P. falciparum–cultured parasites panel

The programme selected culture-adapted strains of *P. falciparum* from various geographical locations, including 13 strains with type B HRP2 sequence, five with type A and two with type C (30). All specimens were derived from the CDC

culture bank and diluted in O-positive blood from donors in the USA (28).

Wild-type parasite panel

The parasite-positive wild-type (clinical) panel consisted of samples from 100 cases of *P. falciparum* and 35 cases of *P. vivax* malaria, from 11 collection sites in Africa, Asia and South America (Figs 2, 4a and 4b). Samples were collected from febrile patients and processed by standard methods designed to preserve the target antigen concentration (27). After dilution and cryopreservation, the samples were transferred to the global bank (WHO specimen bank) at CDC for further characterization. The concentrations of sample antigens (HRP2, pLDH, aldolase) determined by quantitative ELISA are shown in Table 3. The results are based on 98 *P. falciparum* samples for pLDH, 99 *P. falciparum* samples for HRP2 and 100 for aldolase, 34 *P. vivax* samples for pLDH and 35 *P. vivax* samples for aldolase. This panel is closely comparable to those of previous rounds (Annex S1).

Negative blood sample panel

The negative panel consisted of 52 "clean" parasite-negative samples from donor-derived blood obtained in banks or from volunteers in non-endemic (USA) and endemic areas (Cambodia, Kenya, Madagascar, the Philippines and Senegal) that had been confirmed to be malaria-negative by microscopy and PCR. The negative sample panel also contained 48 parasite-negative samples from donors with diseases that might be used in the differential diagnoses of malaria, that contained blood factors known to be common in the community or that could result in false-positive reactions in immunochromatographic tests (Table 2). All negative control samples were confirmed to be free of *Plasmodium* parasites by nested-PCR.

¹ Three (3%) of the 100 high-parasite-density *P. falciparum* dilution samples contained 5000 rather than 2000 parasites/μL.

Figure 4a: Origin of phase 2 *P. falciparum* wild-type (clinical) samples (n=100)




Figure 4b: Origin of phase 2 *P. vivax* wild-type (clinical) samples (n=35)




Table 2: Characteristics of *Plasmodium* spp. negative samples

Nature of negative sample ^a	No.
Clean-negative ^b	52
Anti-nuclear antibody positive (sera)	12
Anti-mouse antibody positive (plasma)	3
Rheumatoid factor positive (whole blood and sera)	6
Rapid plasma reagin positive (sera)	6
Chagas' disease antibody positive (plasma)	2
Dengue antibody positive (whole blood sera)	7
Leishmaniasis antibody positive (sera)	4
Schistosomiasis antibody positive (whole blood and sera)	8

^a Whole blood unless indicated. Sera and plasma samples were reconstituted packed cells

^b Healthy volunteers with no known current illness or blood abnormality

5.4. Product registration

Receipt of each shipment of RDTs at the CDC was recorded in a dedicated RDT register. Temperature monitoring devices were offered to manufacturers free of charge to accompany RDT shipments to the CDC. All RDTs were stored at room temperature (21–24°C) immediately, and temperature monitors were labelled with the date of receipt and forwarded for data extraction and analysis, when applicable.

5.5. Specimen panel registration

All panel specimens were assigned unique identification numbers at the collection sites and stored in aliquots of 50 µL at –70°C until testing. All data pertaining to specimen identification, storage location and characterization are stored in a secure, dedicated database.

5.6. Test phases

The evaluation is divided into two phases. Each lot of RDTs was evaluated independently. Lots 1 and 2 of each product were tested alternately against defined sample sets¹, testing

¹ A sample set usually consists of 13 *P. falciparum* specimens and 5 *P. vivax* specimens at 200 parasites/µL and 2000 parasites/µL and 13 malaria-negative samples.

of a set of lot 1 of all products was completed, then a set of lot 2 was tested, until both lots of all products had been tested against all panel samples.

Phase 1. A screening step is used to allow selection of RDTs that meet the minimal quality requirements. Products from two lots were evaluated against a panel of 20 culture-derived *P. falciparum* samples at high (2000 parasites/µL) and low (200 parasites/µL) parasite density, and against 20 clean negative samples. To progress to the full evaluation (phase 2), a product evaluated in phase 1 must achieve a minimum PDS of 80% against the samples containing 2000 parasites/µL and <50% false positive rate against clean negative samples.

Phase 2. Products from two lots are evaluated against a panel of diluted clinical blood samples containing wild-type parasites and a parasite-negative panel, evaluated for heat (thermal) stability and assessed for ease of use. Because the number of aliquots were smaller, fewer replicate RDTs were performed.

- Performance assessment: The mixed parasite-positive and parasite-negative panel comprised 100 *P. falciparum*, 35 *P. vivax* at two parasite densities (200 parasites/µL and 2000 parasites/µL²) and 100 parasite-negative samples.
- Evaluation of heat stability for *P. falciparum*-detecting products: 15 RDTs from each of two lots were tested against a single culture-derived *P. falciparum* isolate (Nigeria XII strain, *P. falciparum* HRP2 sequence type B) with a typical antigen concentration³ at 200 parasites/µL, five RDTs from each lot against *P. falciparum* Nigeria XII strain at 2000 parasites/µL and four RDTs from each lot against a negative sample, which were all tested at baseline and after RDTs were maintained for 60 days at room temperature (< 25°C), 35°C and 45°C, at 75% humidity.

Evaluation of heat stability for *P. vivax*-detecting products: Four RDTs from each of the two lots were tested against a single wild-type *P. vivax* sample⁴ (from Ethiopia) at 200 parasites/µL, two RDTs from each lot against *P. vivax* at 2000 parasites/µL and four RDTs from each lot against a negative sample, at baseline and after RDTs were

² Three (3%) of the 100 *P. falciparum* high parasite density dilution samples contained 5000 parasites/µL rather than 2000.

³ The *P. falciparum* sample had 18.8 ng/mL of HRP2, 21.1 ng/mL of pLDH and 0.49 ng/mL of aldolase.

⁴ The *P. vivax* sample had 143.9 ng/mL of pLDH and 44.4 ng/mL of aldolase.

Table 3: Malaria antigen concentrations (ng/mL) in round 7 wild-type, low parasite density (200 parasites/µL) samples

	pLDH		HRP2	Aldolase	
	<i>P. falciparum</i>	<i>P. vivax</i>	<i>P. falciparum</i>	<i>P. falciparum</i>	<i>P. vivax</i>
Mean	15.9	16.9	11.8	1.4	8.2
Median	13.0	16.6	6.8	1.3	8.0
Maximum	53.5	44.8	62.5	9.1	15.1
Minimum	0.2	1.6	0.7	0.0	3.2
Standard deviation	11.6	11.2	13.0	1.3	3.6

maintained for 60 days at room temperature (21–24°C), 35°C and 45°C, at 75% humidity. The pLDH concentrations in the samples chosen were above average in order to increase the probability of good RDT baseline reactivity, thereby allowing an interpretable assessment of stability or degradation.


- Ease-of-use assessment: After technicians had become familiar with the test device, they jointly described its blood safety characteristics, the quality of the instructions, the number of timed steps and the total time to a result, using a standard reference guide (28).
- Assessment of labelling, packaging and instructions for use: Technicians assessed the product components to

determine whether they met each of the recommended or preferred criteria, assessed in the following categories:

- labelling of the RDT box (58 criteria assessed);
- labelling of the primary cassette packaging (16 criteria assessed);
- labelling of the cassette (11 criteria assessed);
- labelling of the buffer bottle (15 criteria assessed);
- labelling of the accessories (transfer devices, lancets, alcohol swabs and desiccant) (19 criteria assessed); and
- content and format of the instructions for use (119 criteria assessed). See supplemental files for full details.

Figure 5: Testing procedure and calculation of panel detection score and band intensity for product A against a sample density of 200 parasites/μL

The first reading was at the minimum time specified by the manufacturer; the second reading was up to 30 min later^a. A sample is considered detected only if all first test readings, from both lots, are positive, i.e. readings a, b, c and d must be positive.




Based on the positive results of first test reading (2 tests per lot), the mean band intensity score = $a+b+c+d/4$ (excluding negative results).

^a Second reading results are for internal use only

Figure 6: Testing procedure and calculation of panel detection score and band intensity for product A against a sample density of 2000 parasites/μL

The first reading was at the minimum time specified by the manufacturer; the second reading was up to 30 min later^a. A sample is considered detected only if all first test readings, from both lots, are positive, i.e. readings a and b must be positive.



Based on positive results of first test reading (2 tests per lot), in each lot, the mean band intensity score = $a+b/2$

^a Second reading results are for internal use only

- RDT anomalies: During testing, technicians regularly reported the RDT anomalies listed below (not all of which were observed in round 7) and in Fig. AS2.1. When anomalies were noted frequently, a photograph was taken of at least one example.

- red background
- red background obscuring test line(s)
- incomplete clearing
- incomplete migration
- failed migration
- ghost test line(s)
- patchy, broken test line(s)
- diffuse test line(s)
- strip misplaced in cassette (shift)
- specimen pad not seen in sample window
- buffer remains pooled in buffer well

5.7. Performing rapid tests

All RDTs were maintained at room temperature (21–24 °C) until first use. When applicable, the desiccant was inspected for colour change, and products were discarded if they were present. Technicians were rotated and blinded to the sample type and to each other's results. RDTs were labelled with a sample identification number and the date on which test was performed. The tests were used according to the manufacturer's instructions, except that the recommended volume of blood was transferred by micropipette from the sample tube; co-packaged blood transfer devices were not

used. The result was recorded by a technician at the minimum specified reading time, and a second technician re-read the result within 30 min for internal monitoring and to obtain information for the manufacturer. Annexes 1 and 2 give a descriptive, illustrated summary of the test characteristics and steps and a guide to interpretation of results.

5.8. Interpreting the results

The results of control and test lines were recorded as negative or positive by each technician. Each test line was read against a standard colour chart and the band intensity graded as 0 (no visible band), 1, 2, 3 or 4 (1 being the weakest colour intensity and 4 being the strongest). If the control line was recorded as "0" (no visible band) by either technician, the test was recorded as invalid.

Figs 5 and 6 illustrate the testing sequence at low and high parasite density.

5.9. Recording anomalies

Anomalies are defined as unexpected features that appear during performance of an RDT. Anomalies have been observed since round 1. After the appearance of each, technicians agreed on terms with which to identify them. During earlier rounds of testing, their presence was recorded informally (and reported to manufacturers), but, since round 6, the frequency of anomalies has been recorded. Some anomalies do not interfere with the interpretation of results, while others may obscure test or control lines and therefore affect the interpretation and create confusion. Manufacturers are encouraged to reduce or eliminate anomalies and to acknowledge them in their instructions for use.

6. DATA MANAGEMENT

Receipt of products was hand-recorded in a RDT register at the CDC as per standard operating procedures. Data associated with specimen collection and characterization were recorded, first on hard-copy report forms as per the standard operating procedure at the collection sites (Fig. 2), the Hospital of Tropical Diseases (quantitative ELISA results) and the CDC (PCR results), then entered directly into Excel, followed by importation into a specially developed database.

The results of product panel testing and heat stability testing conducted at the CDC were recorded on report forms by each technician individually, as per the standard operating procedure. The results were entered in duplicate and analysed for discrepancies.

All source documents and electronic records of the study data are maintained in secure storage until the conclusion of the evaluation, data analysis and publication of the report.

Individual product testing reports and raw data were sent to manufacturers in December 2016 for a 30-day review period before production of the final report.

7. QUALITY ASSURANCE

Product testing follows standard operating procedures developed during previous testing rounds, which are based on recommendations by expert consultants, with minor modifications by the steering committee before round 7 (28). Overall, the quality of critical steps was controlled as described below.

7.1. Quality of malaria RDTs and their use

All RDTs were stored in a controlled environment at room temperature (21–24 °C). The pouch was opened, and, if applicable, the desiccant was checked for colour change immediately before use. The manufacturer's instructions were followed, except for use of the blood transfer device provided by the manufacturer: a micropipette was used to ensure the correct blood volume.

A temperature monitoring device was offered to manufacturers to be shipped with the RDTs to the testing site (CDC). Lots were analysed at temperatures above and below the manufacturer's recommended storage conditions.

7.2. Quality and objectivity of RDT readings

The results were read under good lighting, using standard colour charts by trained technicians tested for visual acuity and were doubly entered into the database. Technicians were rotated, and the readings of a second technician were

used for internal monitoring. The summarized results were reviewed in detail, and potential discrepancies were identified and cross-checked against source laboratory report forms.

All wild-type parasite samples used in phase 2 were randomized with parasite-negative samples and re-labelled. Reading of the RDT results by the first and second technician is blinded.

7.3. Quality of WHO specimen bank samples

Standard operating procedures were established for the preparation of all specimen bank samples (26). Culture lines of parasites and wild-type samples were selected on the basis of previous evidence and data from specific studies. All diluted parasite sample aliquots were stored and transported at –70°C and were used only once within 8 hours of thawing.

7.4. Quality of the product testing site

The Division of Parasitic Diseases and Malaria, Center for Global Health, CDC, is the main operating component of the Department of Health and Human Services of the USA for malaria control and prevention. Laboratories within the Division are accredited by Clinical Laboratory Improvement Amendments and are monitored by an internal quality management system.

8. ETHICAL CONSIDERATIONS

Each specimen collection site obtained approval from a WHO research ethics review committee and/or a local institutional review board for specimen collection, transport and archiving

of blood samples for the purpose of RDT product testing, lot testing and quality assurance.

9. DATA ANALYSIS

9.1. Measures of parasite detection: panel detection score and positivity rates

As shown in Fig. 5, a product must return four positive test results at the manufacturers' recommended minimum reading time (two from lot 1, two from lot 2 at the initial reading time) when tested against a parasite density of 200 parasites/μL to contribute to its PDS. When tested against 2000 parasites/μL (Fig. 6), the product must return two positive tests at the manufacturers' recommended minimum reading time (one from each lot). Thus, the PDS is a measure of inter-test and inter-lot consistency, as well as the ability of the test to detect antigen. The PDS for *P. falciparum* indicates an RDT result that confirms the presence of *P. falciparum* when tested against cultured and wild-type *P. falciparum* samples, while the *P. vivax* PDS indicates *Plasmodium*-positive/*P. falciparum*-negative results when tested with wild-type *P. vivax* samples.

The positivity rate is the percentage of all tests of a particular product that returned a positive result at the manufacturers' recommended minimum reading time when tested against a *P. falciparum* or *P. vivax* sample.

9.2. False-positive results

False-positive results are analysed and reported as two groups: those with incorrect species identification and those that returned a positive result for samples that do not contain *Plasmodium* spp. Specifically, the false-positive rate is the

percentage of all tests of a particular product that returned a positive test result when it should not have been obtained, when read at the manufacturer's recommended minimum reading time.

9.2.1 Incorrect species identification

A test is considered to have returned an incorrect species result if a positive *P. falciparum* test line appears when testing a sample containing non-*P. falciparum* (*P. vivax*) parasites. Fig. 7 illustrates the various possibilities for incorrect species identification in combination tests. For example, if *P. falciparum* samples result in only a visible pan-specific (or non-*P. falciparum*-specific) test line in combination tests, the result is considered to be a false-positive for non-*P. falciparum* parasites.

9.2.2 False-positive results for *Plasmodium*-negative samples

Any positive reading of samples with no *Plasmodium* parasites is considered a false positive. In phase 2, parasite-negative samples are clean negative samples and samples containing other infectious agents (dengue, leishmania, Chagas, schistosoma and rapid plasma reagin, which is indicative of syphilis infection) and immunological factors (rheumatoid factor, anti-nuclear antibodies, anti-mouse antibodies) (Table 2).

9.3. Band intensity

All positive test results were recorded with their band intensity against a standard reference chart, matched closely to

Figure 7: Classification of incorrect species identification with combination malaria RDTs

Pf/pan combination tests

Panel sample	Pf + / Pan -	Pf + / Pan +	Pf - / Pan +	Pf - / Pan -
Pf			False-positive (non-Pf)	Negative
Pv	False-positive (Pf)	False-positive (Pf)		Negative

Pf/Pv combination tests

Panel	Pf + / Pv -	Pf + / Pv +	Pf - / Pv +	Pf - / Pv -
Pf		False-positive (Pv)	False-positive (non-Pf)	Negative
Pv	False-positive (Pf)	False-positive (Pf)		Negative

line colour. On the basis of the results of the first reader, the distribution of band intensity results is presented as the mean band intensity of positive results. In addition, the intensity was expressed for each possible result (0, 1, 2, 3 or 4) as the percentage recorded at that level¹.

9.4. Lot agreement

Agreement between test lots is calculated from the number of samples that return a positive result on both RDTs tested in that lot against parasite-positive samples at 200 parasites/μL, and on the single RDT from each lot tested against samples at 2000 parasites/μL. High inter-lot agreement indicates consistency in detecting malaria parasites. When one test is invalid and the other positive, positive agreement is recorded. Fig. 8 shows sample calculations for lot agreement.

9.5. Invalid tests

Invalid tests are those deemed invalid during testing of both lots, with samples at 200 parasites/μL and 2000 parasites/μL.

9.6. Heat (thermal) stability

The results of heat stability testing are reported as the number of positive tests against one cultured *P. falciparum* or one wild-type *P. vivax* parasite sample at 200 and 2000 parasites/μL based on the first reading of two lots at each parasite density (maximum score is 30 (*P. falciparum*) or eight (*P. vivax*) against 200 parasites/μL samples and 10 (*P. falciparum*) or four (*P. vivax*) against 2000 parasites/μL.

samples)² and mean band intensity (for positive tests only based on the first reading) after the lots were stored at room temperature (21–25°C) and at 35°C and 45°C for 2 months. At some point during the 60-day incubation period for the late entry test (CareStart™ Malaria Pf/PAN (pLDH)- RMLM-05071), the humidity regulator in the 45°C stability chamber was compromised leading to water-soaking of all test boxes. The precise timing of this event and the effect on temperature and humidity are unknown. Testing was still performed because all cassette packaging was intact.

9.7. Anomalies

The presence and frequency of commonly observed anomalies – red background, red background obscuring test line(s), incomplete clearing, incomplete migration, failed migration, strip misplaced in cassette (shift), specimen pad not seen in the sample window, ghost test line(s), diffuse test line(s), patchy broken line(s) and buffer remains pooled in buffer well – were routinely recorded for all round-7 products. Photographs and descriptions are shown in Fig. AS2.1.

9.8. Labelling and instructions for use

For each product, technicians recorded whether the product met each of the recommended criteria. The results were pooled for analysis. The proportions of products that met a selection of recommended criteria is presented graphically in Figs 31–38.

¹ A standard intensity comparison chart is used, which allows matching to the closest of four common colour variants of labelled antibodies used in RDTs, each at four levels of intensity.

² Fifteen tests per lot against 200 parasites/μL samples, five tests per lot against 2000 parasites/μL for *P. falciparum* samples, four tests per lot against 200 parasites/μL samples and two tests per lot against 2000 parasites/μL for *P. vivax* samples. Invalid results were excluded from the analysis.

Figure 8: Explanation of lot agreement calculation

	Test results (1 = positive, 0 = negative)				Derived values (1 = both positive, 0 = both negative)			
	Lot 1		Lot 2		(a)	(b)	(d)	(f)
	Test 1 reader 1	Test 2 reader 1	Test 1 reader 1	Test 2 reader 1	Lot 1 tests	Lot 2 tests	Comparison of lot results	Contribution to overall
Sample 1	1	1	1	1	1	1	1	1
Sample 2	1	0	0	0	Disagree	0	Can't compare	0
Sample 3	0	1	0	1	Disagree	Disagree	Can't compare	0
Sample 4	0	0	0	0	0	0	0	0
Sample 5	1	1	1	1	1	1	1	1

PDS = sum (f) / number of samples = 2/5 = 40

Lot 1 PDS = sum (a) / number of samples = 2 / 5 = 40

Lot 2 PDS = sum (b) / number of samples = 2 / 5 = 40

Positivity = number of positive results / total number of tests = 11 / 20 = 55%

Agreement between tests = (count number of 0 and 1s in (a) and (b)) / (number of samples x 2 lots) = 7 / 10 = 70%

Agreement between lots = (count number of 0 and 1s in (d)) / (number of samples -- number of "can't compare" in (d)) = 3 / 3 = 100%

Note: reader 1 = Technician 1 in raw data files

10. ASSOCIATION BETWEEN PARASITE DENSITY AND ANTIGEN CONCENTRATION

Malaria RDTs detect parasite-derived antigen. The relation of the concentration of antigen available from the blood sample (after lysis of red cells and parasites) to the peripheral parasite density varies widely because of a series of host and parasite factors (Box 4).

In establishing panels for the product testing programme that reflect possible variations in antigen concentration for parasitaemia of 200 parasites/ μ L, a large number (> 300) of wild-type parasite samples from clinical cases in different geographical areas were analysed by quantitative ELISA for

HRP2, pLDH and aldolase. Only samples with antigen values within the 90th percentile for HRP2, pLDH and aldolase were selected for the performance panels. Furthermore, the distribution of antigen levels for HRP2, pLDH and aldolase was compared with that in previous rounds to ensure consistency. No statistically significant differences in average antigen levels between the panels for rounds 1–7 were detected for any of the antigens ($p > 0.5$, Kruskal-Wallis test). Therefore, the panels used for the product testing rounds can be considered comparable (Annex S1).

Box 4. Explanations for variable antigen concentrations in samples with the same parasite density

- variation in antigen expression among isolates
- different durations of infections (accumulating antigens)
- different parasite growth stages at the time of collection (expressing different levels of antigens)
- presence of circulating HRP2 from previous cycles of growth
- HRP2 produced by parasites sequestered in the host's vascular tissues that cannot be accounted for in the estimate of parasite density on the blood slide (29)

11. EVALUATION OF MALARIA RAPID DIAGNOSTIC TESTS IN THE LABORATORY AND IN THE FIELD

Despite the strengths of the product testing programme, the evaluations are not completely analogous to field testing of malaria RDTs. In order to compose a panel that could be used to evaluate RDTs reproducibly, blood samples must be diluted, frozen and stored below -70°C ; however, blood that has undergone freezing and thawing is lysed and may not have exactly the same characteristics as fresh blood. Another difference from field evaluation is use of a micro-pipette to place blood in the RDT device rather than the blood transfer device provided by the manufacturer. This is necessary because blood is collected from a cryo-tube rather than a finger-prick and because the blood transfer devices provided with the different products vary (31). This technique also ensures the consistency of testing by reducing the likelihood of operator error. As all samples in the panel used for the evaluation are prepared from parasites that express HRP2, the results will not be predictive of field trial results of parasite populations with significant levels of HRP2 deletion (12–13). In addition, the population frequency of blood immunological factors or

infectious diseases, which can result in false-positive results, may vary. Therefore, the sensitivity and specificity of an RDT in the field depends on the epidemiological situation. The evaluation reported here does not predict sensitivity or specificity in a given field situation but the rates of detection of target antigens and false-positive results of RDTs against a standardized panel in a controlled, repeatable manner. As the panel is meant to be a close approximation to field samples, the detection rates of different products will be reflected in similar differences in the field. The panel is designed to include a large number of samples that are close to the limit of detection of RDTs (200 parasites/ μ L) and is therefore likely to discriminate between them more clearly than a field trial. It follows that, in settings where the parasite density is very high, no differences in the PDS or positivity rates of tests or much smaller differences will be observed than those reported against the WHO evaluation panel. Furthermore, where the parasite density is very low, the detection rates may be lower than those reported here.

Field trials have a place in product selection, particularly in determining which of a short-list of products is most appropriate for the technicians and situation of its intended use in a programme (e.g. ease-of-use characteristics). Such trials should have carefully defined objectives and procedures designed to achieve them. Trials to determine the probable field sensitivity and specificity of a product also have a place but require large samples and populations with low

parasite densities if significant differences are to be found between well-performing products; they must also be closely controlled and are therefore expensive. Such trials do not allow comparison of a large number of products. WHO has published recommendations for good practice in malaria field trials (32), which should be followed to improve the reproducibility and quality of the results.

12. RESULTS

12.1. Summary

Round 7 of WHO malaria RDT product testing provided results for 46 products evaluated against *P. falciparum* culture samples, and all the products proceeded to evaluation against wild-type samples collected from parasitaemic patients on three continents and a large panel of parasite-negative samples. Heat stability was assessed at the temperatures commonly encountered in malaria-endemic countries. Thirteen research institutes were engaged in either sample collection or sample characterization to establish the evaluation panels. Between February 2016 and August 2016, approximately 65 000 RDTs were tested at the CDC.

The main results are presented in Tables 4 and 5, which group the RDTs by the species they are designed to detect, i.e. *P. falciparum* only, *P. falciparum* and all species or *P. falciparum* and *P. vivax*. Note that only tests against *P. falciparum* and *P. vivax* were evaluated, and the evaluation therefore does not indicate whether a product intended to detect other species, i.e. *P. malariae*, *P. ovale*, could do so.

PDS values at both high and low parasite concentrations are presented, as are false-positive rates and the percentages of invalid test results. Tests in each category are listed alphabetically, but the results are colour-coded according to WHO-recommended RDT procurement selection criteria (Box 3); WHO prequalification status is also indicated. When choosing an appropriate product, it is important also to review its thermal stability (Tables 6a and 6b) according to the expected conditions of transport and storage in the field.

The results of the evaluation are listed below.

- The overall range of results against wild-type *P. falciparum* and negative samples, including *P. falciparum* PDS, *P. falciparum* positivity rate and heat stability, were similar to those in rounds 1–6 (3–8), the false-positivity rates and *P. vivax* PDS and *P. vivax* positivity rates were similar to those in round 6, and better than in previous rounds.

The median PDS for *P. falciparum* at low parasite densities in round 7 (89.5%) was slightly higher than in rounds 5 and 6 (both 86%) and similar to that seen in round 4 (89.3%). No products in round 7 scored a PDS of 100%

for the *P. falciparum* detecting line. The PDS for *P. vivax* at low densities has improved consistently since round 1 (median, 30%), the results for rounds 2, 3, 4, 5, 6 and 7 being 75.0%, 51.4%, 61.8%, 65.7%, 82.9% and 90.0%, respectively. Six products achieved 100% PDS on their pan-pLDH and *P. vivax* pLDH lines when tested against *P. vivax* but had lower scores for their *P. falciparum* detecting lines. The median false-positive rate on clean negative samples and samples containing other infectious agents was 0%, while samples containing immunological factors had a median overall false-positive rate of 2.8%.

- A number of RDTs consistently detected malaria at a low parasite density (200 parasites/ μ L), had low false-positive rates, were stable at tropical temperatures, are relatively easy to use and can detect *P. falciparum*, *P. vivax* or both. This increases the number of well-performing tests from that in rounds 1–6.
- The one *P. falciparum*-only test detecting pf-pLDH did not meet procurement criteria; however, one combination non-HRP2 detecting RDT met criteria for *P. falciparum* and *P. vivax* targeting pf-pLDH and pan-pLDH, respectively.
- The performance of products varied at low parasite density (200 parasites/ μ L), but most showed high detection rates for *P. falciparum* and *P. vivax* at 2000 parasites/ μ L.
- All, except two, round-7 products had an HRP2 detecting line, and most of these products achieved a high PDS for *P. falciparum* detection at low parasite density.
- Several combination tests achieved PDS at the upper end of the range for both *P. falciparum* and *P. vivax*. (Fig. S3).
- There was minimal lot-to-lot variation in the test performance of round-7 products.
- Overall, approximately half of the combination tests with Pf and Pan lines in which HRP2 was used for detection of *P. falciparum*, returned positive results only on the HRP2 band at lower densities of *P. falciparum*. Results were product-specific, with values ranging from 5% to 89%. Manufacturers' instructions should therefore classify *P. falciparum* infections as positive in either the HRP2 test line alone or in combination with the pan-pLDH line.

Table 4: Summary of phase 1 performance of 45 malaria RDTs^a against 20 cultured *P. falciparum* lines at low (200) and high (2000) parasite density (parasites/μl)

Product	Product code	Manufacturer	Panel detection score ^b (n=20)		False-positive non-Pf infection ^c (%)		Invalid rate (%) (n=120)
			200 parasites/μl	2000 parasites/μl	200 parasites/μl (n=80)	2000 parasites/μl (n=40)	
Pf only							
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	Advvy Chemical Private Limited	100.0	100.0	NA	NA	0.0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	100.0	100.0	NA	NA	0.0
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc. [£]	100.0	100.0	NA	NA	0.0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	100.0	100.0	NA	NA	0.0
BioTrace™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	100.0	100.0	NA	NA	0.0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	100.0	100.0	NA	NA	0.0
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line	RMSM-05071	Access Bio, Inc.	100.0 (100/35) ^d	100.0 (100/95) ^d	NA	NA	0.0
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	100.0	100.0	NA	NA	0.0
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	100.0	100.0	NA	NA	0.0
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	100.0	100.0	NA	NA	0.0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	100.0	100.0	NA	NA	0.0
Malaria Pf Rapid Test	GCMAL(p.f)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	100.0	100.0	NA	NA	0.0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	100.0	100.0	NA	NA	0.5
One Step Malaria HRP2 (P.f) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	100.0	100.0	NA	NA	0.0
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	95.0	100.0	NA	NA	0.0
PALUTOP + pf®	5531	ALLDIAG SA	100.0	100.0	NA	NA	0.0
Parahit f® Ver 1.0 – Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	80.0	100.0	NA	NA	0.0
Parahit® f Ver 1.0 – Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	100.0	100.0	NA	NA	0.0
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc. [£]	90.0	100.0	NA	NA	0.0
Pf and Pan							
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advvy Chemical Private Limited	75.0	100.0	0.0	0.0 (39)	0.5
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60AI-40	Alere Medical Private Limited	100.0	100.0	0.0	0.0	0.0
AllTest™ Malaria Pf./Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	80.0	100.0	0.0	0.0	0.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	100.0	100.0	0.0	0.0	0.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	80.0	100.0	0.0	0.0	0.0
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C32RHA25	RapiGEN Inc.	100.0	100.0	0.0	0.0	0.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	100.0	100.0	0.0	0.0	0.0
BioTrace™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	100.0	100.0	0.0	0.0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	100.0	100.0	0.0	0.0	0.0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	100.0	100.0	0.0	0.0	0.0
Is It... Malaria Pf PAN	MPFPAN050	Medsorce Ozone Biomedicals Pvt. Ltd.	100.0	100.0	0.0	0.0	0.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	100.0	95.0	0.0	2.5	0.0
Rapid 1–2–3 HEMA® CASSETTE MALARIA PF/PAN	MAL–PF/Pan-CAS/25	Hema Diagnostic Systems	100.0	100.0	0.0	0.0	0.0
Pf and Pv							
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	100.0	100.0	0.0	0.0	0.0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	80.0	100.0	0.0 (78)	0.0	1.5
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	100.0	100.0	0.0	0.0	0.5
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RWVM-03091	Access Bio Ethiopia	100.0	100.0	0.0	0.0	0.0

Table 4: Summary phase-1 performance of 41 malaria RDTs against 20 cultured *P. falciparum* lines at low (200) and high (2000) parasite density (parasites/ μ L) (continued)

Product	Product code	Manufacturer	Panel detection score ^b (n=20)		False-positive non-Pf infection ^c (%)		Invalid rate (%) (n=120)
			200 parasites/ μ L	2000 parasites/ μ L	200 parasites/ μ L (n=80)	2000 parasites/ μ L (n=40)	
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMV/M-05072	Access Bio, Inc.	100.0	100.0	0.0	0.0	0.0
CareUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	100.0	100.0	0.0	0.0	0.0
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	100.0	100.0	0.0	0.0	0.0
Malaria Pf/PAN Test	PROPMALPPV001	Real World Diagnostics	100.0	100.0	25.0	97.5	0.0
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	100.0	100.0	0.0	0.0	0.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	90.0	100.0	0.0 (79)	0.0	0.5
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	100.0	100.0	12.5	15.0	0.0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	100.0	100.0	0.0	0.0	0.0
Pf, Pv and Pan							
PALUTOP +4 optima®	5499	ALLDIAG SA	100.0	100.0	1.3	0.0	0.0

NA, not applicable

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species

^a Phase-1 performance tests for CareStart Pf/PAN (pLDH) Ag RDT (RMLM-05071) not conducted

^b A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive

^c Pan or Pv line only positive indicates a false positive non *P. falciparum* infection

^d Product PDS shown along with PDS for HRP2 band and Pf-pLDH band, respectively

^e An Alere company

Table 5: Summary of phase 2 performance of 46 malaria RDTs against wild-type (clinical) *P. falciparum* and *P. vivax* samples at low (200) and high (2000^a) parasite density (parasites/μl) and *Plasmodium* spp. negative samples

Product	Product code	Manufacturer	Panel detection score ^b				False positive rates (%)						Total false positive rates ^c (%)	
			200 parasites/μl		2000 parasites/μl		200 parasites/μl		2000 parasites/μl		2000 parasites/μl		Clean negative samples	Invalid rate (%) (n=1210)
			Pf samples (n=100)	Pv samples (n=35)	Pf samples (n=100) ^a	Pv samples (n=35)	PF samples	False positive non-Pf infection ^c (n=400)	False positive non-Pf infection ^c (n=140)	PF samples	False positive non-Pf infection ^c (n=200)	False positive non-Pf infection ^d (n=70)		
Pf only														
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA017	Advx Chemical Private Limited	80.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	0.0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	93.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.4	0.0	0.0
Alere™ Malaria Ag Pf	05FK140-40-0	Standard Diagnostics, Inc.	98.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.9 (231)	0.1	0.1
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	93.0	NA	100.0	NA	NA	0.7	NA	NA	0.0	1.3	0.0	0.0
BioTracer™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	97.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	96.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.4	0.0	0.0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line	RMSM-05071	Access Bio, Inc.	94.0 (94/38) ^f	NA	99.0 (99/92) ^f	NA	2.1	NA	NA	NA	1.4	0.4	0.0	0.0
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	94.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.9	0.0	0.0
DIAQUICK Malaria Pf. Cassette	W06200	DIALAB	86.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	0.0
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	94.0	NA	100.0	NA	NA	5.0	NA	NA	1.4	1.7	0.0	0.0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	85.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	0.0
Malaria Pf Rapid Test	GCMAL(pf)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	89.0	NA	100.0	NA	0.0 (139)	NA	NA	NA	0.0	0.0	0.1	0.1
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	86.0	NA	99.0	NA	2.9	NA	NA	NA	1.4	0.4 (231)	0.1	0.1
One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	93.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	73.0	NA	99.0	NA	0.7	NA	NA	NA	0.0	0.0	0.0	0.0
PALUTOP + pf®	5531	ALDIAG SA	92.0	NA	99.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	0.0
Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	74.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	0.0
Parahit® F Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	77.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0	0.0	0.0
SD BIOLINE Malaria Ag Pf. (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	90.0	NA	100.0	NA	NA	0.0	NA	NA	0.0	0.0 (231)	0.1	0.1
Pf and Pan														
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA016	Advx Chemical Private Limited	67.0	45.7	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	05FK60AL-40	Alere Medical Private Limited	85.0	91.4	98.0	100.0	1.3	0.0	1.0	1.0	0.0	0.0	0.0	0.0
AlITest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	69.0	71.4	96.0	100.0	1.3	0.0	2.0	2.0	0.0	0.9	0.0	0.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	88.0	100.0	98.0	100.0	0.5 (399)	0.0	1.0	1.0	0.0	1.3	0.1	0.1
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	93.0	91.4	98.0	100.0	0.3 (399)	1.4 (138)	1.0	1.0	0.0	1.3 (231)	0.3	0.3
BIOCREDIT Malaria Ag Pf/Pan (HRP-II)(pLDH)	C32RHA25	RapiGEN Inc.	91.0	100.0	99.0	100.0	0.0	0.0	0.5	0.5	0.0	3.9	0.0	0.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	85.0	85.7	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	96.0	97.1	99.0	94.3	0.8	0.7	0.5	0.5	2.9	0.9	0.0	0.0
CareStart™ Malaria Pf/PAN Rapid Card	RMLM-05071	Access Bio, Inc.	73.0	0.0	100.0	71.4	0.0	0.7	0.0	0.0	0.0	1.7	0.0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	93.0	94.3	99.0	97.1	1.3	0.0	0.5	0.5	0.0	0.0 (231)	0.1	0.1
ICT MALARIA DUAL TEST	MLD3	ICT INTERNATIONAL	85.0	31.4	98.0	100.0	0.3	0.0	1.0	1.0	0.0	1.3	0.0	0.0
Is It... Malaria PF PAN	MPPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	93.0	100.0	99.0	100.0	2.0	0.0	0.5	0.5	0.0	3.9	0.0	0.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	92.0	25.7	98.0	91.4	0.8 (399)	3.6 (139)	1.0	1.0	4.3	33.2	0.2	0.2
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-PfPan-CAS/25	Hema Diagnostic Systems	92.0	100.0	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0

Table 5: Summary phase-2 performance of 41 malaria RDTs against wild-type (clinical) *P. falciparum* and *P. vivax* samples at low (200) and high (2000^a) parasite density (parasites/μL) and *Plasmodium* spp. negative samples (continued)

Product	Product code	Manufacturer	Panel detection score ^b				False positive rates (%)				Total false positive rates ^c (%)	
			200 parasites/μl		2000 parasites/μl		200 parasites/μl		2000 parasites/μl		Clean negative samples	Invalid rate (%) (n=1210)
			Pf samples (n=100)	Pv samples (n=35)	Pf samples (n=100) ^a	Pv samples (n=35)	PF samples	Pv samples	PF samples	Pv samples		
PF and Pv												
ADVANCED QUALITY™ ONE STEP Malaria (pf/pv) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	92.0	97.1	98.0	100.0	1.0	0.0	1.0	1.4 (69)	0.4	0.1
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	75.0	100.0	98.0	100.0	1.0 (399)	0.0 (139)	1.0 (199)	1.5 (68)	0.0 (230)	0.6
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	85.0	91.4	99.0	100.0	0.0	0.0	0.0	0.0 (69)	0.0 (229)	0.3
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	91.0	97.1	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-05072	Access Bio, Inc	89.0	100.0	99.0	100.0	1.8	0.0	2.0	0.0	0.0 (231)	0.1
CareUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	93.0	88.6	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf/Pv Rapid Test	GCWAL(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	89.0	57.1	99.0	100.0	0.0	0.0	0.5 (199)	0.0	0.0 (231)	0.3
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	86.0	2.9	99.0	8.6	22.3	4.3	92.5	7.1	24.6	0.0
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	92.0	65.7	100.0	100.0	0.3	0.0	1.0	0.0	1.3	0.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	78.0	85.7	100.0	100.0	0.5	0.7	0.0	1.4	0.0	0.0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiduck Diagnostics Inc.	79.0	88.6	99.0	100.0	39.8	0.0	27.5	0.0	22.9 (231)	0.1
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	85.0	88.6	98.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0
Pf, Pv and Pan												
PALUTOP +4 optima®	5499	ALLDIAG SA	91.0	82.9 (82.9/100) ^g	99.0	100.0 (100/100) ^g	1.3	0.7	0.5	0.0	0.0	0.0

NA, not applicable

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species

^a 3 (3%) of the 100 *P. falciparum* high parasite density dilution samples were at 5000 parasites/μL rather than 2000

^b A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive

^c For combination tests, pan or Pv line, only, positive indicates a false positive non *P. falciparum* infection

^d Positive Pf line indicates a false positive *P. falciparum* infection

^e The total number of times a positive result for malaria was generated when it should not have been

^f Product PDS shown along with PDS for HRP2 band and Pf-pLDH band, respectively

^g Product PDS shown along with PDS for Pv-pLDH band and Pan-pLDH band, respectively

Performance measure

Panel detection score for Pf and Pv 200/μL samples

False positive rates against clean negatives

Invalid rate

Recommended WHO procurement criteria

≥ 75%


< 10%

< 5% of tests conducted

- Only one of two tests met the WHO procurement criterion for detection of *P. falciparum* with Pf-pLDH alone. This test had a PDS of 75%, a false-positive rate of 0% and an invalid rate of 0.6%. However, the test had diminished performance after incubation at 35°C and 45°C (Figs. 22, 23). The PDS in other Pf-pLDH tests in which HRP2 was used to detect Pf on the same test line, ranged from 90% to 94%, however it cannot be distinguished if this performance results from detection of HRP2, Pf-pLDH or both. Tests that can detect *pfhrp2*-deleted parasites are a high priority in malaria-endemic countries with a high prevalence of such parasites (12, 13, 33, 34).
- No consistent pattern was seen in the changing performance of the five compulsorily resubmitted products. The PDS of some of the *P. falciparum* and *P. vivax* tests improved over their results in round 3, while that of others decreased.

Tables 4 and 5 summarize the performance of malaria RDTs against cultured *P. falciparum* parasites, blood containing wild-type *P. falciparum* and *P. vivax* parasites and *Plasmodium* spp.-negative samples. Detailed phase-1 and phase-2 results of product testing are given in Annexes 3 and 4, respectively. The data are shown graphically in Figs. 9–19.

Figure 9: Phase-1 *P. falciparum* panel detection score of malaria RDTs^a at low (200) and high (2000) parasite density (parasites/ μ L)



^a All but 2 RDTs target HRP2 for falciparum detection. Two products target only pf-pLDH for falciparum detection (RMLM-05071 and C60RHA25). Two products (RMAM-05071 and 05FK130-40-0) target both HRP2 and pf-pLDH on the same line. One product (RMSM-05071) targets both HRP2 and pf-pLDH on separate lines; for this product HRP2 and pf-pLDH based results are presented separately in table 4.

^b A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.

12.2. Phase 1: *P. falciparum* culture panel


All but one of the products consistently detected 100% of cultured *P. falciparum* parasites at high parasite density (2000 parasites/μL); the PDS of the exception was 95%. The PDS was more variable (75–100%) at low parasite density (200 parasites/μL) (Fig. 9).

12.3. Phase 2: wild-type *P. falciparum* and *P. vivax*- and *Plasmodium* spp.-negative samples.

12.3.1 *P. falciparum* detection

All 46 products in round 7 were designed to detect *P. falciparum*. As in phase 1, all the tests had very high scores at the high parasite density, with a PDS ≥ 96%. Seventeen of the 19 products specific for *P. falciparum* alone achieved a PDS ≥ 75% against samples with low parasite density (Table 5, Fig. 10).

Figure 10: Phase-2 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000^a) parasite density (parasites/μL)^{b,c}



^a 3 (3%) of the 100 *P. falciparum* high parasite density dilution samples were at 5000 parasites/μL rather than 2000

^b Phase 2 evaluation panel consisted of 100 clinical blood samples containing wild type *P. falciparum*. RDTs performed = 2 tests x 2 lots at 200 p/μL and 1 test x 2 lots at 2000 p/μL;

^c All but 2 RDTs target HRP2 for falciparum detection. Two products target only pf-pLDH for falciparum detection (RMLM-05071 and C60RHA25). Two products (RMAM-05071 and 05FK130-40-0) target both HRP2 and pf-pLDH on the same line. One product (RMSM-05071) targets both HRP2 and pf-pLDH on separate lines; for this product HRP2 and pf-pLDH based results are presented separately in table 5.


^d A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.

Only one of two tests met WHO procurement criteria based on detection of *P. falciparum* with Pf-pLDH alone. This test achieved a PDS of 75%, a false-positive rate of 0% and an invalid rate of 0.6%. The PDS in other Pf-pLDH tests in which HRP2 was used to detect Pf on the same test line, ranged from 90% to 94%, however it cannot be distinguished if this performance results from detection of HRP2, Pf-pLDH or both. Tests that can detect *pfhrp2* gene-deleted parasites are a high priority in malaria-endemic countries with a high prevalence of such parasites (12, 13, 33, 34).

12.3.2 *P. vivax* detection

Fig. 11 shows that 25 of 27 (93%) products designed to detect *P. vivax* consistently detected $\geq 75\%$ at high parasite density (2000 parasites/ μL), and 19 (70%) achieved the same threshold of PDS against samples with 200 parasites/ μL . The overall detection rate in low-parasite density wild-type *P. vivax* samples was lower than that for *P. falciparum*. At a low parasite density (200 parasites/ μL), 13 products had a PDS $\geq 90\%$, and 18 had a PDS $< 75\%$ (Table 5, Fig. 11), which is an improvement on round-5 results, in which only eight products had a PDS $\geq 90\%$, and 19 had a PDS $< 75\%$.

Figure 11: Phase-2 *P. vivax* panel detection score of malaria RDTs at low (200) and high (2000) parasite density (parasites/ μL)^{a,b}



^a Phase-2 evaluation panel consisted of 35 clinical blood samples containing wild type *P. vivax*; RDTs performed = 2 tests x 2 lots at 200 p/ μL and 1 test x 2 lots at 2000 p/ μL ;

^b All RDTs target pan-pLDH or pv-pLDH

^c A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.

12.3.3 Combined detection of *P. falciparum* and *P. vivax*

Of the 27 pan-specific and combination tests, 19 (70%) had a PDS $\geq 75\%$ for both *P. falciparum* and *P. vivax* at a low parasite density (200 parasites/ μL) (Table 5). Most products performed well at a high parasite density.

12.3.4 *P. falciparum* and *P. vivax* positivity rate


The positivity rate was calculated in addition to the PDS. As expected, the positivity rates were higher than the PDS but mirrored the PDS against wild-type *P. falciparum* and *P. vivax* samples (Figs 12 and 13).

12.3.5 Band intensity

Although RDTs do not provide quantitative results, the technicians graded positive results according to a standard colour chart and calculated the mean band intensity for positive results (Annex 4, Tables A3.2 (for phase 1), A4.2 and A4.3 (for phase 2)). A positive correlation was found between the PDS and band intensity (Spearman rank correlation, $r = 0.75$, $p < 0.001$ for the *P. falciparum* phase-2 panel and $r = 0.82$, $p < 0.001$ for the *P. vivax* panel).

Of the combination RDT products containing a pan test band that gave a positive indication for *P. falciparum* against low-density *P. falciparum* samples, 51.6% (2473/4796) gave positive results on both the *P. falciparum* and pan test

Figure 12: Phase-2 *P. falciparum* panel detection score and positivity rate at 200 parasites/ μL ^a



^a Phase-2 evaluation panel consisted of 100 clinical blood samples containing wild-type *P. falciparum*. RDTs performed = 2 tests x 2 lots at 200 p/ μL and 1 test x 2 lots at 2000 p/ μL ;

^b A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive;

^c The total number of times a test returned a positive result divided by the total number of times it should have (x100).


bands, and 47.8% (2292/4796) were positive only on the *P. falciparum* test band. A small proportion (0.6%, 31/4796) were positive only on the pan test band.

When the pan test band in the combination products was positive, the intensity of the band was the same as the *P. falciparum* test band in 11.2% of tests, while 33.0%, 39.1% and 16.7% of the pan tests bands were one, two and three

intensities lower than the corresponding *P. falciparum* test bands, respectively. Only 0.1% of tests had a pan band intensity larger than the corresponding *P. falciparum* test band.

When tested at low parasite density, none of the tests achieved 75% with a band intensity > 2 for *P. falciparum* or *P. vivax*, although 12 achieved at least 50% with this intensity for *P. falciparum* and 1 for *P. vivax*.

Figure 13: Phase-2 *P. vivax* panel detection score and positivity rate at 200 parasites/ μ L^a



^a Phase-2 evaluation panel consisted of 35 clinical blood samples containing wild type *P. vivax*; RDTs performed = 2 tests x 2 lots at 200 p/ μ L and 1 test x 2 lots at 2000 p/ μ L;

^b A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive;


^c The total number of times a test returned a positive result divided by the total number of times it should have (x100).

12.3.6 False-positive rates

None of the products had a false-positive rate > 10% with 52 clean-negative samples of the *P. falciparum* test line (Fig. 14); three products had false-positive rates > 10% with pan or *P. vivax* test lines (Fig. 15). Fifteen products had false-positive rates > 5.6% (for one or both lots), against samples containing

immunological factors. The rates of 9 of these were 5.6–7.4%, and those of a further six were 11.1–24.1% in both lots. These rates are worse than those in round 6 but similar to those in previous rounds. False positivity was seen predominantly for samples containing immunological factors (seven of the eight instances of false positivity > 10%).

Figure 14: Phase-2 *P. falciparum* (*P. falciparum* test line) false-positive rate against clean-negative samples^a




^a Phase-2 evaluation panel included 100 *Plasmodium* spp.-negative samples, of which 52 were clean negatives from healthy volunteers with no known current illness or blood abnormality.

The false-positivity rates for samples containing non-*Plasmodium* spp. agents were similar to those in round 6. In only four products was the false-positivity rate > 3.3%, and only one had a false positivity rate > 10% (10% and 13%

in each of the two lots); three products had false-positivity rates of 6.7% for one or both lots. False positivity was seen against all four of the samples of infections pathogens used: schistosoma, leishmaniasis, Chagas disease and dengue.

Figure 15: Phase-2 *Plasmodium* spp. (pan or *P. vivax* test line) false-positive rate against clean-negative samples^a



^a Phase-2 evaluation panel included 100 *Plasmodium* spp.-negative samples of which 52 were clean negatives, from healthy volunteers with no known current illness or blood abnormality.


Only 21 samples contained non-*Plasmodium* infectious agents and 27 samples contained immunological factors. For detailed information on the blood abnormalities and pathogens that generated false-positive results in specific products, see Annex 4 (Tables A4.6–A4.9).

Products were assessed for false-positivity rates for species that they were not designed to detect (Tables A4.4 and A4.5). Overall, the rates were low; only two combination products

showed > 10% false positivity for a non-*P. falciparum* infection when tested against samples of *P. falciparum* at 200 or 2000 parasites/μL.

There was no clear trend of higher false-positive rates in tests with higher PDS, indicating no clear association between the sensitivity and specificity of the tests at these detection thresholds (Figs 16 and 17).


Figure 16: Phase-2 *P. falciparum* false-positive rate^a versus *P. falciparum* panel detection score^b at low parasite density (200 parasites/μL)



^a False-positive rate is for clean-negatives, only;

^b A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.

Figure 17: Phase-2 *P. vivax* false-positive rate^a versus *P. vivax* panel detection score^b at low parasite density (200 parasites/μL)



^a False-positive rate is for clean negatives only.

^b A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.


12.4. Performance of resubmitted products

Of the 46 products in round 7, 15 (33%) had been evaluated previously. For six of the resubmissions, this was the second testing, and nine had been tested more than twice. Figs 18 and 19 show the performance in the current and previous testing of products against wild-type *P. falciparum* and *P. vivax* at 200 parasites/μL and clean-negative samples that had been resubmitted compulsorily and voluntarily.

The change in PDS between the two rounds varied for the five products that had not been tested since round 3 (compulsory

resubmissions): two had improved performance against *P. falciparum* (increases of 6 and 7 percentage points), and three showed worse performance (decreases of 7, 8 and 11 percentage points). The changes in the two pan-detecting products in their ability to detect *P. vivax* differed from those in round 3: the PDS of one increased by 5 percentage points, while that of the other dropped from 91% in round 3 to 0 in round 7.

Figure 18: Phase-2 *P. falciparum* panel detection score^a at low parasite density (200 parasites/μL) during initial and subsequent testing of compulsorily and voluntarily resubmitted malaria RDTs



^a Panel detection score – A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.


^b Clean-negative blood samples from healthy volunteers with no known current illness or blood abnormality.

For the 10 products that were voluntarily resubmitted for testing, no significant correlation was found between the PDS for *P. falciparum* at lower parasite density in consecutive submissions (Spearman rank correlation, $r = -0.30$, $P = 0.405$). The median change in detection of *P. falciparum* was +7.5% (range, -8.0 to 40.0%), which was almost significantly different from zero (Wilcoxon signed rank test, $P = 0.052$). Most of the products (8/10) detected *P. vivax*, and detection of this parasite improved overall (median change, 28.6%; range, -8.6 to 65.7%), which was almost statistically significant (Wilcoxon signed rank test, $P = 0.058$). No statistically significant correlation was found between the PDS of

consecutive submissions against *P. vivax* at lower parasite density (Spearman rank correlation, $r = 0.503$, $P = 0.20$).

On re-testing, approximately half of the resubmitted products (7/15) showed no change or an improvement in their false-positivity rate against clean negative samples; the median change in false-positivity rate was +0.4%. Most of the changes on re-testing were small (< 2.5%), except for two products, in which the false-positivity rate decreased by 7.3% for one product and increased by 22.9% for another. Both of these products were voluntarily resubmitted for testing in Round 7.

Figure 19: Phase-2 *P. vivax* panel detection score^a at low parasite density (200 parasites/μL) during initial and subsequent testing of compulsorily and voluntarily resubmitted malaria RDTs



^a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.

^b Clean-negative blood samples from healthy volunteers with no known current illness or blood abnormality.

13. HEAT STABILITY

13.1. Summary

A single *P. falciparum* culture sample and single wild-type *P. vivax* sample were used as the reference samples to test heat stability. Continuous in vitro culture of a wild-type *P. vivax* sample is difficult, largely because of selective invasion of reticulocytes by the parasite. Round 7 was the second in which the stability of test lines to detect non-*P. falciparum* parasites was tested. Because of the large number of aliquots used to assess heat stability, fewer replicate RDTs were tested against *P. vivax*, with four assessed against the 200 parasites/μL sample and two against the 2000 parasites/μL sample, for each of the two lots. The results of heat stability testing are summarized in Tables 6a and 6b, and detailed results are presented in Annex 4 (Tables A4.10–A4.18) and in Figs. 20–29, which show the results for the two lots combined. The maximum obtainable scores were 30 (15 tests per lot) against *P. falciparum* for 200 parasites/μL and 10 for 2000 parasites/μL (five tests per lot). The maximum score obtainable against *P. vivax* was 8 for 200 parasites/μL (four tests per lot) and 4 for 2000 parasites/μL (two tests per lot).

Confirmatory data on the stability of recent production lots of all tests can be obtained from the manufacturers and through the WHO–FIND lot-testing programme during product selection for procurement of RDTs.

13.2. *Plasmodium falciparum*

All of the 19 *P. falciparum*-only RDTs with an HRP2 test line were heat stable. Thus, they detected a cultured *P. falciparum* sample the same number of times when stored at room temperature (< 25°C) or at 35°C or 45°C (with 75% humidity) for 2 months (Fig. 20) as at baseline. One *P. falciparum*-only detecting product had a line that detected *P. falciparum* pLDH (in addition to an HRP2 line). Both lines were heat stable.

Of the 27 combination tests, 25 had an HRP2-detecting line. Of these, 24 tests were heat stable against a cultured *P. falciparum* sample. The 25th showed slight deterioration after 2 months' storage at 45 °C. One of the 24 heat-stable products showed a slight loss in detection when stored at 35 °C but not at 45 °C. The two combination tests with only pLDH-detecting lines for *P. falciparum* both showed some heat instability: one with a slight decline in performance at 35 °C and then again at 45 °C, and the second with a major decrease in performance at 35 °C and then again at 45 °C.

Many combination test products had pan lines that poorly detected low-density *P. falciparum* samples at baseline. Furthermore, tests with a baseline positivity < 100% showed unpredictable variation in positivity rates on subsequent testing, indicating that they were on the borderline of visibility. Two of the three combination tests with good (i.e. scoring at least 28/30) baseline pan line reactivity to the low-density sample showed good detection throughout, while one showed a marked reduction in performance after 2 months at 45 °C. The stability of pan-pLDH-detecting test lines was much poorer than that of HRP2-detecting test lines (Figs 20–25).

13.3. *Plasmodium vivax*

Testing of the heat stability of *P. vivax*-detecting lines using a *P. vivax* clinical sample was introduced in round 6. Many (11/14) of the combination RDTs with a pan-LDH test line were heat stable after 2 months' storage at 45 °C when tested against a wild-type *P. vivax* sample. Two of the 11, however, showed some variation in performance under other conditions: one had slightly poorer performance at baseline and after storage at room temperature, and the other had very poor performance after storage at 35 °C. Of the three tests that did not detect 100% of samples after storage at 45 °C, two showed 100% detection at baseline but some decrease after storage at 35 °C and 45 °C (one with only a slight decrease and the other with a more significant decrease). The third of the three tests performed very poorly at baseline (only 2 of 8 samples detected) and did not detect any samples after storage at any temperature.

The *P. vivax* pLDH line appeared to be more stable, 11 of 13 being heat stable under all testing conditions and a further one showing only a slight decrease in detection at 35 °C and 100% detection at 45 °C. The exception was a product in which the *P. vivax* pLDH line did not detect any of the *P. vivax* samples at baseline or after storage at room temperature and only slightly better performance after incubation with one of eight samples detected after storage at 35 °C and three of eight samples detected after storage at 45 °C (Figs 26–29).

Overall, both *P. falciparum* and *P. vivax* detecting products appeared more stable against samples with high (2000 parasites/μL) rather than low (200 parasites/μL) parasite density, as minor deterioration is not apparent at high parasite density.

Table 6a: Heat stability testing results for 46 malaria RDTs on a cultured *P. falciparum* sample at low (200) and high (2000) parasite density (parasites/μL). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C^a

Product	Product code	Manufacturer	Positive test results for <i>P. falciparum</i> (PF line)				Positive test results for <i>P. falciparum</i> (pan line)				Positive test results for <i>P. falciparum</i> (pan line)				
			200 parasites/μL				200 parasites/μL				2000 parasites/μL				
			Baseline	Room temp	35°C	45°C	Baseline	Room temp	35°C	45°C	Baseline	Room temp	35°C	45°C	
			Number of tests positive (max. 30)				Number of tests positive (max. 30)				Number of tests positive (max. 10)				
			Lots 1 and 2 combined				Lots 1 and 2 combined				Lots 1 and 2 combined				
PF only															
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	Advv Chemical Private Limited	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
Alere™ Malaria Ag Pf	05FK140-40-0	Standard Diagnostics, Inc.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
BioTracer™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line	RMSM-05071	Access Bio, Inc.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
DIAQUICK Malaria Pf. Cassette	W06200	DIALAB	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
Malaria Pf Rapid Test	GCMAL(pf)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
One Step Malaria HRP2 (P.f) Test	W37- C	Guangzhou Wondfo Biotech Co., Ltd.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
PALUTOP + pf®	5531	ALLDIAG SA	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
Parahit® f Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
SD BIOLINE Malaria Ag Pf (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	30	30	30	30	NA	NA	NA	10	10	10	NA	NA	NA
PF and Pan															
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advv Chemical Private Limited	30	29	30	30	0	0	0	10	10	10	10	10	10
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	05FK60AL-40	Alere Medical Private Limited	30	30	30	30	14	11	21	10	10	10	10	10	10
AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	30	30	30	30	0	3	0	5	10	10	9	10	10
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	30	30	30	30	23	26	15	3	10	10	10	10	10
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	30	30	30	30	15	25	27	30	10	10	10	10	10
BIOCREDIT Malaria Ag Pf/Pan (HRP1)(pLDH)	C32RHA25	Rapigen Inc.	30	30	30	30	24	18	8	2	10	10	10	10	10
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	30	30	30	30	0	0	0	0	10	10	10	10	10
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	30	30	30	30	30	29	30	21	10	10	10	10	10
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	30	30	30	30	29	0	2	0	10	10	10	9	10
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	30	30	30	30	30	28	30	30	10	10	10	10	10
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	30	30	30	30	1	0	1	4	10	10	9	10	10

(continued)

Table 6a: Heat stability testing results for 46 malaria RDTs on a cultured *P. falciparum* sample at low (200) and high (2000) parasite density (parasites/μL). Positivity rate at baseline (room temperature) and after 60 days' incubation at room temperature, 35°C and 45°C^a (continued)

Product	Product code	Manufacturer	Positive test results for <i>P. falciparum</i> (PF line)				Positive test results for <i>P. falciparum</i> (pan line)				Positive test results for <i>P. falciparum</i> (PF line)				Positive test results for <i>P. falciparum</i> (pan line)			
			200 parasites/μL				200 parasites/μL				2000 parasites/μL				2000 parasites/μL			
			Baseline	Room temp	35°C	45°C	Baseline	Room temp	35°C	45°C	Baseline	Room temp	35°C	45°C	Baseline	Room temp	35°C	45°C
			Number of tests positive (max. 30)				Number of tests positive (max. 30)				Number of tests positive (max. 10)				Number of tests positive (max. 10)			
			Lots 1 and 2 combined				Lots 1 and 2 combined				Lots 1 and 2 combined				Lots 1 and 2 combined			
Is It... Malaria Pf/PAN	MPPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	30	30	28	30	28	29	28	28	10	10	10	10	10	10	10	
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	30	30	30	30	16	15	26	20	10	10	10	10	10	10	10	
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	30	30	30	30	0	5	0	10	10	10	10	10	10	10	10	
Pf and Pv																		
ADVANCED QUALITY™ ONE STEP Malaria (pf/p.v.) Tri-line Test	ITP11003-TC25	Intec Products, Inc.	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	G60RHA25	RapiGEN Inc.	28	30	26	17 (29)	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
Malaria Pf/Pv Rapid Test	GMAL(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
Malaria Pf/PAN Test	PROPMALPF001	Real World Diagnostics	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	30	30	30	30	NA	NA	NA	NA	10	10	10	10	NA	NA	NA	
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	30	30	30	30	NA	NA	NA	NA	10	10	10	9 (9)	NA	NA	NA	
Pf, Pv and Pan																		
PALUTOP +4 optima®	5499	ALLDIAG SA	30	30	30	30	30	30	30	30	10	10	10	10	10	10	10	

NA, not applicable

Pf, *Plasmodium falciparum*; Pv, *Plasmodium vivax*; pan, *Plasmodium* species

^a Positive results presented in the table are based on stability of a positive reader 1 result

^b Product result shown along with results for HRP2 band and Pf-pLDH band, respectively

Table 6b: Heat stability testing results for 27 combination malaria RDTs on a wild-type *P. vivax* sample at low (200) and high (2000) parasite density (parasites/μL). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C^a


Product	Product code	Manufacturer	Positive test results for <i>P. vivax</i> (Pv line)				Positive test results for <i>Plasmodium</i> (pan line)				Positive test results for <i>P. vivax</i> (Pv line)				Positive test results for <i>Plasmodium</i> (pan line)			
			200 parasites/μL				200 parasites/μL				2000 parasites/μL				2000 parasites/μL			
			Baseline	Room temp	35°C	45°C	Baseline	Room temp	35°C	45°C	Baseline	Room temp	35°C	45°C	Baseline	Room temp	35°C	45°C
			Number of tests positive (max. 8) Lots 1 and 2 combined				Number of tests positive (max. 8) Lots 1 and 2 combined				Number of tests positive (max. 4) Lots 1 and 2 combined				Number of tests positive (max. 4) Lots 1 and 2 combined			
Pf and pan			NA	NA	NA	NA	8	7	4	8	NA	NA	NA	NA	4	4	4	4
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA016	Adv Chemical Private Limited	NA	NA	NA	NA	8	7	4	8	NA	NA	NA	NA	4	4	4	4
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60AI-40	Alere Medical Private Limited	NA	NA	NA	NA	8	8	8	8	NA	NA	NA	NA	4	4	4	4
AlITest™ Malaria Pf/Pan Rapid Test Cassette	IMPV-402	Hangzhou AllTest Biotech Co. Ltd.	NA	NA	NA	NA	7	7	8	8	NA	NA	NA	NA	4	4	4	4
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	NA	NA	NA	NA	8	8	8	8	NA	NA	NA	NA	4	4	4	4
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	NA	NA	NA	NA	8	8	7	7	NA	NA	NA	NA	4	4	4	4
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C32RHA25	RapiGEN Inc.	NA	NA	NA	NA	8	8	8	8	NA	NA	NA	NA	4	3	4	4
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	NA	NA	NA	NA	8	8	8	8	NA	NA	NA	NA	4	4	4	4
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	NA	NA	NA	NA	8	8	8	8	NA	NA	NA	NA	4	4	4	4
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	NA	NA	NA	NA	2	0	0	0	NA	NA	NA	NA	3	1	4	2
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	NA	NA	NA	NA	8	8	8	8	NA	NA	NA	NA	4	4	4	4
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	NA	NA	NA	NA	8	7	8	8	NA	NA	NA	NA	4	4	4	4
Is It... Malaria PF PAN	MPFPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	NA	NA	NA	NA	8	8	8	8	NA	NA	NA	NA	4	4	4	4
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	NA	NA	NA	NA	8	8	7	5	NA	NA	NA	NA	4	4	4	4
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-PF/Pan-CAS/25	Hema Diagnostic Systems	NA	NA	NA	NA	8	8	8	8	NA	NA	NA	NA	4	4	4	4
Pf and Pv																		
ADVANCED QUALITY™ ONESTEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	8	8	8	8	NA	NA	NA	NA	4	4	4	3 (3)	NA	NA	NA	NA
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
CareUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
Malaria Pf/Pv Rapid Test	GCMAUp(pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	0	0	1	3	NA	NA	NA	NA	0	0	1	0	NA	NA	NA	NA
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumquick Diagnostics Inc.	8	8	8	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	8	8	7	8	NA	NA	NA	NA	4	4	4	4	NA	NA	NA	NA
Pf, Pv and Pan																		
PALUTOP +4 optima®	5499	ALLDIAG SA	8	8	8	8	8	8	8	8	4	4	4	4	4	4	4	4

NA, not applicable

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species Pvom, *Plasmodium vivax*, *ovale* and *malariae*


^a Positive results presented in the table are based on stability of a positive reader 1 result

Figure 20: Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a low-density *P. falciparum* sample (200 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation




^a Maximum score is 30 (15 tests x 2 lots)

Figure 21: Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a high-density *P. falciparum* sample (2000 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation.




^a Maximum score is 10 (5 tests x 2 lots);

Figure 22: Heat stability of *P. falciparum*-specific test line in combination tests against a low-density *P. falciparum* sample (200 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation.



^a Maximum score is 30 (15 tests x 2 lots)

Figure 23: Heat stability of *P. falciparum*-specific test line in combination tests against a high-density *P. falciparum* sample (2000 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation.



^a Maximum score is 10 (5 tests x 2 lots)

Figure 24: Heat stability of pan line of combination tests against a low-density *P. falciparum* sample (200 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation.




Figure 25: Heat stability of pan line of combination tests against a high-density *P. falciparum* sample (2000 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation.




Figure 26: Heat stability of pan line of combination tests against a low-density *P. vivax* sample (200 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation.






Figure 27: Heat stability of pan line of combination tests against a high-density *P. vivax* sample (2000 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation




^a Maximum score is 4 (2 tests x 2 lots)

Figure 28: Heat stability of *P. vivax*-specific test line in combination tests against a low-density *P. vivax* sample (200 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation.



^a Maximum score is 8 (4 tests x 2 lots)

Figure 29: Heat stability of *P. vivax*-specific test line in combination tests against a high-density *P. vivax* sample (2000 parasites/ μ L). Positivity rate at baseline and after 60 days' incubation.



^a Maximum score is 4 (2 tests x 2 lots)

14. DESCRIPTION OF EASE OF USE, ANOMALIES, LABELLING AND INSTRUCTIONS FOR USE

14.1. Ease of use

After becoming proficient in using a product, two technicians submitted a joint agreed assessment of its usability. The results, which are a description of the product with emphasis on aspects considered important for ease of use in the field, are presented in Table 7. The assessment did not include a comparison of blood transfer devices, which are critical to both the safety and the accuracy of the testing procedure and pose a significant challenge to many users. These may vary by manufacturer in many products. Procurement decisions should be based on which transfer devices are best suited for the intended users, which should be discussed with the manufacturer before procurement. It is strongly recommended that RDT packaging, contents, safety and ease of use be assessed in the field as part of product selection (Annex S2, Table AS2.1).

14.2. Anomalies

In round 7, technicians regularly recorded anomalies from a list of problems encountered with some production lots evaluated in past rounds of testing and at WHO-FIND lot-testing laboratories. Since March 2012, these observations have been included in all WHO-FIND lot testing reports and were recorded as part of product testing for the first time in round 5. Table 8 shows the percentage of tests per product in which specific anomalies were observed and the frequency of tests with an anomaly in each product. Generally, users should be aware of major anomalies that may be encountered in production lots (Fig. AS2.1), as they can affect interpretation of RDT results. In round 7, 33 of the 46 products had between one and five different types of anomaly; in 13 products, no anomaly was seen (Table 8, Fig. 30). Incomplete clearing and red background (not obscuring test lines) were the most common anomalies, seen in 48% and 24% of products, respectively. Incomplete migration, failed migration and a red background obscuring the test lines were seen next most often, in 15%, 11% and 11% of products, respectively. In most (31) of the 33 products with anomalies, they were found in < 1% of the tests; in two products, anomalies occurred in 1.4% of tests (Table 8). This rate is much lower than that in round 6, when all products had between one and six anomalies and approximately half had a frequency > 2%.

14.3. Labelling and instructions for use

Adherence to a list of recommendations for instructions for use and product labelling were assessed for the first time in Round 7. Figs 31–38 show the percentages of products that adhered to the recommendations, grouped by theme.

Generally good adherence was found to the recommendations for labelling of the main package (Fig. 31) and the device (Fig. 32), with exceptions in the guidance on storage conditions and the inclusion of appropriate warning labels. Labelling of the buffer bottle (Fig. 33) and accessories (Figs 34–36) met only a few recommendations (see below). The instructions for use were highly variable, and many recommendations, including critical ones, were not met.

An important area of divergence from the recommendations was for laboratory safety. For example, none of the blood transfer devices carried labels indicating that they were for single use only, and 59% of lancet packages had no indication that those with damaged packaging should not be used (Fig. 35). The instructions for use of less than 10% of products advised disposal of tests in biohazard waste containers, and those of less than 20% advised disposal of lancets in sharps containers (Fig. 38). Only 26% of the instructions advised that a new pair of gloves should be used at each step (Fig. 38).

Important omissions were also found in basic product information: 28% of instructions for use did not mention that some necessary materials were not included in the kit (Fig. 37), and 33% did not list limitations of product. In terms of product specifications, nearly all the instructions listed the diagnostic sensitivity and specificity of the product, but few mentioned analytical sensitivity or specificity or gave information on parasite densities and reference methods (Fig. 37). Adherence to recommendations for describing procedures was also variable. While all gave good guidance on the interpretation of line combinations for positive results, fewer than half advised that a faint line should be considered a positive result (Fig. 38).

Figure 30: Percentage of RDTs with various anomalies observed in production lots




Figure 31: Adherence to box labelling recommendations




Figure 32: Adherence to cassette labelling recommendations




Figure 33: Adherence to buffer bottle labelling recommendations




Figure 34: Accessory labelling – use of internationally recognized symbols




Figure 35: Completeness of information on accessory packaging – blood transfer device and lancet




Figure 36: Completeness of information on accessory packaging – dessicant and alcohol swab




Figure 37: Completeness of information included in the IFU: intended use and precautions and limitations




Figure 38: Completeness of information included in the IFU – procedure and performance specifications.




Table 7: Ease-of-use description of 46 malaria RDTs included in round 7

Product	Product code	Manufacturer	Blood safety ^a			Instruction quality ^b			Combined score (max.5)	Number of timed steps	Total time to result	Desiccant with colour indicator (yes/no)	Buffer					Blood transfer device	Format	Language of instruction	Items included in RDT box ^c	
			Mixing wells involved	Retractable needle	Strip Exposed	Score (max. 3)	Mixing wells involved	Retractable needle					Strip Exposed	Score (max. 3)	Does not flow freely	Insufficient volume	Empty (bottle or vial)					Discoloured
Pf only																						
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	Advy Chemical Private Limited	1	NA	1	2			2	2	4	1	20	no					pipette	cassette	English	
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	Intec Products, Inc.	1	0	1	2			2	2	4	1	20	no					loop	cassette	English	Alcohol Swab / Lancet
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	1	1	1	3	1		2	2	5	1	20	no					loop	cassette	English	Alcohol Swab / Lancet
BioTrace™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	1	0	1	2			2	2	4	1	20	yes					loop	cassette	English	Alcohol Swab / Lancet
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	1	0	1	2			2	2	4	1	20	no					inverted cup	cassette	English	Alcohol Swab / Lancet
CareStart™ Malaria Pf(HRP2)(pLDH) Ag Combo 3-Line	RMSM-05071	Access Bio, Inc.	1	0	1	2			2	2	4	1	20	no					pipette	cassette	English	Alcohol Swab / Lancet
careUS™ Malaria Pf (HRP2) Ag ^d	RMO-M05082	WELLS BIO, INC	1	0	1	2			2	2	4	1	20	no					pipette	cassette	English	Alcohol Swab / Lancet
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	1	0	1	2			2	2	4	1	20	no					pipette	cassette	English, German	Alcohol Swab / Lancet
GMD Malaria Pf test	MDMALPH005	Medical Diagnostech (Pty) Ltd	1	0	1	2			2	2	4	1	30	no					pipette	cassette	English	Alcohol Swab / Lancet
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	1	0	1	2			2	2	4	1	15	yes					inverted cup	cassette	English	Alcohol Swab / Lancet
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	1	1	1	3			2	2	5	1	15	no					inverted cup	cassette	English	Alcohol Swab / Lancet
Malaria Pf Rapid Test	GCMAL(pf)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	1	NA	1	2			2	2	4	1	20	no					pipette	cassette	English	
One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	1	0	1	2			2	2	4	1	15	yes					pipette	cassette	English	Alcohol Swab / Lancet
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	GMDMALPF001	Meril Diagnostics Pvt. Ltd.	1	NA	1	2		1		1	3	1	20	no					pipette	cassette	English	
PALUTOP + pf®	5531	ALLDIAG SA	1	NA	1	2			2	2	4	1	20	no					loop	cassette	English, French	
Parahit® Ver 1.0 - Dipstick	551C103-50	ARKRAY Healthcare Pvt Ltd	1	1	0	2			2	2	4	1	25	no					pipette	dipstick	English	Alcohol Swab / Lancet
Parahit® F Ver 1.0 - Device	551C104-50	ARKRAY Healthcare Pvt Ltd	1	1	1	3			2	2	5	1	25	no					pipette	cassette	English	Alcohol Swab / Lancet
Alere™ Malaria Ag P.f.	05FK140-40-0	Standard Diagnostics, Inc.	1	0	1	2			2	2	4	1	20	yes					inverted cup	cassette	English	Alcohol Swab / Lancet
SD BIOLINE Malaria Ag P.f. (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	1	0	1	2			2	2	4	1	15	yes					inverted cup	cassette	English	Alcohol Swab / Lancet
Pf and Pan																						
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	1	0	1	2			2	2	4	1	20	no					inverted cup	cassette	English	Alcohol Swab / Lancet
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	1	0	1	2			2	2	4	1	20	no					inverted cup	cassette	English	Alcohol Swab / Lancet
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advy Chemical Private Limited	1	NA	1	2			2	2	4	1	20	no					pipette	cassette	English	
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	05FK60AL-40	Alere Medical Private Limited	1	NA	1	2			2	2	4	1	30	no					loop	cassette	English	
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	1	NA	1	2			2	2	4	1	30	no					loop	cassette	English	
BioTrace™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	1	0	1	2			2	2	4	1	20	yes					loop	cassette	English	Alcohol Swab / Lancet
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	1	NA	1	2			2	2	4	1	15	no					inverted cup	cassette	English	

Table 7: Ease-of-use description of 46 malaria RDTs included in round 7 (continued)

Product	Product code	Manufacturer	Blood safety ^a			Instruction quality ^b				Combined score (max.5)	Number of timed steps	Total time to result	Desiccant with colour indicator (yes/no)	Buffer				Blood transfer device	Format	Language of instruction	Items included in RDT box ^c		
			Mixing wells involved	Retractable needle	Strip Exposed	Score (max. 3)	Mixing wells involved	Retractable needle	Strip Exposed					Score (max. 3)	Does not flow freely	Insufficient volume	Empty (bottle or vial)					Discoloured	
AllTest™ Malaria P.f./Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	1	NA	1	2			2	2	4	1	10	no					pipette	cassette	English		
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN CAS/25	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	1	0	1	2			2	2	4	1	20	no					pipette	cassette	English	Alcohol Swab / Lancet	
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	1	0	1	2			2	2	4	1	30	no					inverted cup	cassette	English	Alcohol Swab / Lancet	
Is It... Malaria Pf PAN	MFPFAN050	Medsource Ozone Biomedicals Pvt. Ltd.	1	NA	1	2			2	2	4	1	20	yes	x				loop	cassette	English		
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	1	0	1	2			2	2	4	1	30	yes					pipette	cassette	English		
BIOCREDIT Malaria Ag Pf/Pan (HRP2/pLDH)	C32RHA25	RapiGEN Inc.	1	NA	1	2			2	2	4	1	30	no					pipette	cassette	English		
Pf and Pv																							
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-05072	Access Bio, Inc.	1	0	1	2			2	2	4	1	20	no					pipette	cassette	English	Alcohol Swab / Lancet	
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	1	0	1	2			2	2	4	1	20	no					inverted cup	cassette	English	Alcohol Swab / Lancet	
Rapid Test Kit for Malaria Ag Pf/Pv- Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	1	NA	1	2			2	2	4	1	30	no					loop	cassette	English		
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	1	1	1	3			2	2	5	1	20	no					loop	cassette	English	Alcohol Swab / Lancet	
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	1	NA	1	2			2	2	4	1	15	no					inverted cup	cassette	English		
One Step Malaria HRP2/pLDH (P.f/P.v.) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	1	0	1	2			2	2	4	1	15	yes					pipette	cassette	English	Alcohol Swab / Lancet	
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	Intec Products, Inc.	1	0	1	2			2	2	4	1	20	no					loop	cassette	English	Alcohol Swab / Lancet	
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	1	NA	1	2			2	2	4	1	20	no					pipette	cassette	English		
Malaria Pf/PAN Test	PROMALPFV001	Real World Diagnostics	1	0	1	2			2	2	4	1	30	no					pipette	cassette	English	Alcohol Swab / Lancet	
One Step Test for Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	1	NA	1	2		1		1	3	1	20	no					pipette	cassette	English		
MERISCREEN Malaria Pf/Pv Ag	C60RHA25	RapiGEN Inc.	1	NA	1	2			2	2	4	1	30	no					pipette	cassette	English		
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	RVM-M05082	WELLS BIO, INC	1	0	1	2			2	2	4	1	20	no					pipette	cassette	English	Alcohol Swab / Lancet	
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	GCMAL(p.f/v)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	1	NA	1	2			2	2	4	1	20	no					pipette	cassette	English		
Malaria Pf/Pv Rapid Test																							
Pf and Pv and Pan																							
PALUTOP +4 optima®	5499	ALLDIAG SA	1	NA	1	2			2	2	4	1	20	no					loop	cassette	English, French		

Pf, Plasmodium falciparum; Pv, Plasmodium vivax; pan, Plasmodium species

IFU, instructions for use

^a Mixing wells involved: Yes=0; No=1; retractable needle: yes=1; no=0; strip exposed, not within card or cassette: exposed=0, covered=1^b No diagrams=0; diagram of results=1; diagram of result and method=2^c Procurers should verify which accessories accompany test kits with the manufacturer and ensure they procure the appropriate products.

Table 8: Percentage distribution of anomalies observed by product in phase 2

Product	Product code	Manufacturer	Percentage of tests with at least one anomaly	Percentage of tests with specified anomaly						
				Red background	Red background obscuring test line(s)	Incomplete clearing	Incomplete migration	Failed migration	Strip misplaced in cassette (shift)	Patchy broken test line
Pf only										
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	Advy Chemical Private Limited	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0
Alere™ Malaria Ag Pf	05FK140-40-0	Standard Diagnostics, Inc.	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria P.f Rapid Card	17912	Bio Focus Co., Ltd.	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line	RMSM-05071	Access Bio, Inc.	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.1
CareUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	1.4	0.8	0.4	0.2	0.0	0.0	0.0	0.0
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf Rapid Test	GCMAL(p.f)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Malaria HRP2 (P.f) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0
MERISCREEN Malaria Pf HRP-II Ag	5531	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PALUTOP + pf®	55C103-50	ARKRAY Healthcare Pvt Ltd	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Parahit® Ver 1.0 - Dipstick	55C104-50	ARKRAY Healthcare Pvt Ltd	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0
Parahit® f Ver 1.0 - Device	05FK130-40-0	Standard Diagnostics, Inc.	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0
SD BIOLINE Malaria Ag Pf. (HRP2/pLDH) 2 Lines										
Pf and Pan										
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advy Chemical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II)pLDH)	05FK60A1-40	Alere Medical Private Limited	0.2	0.1	0.0	0.1	0.0	0.0	0.0	0.0
AllTest™ Malaria P.f/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0.6	0.0	0.0	0.4	0.1	0.2	0.0	0.0
BIOCREDIT Malaria Ag Pf/Pan (HRP1/pLDH)	C32RHA25	RapiGEN Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria P.f/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria P.f/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0.5	0.2	0.0	0.3	0.0	0.0	0.0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	0.5	0.5	0.0	0.1	0.0	0.0	0.0	0.0
Is It... Malaria Pf PAN	MPFPAN050	Medsorce Ozone Biomedicals Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	0.8	0.2	0.0	0.5	0.0	0.2	0.0	0.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0
Pf and Pv										
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0.2	0.2	0.0	0.0	0.0	0.0	0.1	0.0

Table 8: Percentage distribution of anomalies observed by product in phase 2 (continued)

Product	Product code	Manufacturer	Percentage of tests with at least one anomaly	Percentage of tests with specified anomaly						
				Red background	Red background obscuring test line(s)	Incomplete clearing	Incomplete migration	Failed migration	Strip misplaced in cassette (shift)	Patchy broken test line
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0.6	0.3	0.1	0.2	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	0.2	0.2	0.0	0.0	0.1	0.0	0.0	0.0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf/Pv Rapid Test	GCMAL(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.7	0.4	0.1	0.0	0.2	0.1	0.0	0.0
Malaria Pf/PAN Test	PROPMALPPV001	Real World Diagnostics	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
One Step Malaria HRP2/pLDH (P-f/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	1.4	0.6	0.1	0.5	0.1	0.0	0.0	0.1
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Pf, Pv and Pan										
PALUTOP +4 optima®	5499	ALLDIAG SA	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1

15. DISCUSSION OF KEY FINDINGS

This report describes the performance of many of the commercially available malaria antigen-detecting RDTs manufactured under the ISO 13485:2003 quality standard. For malaria RDTs to improve the management of febrile illness in malaria-endemic areas, they must have adequate:

- sensitivity, to detect nearly all clinically significant cases of malaria;
- specificity, to accurately discriminate non-malarial febrile illness from malaria in order to ensure appropriate management and accurate disease monitoring;
- stability, to maintain accuracy after transport and storage in ambient conditions; and
- ease-of-use, and adequate labelling and instructions for use to ensure safe, correct preparation and accurate interpretation of results.

Malaria RDTs were evaluated in terms of these four requirements in order to assist national malaria control programmes and other procurement agencies in selecting products appropriate for their needs. The evaluation constitutes the laboratory component of the WHO programme for prequalification of in vitro diagnostics. The panel used ensured successful discrimination between the RDTs evaluated. A number of products showed a high rate of antigen detection, a low false-positive rate and good heat stability. These attributes are essential for tests used as a basis for decisions about malaria treatment in the populations of most malaria-endemic countries.

Overall, the mean PDS against low-density *P. falciparum* samples in round 7 was 87.2%, slightly higher than in round 6 (83.6%) and continuing the pattern of improvements in each round.¹ For *P. vivax* tests, the mean PDS of 76.8% is the highest achieved so far.² The median false-positive rate was 0%, which is lower than in round 6 (0.5%). Overall, a high level of performance has been maintained in *P. falciparum*-only tests, and improved performance has been seen in *P. vivax*-detecting RDTs. As previously, too few Pf-pLDH-based RDTs were submitted for evaluation: only three were assessed in round 7. The mean PDS (at 200 parasites/μL) was 62% (range, 38–75%) in rounds 2–6 (17 products) and 2.0–88.9% in rounds 2–7.

Five products tested in round 3 of the programme were resubmitted for testing in round 7. Two performed better 5 years after initial testing, but three performed less well, and two of these no longer met the WHO criteria for procurement.

The evaluation is performed against a standardized panel of cultured *P. falciparum* and frozen blood samples by experienced technicians in a research laboratory and is not

therefore a field evaluation of the accuracy of RDTs in a specific epidemiological context in the hands of the intended users. The panel is designed to mimic fresh blood samples from actual cases as closely as possible, while allowing direct comparison of a large number of products simultaneously, with control for confounding factors, and is calibrated to a level likely to discriminate differences in the performance of various products. The discussion points below should therefore be taken into account in interpreting the results.

15.1. Panel detection score and its relation to sensitivity

Evaluation of the RDTs against the phase-2 wild-type parasite panel with a parasite density of 200 parasites/μL (Figs 10 and 11) revealed a range of frequency and consistency of antigen detection between products, recorded as the PDS. As expected, testing at higher parasite density (2000 parasites/μL) resulted in smaller differences in performance. As two tests from two different lots were tested at 200 parasites/μL and as all four tests had to be positive in order for a sample to be considered "detected" by an RDT, a positive result indicates the ability of a product to detect the target antigen in the sample and to do this consistently (both tests from both lots). A parasite density of about 200 parasites/μL should be detected to ensure high field sensitivity for clinically significant malaria infection in many malaria-endemic populations (11).

The PDS in the panels used in this evaluation differs from the test sensitivity in clinical settings for five main reasons.

- (i) The performance of different lots or batches of the same product may vary. Variation in lot performance is an issue for all diagnostics; therefore, the results found in the evaluation may not predict the results for subsequent RDT lots. It is important to test lots before their distribution in the field to ensure that the expected performance is maintained (section 16.2).
- (ii) In clinical settings, patients show wide variation in parasite density, the range depending on the local epidemiology of the disease. The parasite density in the population tested affects the clinical sensitivity of a test. The PDS against a test panel of blood samples diluted to 200 parasites/μL is likely to underestimate the clinical sensitivity of an RDT in areas where symptomatic patients have much higher parasite densities. Many tests that show only moderate detection of the 200-parasites/μL panel may perform well in such settings, as indicated by the better PDS of most products against the panel at 2000 parasites/μL. The small differences in PDS seen in Figs S1, S2 and 9–11 and Tables 4 and 5 found among the better-performing RDTs in this evaluation are unlikely to result in noticeable differences in clinical sensitivity, and other issues, such as required storage conditions, stability, cost, experience and training

¹ The PDS values for *P. falciparum* in rounds 1, 2, 3, 4 and 5 were 67.2%, 69.9%, 75.5%, 81.6% and 81.0%, respectively.

² The PDS values for *P. vivax* in rounds 1, 2, 3, 4, 5 and 6 were 36.0%, 58.9%, 47.1%, 51.3%, 61.3% and 70.7%, respectively.

of the intended users, ease of use (Annex S2) and manufacturing capacity, may be equally important in test selection. Consideration of the parasite density in target populations and the probable sensitivity of RDTs in the field indicates that, even in areas with high transmission and strong malaria immunity, the population may include individuals with a low parasite density but clinically significant infection (e.g. young children, pregnant women, people who regularly use bed nets, immigrants and people with reduced immunity). The ability to detect low parasite-density infections reliably, therefore, remains important. As some countries move towards elimination of malaria, population immunity will decrease and/or clinical cases may be detected earlier, and it could become increasingly important to use diagnostic tests that detect low parasite density (i.e. with a high PDS against samples with 200 parasites/μL).

(iii) The performance of tests against the challenge panel may not always predict sensitivity in clinical testing, e.g. when antigen expression by certain parasite populations differs greatly from that in the panel. For example, *P. falciparum* strains in some areas of Africa (Eritrea (33), Democratic Republic of the Congo), India (13) and South America (34) do not express HRP2 antigens because of gene deletions (12–13). If a significant proportion of parasites in a given area do not express HRP2 and HRP3, leading to false negative results, tests to detect other target antigens (e.g. pLDH or aldolase) must be used. To date, parasite populations with a high frequency of non-expression of target antigens have been identified in several countries in South America (12) and in Eritrea (33, 34). The reactivity of the non-HRP2, Pf-specific test lines against phase 1 and 2 Pf (HRP2-containing) samples is currently the best predictor of how well these RDTs would detect *pfhrp2*-negative parasites. In most cases, the Pf panel detection score for products based on pf-pLDH-specific test lines is < 75, the cut-off for procurement. In round 7, one combination test met the procurement criterion, with a PDS of 75 against 200 parasites/μL Pf samples. For a summary of options and test performance in round 7 and previous rounds, refer to the WHO interim guidance on investigating false-negative RDTs and *pfhrp2/3* gene deletions.¹

(iv) The conditions under which RDTs are transported and stored can alter their sensitivity in the field. The tests evaluated in round 7 were shipped and stored under conditions intended to safeguard them from degradation by high temperature or other extreme conditions. If such precautions are not taken with purchased RDTs, loss of performance could result. The ambient temperature of storage conditions varies widely in the settings in which these tests are commonly used, as does the temperature during transport; therefore, the requirements for the heat stability of a product will differ. Tests should be transported and stored well within the temperature range recommended by the manufacturer (see Annex 1) and extremes of temperature avoided (32, 35).

(v) Diagnostic sensitivity and specificity depend on the quality of preparation and interpretation of the tests. Highly trained technicians tested all the products in this evaluation. In clinical settings, malaria RDTs are often used by health workers with limited training and supervision; therefore, simple design and clearly interpretable results are required to ensure translation of the technical proficiency of a product into accurate diagnoses in the field (36).

15.2. False-positive rate and specificity

False-positive rates are reported against a panel of 52 clean-negative samples taken from blood donated in low-transmission settings by people without symptoms of malaria. In addition, false-positive rates were calculated with a smaller number of samples with specific characteristics that affect the likelihood of a false-positive result from an immunodiagnostic test (e.g. rheumatoid factor, anti-nuclear antibody) or that may be significant in a specific population in a malaria-endemic area (e.g. leishmaniasis, dengue). The importance of these results depends on the intended area of use. High false-positive rates with samples of blood from dengue patients, for example, might not be a significant factor in regions in which dengue does not occur. In view of the small number of samples in each category in this evaluation, the results should be considered primarily a guide to potential cross-reactions, which should be closely monitored if they are relevant to the target population.

In general, it is preferable to procure a product with a low rate of false-positive reactions. In the case of many diagnostic tests, a trade-off must be made between a preference for a high rate of antigen detection (sensitivity) and a low false-positive rate (specificity). The context in which the test will be used will guide the relative importance of these two factors in the choice of one product over another. Overall, in this evaluation, there was no correlation between a lower PDS (loss of sensitivity) and a low false-positive rate (high specificity). A number of products had both a high PDS and a low false-positive rate.

15.3. Reactivity of combination HRP2 and pan-pLDH test lines against *P. falciparum* samples

Instructions for the use of *P. falciparum*/pan and pan/*P. falciparum* combination tests classify *P. falciparum* infections as either HRP2 test line-positive alone or in combination with the pan-pLDH line. Combination tests that return only a positive HRP2 test line may be incorrectly interpreted as false positives for malaria infection secondary to persistent (HRP2) antigenaemia. The results in this report clearly indicate that most combination tests in which HRP2 is used for the detection of *P. falciparum* return positive results only on the HRP2 band at lower densities of *P. falciparum* (Table A4.2). When both the HRP2 and the pan test bands were positive, the mean band intensity was significantly lower on the pan test

¹ http://apps.who.int/iris/bitstream/10665/208819/1/WHO_HTM_GMP_2016.4_eng.pdf (accessed 8 March 2017).

band than on the HRP2 test band. Therefore, it is important to reinforce adherence to the manufacturer's instructions for use (Annex 2) and to emphasize that for combination HRP2/pan-pLDH tests, a HRP2 test line-positive alone may well be attributed to the poor reactivity of pan-pLDH lines.

15.4. Heat (thermal) stability

The RDTs evaluated were held for 2 months at room temperature (21–25°C) and at 35°C and 45°C at 75% humidity and tested to evaluate stability at these temperatures as compared with baseline detection. The importance of thermal stability depends on the conditions under which a product will be transported and stored. Thus, stability at high temperatures is vital if an RDT is to be stored at clinics in a country where the ambient temperature can reach 45°C in the hot season but is less critical in a high-altitude or cooler environment where the temperature rarely rises above 35°C. Many commercially available RDTs indicate 30°C or 40°C as the maximal storage temperature (Annex 1). Higher temperatures were tested in this evaluation because malaria-endemic countries often have maximum ambient temperatures of 35°C, although use of cool storage can allow storage of products below this temperature. When RDTs are likely to be transported and stored at high ambient temperatures, heat (thermal) stability must be considered a significant factor in ensuring sensitivity.

High humidity accelerates the degradation of malaria RDTs and other lateral flow tests. All the products in this evaluation were packaged in individual envelopes containing desiccant and designed to be moisture-proof. This allows the user to open the envelope of a test at the time of use, limiting exposure to high humidity. During the stability-testing phase of this evaluation, the RDTs were stored at 75% humidity. The packaging should, if in good condition, protect the contents from exposure to high humidity during storage. The results presented here provide an assessment of both the stability of the RDT and the quality of its packaging.

Several *P. falciparum*-detecting products were highly stable at the temperatures and times used in the evaluation. In this round, as in previous ones, pan-specific lines (pLDH) performed less well at baseline and were less stable than HRP2 test lines, so that it was difficult to assess post-incubation stability. When tested against *P. vivax*, many of the pan-pLDH lines were highly stable at all temperatures and times tested. In most products, the *P. vivax* pLDH lines were also highly stable. These results for *P. vivax* are an improvement over round 6.

While the temperature and humidity were held constant in this evaluation, temperatures in the field fluctuate with the time of day and season. Two months' storage at a set temperature cannot accurately predict long-term stability under field conditions, but loss of sensitivity for parasite detection over this period indicates that significant sensitivity will be lost if RDTs are stored at similar or higher temperatures for a significant period of their storage time and the likelihood of greater susceptibility to degradation during short exposure to much higher temperatures, such as during transport (37, 38).

15.5. Ease-of-use description

The sensitivity and specificity of RDTs depend on the quality of preparation and interpretation. In general, a simpler format with fewer steps or fewer required extraneous materials is likely to be prepared and interpreted more reliably. Thus, cassette-format RDTs are generally more reliably prepared and interpreted than products in dipstick format (39). The extra cost of this format may be offset by the advantages of greater accuracy and, in some cases, less additional equipment required to perform them.

The method by which blood is transferred from the patient to the test is important for the safety of the user and for the accuracy of the volume transferred. Devices for blood transfer are supplied with RDTs but vary widely in design and accuracy (31). The performance of blood transfer devices was not formally assessed in this evaluation, as blood was transferred from a tube with a micropipette to ensure that the volume specified by the manufacturer was used. Procurement programmes for RDTs should consider the adequacy of the blood transfer device supplied, including the experience of health workers and the cost and time required for retraining. It may be appropriate to discuss with manufacturers the possibility of changing the blood transfer device from that usually supplied.

The clarity of results is important for interpreting tests. A clearly visible (intense) test line is less likely to be overlooked than a line that is barely visible. While reading proficiency and adequate workplaces should be ensured, some health workers might have suboptimal vision or work in inadequate lighting. Although the intensity of the test band was found to be correlated with the PDS of RDTs, PDS is determined only from a positive or negative result under ideal working conditions. Thus, it is important when selecting RDTs also to consider the relative intensity of the test bands, with a preference for intense bands (i.e. an intensity > 2).

The importance of format and the simplicity of the test design depend on the intended users. Trained laboratory technicians can handle a complicated procedure more reliably than village volunteers with limited supervision. In all cases, proficiency-based training and adequate supervision should be included in any RDT-based diagnostic programme, and clear instructions should be provided in a language and format appropriate for the user (40, 41). Annex S2 provides guidance on conducting a field-based ease-of-use assessment (Table AS3.1).

15.6. Labelling and instructions for use

The labelling on primary packaging (the box), device packaging and the device itself was generally consistent and adhered to most of the recommendations. A notable exception was that almost all products failed to include warning labels on the boxes and cassette packaging. Much poorer adherence to the recommendations and less consistency among products was seen in labelling of buffers and other accessories.

Adherence to the recommendations for instructions for use was variable. Product information and intended use were generally included, with notable exceptions, such as the failure to list all the materials required but not provided. Other aspects of the instructions often did not meet the recommendations; for example, the instructions for over one third of the products did not include precautionary notes on the use of damaged products or product limitations. With regard to performance, the instructions for most products covered diagnostic sensitivity and specificity, but very few included analytical sensitivity and specificity or issues of parasite density and reference methods. Adherence to the recommendations for information on procedures was generally poor, particularly for safety practices and interpretation: fewer than half the product instructions advised that a faint line should be considered a positive result.

Wide differences in how information is presented to users can affect the ease and consistency of use and potentially affect proper use. There is considerable scope for improvement in the instructions for use of currently recommended products.

15.7. Anomalies in RDT production lots

Anomalies that affected interpretation of the results were encountered with variable frequency in the production lots submitted for evaluation. A glossary of RDT anomalies has been prepared (Fig. AS2.1) on the basis of the experience of several rounds of product testing, with 4095 lots tested in the WHO-FIND lot testing programme. This glossary may be used in RDT training programmes to illustrate potential problems with some production lots and how to report them accurately. As many of the anomalies are infrequent, they might not be picked up in manufacturers' quality control or lot release procedures; therefore, this information is also useful for manufacturers that wish to improve their processes.

15.8. Inter-lot variation

Only two production lots of each product were evaluated in the testing programme. Malaria RDTs are complex biological products made up of components that are commonly supplied from different sources and are subject to a variety of conditions during manufacture that may affect the quality of the final product. All manufacturers that entered this evaluation provided at least one current ISO 13485:2003 certificate for a manufacturing facility. This standard is designed to ensure consistency in the quality of the final product, if correctly implemented. The results presented here indicate that inter-lot variation does occur, and WHO strongly recommends that a sample of RDTs from each production lot be tested before their dissemination to the field, to ensure that they meet an appropriate standard. This can be facilitated by WHO through two WHO-recognized lot-testing facilities (section 16.2).

Inter-test variation will be detected to some extent by routine lot testing. Ensuring that manufacturers follow good

manufacturing standards should minimize the likelihood of inconsistencies due to poor practice in the manufacturing process. Culture-based panels that are subsets of the phase-1 panel used in this evaluation are available as reference standards for manufacturers against which to set their lot-release criteria.¹

15.9. Selecting RDTs: target antigens, species and sensitivity

Target antigens

The malaria RDTs evaluated detect one or more of three parasite antigens, HRP2, pLDH and aldolase, in various combinations. HRP2 is present only in *P. falciparum*, whereas aldolase and pLDH are present in all four species and may be used as pan or all-species targets. Some tests use differences in pLDH sequences between species as a means to differentiate *P. falciparum* from *P. vivax* and other species. There is considerable overlap in the PDS of products that target the different antigens in this evaluation. While the products with the highest PDS for *P. falciparum* targeted HRP2, a number of pLDH-detecting products had high PDS against *P. vivax*. The thermal stability of tests that target these different antigens also overlapped for samples with high parasite density.

In choosing an RDT, account should be taken of the target antigen: HRP2-detecting RDTs should not be used in areas where false negative RDT rates due to non-expression of HRP2 is common (> 5%) (33, 34). Five *P. falciparum* RDT products were evaluated in round 7 that detected *P. falciparum* with Pf-pLDH, two combination tests had only Pf-pLDH, and three had HRP2 as well. Of the three with both HRP2 and Pf-pLDH, two combined the two antigens on a single test line, and the other had two separate test lines to detect *P. falciparum*. Only one of the three products with separate pf-pLDH test lines met WHO procurement criteria with a *P. falciparum* PDS of 75% at 200p/μl. However, the pf-pLDH test lines on all three products performed well at 2000p/μl (PDS range: 92–100%). Detection of Pf-pLDH is known to be less sensitive than detection of HRP2 at low parasite densities, and low-density infections with HRP2-deleted *P. falciparum* parasites could therefore be missed.

Tests that detect only HRP2 (without pLDH or aldolase lines) will be of limited use where non-*falciparum* malaria is common. pLDH (and possibly aldolase) RDTs may have further advantages when antigen persistence (common with HRP2) result in a high false-positive rate in areas where early retesting in the weeks immediately after treatment is common. As mentioned in section 2.3, however, combination tests with both HRP2 and pan test lines should not be used for discriminating between acute infection and persistent antigenaemia, as the overall reactivity of pan test lines is much lower than that of HRP2 test lines, particularly at low parasite density.

¹ http://www.who.int/malaria/areas/diagnosis/rapid-diagnostic-tests/malaria_specimen_bank/en/

Species-specific vs non-species-specific RDTs

RDTs are mainly tools for making clinical decisions, but their role in surveillance has grown dramatically. If all infections are managed in the same way, ie. with artemisinin-based combination therapy, there is no clinical advantage of having an RDT that can distinguish falciparum from non-falciparum infection: a pan-only test would suffice. If treatment of the two infections is different, however, distinguishing between falciparum and non-falciparum infection is a priority, and a combination test must be used (Pf/Pan). When the results of RDTs are used for species-specific monitoring, a species-specific RDT is preferable (Pf/Pv). No currently available RDT can specifically identify *P. malariae* or *P. ovale* infections. Furthermore, pan-species and Pvom tests are not evaluated against these, as there is no source of suitable mono-species infections. Published data suggest, however, that the sensitivity of RDTs for detecting these species is significantly poorer than that for detecting *P. falciparum* and *P. vivax* (42).

RDT sensitivity and the role of highly sensitive diagnostic tools

RDTs are considered to be tools to detect symptomatic malaria infections, with ≥ 200 parasites/ μ L (11); however, the threshold of parasitaemia associated with symptoms depends on both transmission intensity and individual immunity to malaria. In a review of parasite densities in various epidemiological settings (43), the best estimate of the proportion of symptomatic people with a parasite density >200 parasites/ μ L who seek care at a health facility was 90–95% for *P. falciparum* and approximately 85% (range, 78–92%) for *P. vivax*. The performance panels used in product testing challenge the RDTs to consistently detect samples with antigen concentrations at the 200 parasites/ μ L threshold, corresponding to minimal HRP2 antigen concentrations of 0.59–0.80 ng/mL and expected to detect the majority of clinically symptomatic malaria infections in endemic settings. The individual and public health benefits of detecting and treating submicroscopic or very-low-density parasitaemia are poorly understood and would require rigorous risk-benefit analysis (44,45). Nonetheless, highly sensitive tests like PCR and LAMP have been used for surveillance and focus investigation in low-transmission areas, and a highly sensitive HRP2-based RDT (Alere™ Malaria Ag Pf (05FK140), Standard Diagnostics) has

been commercialized with claims of an analytical sensitivity of 0.05–0.08 ng/mL of HRP2 (46). This is approximately 10 times the detection limit of the best conventional RDTs that detect the samples in the product testing panel. (Annex S1). The current performance panels cannot discriminate between products that can detect samples with antigen concentrations comparable to < 200 parasites/ μ L (considered to be highly sensitive) and those that detect only > 200 parasites/ μ L (conventional RDTs). Therefore, as expected, the performance of the highly sensitive RDT in round 7 was similar to that of other high-performing conventional RDT able to detect the majority of clinically significant infections. As for other high sensitive tests, the use of the high-sensitive HRP2-based RDT evaluated in round 7 is not recommended for malaria clinical case management, as it is anticipated to lead to the problems listed below:

- i) Detection of low levels of HRP2 antigen concentrations associated with low density falciparum infections may be associated with decreased specificity of diagnosis of clinical malaria. Since the association between antigenemia and parasitemia and fever varies from place to place, season to season, their use may potentially lead to misdiagnosis and overtreatment of fever, as malaria.
- ii) Persistent HRP2 antigenemia over longer period following successful treatment may also cause more false positive clinical cases.
- iii) If highly sensitive diagnostic tests are used for clinical case management or surveys, there is a potential threat of antimalarial stock outs due to increased test positivity caused by low density, asymptomatic infections.
- iv) If end-users abruptly see an unexpected increase in the number of malaria cases following the introduction of a highly sensitive RDT, this may undermine their confidence in conventional malaria RDTs as case management tools for acute febrile illness.

More research is needed to determine the clinical consequences of submicroscopic infections, their contribution to onward disease transmission and the role of highly sensitive diagnostic tests in surveillance for targeting malaria elimination.

16. USING RESULTS TO ENSURE HIGH-QUALITY DIAGNOSIS IN THE FIELD

This report provides data to guide malaria control programmes in selecting products that are likely to perform to a high standard in the context in which the programme operates. The report does not provide a list for procurement but should aid potential buyers by providing comparative data on the performance of the available products. Final product selection requires that these data be considered systematically, taking into account the distribution of parasite density in the target population in whom the tests will be used, the experience and training of the intended users and other criteria such as climate and transport/storage conditions, price and supply aspects, and others. Box 3 lists WHO's *current* minimum RDT selection criteria, as endorsed by the Malaria Policy Advisory Committee, and Tables S2, S3 and 5 are colour-coded to reflect these minimum performance criteria for product selection. As WHO prequalification will become a requirement as of 1 January 2018, the prequalification status of each product is also indicated. A web-based tool for filtering product testing results by various parameters is available on the FIND website and has now been updated to allow rapid identification of products with the same blood volume, number of buffer drops and time until reading.¹ Annex 1 groups products according to similar procedure characteristics. Furthermore, an algorithm to guide selection is given in Annex S3, and detailed guidance was published by WHO in *Recommended selection criteria for procurement of malaria rapid diagnostic tests, Good practices for selecting and procuring rapid diagnostic tests for malaria (16)* and *Universal access to malaria diagnostic testing (17)*.

While malaria RDTs can be used in a number of settings, the greatest impact on public health will ensue from extending access to accurate, parasite-based diagnoses of malaria to regions and populations where good-quality microscopy-based analysis is impractical to maintain. This will allow implementation of WHO recommendations on universal parasite-based diagnosis before antimalarial therapy (2) and currently applies to most people at risk for malaria in endemic countries (1). In many settings where RDTs have been introduced, the true rate of parasitaemia has been found to be considerably lower than expected, so that health systems can reduce wastage of antimalarial medicines and focus on appropriate management of non-malarial causes of fever, including early pneumonia and sepsis. In order for an RDT programme to have its full potential public health impact, it must therefore address not only malaria but also the management of other common and severe febrile illnesses that occur locally in the differential diagnosis of malaria (46).

¹ An interactive guide designed to short-list tests according to programme needs, based on the performance of tests in rounds 3–6 of the WHO product testing programme can be found at: <https://www.finddx.org/malaria/interactive-guide/> (accessed 8 March 2017).

16.1. WHO prequalification

The WHO programme for prequalification of in vitro diagnostics promotes access to good-quality in vitro diagnostic tests by applying the principles of a comprehensive regulatory assessment. This includes inspection of the manufacturer's quality management system, assessment of technical documentation (dossier review) and an independent performance evaluation.

The results of the WHO malaria product testing programme fulfill the performance evaluation component of the prequalification process. Twelve malaria RDT products have been prequalified.² Prequalification has not been a requirement for eligibility for United Nations procurement tenders for malaria RDTs, as it is for other RDTs, such as for HIV; however, WHO prequalification will determine the eligibility of malaria RDTs for procurement after 31 December 2017. WHO product testing will continue to be the independent performance laboratory evaluation component of the prequalification process. Round 8 of product testing is under way. All manufacturers who submit products to round 8 are required also to submit applications for WHO prequalification.

16.2. Beyond procurement

Diagnostic tests are usually used at the start of a health system intervention, and their use is based on the assumption that appropriate patient management, based on testing, will follow. Thus, successful introduction of RDTs requires careful planning beyond rational procurement to ensure consistent supplies of all the necessary materials (including gloves, sharps disposal containers and supplies required for further case management), training of users, community sensitization and monitoring of diagnostic quality and results. This extends malaria management to management of other febrile diseases and health service delivery systems and requires integration with other health programmes.

While this report does not provide a list for procurement, it provides information to guide procurement of RDTs within this framework. Factors beyond the performance characteristics reported here, however, must influence procurement decisions. An example of an algorithm, including an ease-of-use assessment, is provided in Annexes S2 and S3 to guide decisions.

Details of implementation will vary widely between programmes, depending on local capacity and needs. Further recommendations on budgeting, planning and implementation can be found in Annex 5 and in the relevant WHO guidance document (17).

² http://www.who.int/diagnostics_laboratory/evaluations/pq-list/malaria/public_report/en/ (accessed 8 March 2017).

16.3. Post-market surveillance: lot verification

Post-market surveillance confirms manufacturer compliance with quality expectations and is an important component of any quality assurance scheme. Specifically for malaria RDTs, post-market surveillance ensures that the quality reported in product testing is found in what is available on the market to the user. Post-market surveillance can be performed proactively through lot verification (described next), which is recommended to all procurers, or reactively through completion of a "WHO user complaint form for reporting problems and/or adverse events related to diagnostic products" and submitted to the following email address: diagnostics@who.int.

As a complement to product testing, WHO and FIND currently support laboratories that perform continued quality assurance of RDTs in the form of lot testing. This programme responds to requests from all purchasers, including national malaria programmes, manufacturers and procurement bodies, to assess the quality of RDT lots before shipment from the production facility or, when they arrive in a country, before distribution to the field and for clinical use. Testing is performed against parasite-positive and -negative panels prepared and characterized in the same way as the panels used in this evaluation. A number of national institutions have also developed this capacity, and, more recently, several countries have begun pilot-testing malaria recombinant antigen panels to monitor trends in lot performance. Lot testing reassures countries that the product they have

purchased performs to a high standard and helps to ensure that manufacturers produce consistently good lots and improve their products. The results support decisions for accepting or rejecting lots. Lot testing provides information about the adequacy of RDTs for clinical use, their stability over their shelf life and any anomalies observed during testing that may also be encountered in the field.

Countries and manufacturers ship 100–150 RDTs to regional, WHO-recognized lot testing centres, where they are evaluated against a small panel of parasites at low density and against negative samples (Fig. 2). They are subsequently incubated at a temperature close to the manufacturer's specified storage temperature and retested 6 months before expiry. Initial results are available after 5 days, and definitive results after subsequent confirmatory testing, if required. Details of the protocol can be found in the methods manual for lot testing (27). As lot-to-lot variation has previously been noted in many products, purchasers are encouraged to participate in the lot-testing programme to confirm the quality of RDT lots prior to use. Certain anomalies resulting from defects in production lots or RDT degradation, or even defects of some kit accessories, may affect the running of the test or interpretation and may warrant a field safety notice and corrective action. In such instances, a special lot testing service can be provided, which is determined case by case.

Lot testing is free of charge, but the requester must cover shipping costs, including related tax and duties. To access lot testing through the WHO-FIND programme, contact christian.nsanjabana@finddx.org and cc: Malaria_rdt@who.int at least 2 weeks before RDTs are ready for shipment.

17. CONCLUSIONS

This report adds to the large data set on malaria RDT performance published regularly since 2009 (3–8). The product testing programme continues to be an authoritative source in the field of malaria RDT evaluations in terms of the number of products evaluated, its independence and its comprehensiveness. New laboratory methods have been developed and validated to support parasite characterization, and this work has generated new findings on variation in antigen content at similar parasite densities and in the structure and expression of histidine-rich proteins. Round 7 introduced a new component of the product evaluation:

examining the labelling and instructions for use associated with each product in a standardized manner, to demonstrate their performance against a set of standards for these components. Publication of the results of past WHO product testing rounds has affected the procurement practices of countries and procurement agencies and contributed to a shift in the malaria RDT market towards better-performing products (1, 48). The report of round 7 adds to the number of well-performing RDTs for which comprehensive performance data are now available including the first high-sensitive RDT and provides updated data on 15 product resubmissions.

18. REFERENCES

1. *World malaria report 2016*. Geneva: World Health Organization; 2016.
2. *Guidelines for the treatment of malaria. 3rd edition*. Geneva: World Health Organization; 2015.
3. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 1 (2008)*. Geneva: World Health Organization; 2009.
4. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 2 (2009)*. Geneva: World Health Organization; 2010.
5. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 3 (2010–11)*. Geneva: World Health Organization; 2011.
6. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 4 (2012)*. Geneva: World Health Organization; 2012.
7. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 5 (2013)*. Geneva: World Health Organization; 2014.
8. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 6 (2014–2015)*. Geneva: World Health Organization; 2015.
9. *Informal consultation on laboratory methods for quality assurance of malaria rapid diagnostic tests*. Manila: WHO Regional Office for the Western Pacific; 2004 (RS/2004/GE/26(PHL)).
10. *Prequalification of in vitro diagnostics*. Geneva: World Health Organization (http://www.who.int/diagnostics_laboratory/evaluations/en/, accessed 8 March 2017).
11. *Parasitological confirmation of malaria diagnosis. Report of a WHO technical consultation*. Geneva, 6–8 October 2009. Geneva: World Health Organization; 2010.
12. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large proportion of *P. falciparum* isolates in the Amazon region of Peru lack *pfhrp2* and *pfhrp3*: implications for malaria rapid diagnostic tests. *PLoS One* 2010;5:e8091.
13. Bharti PK, Chandel HS, Ahmad A, Krishna S, Udhayakumar V, Singh N. Prevalence of *pfhrp2* and/or *pfhrp3* gene deletion in *Plasmodium falciparum* population in eight highly endemic states in India. *PLoS One* 2016;11:e0157949.
14. Jacobs J, Barbé B, Gillet P, Aidoo M, Serra-Casas E, Van Erps J, et al. Harmonization of malaria rapid diagnostic tests: best practices in labelling including instructions for use. *Malar J* 2014;13:505.
15. *Malaria RDT interactive guide*. Geneva: Foundation for Innovative New Diagnostics (<https://www.finddx.org/malaria/interactive-guide/>, accessed 8 March 2017).
16. *Good practices for selecting and procuring rapid diagnostic tests for malaria*. Geneva: World Health Organization; 2011.
17. *Universal access to malaria diagnostic testing: an operational manual*. Geneva: World Health Organization; 2011(revised 2013).
18. Kolaczinski J, Mohammed N, Ali I, Ali M, Khan N, Ezard N, et al. Comparison of the OptiMAL rapid antigen test with field microscopy for the detection of *Plasmodium vivax* and *P. falciparum*: considerations for the application of the rapid test in Afghanistan. *Ann Trop Med Parasitol* 2004;98:15–20.
19. Richter J, Gobels K, Muller-Stover I, Hoppenheit B, Haussinger D. Co-reactivity of plasmodial histidine-rich protein 2 and aldolase on a combined immunochromatographic-malaria dipstick (ICT) as a potential semi-quantitative marker of high *Plasmodium falciparum* parasitaemia. *Parasitol Res* 2004;94:384–385.
20. Mai Huong NM, Davis TM, Hewitt S, Huong NV, Uyen TT, Nhan DH, et al. Comparison of three antigen detection methods for diagnosis and therapeutic monitoring of malaria: a field study from southern Vietnam. *Trop Med Int Health* 2002;7:304–308.
21. Mason DP, Kawamoto F, Lin K, Laoboonchai A, Wongsrichanalai C. A comparison of two rapid field immunochromatographic tests to expert microscopy in the diagnosis of malaria. *Acta Trop* 2002;82:51–59.
22. van den Broek I, Hill O, Gordillo F, Angarita B, Hamade P, Counihan H, et al. Evaluation of three rapid tests for diagnosis of *P. falciparum* and *P. vivax* malaria in Colombia. *Am J Trop Med Hyg* 2006;75:1209–1215.
23. McMorro M, Masanja MI, Abdulla SM, Kahigwa E, Kachur SP. Challenges in routine implementation and quality control of rapid diagnostic tests for malaria – Rufiji District, Tanzania. *Am J Trop Med Hyg* 2008;79:385–390.
24. Wanji S, Kimbi HK, Eyong JE, Tendongfor N, Ndamukong JL. Performance and usefulness of the Hexagon rapid diagnostic test in children with asymptomatic malaria living in the Mount Cameroon region. *Malar J* 2008;7:89.
25. Willcox ML, Sanogo F, Graz B, Forster M, Dakouo F, Sidibe O, et al. Rapid diagnostic tests for the home-based management of malaria, in a high-transmission area. *Ann Trop Med Parasitol* 2009;103:3–16.
26. Belizario VY, Pasay CJ, Bersabe MJ, de leon WU, Guerro DM, Bugaoisan VM. Field evaluation of malaria rapid diagnostic tests for the diagnosis of *P. falciparum* and non-*P. falciparum* infections. *Southeast Asian J Trop Med Public Health* 2005;36:552–561.

27. *Methods manual for laboratory quality control testing of malaria rapid diagnostic tests, version 8*. Geneva: World Health Organization; 2016.
28. *Methods manual for product testing of malaria rapid diagnostic tests (version 6)*. Geneva: World Health Organization; 2014.
29. Call for expressions of interest for round 7 of the WHO Malaria Rapid Diagnostic Test Product Testing Programme (http://www.who.int/malaria/news/2015/rdt_call_for_testing_round7/en/) (accessed 10 March 2017).
30. Baker J, Ho MF, Pelecanos A, Gatton M, Chen N, Abdullah S, et al. Global sequence variation in the histidine-rich proteins 2 and 3 of *Plasmodium falciparum*: implications for the performance of malaria rapid diagnostic tests. *Malar J* 2010;9:129.
31. Hopkins H, Oyibo W, Luchavez J, Mationg ML, Asimwe C, Albertini A, et al. Blood transfer devices for malaria rapid diagnostic tests: evaluation of accuracy, safety and ease of use. *Malar J* 2011;10:30.
32. *Methods for field trials of malaria rapid diagnostic tests*. Manila: World Health Organization Regional Office for the Western Pacific; 2009.
33. Berhane A, Mihreteab S, Mohammed S, Embaye G, Hagos F, Zehaie A, et al. PfHRP2 detecting malaria RDTs: alarming false negative results in Eritrea. Poster 879. In: 65th annual meeting of the American Society for Tropical Medicine and Hygiene. Oakbrook Terrace, IL; 2016.
34. Cheng Q, Gatton M, Barnwell J, Chiodini P, McCarthy J, Bell D, et al. *Plasmodium falciparum* parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting. *Malaria J* 2014;13:283.
35. *Transporting, storing and handling malaria rapid diagnostic tests at central and peripheral storage facilities*. Manila: World Health Organization Regional Office for the Western Pacific; 2009.
36. Training materials for the use of malaria RDTs. Geneva: Foundation for Innovative Diagnostics; 2011 (<http://www.who.int/malaria/areas/diagnosis/rapid-diagnostic-tests/job-aids/en/>), accessed 10 March 2017).
37. Jorgensen P, Chanthap L, Rebueno A, et al., Malaria rapid diagnostic tests in tropical climates: the need for a cool chain. *Am J Trop Med Hyg* 2006;74(5):750–754.
38. Chiodini PL, Bowers K, Jorgensen P, Tsuyuoka R, Bell D. The heat stability of *Plasmodium* lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid diagnostic tests. *Trans R Soc Trop Med Hyg* 2007;101:331–337.
39. Rennie W, Phetsouvanh R, Lupisan S, Vanisaveth V, Hongvanthong B, Phompida S, et al. Minimising human error in malaria rapid diagnosis: clarity of written instructions and health worker performance. *Trans R Soc Trop Med Hyg* 2007;101:9–18.
40. Harvey SA, Jennings L, Chinyama M, Masaninga F, Mulholland K, Bell DR. *Improving community health worker use of malaria rapid diagnostic tests in Zambia: package instructions, job aid and job aid-plus-training*. *Malar J* 2008;7:160.
41. Tavrow P, Knebel E, Cogswell L. *Using quality design to improve malaria rapid diagnostic tests in Malawi. In: Operations research results 1(4)*. Bethesda, MD: United States Agency for International Development; 2000.
42. Heutmekers M, Gillet P, Maltha J, Scheirlinck A, Cnops L, Bottieau E, et al. Evaluation of the rapid diagnostic test CareStart pLDH Malaria (Pf-pLDH/panpLDH) for the diagnosis of malaria in a reference setting. *Malar J* 2012;11:204.
43. Parasitological confirmation of malaria diagnosis: WHO technical consultation, Geneva, 6–8 October 2009. Geneva: World Health Organization; 2009.
44. Lindblade KA, Steinhardt L, Samuels A, Kachur SP, Slutsker L. The silent threat: asymptomatic parasitemia and malaria transmission. *Expert Rev Anti-infect Ther* 2013;11:623–639.
45. Chen I, Clarke SE, Gosling R, Hamainza B, Killeen G, et al. (2016) "Asymptomatic" Malaria: A Chronic and Debilitating Infection That Should Be Treated. *PLOS Medicine* 13(1): e1001942.
46. Malaria Ag P.f Ref: 05Fk140. Instructions for use. San Diego, CA: Alere.
47. D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sango W, Kahama-Marjo J, et al. Beyond malaria – causes of fever in outpatient Tanzanian children. *N Engl J Med*. 2014;370:809–817.
48. Incardona S, Serra-Casas E, Champouillon N, Nsanzabana C, Cunningham J, Gonzalez IJ. Global survey of malaria rapid diagnostic test (RDT) sales, procurement and lot verification practices: assessing the use of the WHO-FIND Malaria RDT Evaluation Programme (2011–2014). *Malaria Journal* 2017; 16:196

ANNEXES

Annex S1: Characteristics of evaluation panels used in rounds 1–7 of WHO malaria RDT product testing, 2008–2016

Currently, the basis for diagnosing malaria with antigen-detecting RDTs is the detection in a patient's blood of one or more target malaria antigens, including HRP2 (*P. falciparum* only), pLDH (*Plasmodium* spp. pan-pLDH), *P. falciparum* (Pf-pLDH), non-*falciparum* (Pv-pLDH, Pvom-pLDH) and aldolase (all *Plasmodium* spp). The antigen concentration in samples with the same parasite density varies. Therefore, the concentrations of malaria antigens in the samples that comprise evaluation panels must be consistent in successive rounds of WHO malaria RDT product testing to ensure that the results of each round are highly comparable (statistically equivalent).

Therefore, antigen concentrations were quantified in triplicate in all panel samples, including dilution pairs of 200 and 2000 parasites/μL, by quantitative ELISA. Only results that were consistent in the triplicate runs and showed a value factor between the 200 and the 2000 parasites/μL dilutions close to 10 were considered acceptable and eligible for the performance evaluation panel. In some instances, the antigen concentration was below the detection limit of the ELISA, particularly for aldolase, which is present in malaria parasite samples at much lower concentrations than the other two antigens. Samples that gave inconsistent results for more than one of the three antigens were excluded from the panel.

Despite careful standardization of procedures, the tables and figures below show a wide variation in antigen concentrations for the same parasite density. There are a number of possible explanations, including differences in the level of antigen expression by isolates; different durations of infection (accumulating antigens); different parasite growth stages at the time of collection (expressing different levels of antigen); the presence of circulating HRP2 from previous growth cycles; and HRP2 produced by parasites sequestered in the host's vascular tissues that cannot be accounted for in the estimate of parasite density on the blood slide.

Before each round of WHO malaria RDT product testing, the distribution of HRP2, pLDH and aldolase concentrations at 200 parasites/μL dilution of the wild-type *P. falciparum* and wild-type *P. vivax* samples selected for the phase-2 panels were systematically compared with those in the previous round to ensure there was no statistically significant difference. The figures and tables below show the distribution of antigen concentrations in all six performance evaluation panels. No statistically significant differences were seen (Kruskal-Wallis test; $p > 0.5$), confirming that the results of each new round are additive (and comparable) to the previous ones. In the following box and whisker plots, the end of whiskers represent minimum and maximum values; the box represents middle 50% of data and the line through box represents median values; the crosses represent the mean values.

Figure AS1.1: Box-and-whisker plot of distribution of *P. falciparum* HRP2 concentration (ng/mL) in product testing phase 2 (wildtype) panels.




Figure AS1.2: Box-and-whisker plot of distribution of *P. falciparum* pLDH concentration (ng/mL) in product testing phase 2 (wildtype) panels.




Figure AS1.3: Box-and-whisker plot of distribution of *P. vivax* pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels.




Figure AS1.4: Box-and-whisker plot of distribution of *P. falciparum* aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels.




Figure AS1.5: Box-and-whisker plot of distribution of *P. vivax* aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels.




Table AS1.1: Statistics for *P. falciparum* HRP2 concentration (ng/mL) in product testing phase 2 (wild-type) panels.

	Round 1	Round 2	Round 3	Round 4	Round 5	Round 6	Round 7
Number of values ^a	78	99	99	98	99	99	99
Minimum	0.80	0.62	0.62	0.62	0.59	0.67	0.67
25% percentile	2.90	1.90	2.10	2.97	2.15	2.48	2.15
Median	9.57	6.76	6.83	6.98	6.76	8.12	6.76
75% percentile	18.94	16.91	17.37	15.65	15.31	15.51	16.99
Maximum	73.70	73.70	66.70	62.48	62.48	62.48	62.48
Mean	15.28	12.70	12.77	12.72	11.65	12.15	11.83
Std. Deviation	16.98	15.75	15.19	14.72	13.25	13.29	13.01

^a The number of values is the number of samples for which consistent ELISA results were obtained.

Table AS1.2: Statistics for *P. falciparum* pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels.

	Round 1	Round 2	Round 3	Round 4	Round 5	Round 6	Round 7
Number of values ^a	74	93	92	92	94	98	98
Minimum	0.71	0.19	0.19	0.19	0.19	0.19	0.19
25% percentile	6.68	6.27	6.23	6.20	6.90	7.04	7.20
Median	11.95	10.31	11.18	10.92	12.24	11.85	12.99
75% percentile	23.75	20.10	22.70	21.28	23.05	20.36	21.51
Maximum	47.15	47.15	47.15	53.53	43.02	53.53	53.53
Mean	15.31	13.71	15.08	14.97	15.53	15.61	15.93
Std. Deviation	11.47	10.90	11.72	11.98	11.43	12.00	11.60

^a The number of values is the number of samples for which consistent ELISA results were obtained.

Table AS1.3: Statistics for *P. vivax* pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels.

	Round 1	Round 2	Round 3	Round 4	Round 5	Round 6	Round 7
Number of values ^a	20	37	33	32	34	34	35
Minimum	5.10	1.64	1.64	1.64	1.64	1.64	1.64
25% percentile	8.10	8.40	7.30	6.96	6.26	6.72	6.86
Median	12.65	17.00	19.78	17.50	13.22	15.17	16.62
75% percentile	27.40	29.69	31.89	29.84	23.42	23.14	22.89
Maximum	44.40	47.90	47.90	47.90	47.90	44.79	44.79
Mean	17.38	20.24	20.99	20.00	16.84	16.90	16.87
Std. Deviation	11.57	13.27	13.55	13.00	12.59	11.78	11.17

^a The number of values is the number of samples for which consistent ELISA results were obtained.

Table AS1.4: Statistics for *P. falciparum* aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels.

	Round 1	Round 2	Round 3	Round 4	Round 5	Round 6	Round 7
Number of values ^a	77	98	99	97	98	99	99
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
25% percentile	0.84	0.74	0.67	0.64	0.52	0.44	0.59
Median	1.58	1.49	1.40	1.25	1.17	1.18	1.25
75% percentile	2.25	2.25	2.23	2.25	2.07	2.02	1.88
Maximum	9.90	9.90	9.90	9.08	7.74	9.08	9.08
Mean	1.93	1.79	1.76	1.72	1.52	1.50	1.43
Std. Deviation	1.73	1.66	1.69	1.68	1.52	1.61	1.34

^a The number of values is the number of samples for which consistent ELISA results were obtained.

Table AS1.5: Statistics for *P. vivax* aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels.

	Round 1	Round 2	Round 3	Round 4	Round 5	Round 6	Round 7
Number of values ^a	20	40	34	33	35	35	35
Minimum	3.21	1.70	1.70	1.70	3.21	1.70	3.21
25% percentile	4.02	4.11	4.07	4.41	5.55	4.94	5.27
Median	6.33	6.15	6.10	6.16	6.86	6.54	7.96
75% percentile	8.47	8.47	8.32	9.10	9.43	9.68	10.52
Maximum	13.15	13.40	13.30	15.00	15.00	15.08	15.08
Mean	6.73	6.81	6.45	6.86	7.78	7.74	8.22
Std. Deviation	2.89	3.15	2.90	3.23	3.30	3.69	3.61

^a The number of values is the number of samples for which consistent ELISA results were obtained.

Annex S2: Malaria RDT field assessment and anomalies

Fig. AS2.1 shows examples of observations and anomalies encountered and routinely recorded for RDTs in round 7 of WHO Malaria RDT Product Testing at the CDC. Most of these anomalies would not invalidate the results, as reactivity in the control and test line areas is still visible, but they may pose challenges to health workers in interpreting the results. Furthermore, they should be reported to manufacturers.

An extended list of notable observations on RDT packaging, kit accessories (buffer vials, desiccants) and instructions for use is being prepared for use in both product testing and lot testing in the WHO-FIND Malaria RDT Evaluation Programme.

Table AS2.1: Field assessment of RDT packaging, safety and ease-of-use to guide product selection

Date of assessment				
Commercial name				
Product code				
Lot number(s)				
	Yes	No	NA	Problems /Comments
Packaging and accessories				
The RDT box is in good condition				
RDTs are in individual sealed package				
The correctly indicated number of RDTs are in the box				
Desiccant is included in each individual RDT package				
An expiry date is visible on each RDT package				
All required accessories are included in the correct quantities (RDT, buffer, blood transfer device, alcohol swab, lancet, gloves, test tubes (for dipsticks, only))				If no, what is not included:
Instructions				
Instructions are included				
Instructions are in the national language(s)				
The instructions are for the correct product				
The instructions include figures displaying all possible interpretations of the RDT results				
The text and figures are accurate and consistent (specifically order of test lines and results interpretation)				
Preparation and procedure				
The test package is easy to open				
It is easy to write on the test device				
The test lines on the device are clearly labelled				
It is easy to use the device for blood collection				
It is easy to open the buffer bottle or vial				
The buffer bottle or vial have sufficient volume for testing all RDTs in the box				
The buffer bottle or vial dispenses even drops				
It is easy to fill the sample well correctly with the provided blood transfer device				
It is easy to fill the buffer well correctly (no overflow)				
The buffer and sample flow well along the test strip				
Result interpretation				
Control and test lines				
Control line is clear				
Test line(s) are clear				
Good clearance of blood by time of reading				If no, number of tests in the box affected:
Steps and reading time				
Reading time <30 min				
Two or fewer timed steps				
Was one or more of the last 10 tests you performed invalid (no control line)?				
If YES, how many?				
Safety				
Are there mixing wells (risk of blood splash)?				
Retractable needle for finger prick?				
Is the RDT in a cassette format (unexposed strip)?				
Have waste disposal safety concerns been addressed? (If no, please describe)				

NA, not applicable


Figure AS2.1 illustrates examples of RDT observations/anomalies encountered and routinely recorded during round 6 of WHO Malaria RDT Product Testing at the CDC. In most cases, these anomalies do not invalidate the results, as reactivity in the control and test line areas are still visible, but they may pose challenges to health workers interpreting the results. Furthermore, they should be reported to manufacturers.

An expanded list of notable observations concerning RDT packaging, kit accessories (buffer vials, desiccants) and instructions for use, is under development for use in both product testing and lot testing activities of the WHO-FIND Malaria RDT Evaluation Programme.

Figure AS2.1: Malaria RDT anomalies encountered in production lots

a) Observations on the test strip

Red background



Background staining is relatively common. In this example, the result is positive as test lines are positive; however, a more intense red background may obscure weak positive test lines, giving false-negative results.

Incomplete clearing



In this example, the result is positive as the test line is visible. Poor clearing of blood may obscure weak positive test lines, giving false-negative results.

b) Observations of flow problems

Failed migration



Blood and buffer did not run the length of the strip


Incomplete migration



One portion of the nitrocellulose near the test band was not absorptive and remained dry during wicking, creating irregular migration of blood/buffer with red background. In this example, the result is positive, as the test line is clearly visible.


c) Observations on test lines

Ghost test lines




White lines on a stained background. In this example, the result is negative, as the test line is not dark and is thus not visible.

Patchy broken test line(s)



The test line is visible but interrupted (broken).

Diffuse test line(s)



Test line wider than control, without clearly defined edge.


d) RDT structural problems

Strip misplaced in the cassette (shift)



Strip can be seen only partially in the results window.

Specimen pad not seen in sample window



Normally, the colour of the conjugated antibody can be seen in the sample window (commonly purple, pink or blue).


Buffer remains pooled in the buffer well



The buffer is not completely absorbed and this may result in failed migration or incomplete clearing.

Annex S3: Selection of an appropriate RDT

Figure AS3.1: How to select of an appropriate RDT



^a Pf-only or mixed Pf/non-Pf infections: Most areas of sub-Saharan Africa and lowland Papua New Guinea; Pf and non-Pf infections (single species): Most endemic areas of Asia and the Americas and isolated areas of the Horn of Africa; Mainly *P. vivax*-only: areas of East Asia, central Asia, South America, and some highland areas elsewhere

^b Tests with a *P. falciparum*-specific line and pan-specific line will not distinguish *P. falciparum*-only infections from mixed *P. falciparum* infections. Distinguishing *P. falciparum* from mixed *P. falciparum-vivax* infections is important only if a full course of primaquine is routinely given for infections due to *P. vivax*. This must be weighed against the loss of ability to detect *P. malariae* and *P. ovale* if a test has only *P. falciparum*- and *P. vivax*-specific lines. Inclusion of further test lines (e.g. Pf-Pv-pan-pLDH) to detect these increases the complexity of test interpretation. A programme should prioritize these various advantages and disadvantages according to local conditions in the initial stage of making procurement decisions.

^c *P. falciparum* parasites lacking HRP2 +/- HRP3 genes have been identified with high frequency in parts of South America, Africa (Eritrea, Democratic Republic of the Congo, Ghana) and India (1–6).

^d See references (7–12).

^e WHO RDT procurement criteria (13) : http://www.who.int/malaria/publications/atoz/rdt_selection_criteria/en/ (accessed 14 June 2017).

For a comprehensive guide to procurement of malaria RDTs extending beyond selection to quantification, budgeting, technical specifications, management of tenders, contracts, supply management and monitoring of supplier performance and managing product variations, see reference in the full report (16).

Annex 1: Characteristics of RDTs evaluated in round 7

Manufacturer	Product name	Product code	Sequence and type of bound antibody ^b					Required volume of whole blood (µl)	Buffer drops	Minimum time to results ^c (mins)	Maximum reading time (mins)	Protocol group ^f	Results Interpretation ^d (type A-J)	Format type ^e	Recommended storage temperature (°Celsius)	Shelf-life (months)
			C T1 T2 T3													
			C	T1	T2	T3										
Access Bio, Inc.	CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag, Combo	RMVM-05072	Pv pLDH	HRP2			5	2	20			1	E	Cassette	1-40	24
Access Bio, Inc.	CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line	RMSM-05071	Pf pLDH	HRP2			5	2	20			1	J	Cassette	1-40	24
Access Bio, Inc.	CareStart™ Malaria Screen	RMAM-05071	Pan pLDH	HRP2 + Pf pLDH			5	2	20			1	C	Cassette	1-40	24
Access Bio, Inc.	CareStart™ Pf/PAN (pLDH) Ag RDT	RMLM-05071	Pan pLDH	Pf pLDH			5	2	20			1	C	Cassette	4-30	24
Access Bio Ethiopia	CareStart™ Malaria HRP2 (Pf)	RMOM-03091	HRP2				5	2	20			1	A	Cassette	1-40	36
Access Bio Ethiopia	CareStart™ Malaria HRP2/pLDH (Pf/Pv) Combo	RMVM-03091	Pv pLDH	HRP2			5	2	20			1	E	Cassette	1-40	36
Advay Chemical Private Limited	Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Pan pLDH	HRP2			5	4	20	30		3	C	Cassette	2-40	24
Advay Chemical Private Limited	Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA1017	HRP2				5	4	20	30		3	A	Cassette	2-40	24
Alere Medical Private Limited	Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60AL-40	Pan pLDH	HRP2			5	4	30	30		5	C	Cassette	1-40	24
Alere Medical Private Limited	SD Bioline Malaria Ag Pf/Pv	05FK801-40	Pv pLDH	HRP2			5	4	30	30		5	E	Cassette	1-40	24
ALLDIAG SA	PALUTOP +4 optima®	5499	Pan pLDH	Pv pLDH	HRP2		5	2	20	30		1	G	Cassette	4-30	24
ALLDIAG SA	PALUTOP + pf®	5531	HRP2				5	2	20	30		1	A	Cassette	4-45	24
ARKRAY Healthcare Pvt Ltd	Parahit® f Ver 1.0 – Device	55IC104-50	HRP2				8	4	25	30		9	A	Cassette	4-40	24
ARKRAY Healthcare Pvt Ltd	Parahit® f Ver 1.0 – Dipstick	55IC103-50	HRP2				8	4	25	30		9	A	Dipstick	4-40	24
ASAN Pharmaceutical Co., Ltd	Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	Pan pLDH	HRP2			5	4	30	30		5	C	Cassette	1-30	24
Aspen Laboratories Pvt. Ltd.	Aspen® Malaria Ag Pf/Pv	AS0060	Pan pLDH	HRP2			5	3	20	30		2	C	Cassette	2-40	24
Aspen Laboratories Pvt. Ltd.	Aspen® Malaria Ag Pf	AS0015	HRP2				5	3	20	30		2	A	Cassette	2-40	24
Bio Focus Co., Ltd.	BioTracer™ Malaria Pf Rapid Card	17912	HRP2				5	4	20	20		3	A	Cassette	1-40	24
Bio Focus Co., Ltd.	BioTracer™ Malaria Pf/PAN Rapid Card	17012	Pan pLDH	HRP2			5	4	20	20		3	C	Cassette	1-40	24
Biosynex	Biosynex® Malaria Pf/Pv	0581_K25	Pv pLDH	HRP2			5	4	15	30		7	E	Cassette	2-30	24
Biosynex	Biosynex® Malaria Pf/Pan	0584_K25	Pan pLDH	HRP2			5	4	15	30		7	C	Cassette	2-30	24
DIALAB	DIAQUICK Malaria P.f. Cassette	W06200	HRP2				5	4	20	30		3	A	Cassette	2-30	24
Guangzhou Wondfo Biotech Co., Ltd.	One Step Malaria HRP2 (P.f) Test	W37-C	HRP2				5	4	15	30		7	A	Cassette	1-35	24
Guangzhou Wondfo Biotech Co., Ltd.	One Step Malaria HRP2/pLDH (Pf/Pv) Test	W066-C	Pv pLDH	HRP2			5	4	15	30		7	E	Cassette	1-35	24
Hangzhou AllTest Biotech Co. Ltd.	AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Aldolase	HRP2			5	3	10	20		10	C	Cassette	2-30	24
Hema Diagnostic Systems	Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	HRP2	Pan pLDH			5	3	20	30		2	D	Cassette	4-30	24
ICT INTERNATIONAL	ICT MALARIA DUAL TEST	ML03	HRP2	Pan pLDH			5	5	30	30		11	D	Cassette	4-40	24
ICT INTERNATIONAL	ICT MALARIA P.F. CASSETTE TEST	ML01	HRP2				5	5	15			12	A	Cassette	4-40	24
InTec Products, Inc.	ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	HRP2				5	3	20			2	A	Cassette	2-40	24
InTec Products, Inc.	ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v) Tri-line Test	ITP11003-TC25	Pv pLDH	HRP2			5	3	20			2	E	Cassette	2-40	24
Lumiquick Diagnostics Inc.	QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Pv pLDH	HRP2			5	3	20			2	E	Cassette	4-30	18
Medical Diagnostech (Pty) Ltd	MD Malaria Pf	MDMALPFH005	HRP2				5	4	30			5	A	Cassette	4-40	24
Medsorce Ozone Biomedicals Pvt. Ltd.	Is It... Malaria Pf PAN	MPPFAN050	Pan pLDH	HRP2			5	3	20	25		2	C	Cassette	2-40	24

(continued)

Annex 1: Characteristics of RDTs evaluated in round 6 (continued)

Manufacturer	Product name	Product code	Sequence and type of bound antibody ^b				Required volume of whole blood (µl)	Buffer drops	Minimum time to results ^c (mins)	Maximum reading time (mins)	Protocol group ^f	Results Interpretation ^d (type A-J)	Format type ^e	Recommended storage temperature Shelf-life (months)
			C	T1	T2	T3								
Meril Diagnostics Pvt. Ltd.	One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02					5	4	20	30	3	E	Cassette	2-30
Meril Diagnostics Pvt. Ltd.	One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01					5	4	20	30	3	A	Cassette	18
NG Biotech	NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005					5	4	30	30	5	D	Cassette	2-40
RapiGEN Inc.	BIOCREDIT Malaria Ag Pf/Pan (HRP2/pLDH)	C32RHA25					5	4	30	30	5	C	Cassette	1-40
RapiGEN Inc.	BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25					5	4	30	30	5	E	Cassette	1-40
Real World Diagnostics	Malaria Pf/PAN Test	PROPMALPPFV001					5	4	30	30	5	F	Cassette	4-40
Shanghai Kehua Bio-engineering Co., Ltd.	KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C					5	4	15	20	7	A	Cassette	4-30
Standard Diagnostics, Inc.	SD BIOLINE Malaria Ag Pf: (HRP2/pLDH) 2 Lines	05FK130-40-0					5	4	15	15	7	A	Cassette	1-40
Standard Diagnostics, Inc.	Alere™ Malaria Ag Pf	05FK140-40-0					5	4	20	20	3	A	Cassette	1-30
WELLS BIO, INC	careUS™ Malaria Pf (HRP2) Ag	RMO-M05082					5	2	20	20	1	A	Cassette	1-40
WELLS BIO, INC	careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082					5	2	20	20	1	E	Cassette	1-40
Zhejiang Orient Gene Biotech Co., Ltd.	Malaria Pf Rapid Test	GCMA(Lpf)-402a					5	3	20	30	2	A	Cassette	2-30
Zhejiang Orient Gene Biotech Co., Ltd.	Malaria Pf/Pv Rapid Test	GCMA(Lpf/pv)-402a					5	3	20	30	2	F	Cassette	2-30

^a pLDH, plasmodium lactate dehydrogenase; HRP2, histidine rich protein 2; pv, *P. vivax*; pf, *P. falciparum*

^b Sequence when test held in a horizontal position and the sample well is at the far right and control line, far left


^c From placement of buffer, or from 'intermediate' step, if applicable

^d See Annex 2

^e Formats include: cassette (A); card (B); hybrid (C); dipstick (D); or other (E). Each product should ideally be accompanied by all required materials (lancet, pipette, etc) particularly when used at the village health worker level; however, this is often not the case and the contents depend on the request of the procuring agent.

^f Products have been assigned into different groups based on their procedural characteristics, specifically, blood volume (µL), number of buffer drops and minimum reading time (minutes). The groups are as follows: group 1: 5µL, 2 drops, 20 mins; group 2: 5µL, 3 drops, 20 mins; group 3: 5µL, 4 drops, 20 mins; group 4: 5µL, 2 drops, 30 mins; group 5: 5µL, 4 drops, 30 mins; group 6: 5µL, 3 drops, 15 mins; group 7: 5µL, 4 drops, 15 mins; group 8: 10µL, 3 drops, 10 mins; group 9: 8µL, 4 drops, 25 mins; group 10: 5µL, 3 drops, 10 mins; group 11: 5µL, 5 drops, 30 mins; group 12: 5µL, 5 drops, 15 mins.


A Cassette



B Card




C Cassette hybrid



Sample and mixing wells

D Dipstick




E Other


Annex 2: Malaria RDTs: guide to interpretation of results

Type A: Guide to results of generic Pf malaria RDTs


Results window: C=control line; T=test line with bound HRP2 or Pf-specific pLDH antibody.





Negative results: One line 'C' appears in the results window.



Positive results: *P. falciparum* infection. Two lines 'C' and 'T' appear in the results window.
Test is positive even if the test line is faint.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type B: Guide to results of generic major *Plasmodium* species (pan) malaria RDTs


Results window: C=control line; T=test line with bound pan-specific pLDH or aldolase antibody.





Negative results: One line 'C' appears in the results window.



Positive results: *Plasmodium* species (*P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale*) infection. Two lines 'C' and 'T' appear in the results window. Test is positive even if the test line is faint.



Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type C: Guide to results of generic pan-Pf malaria RDTs

Results window: C=control line; T1=test line with bound pLDH or aldolase antibody; T2=test line with bound HRP2 and/or Pf-specific pLDH antibody.




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum: Two lines 'C' and 'T2' appear in the results window.







Non-*falciparum* infection (*P. vivax*, *P. ovale*, *P. malariae*) or mixed infection: Two lines 'C' and 'T1' appear in the results window.



P. falciparum or mixed infection. Three lines 'C', 'T1' and 'T2' appear in the results window.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type D: Guide to results of generic Pf-pan malaria RDTs

Results window: C=control line; T1=test line with bound HRP2 or Pf-specific LDH antibody;
T2=test line with bound pLDH or aldolase antibody.




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum infection. Two lines 'C' and 'T1' appear in the results window.







Non-*falciparum* infection (*P. vivax*, *P. ovale*, *P. malariae*) or mixed infection. Two lines 'C' and 'T2' appear in the results window.



P. falciparum or mixed infection. Three lines 'C', 'T1' and 'T2' appear in the results window.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type E: Guide to results of generic Pv-Pf malaria RDTs

Results window: C=control line; T1=test line with bound *P. vivax*-specific pLDH;
T2=test line with bound HRP2 or Pf-specific pLDH antibody.




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum infection. Two lines 'C' and 'T2' appear in the results window.







P. vivax infection. Two lines 'C' and 'T1' appear in the results window.



P. falciparum and *P. vivax* mixed infection. Three lines 'C', 'T1' and 'T2' appear in the results window.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type F: Guide to results of generic Pf-Pv malaria RDTs

Results window: C=control line; T1= test line with bound HRP2 or Pf-specific pLDH antibody;
T2=test line with bound *P. vivax*-specific pLDH.




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum infection. Two lines 'C' and 'T1' appear in the results window.







P. vivax infection. Two lines 'C' and 'T2' appear in the results window.



P. falciparum and *P. vivax* mixed infection. Three lines 'C', 'T1' and 'T2' appear in the results window.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type G: Guide to results of generic pan-Pv-Pf malaria RDTs

Results window: C=control line; T1=test line with bound pLDH or aldolase antibody; T2=test line with bound *P. vivax*-specific pLDH; T3=test line with bound HRP2 or Pf-specific pLDH antibody




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum infection. Two lines 'C' and 'T3' appear in the results window.




P. vivax infection. Two lines 'C' and 'T2' appear in the results window.




P. falciparum with or without mixed infection with *P. ovale* or *P. malariae*. Three lines 'C', 'T1' and 'T3' appear in the results window.




P. falciparum and *P. vivax* mixed infection. Three lines 'C', 'T2' and 'T3' appear in the results window.




P. falciparum and *P. vivax* mixed infection with or without *P. ovale* and/or *P. malariae* infection. Four lines 'C', 'T1', 'T2' and 'T3' appear in the results window.











P. vivax with or without *P. ovale* and/or *P. malariae* infection. Three lines 'C', 'T1' and 'T2' appear in the results window.



P. malariae with or without *P. ovale* and/or *P. vivax* infection. Two lines 'C' and 'T1' appear in the results window.



Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type H: Guide to results of generic vom¹-Pf malaria RDTs

Results window: C=control line; T1= test line with bound pLDH specific for non-*P. falciparum* (*P. vivax*, *P. ovale* and *P. malariae*); T2=test line with bound HRP2 or Pf-specific pLDH antibody




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum infection. Two lines 'C' and 'T2' appear in the results window.







P. falciparum mixed infection (with *P. vivax*, *P. ovale* and/or *P. malariae*). Three lines 'C', 'T1' and 'T2' appear in the results window.



Non-*P. falciparum* infection (*P. vivax*, *P. ovale* and *P. malariae*) or mixed infection. Two lines 'C' and 'T1' appear in the results window.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




¹ vom, *P. vivax*, *P. ovale*, *P. malariae*

Type I: Guide to results of generic Pv malaria RDTs


Results window: C=control line; T=test line with bound *P. vivax*-specific pLDH.





Negative results: Only one line 'C' appears in the results window.



Positive results: *P. vivax* infection. Two lines 'C' and 'T' appear in the results window.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type J: Guide to results of generic Pf-Pf malaria RDTs

Results window: C=control line; T1= test line with bound pLDH specific for *P. falciparum*; T2=test line with bound HRP2.




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum infection. Two lines 'C' and 'T1' appear in the results window.







P. falciparum infection. Two lines 'C' and 'T2' appear in the results window.



P. falciparum infection. Three lines 'C', 'T1' and 'T2' appear in the results window.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type K: Guide to results of generic Pv-Pf-Pf malaria RDTs

Results window: C=control line; T1= test line with bound *P. vivax*-specific pLDH; T2=test line with bound HRP2 or Pf-specific pLDH antibody; T3=test line with bound HRP2 or Pf-specific pLDH antibody. If an RDT has bound HRP2 antibodies on T2, T3 will have bound Pf-specific pLDH and vice versa (T2 Pf antigen target $\neq$ T3 Pf antigen target).




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum infection. Two lines 'C' and 'T3' appear in the results window.




P. falciparum infection. Two lines 'C' and 'T2' appear in the results window.




P. falciparum infection. Three lines 'C', 'T2' and 'T3' appear in the results window.




P. falciparum infection and *P. vivax* mixed infection. Three lines 'C', 'T1' and 'T2' appear in the results window.




P. falciparum infection and *P. vivax* mixed infection. Three lines 'C', 'T1' and 'T3' appear in the results window.











P. falciparum infection and *P. vivax* mixed infection. Four lines 'C', 'T1', 'T2' and 'T3' appear in the results window.



P. vivax infection. Two lines 'C' and 'T1' appear in the results window.




Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.




Type L: Guide to results of generic pan-Pf-Pf malaria RDTs

Results window: C=control line; T1= test line with bound PAN-pLDH or aldolase antibody; T2=test line with bound HRP2 or Pf-specific pLDH antibody; T3=test line with bound HRP2 or Pf-specific pLDH antibody. If an RDT has bound HRP2 antibodies on T2, T3 will have bound Pf-specific pLDH and vice versa (T2 Pf antigen target $\neq$ T3 Pf antigen target)




Negative results: Only one line 'C' appears in the results window.




Positive results:


P. falciparum infection. Two lines 'C' and 'T2' appear in the results window.




P. falciparum infection. Two lines 'C' and 'T3' appear in the results window.




P. falciparum infection. Three lines 'C', 'T2' and 'T3' appear in the results window.




P. falciparum infection with or without mixed infection with *P. vivax*, *P. ovale* and/or *P. malariae*. Three lines 'C', 'T1' and 'T2' appear in the results window.




P. falciparum infection with or without mixed infection with *P. vivax*, *P. ovale* and/or *P. malariae*. Three lines 'C', 'T1' and 'T3' appear in the results window.











P. falciparum infection with or without mixed infection with *P. vivax*, *P. ovale* and/or *P. malariae*.
Four lines 'C', 'T1', 'T2' and 'T3' appear in the results window.



Non-*P. falciparum* infection (*P. vivax*, *P. ovale*, *P. malariae*) or mixed infection.
Two lines 'C' and 'T1' appear in the results window.



Invalid results: No 'C' line appears in the results window. Repeat the test with a new RDT if no control line appears.



Annex 3: Phase-1 results

Table A3.1: Lot variability in positive results^a against phase-1 *P. falciparum* culture samples at low (200) and high (2000) parasite density (parasites/μL)

Product	Product code	Manufacturer	P. falciparum samples (n=20)							
			Total positive results returned							
			200 parasites/μL				2000 parasites/μL			
			Lot 1		Lot 2		Lot 1		Lot 2	
			Test 1	Test 2	No. positive agreements ^b (max=20)	Test 1	Test 2	No. positive agreements ^b (max=20)	Test 1	Test 2
PF only										
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	Advvy Chemical Private Limited	20	20	20	20	20	20	20	20
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	20	20	20	20	20	20	20	20
Alere™ Malaria Ag Pf	05FK140-40-0	Standard Diagnostics, Inc.	20	20	20	20	20	20	20	20
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	20	20	20	20	20	20	20	20
BioTracer™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	20	20	20	20	20	20	20	20
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	20	20	20	20	20	20	20	20
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line	RMSM-05071	Access Bio, Inc.	20	20	20	20	20	20	20	20
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	20	20	20	20	20	20	20	20
DIAQUICK Malaria Pf. Cassette	W06200	DIALAB	20	20	20	20	20	20	20	20
ICT MALARIA P.F. CASSETTE TEST	MI01	ICT INTERNATIONAL	20	20	20	20	20	20	20	20
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	20	20	20	20	20	20	20	20
Malaria Pf Rapid Test	GCMA(L)p(β-402a	Zhejiang Orient Gene Biotech Co., Ltd.	20	20	20	20	20	20	20	20
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	20	20	20	20	20	20	20	20
One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	20	20	20	20	20	20	20	20
One Step Test for Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	20	20	20	20	19	20	19	20
MERISCREEN Malaria Pf HRP-II Ag			20	20	20	20	20	20	20	20
PALUTOP + pf®	5531	ALLDIAG SA	20	20	20	20	20	20	20	20
Parahit f® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	18	19	17	19	20	19	20	20
Parahit® f Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	20	20	20	20	20	20	20	20
SD BIOLINE Malaria Ag P.f. (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	18	20	18	20	20	20	20	20
PF and Pan										
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advvy Chemical Private Limited	20	18	18	17	18	16	20	19 (19)
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	05FK60AI-40	Alere Medical Private Limited	20	20	20	20	20	20	20	20
AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	18	16	16	20	19	19	20	20
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	20	20	20	20	20	20	20	20
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	20	20	20	18	18	16	20	20
BIOCREDIT Malaria Ag Pf/Pan (HRPII)(pLDH)	C32RHA25	RapiGEN Inc.	20	20	20	20	20	20	20	20
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	20	20	20	20	20	20	20	20
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	20	20	20	20	20	20	20	20
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	20	20	20	20	20	20	20	20
ICT MALARIA DUAL TEST	MI03	ICT INTERNATIONAL	20	20	20	20	20	20	20	20

Table A3.1 (continued)

Product	Product code	Manufacturer	<i>P. falciparum</i> samples (n=20) Total positive results returned							
			200 parasites/μL				2000 parasites/μL			
			Lot 1		Lot 2		Lot 1		Lot 2	
			Test 1	Test 2	No. positive agreements ^b (max=20)	Test 1	Test 2	No. positive agreements ^b (max=20)	Test 1	Test 2
Is It... Malaria Pf/PAN	MPFPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	20	20	20	20	20	20	20	20
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	20	20	20	20	20	20	20	19
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-PfPan-CAS/25	Hema Diagnostic Systems	20	20	20	20	20	20	20	20
Pf and Pv										
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	20	20	20	20	20	20	20	20
BIOCREDT Malaria Ag Pf/Pv (pLDH/pLDH)	C6ORHA25	RapiGEN Inc.	18 (19)	19 (19)	17 (18)	18	17	16	20	20
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	20	20	20	20	20	20	20	20
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	20	20	20	20	20	20	20	20
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	20	20	20	20	20	20	20	20
CareUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	20	20	20	20	20	20	20	20
Malaria Pf/Pv Rapid Test	GCMAL(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	20	20	20	20	20	20	20	20
Malaria Pf/PAN Test	PROPMALPPV001	Real World Diagnostics	20	20	20	20	20	20	20	20
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	20	20	20	20	20	20	20	20
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Merril Diagnostics Pvt. Ltd.	19 (19)	20	19 (19)	18	20	18	20	20
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	20	20	20	20	20	20	20	20
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	20	20	20	20	20	20	20	20
Pf, Pv and Pan										
PALUTOP +4 optima®	5499	ALLDIAG SA	20	20	20	20	20	20	20	20

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species^a Results are based on the first reader's interpretation according to manufacturer's instructions.^b Number of samples that returned a positive result for both tests. Where one test was invalid and the other positive, positive agreement was recorded.

Table A3.2: Distribution of test band intensity (0–4) scores against phase-1 *P. falciparum* cultured parasites at low (200) and high (2000) parasite density (parasites/μl)

Product	Product code	Manufacturer	200 parasites/μl				2000 parasites/μl				200 parasites/μl				2000 parasites/μl							
			Percentage distribution of Pf test band intensity ^b (n=80)				Percentage distribution of Pf test band intensity ^b (n=40)				Percentage distribution of pan test band intensity ^b (n=80)				Percentage distribution of pan test band intensity ^b (n=40)							
			0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4
Pf only																						
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA017	Adv Chemical Private Limited	0.0	26.3	61.3	12.5	0.0	0.0	0.0	2.5	42.5	55.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP1002-TC25	InTec Products, Inc.	0.0	7.5	52.5	30.0	10.0	0.0	0.0	0.0	7.5	92.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Alere™ Malaria Ag Pf	05FK140-40-0	Standard Diagnostics, Inc.	0.0	0.0	8.8	41.3	50.0	0.0	0.0	0.0	0.0	100.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	0.0	7.5	65.0	21.3	6.3	0.0	0.0	7.5	20.0	72.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
BioTracer™ Malaria P.f Rapid Card	17912	Bio Focus Co., Ltd.	0.0	0.0	25.0	53.8	21.3	0.0	0.0	0.0	0.0	100.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	0.0	0.0	18.8	43.8	37.5	0.0	0.0	0.0	0.0	100.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - HRP2 band			0.0	1.3	38.8	43.8	16.3	0.0	0.0	0.0	2.5	97.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - Pf-pLDH band	RM5M-05071	Access Bio, Inc.	38.8	48.8	12.5	0.0	0.0	2.5	17.5	77.5	2.5	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
CareUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	0.0	0.0	17.5	48.8	33.8	0.0	0.0	0.0	2.5	97.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	0.0	16.3	70.0	11.3	2.5	0.0	0.0	0.0	20.0	80.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	0.0	0.0	47.5	40.0	12.5	0.0	0.0	0.0	5.0	95.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0.0	10.0	61.3	25.0	3.8	0.0	0.0	0.0	7.5	92.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Malaria Pf Rapid Test	GCMAL(pf)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0	50.0	40.0	10.0	0.0	0.0	0.0	7.5	92.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	0.0	6.3	48.8	30.0	15.0	0.0	0.0	0.0	22.5	77.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
One Step Malaria HRP2 (P.f) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	11.3	61.3	26.3	1.3	0.0	0.0	2.5	27.5	70.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Merl Diagnostics Pvt. Ltd.	1.3	43.8	51.3	3.8	0.0	0.0	2.5	5.0	42.5	50.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
PALUTOP + pr®	5531	ALLDIAG SA	0.0	0.0	41.3	42.5	16.3	0.0	0.0	0.0	0.0	100.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	5.0	45.0	48.8	1.3	0.0	0.0	0.0	10.0	25.0	65.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Parahit® f Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	0.0	36.3	58.8	5.0	0.0	0.0	2.5	5.0	30.0	62.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	2.5	2.5	65.0	28.8	1.3	0.0	0.0	2.5	20.0	77.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Pf and Pan																						
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA016	Adv Chemical Private Limited	8.8	45.0	43.8	2.5	0.0	2.5	0.0	17.5	30.0	50.0	98.8	1.3	0.0	0.0	0.0	17.5	77.5	5.0	0.0	0.0
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60A1-40	Alere Medical Private Limited	0.0	1.3	58.8	31.3	8.8	0.0	0.0	0.0	7.5	92.5	76.3	23.8	0.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0
AllTest™ Malaria P.f/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0.0	12.5	70.0	16.3	1.3	0.0	0.0	0.0	27.5	72.5	96.3	3.8	0.0	0.0	0.0	5.0	72.5	22.5	0.0	0.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0.0	6.3	57.5	26.3	10.0	0.0	0.0	0.0	5.0	95.0	56.3	43.8	0.0	0.0	0.0	0.0	20.0	80.0	0.0	0.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	5.0	5.0	62.5	21.3	6.3	0.0	0.0	10.0	10.0	80.0	41.3	57.5	1.3	0.0	0.0	0.0	7.5	92.5	0.0	0.0
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C32RHA25	RapiGEN Inc.	0.0	0.0	28.8	47.5	23.8	0.0	0.0	0.0	0.0	100.0	50.0	48.8	1.3	0.0	0.0	0.0	2.5	97.5	0.0	0.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	0.0	12.5	70.0	16.3	1.3	0.0	0.0	0.0	27.5	72.5	96.3	3.8	0.0	0.0	0.0	0.0	50.0	50.0	0.0	0.0
BioTracer™ Malaria P.f/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0.0	0.0	41.3	45.0	13.8	0.0	0.0	0.0	5.0	95.0	31.3	68.8	0.0	0.0	0.0	0.0	0.0	95.0	5.0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0.0	0.0	45.0	36.3	18.8	0.0	0.0	0.0	0.0	100.0	8.8	83.8	7.5	0.0	0.0	0.0	0.0	60.0	40.0	0.0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	0.0	2.5	48.8	30.0	18.8	0.0	0.0	0.0	5.0	95.0	96.3	3.8	0.0	0.0	0.0	17.5	67.5	15.0	0.0	0.0
Is It... Malaria Pf PAN	MPPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	0.0	2.5	57.5	30.0	10.0	0.0	0.0	0.0	5.0	95.0	20.0	77.5	2.5	0.0	0.0	0.0	2.5	97.5	0.0	0.0

Table A3.2 (continued)

Product	Product code	Manufacturer	200 parasites/µl					2000 parasites/µl					200 parasites/µl					2000 parasites/µl				
			Percentage distribution of Pf test band intensity ^b (n=80)					Percentage distribution of Pf test band intensity ^b (n=40)					Percentage distribution of pan test band intensity ^b (n=80)					Percentage distribution of pan test band intensity ^b (n=40)				
			0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	0.0	1.3	43.8	31.3	23.8	2.5	0.0	0.0	2.5	95.0	38.8	51.3	8.8	1.3	0.0	2.5	22.5	75.0	0.0	0.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0.0	0.0	40.0	40.0	20.0	0.0	0.0	0.0	0.0	100.0	81.3	18.8	0.0	0.0	0.0	0.0	15.0	85.0	0.0	0.0
Pf and Pv																						
ADVANCED QUALITY™ ONE STEP Malaria (pf/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0.0	5.0	61.3	28.8	5.0	0.0	0.0	2.5	5.0	92.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	10.0	62.5	26.3	1.3	0.0	0.0	0.0	32.5	65.0	2.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0.0	8.8	73.8	16.3	1.3	0.0	0.0	0.0	15.0	85.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0.0	2.5	52.5	28.8	16.3	0.0	0.0	0.0	7.5	92.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	0.0	5.0	58.8	23.8	12.5	0.0	0.0	0.0	5.0	95.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
CareUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0.0	0.0	50.0	28.8	21.3	0.0	0.0	0.0	2.5	97.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0	48.8	41.3	10.0	0.0	0.0	0.0	5.0	95.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	0.0	0.0	50.0	33.8	16.3	0.0	0.0	0.0	7.5	92.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	11.3	62.5	23.8	2.5	0.0	0.0	2.5	25.0	72.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
One Step Test for Malaria Pf/Pv Ag MERNSCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	3.8	22.5	60.0	13.8	0.0	0.0	2.5	5.0	42.5	50.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	0.0	12.5	63.8	23.8	0.0	0.0	0.0	0.0	30.0	70.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0.0	0.0	61.3	30.0	8.8	0.0	0.0	0.0	7.5	92.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Pf, Pv and Pan	5499	ALLDIAG SA	0.0	0.0	41.3	43.8	15.0	0.0	0.0	0.0	5.0	95.0	22.5	72.5	5.0	0.0	0.0	0.0	0.0	70.0	30.0	0.0
PALUTOP +4 optima®																						

NA, not applicable

Pf, *Plasmodium falciparum*Pv, *Plasmodium vivax*pan, *Plasmodium* species^a Denotes no band visible^b Calculations include invalid tests

Annex 4: Phase-2 results

Table A4.1: Lot variation in positive results against phase-2 wild-type *P. falciparum* and *P. vivax* samples at low (200) and high (2000) parasite density (parasites/μL)

Product	Product code	Manufacturer	P. falciparum samples (n=100) Total positive results ^a returned						P. vivax samples (n=35) Total positive results ^a returned					
			200 parasites/μL			2000 ^b parasites/μL			200 parasites/μL			2000 parasites/μL		
			Lot 1		No. positive agreements ^c (max=100)	Lot 2		No. positive agreements ^c (max=100)	Lot 1		No. positive agreements ^c (max=35)	Lot 2		No. positive agreements ^c (max=35)
			Test 1	Test 2		Test 1	Test 2		Test 1	Test 2		Test 1	Test 2	
Pf only														
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	Advy Chemical Private Limited	87	89	87	84	85	81	100	100	NA	NA	NA	NA
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	98	97	95	97	98	96	100	99	NA	NA	NA	NA
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	100	99	99	98	100	98	100	100	NA	NA	NA	NA
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	98	98	97	96	97	95	100	100	NA	NA	NA	NA
BioTrace™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	100	99	99	99	98	97	99	100	NA	NA	NA	NA
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	98	99	97	99	99	98	100	100	NA	NA	NA	NA
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line	RMSM-05071	Access Bio, Inc.	95	96	94	98	99	98	99	100	NA	NA	NA	NA
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	98	98	96	98	98	97	100	100	NA	NA	NA	NA
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	93	90	88	91	92	88	99	100	NA	NA	NA	NA
ICT MALARIA PF. CASSETTE TEST	ML01	ICT INTERNATIONAL	97	96	95	99	97	97	100	100	NA	NA	NA	NA
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	94	90	87	91	90	87	100	99	NA	NA	NA	NA
Malaria Pf Rapid Test	GCMAL(pf) - 402a	Zhejiang Orient Gene Biotech Co., Ltd.	96	93	91	96	95	93	100	100	NA	NA	NA	NA
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	88 (99)	90	87 (99)	92	90	88	100	99	NA	NA	NA	NA
One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	97	96	96	97	95	94	100	100	NA	NA	NA	NA
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	79	87	78	83	84	79	99	100	NA	NA	NA	NA
PALUTOP + p [®]	5531	ALLDIAG SA	95	95	93	100	98	98	99	100	NA	NA	NA	NA
Parahit [®] Ver 1.0 - Dipstick	551C103-50	ARKRAY Healthcare Pvt Ltd	84	81	77	82	86	80	100	100	NA	NA	NA	NA
Parahit [®] f Ver 1.0 - Device	551C104-50	ARKRAY Healthcare Pvt Ltd	83	87	80	85	84	81	100	100	NA	NA	NA	NA
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	96	94	94	94	94	92	100	100	NA	NA	NA	NA
Pf and Pan														
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advy Chemical Private Limited	81	77	75	77	77	73	100	100	26	29	23	21
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60AL-40	Alere Medical Private Limited	90	90	88	92	89	88	99	99	35	32	35	35
AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	78	76	73	78	83	76	98	97	28	29	30	27
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	93 (99)	93	89 (99)	94	95 (99)	93 (99)	99	99	35	35	35	35
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	98 (99)	98	97 (99)	95	98	94	98	100	33	34 (34)	35	34 (34)
BIOCREDIT Malaria Ag Pf/Pan (HRPI/pLDH)	C32RHA25	RapiGEN Inc.	92 (99)	93	90 (99)	94	94	93	100	99	35	35	35	35
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	90	91	89	88	87	85	100	100	34	33	32	31

Table A4.1 (continued)

Product	Product code	Manufacturer	<i>P. falciparum</i> samples (n=100) Total positive results ^a returned						<i>P. vivax</i> samples (n=35) Total positive results ^a returned					
			200 parasites/μL			2000 ^b parasites/μL			200 parasites/μL			2000 parasites/μL		
			Lot 1		No. positive agreements ^c (max=100)	Lot 2		No. positive agreements ^c (max=100)	Lot 1		No. positive agreements ^c (max=35)	Lot 2		No. positive agreements ^c (max=35)
			Test 1	Test 2		Test 1	Test 2		Test 1	Test 2		Test 1	Test 2	
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	99	97	97	97	98	97	99	100	35	34	35	34
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	87	85	78	90	88	83	100	100	2	1	1	0
CareStart™ Malaria Screen RDT	RWAM-05071	Access Bio, Inc.	97	96	95	97	97	96	99	100	35	35	33	35
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	94	92	90	92	89	87	99	99	21	17	19	15
Is It... Malaria PF PAN	MPFAN050	Medsource Ozone Biomedicals Pvt. Ltd.	98	95	95	95	95	94	99	100	35	35	35	35
NG-Test MALARIA Pf/PAN (pLDH)	NGB-MAL-W23-005	NG Biotech	97	97	95	95 (99)	95	93 (99)	99	99	24	22 (34)	25	20
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-PF/Pan-CAS/25	Hema Diagnostic Systems	96	95	94	97	94	93	100	100	35	35	35	35
Pf and Pv														
ADVANCED QUALITY™ ONE STEP Malaria (p.f/pv) Tri-line Test	TIP11003-TC25	InTec Products, Inc.	99	97	96	97	94	93	100	98	35	35	34	35
BIOCREDT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	85 (99)	89 (99)	82 (98)	88	88	82	97 (99)	99	35	34 (34)	35	35
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	94	89	89	92	86	86	99	100	34	35	34	32
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RWMM-02091	Access Bio Ethiopia	96	98	95	97	96	95	100	100	35	34	35	35
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RWMM-05072	Access Bio, Inc.	94	91	90	98	95	95	99	100	35	35	35	35
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	97	97	94	96	97	95	100	100	35	35	33	35
Malaria Pf/Pv Rapid Test	GCMAL(p.f/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	96	94	92	94	93	90	99 (99)	99	33	30	27	23
Malaria Pf/PAN Test	PROPHALFPV001	Real World Diagnostics	90 (99)	90	88 (99)	90	90	87	100	99	7	4	11	5
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	94	97	94	96	95	94	100	100	30	30	29	27
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	85	85	82	85	83	80	100	100	34	33	31	34
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	91	91	87	87	86	83	100	99	34	35	31	35
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	92	93	91	89	88	86	99	99	35	32	34	32
Pf, Pv and Pan														
PALUTOP +4 optima®	5499	ALLDIAG SA	94	93	92	96	94	94	99	100	30	32	32	31

NA, not applicable

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species^a Results are based on the first reader's interpretation according to manufacturer's instructions.^b 3 (3%) of the 100 *P. falciparum* high parasite density dilution samples were at 5000 parasites/μL rather than 2000^c Number of samples that returned a positive result for both tests. Where one test was invalid and the other positive, positive agreement was recorded.^d Results presented in the table are based on a positive Pf test line (either HRP2 or Pf-pLDH).

Table A4.2: Distribution of test band intensity scores (0–4) against phase–2 wild–type *P. falciparum* samples at low (200) and high (2000) parasite density (parasites/μl)

Product	Product code	Manufacturer	200 parasites/μl Percentage distribution of Pf test band intensity ^c (n=400)					2000 ^b parasites/μl Percentage distribution of Pf test band intensity ^c (n=200)					200 parasites/μl Percentage distribution of pan test band intensity ^c (n=400)					2000 ^b parasites/μl Percentage distribution of pan test band intensity ^c (n=200)					200 parasites/μl Percentage distribution of Pv test band intensity ^c (n=400)					2000 ^b parasites/μl Percentage distribution of Pv test band intensity ^c (n=200)							
			0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4			
			Pf only																																
ADVANCED QUALITY™ ONE STEP Malaria (pf) Test Alere™ Malaria Ag P.f Aspen® Malaria Ag Pf BioTracer™ Malaria P.f Rapid Card CareStart™ Malaria Pf (HRP2) Ag RDT CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - HRP2 band CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - Pf-pLDH band	RKMA1017	Adv Chemical Private Limited	13.8	25.0	34.0	21.8	5.5	0.0	1.5	18.5	24.0	56.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA			
			2.5	14.0	39.5	29.8	14.3	0.5	1.5	5.0	24.0	69.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			0.8	4.5	22.5	28.8	43.5	0.0	0.5	0.0	9.0	90.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			2.8	20.5	38.8	31.0	7.0	0.0	0.5	11.0	27.0	61.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			1.0	10.8	27.3	37.3	23.8	0.5	0.0	2.5	22.5	74.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			1.3	9.0	26.8	26.8	36.3	0.0	0.0	2.5	13.5	84.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			3.0	15.0	26.0	28.3	27.8	0.5	0.0	4.0	14.5	81.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			46.8	34.5	18.8	0.0	0.0	5.0	30.5	63.5	1.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
RMO-M05082 W06200 ML01 R-409-50-C GCMAL(pf)-402a GMDMALPF001 W37-C	WELLS BIO, INC DIALAB ICT INTERNATIONAL Shanghai Kehua Bio-engineering Co., Ltd. Zhejiang Orient Gene Biotech Co., Ltd. Medical Diagnostics (Pty) Ltd Guangzhou Wondfo Biotech Co., Ltd.	Adv Chemical Private Limited	2.0	7.5	26.8	26.3	37.5	0.0	0.5	1.0	10.0	88.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA			
			8.5	25.0	40.3	21.5	4.8	0.5	1.0	16.5	26.0	56.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			2.8	13.3	31.8	29.0	23.3	0.0	0.0	4.0	19.5	76.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			8.8	18.8	28.3	29.8	14.5	0.5	1.0	7.5	18.5	72.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			5.0	15.5	35.8	25.3	18.5	0.0	0.0	9.5	20.0	70.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			9.8	12.0	29.6	29.8	18.8	0.5	0.5	6.5	26.0	66.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			3.8	18.8	38.5	30.8	8.3	0.0	0.5	7.5	30.0	62.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			16.8	27.0	35.5	17.5	3.3	0.5	2.0	21.0	28.0	48.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag PALUTOP + p [®] Parahit [®] Ver 1.0 - Dipstick Parahit [®] F Ver 1.0 - Device SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	MPHRPD-01 5531 55IC103-50 55IC104-50 O5FK130-40-0	Meril Diagnostics Pvt. Ltd. ALLDIAG SA ARKRAY Healthcare Pvt Ltd ARKRAY Healthcare Pvt Ltd Standard Diagnostics, Inc.	3.0	12.3	29.3	28.5	27.0	0.5	0.5	4.5	18.0	76.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA				
			16.8	33.3	33.8	14.5	1.8	0.0	4.0	22.5	25.5	48.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			15.3	33.8	33.8	15.5	1.8	0.0	4.5	22.5	25.0	48.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			5.5	18.5	35.3	33.8	7.0	0.0	0.5	11.0	27.0	61.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
			Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit Alere Tueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH) AlITest™ Malaria P.f./Pan Rapid Test Cassette	RKMA1016 O5FK60AI-40 IMPV-402	Adv Chemical Private Limited Alere Medical Private Limited Hangzhou AllTest Biotech Co. Ltd.	22.0	27.3	36.5	13.0	1.3	0.0	5.5	22.0	24.5	48.0	95.8	4.3	0.0	0.0	16.5	58.5	25.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
						9.8	14.0	31.8	36.0	8.5	1.0	0.5	9.5	28.5	60.5	50.3	44.8	5.0	0.0	0.0	3.0	10.0	67.5	19.5	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
						21.3	29.8	40.0	8.8	0.3	2.5	3.0	26.0	33.5	35.0	79.3	20.0	0.8	0.0	0.0	6.0	38.5	51.5	4.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
5.8	22.6	26.3				32.3	13.0	1.0	1.0	7.5	20.0	70.5	42.0	52.0	6.0	0.0	0.0	2.5	10.0	67.5	19.0	1.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	2.8	20.3	40.3	28.0	8.8	1.0	0.5	10.5	25.0	63.0	28.0	58.5	13.5	0.0	0.0	2.0	6.0	75.0	15.0	2.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA			
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.																																	

Table A4.2 (continued)

Product	Product code	Manufacturer	200 parasites/µl Percentage distribution of Pf test band intensity ^c (n=400)					2000 ^b parasites/µl Percentage distribution of Pf test band intensity ^c (n=200)					200 parasites/µl Percentage distribution of pan test band intensity ^c (n=400)					2000 ^b parasites/µl Percentage distribution of pan test band intensity ^c (n=200)					200 parasites/µl Percentage distribution of Pv test band intensity ^c (n=400)					2000 ^b parasites/µl Percentage distribution of Pv test band intensity ^c (n=200)				
			0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4
BIOCREDIT Malaria Ag Pf/Pan (HRP1/pLDH)	C32RHA25	RapiGEN Inc.	6.5 (399)	11.3 (399)	25.6 (399)	27.8 (399)	28.8 (399)	0.5	0.5	4.0	16.5	78.5	52.3	41.5	6.3	0.0	0.0	3.5	16.5	62.0	18.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Biosynex [®] Malaria Pf/Pan	0584_K25	Biosynex	11.0	23.5	36.0	23.3	6.3	0.0	2.5	12.0	23.5	62.0	81.8	18.0	0.3	0.0	0.0	5.0	39.0	53.0	3.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
BioTracer [™] Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	2.3	10.3	25.8	39.5	22.3	0.5	0.0	3.5	23.0	73.0	14.8	62.5	22.8	0.0	0.0	2.0	2.0	50.0	40.5	5.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
CareStart [™] Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	12.5	45.3	35.5	6.8	0.0	0.0	1.0	38.0	42.0	19.0	87.0	13.0	0.0	0.0	0.0	9.0	58.5	32.5	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
CareStart [™] Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	3.3	14.0	26.3	26.5	30.0	0.5	0.0	3.0	13.0	83.5	9.8	55.8	33.8	0.8	0.0	1.0	1.0	43.5	45.5	9.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	8.3	14.3	32.8	25.0	19.8	1.0	1.0	5.0	21.0	72.0	81.5	15.8	2.8	0.0	0.0	4.5	36.0	55.0	4.5	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Is It... Malaria Pf PAN	MPPFAN050	Medsources Ozone Biomedicals Pvt. Ltd.	4.3	17.5	28.3	32.3	17.8	0.5	1.0	3.5	22.5	72.5	14.5	74.0	11.5	0.0	0.0	2.0	3.5	70.0	22.5	2.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	4.0	15.5	31.3	31.8	17.5	1.0	0.5	4.0	22.0	72.5	58.3	35.3	6.5	0.0	0.0	2.5	29.0	62.0	6.5	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Rapid 1-2-3 HEMA [®] CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	4.5	11.5	31.0	29.3	23.8	0.0	0.0	5.5	19.0	75.5	61.8	36.3	2.0	0.0	0.0	2.5	20.0	70.0	7.5	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Pf and Pv																																
ADVANCED QUALITY [™] ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	3.3	16.0	35.3	31.5	14.0	1.0	0.5	4.5	25.0	69.0	NA	NA	NA	NA	NA	NA	NA	NA	1.0	0.0	0.0	99.0	0.5	0.0	0.0	0.0	0.0	0.0	0.5	
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	12.3 (399)	56.1 (399)	31.6 (399)	0.0 (399)	0.0 (399)	2.0	2.0	33.0	53.0	10.0	NA	NA	NA	NA	NA	NA	NA	NA	1.0	0.0	0.0	99.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	
Biosynex [®] Malaria Pf/Pv	0581_K25	Biosynex	9.8	22.0	35.0	25.8	7.5	0.5	1.0	13.5	21.0	64.0	NA	NA	NA	NA	NA	NA	NA	NA	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
CareStart [™] Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	3.3	18.5	24.8	27.0	26.5	0.0	0.5	3.0	15.0	81.5	NA	NA	NA	NA	NA	NA	NA	NA	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
CareStart [™] Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-05072	Access Bio, Inc.	5.5	19.0	29.5	25.0	21.0	0.5	0.0	8.0	17.5	74.0	NA	NA	NA	NA	NA	NA	NA	NA	1.8	0.0	0.0	98.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	
CareUS [™] Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	3.3	15.5	23.0	27.3	31.0	0.0	0.5	2.5	12.5	84.5	NA	NA	NA	NA	NA	NA	NA	NA	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	5.8	15.0	37.0	26.8	15.5	1.0	0.0	10.5	20.5	68.0	NA	NA	NA	NA	NA	NA	NA	NA	0.0	0.0	0.0	99.5	0.0	0.0	0.0	0.5	0.0	0.0	0.0	
Malaria Pf/PAN Test	PROPMA/PFPV001	Real World Diagnostics	9.8 (399)	12.0 (399)	29.6 (399)	29.8 (399)	18.8 (399)	0.5	0.5	6.5	18.0	74.5	NA	NA	NA	NA	NA	NA	NA	NA	20.3	2.0	0.0	7.5	29.0	59.5	4.0	0.0	0.0	0.0	0.0	
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	4.5	23.3	34.5	27.3	10.5	0.0	2.0	6.0	29.0	63.0	NA	NA	NA	NA	NA	NA	NA	NA	0.2	0.0	0.0	99.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	15.5	24.0	34.3	23.5	2.8	0.0	1.5	21.0	31.5	46.0	NA	NA	NA	NA	NA	NA	NA	NA	0.5	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
QuickProfile [™] Malaria Pf/Pv Antigen Test	71050	Lumiqquick Diagnostics Inc.	11.3	25.0	33.5	27.3	3.0	0.5	2.0	12.5	36.0	49.0	NA	NA	NA	NA	NA	NA	NA	NA	60.3	36.3	3.5	0.0	0.0	72.5	24.5	3.0	0.0	0.0	0.0	
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	9.5	13.3	31.5	37.8	8.0	1.0	0.5	8.0	29.5	61.0	NA	NA	NA	NA	NA	NA	NA	NA	100.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Pf, Pv and Pan																																
PALUTOP +4 optima [®]	5499	ALDIAG SA	5.8	12.0	27.3	31.5	23.5	0.5	1.0	3.0	21.0	74.5	14.0	53.3	32.0	0.8	0.0	0.0	3.5	36.0	47.0	13.5	99.3	0.8	0.0	0.0	100.0	0.0	0.0	0.0	0.0	

NA, not applicable

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species^a Denotes no visible band^b 3 (3%) of the 100 *P. falciparum* high parasite density dilution samples were at 5000 parasites/µl rather than 2000^c Calculations include invalid tests

Table A4.3: Distribution of test band intensity scores (0–4) for phase-2 wild-type *P. vivax* samples at low (200) and high (2000) parasite density (parasites/μl)

Product	Product code	Manufacturer	200 parasites/μl					2000 parasites/μl					200 parasites/μl					2000 parasites/μl					200 parasites/μl					2000 parasites/μl				
			Percentage distribution of Pf test band intensity ^b (n=140)					Percentage distribution of Pf test band intensity ^b (n=70)					Percentage distribution of pan test band intensity ^b (n=140)					Percentage distribution of pan test band intensity ^b (n=70)					Percentage distribution of Pf test band intensity ^b (n=140)					Percentage distribution of pan test band intensity ^b (n=70)				
			0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4
Pf only	Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	Advxy Chemical Private Limited	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Alere™ Malaria Ag Pf	05FK140-40-0	Standard Diagnostics, Inc.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	99.3	0.7	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	BioTracer™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	CareStart™ Malaria Pf (HRP2)pLDH Ag Combo 3-Line - HRP2 band			99.3	0.7	0.0	0.0	0.0	98.6	1.4	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	CareStart™ Malaria Pf (HRP2)pLDH Ag Combo 3-Line - Pf-pLDH band	RMSM-05071	Access Bio, Inc.	98.6	0.0	0.0	1.4	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	CareUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Pf and Pan	ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	95.0	5.0	0.0	0.0	0.0	98.6	1.4	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Malaria Pf Rapid Test	GC MAL (pf) - 402a	Zhejiang Orient Gene Biotech Co., Ltd.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	97.1	2.9	0.0	0.0	0.0	98.6	1.4	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	99.3	0.7	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	PALUTOP + pf®	5531	ALLDIAG SA	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Parahit® f Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	SD BIOLINE Malaria Ag P.f. (HRP2)/pLDH 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Pf and Pan	Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advxy Chemical Private Limited	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	27.1	66.4	6.4	0.0	0.0	1.4	52.9	42.9	2.9	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Alere TrueLine™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60AI-40	Alere Medical Private Limited	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	2.1	39.3	55.7	2.9	0.0	0.0	11.4	71.4	17.1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	AllTest™ Malaria P.f./Pan Rapid Test Cassette	IMPV-402	Hangzhou AllTest Biotech Co. Ltd.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	15.0	70.7	14.3	0.0	0.0	0.0	31.4	61.4	7.1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	30.0	65.7	4.3	0.0	0.0	1.4	58.6	40.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	98.6	0.0	0.7	0.0	0.0	100.0	0.0	0.0	0.0	0.0	2.9	17.9	75.0	4.3	0.0	0.0	4.3	60.0	35.7	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	BIOCREDIT Malaria Ag Pf/Pan (HRP-II/pLDH)	C32RHA25	RapiGEN Inc.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	39.3	58.6	2.1	0.0	0.0	4.3	54.3	41.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

Table A4.3 (continued)

Product	Product code	Manufacturer	200 parasites/µl				2000 parasites/µl				200 parasites/µl				2000 parasites/µl				200 parasites/µl				2000 parasites/µl									
			Percentage distribution of Pf test band intensity ^b (n=140)				Percentage distribution of Pf test band intensity ^b (n=70)				Percentage distribution of pan test band intensity ^b (n=140)				Percentage distribution of pan test band intensity ^b (n=70)				Percentage distribution of Pf test band intensity ^b (n=140)				Percentage distribution of Pf test band intensity ^b (n=70)									
			0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4	0 ^a	1	2	3	4
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	5.0	67.1	27.1	0.7	0.0	0.0	28.6	60.0	11.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	99.3	0.0	0.7	0.0	0.0	97.1	1.4	0.0	0.0	0.0	0.0	10.7	73.6	15.0	0.7	0.0	0.0	1.4	30.0	68.6	NA	NA	NA	NA	NA	NA	NA	NA	NA	
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	99.3	0.7	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	96.4	3.6	0.0	0.0	0.0	21.4	50.0	25.7	2.9	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	1.4	0.7	61.4	33.6	2.9	1.4	0.0	0.0	5.7	92.9	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	44.3	46.4	8.6	0.7	0.0	0.0	4.3	61.4	32.9	1.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Is It... Malaria Pf PAN	MPPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	11.4	79.3	7.1	2.1	0.0	0.0	4.3	32.9	62.9	NA	NA	NA	NA	NA	NA	NA	NA	NA	
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	96.4	3.6	0.0	0.0	0.0	95.7	4.3	0.0	0.0	0.0	31.4	53.6	15.0	0.0	0.0	0.0	11.4	65.7	22.9	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	39.3	58.6	2.1	0.0	0.0	0.0	14.3	64.3	21.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Pf and Pv																																
ADVANCED QUALITY™ ONE STEP Malaria (p-f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	100.0	0.0	0.0	0.0	0.0	98.6	1.4	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.7	12.9	77.9	8.6	0.0	1.4	0.0	2.9	40.0	55.7
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	100.0	0.0	0.0	0.0	0.0	98.6	1.4	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.7	0.0	49.3	48.6	1.4	2.9	0.0	0.0	1.4	95.7
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.9	47.1	49.3	0.7	0.0	1.4	0.0	14.3	71.4	12.9
CareStart™ Malaria Pf/Pv (HRP2[pLDH] Ag Combo RDT	RMWM-03091	Access Bio Ethiopia	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.7	32.9	60.7	5.7	0.0	0.0	0.0	7.1	40.0	52.9
CareStart™ Malaria Pf/Pv (HRP2[pLDH] Ag Combo RDT	RMWM-05072	Access Bio, Inc.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0	2.1	65.7	28.6	3.6	0.0	0.0	0.0	5.7	94.3
CareUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMW-M05082	WELLS BIO, INC	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.9	32.1	60.0	4.3	0.7	0.0	0.0	8.6	32.9	58.6
Malaria Pf/Pv Rapid Test	GCMA(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	15.0	65.0	20.0	0.0	0.0	0.0	38.6	51.4	10.0	
Malaria Pf/PAN Test	PROPMALPF001	Real World Diagnostics	95.7	4.3	0.0	0.0	0.0	92.9	7.1	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	79.3	18.6	2.1	0.0	0.0	82.9	15.7	0.0	1.4	0.0
One Step Malaria HRP2[pLDH] (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	15.7	70.0	14.3	0.0	0.0	0.0	44.3	45.7	10.0	
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	99.3	0.7	0.0	0.0	0.0	98.6	0.0	1.4	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	5.7	51.4	40.0	2.9	0.0	0.0	0.0	8.6	71.4	20.0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.6	67.9	28.6	0.0	0.0	0.0	0.0	45.7	48.6	5.7
Rapid Test Kit for Malaria Ag Pf/Pv-Alere TrueLine Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	5.0	42.9	48.6	3.6	0.0	0.0	0.0	11.4	71.4	17.1
Pf, Pv and Pan																																
PALUTOP +4 optima®	5499	ALLDIAG SA	99.3	0.7	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	18.6	70.7	10.0	0.7	0.0	0.0	32.9	67.1	9.3	49.3	39.3	2.1	0.0	0.0	21.4	38.6	40.0	

NA, not applicable

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species^a Denotes no visible band^b Calculations include invalid tests

Table A4.4: Phase 2 *P. falciparum* test line false-positive rates for wild-type *P. vivax* samples at low (200) and high (2000) parasite density (parasites/μl)

Product	Product code	Manufacturer	P. vivax samples (n=35)				200 parasites/μl				2000 parasites/μl			
			False positive Pf infection ^a (%)		Overall (n=140)		False positive Pf infection ^a (%)		Overall (n=70)		False positive Pf infection ^a (%)		Overall (n=70)	
			Lot 1 (n=70)	Lot 2 (n=70)	Overall (n=140)	Lot 1 (n=35)	Lot 2 (n=35)	Overall (n=70)	Lot 1 (n=35)	Lot 2 (n=35)	Overall (n=70)	Lot 1 (n=35)	Lot 2 (n=35)	Overall (n=70)
Pf only														
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA1017	Advy Chemical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	0.0	1.4	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - HRP2 band	RMSM-05071	Access Bio, Inc.	1.4	0.0	0.0	0.7	2.9	0.0	0.0	0.0	0.0	0.0	1.4	0.0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - Pf-pLDH band			0.0	2.9	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	5.7	4.3	0.0	5.0	2.9	0.0	0.0	0.0	2.9	0.0	1.4	0.0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf Rapid Test	GCMA(p.f)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0 (69)	0.0	0.0 (139)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostics (Pty) Ltd	2.9	2.9	0.0	2.9	2.9	0.0	0.0	0.0	0.0	0.0	1.4	0.0
One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	0.0	1.4	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MERISCREEN Malaria Pf HRP-II Ag														
PALUTOP + pf®	5531	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Parahit® Ver 1.0 - Dipstick	55C103-50	ARKRAY Healthcare Pvt Ltd	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Parahit® f Ver 1.0 - Device	55C104-50	ARKRAY Healthcare Pvt Ltd	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD BIOLINE Malaria Ag P.f. (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pf and Pan														
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Advy Chemical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	05FK60AI-40	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AllTest™ Malaria P.f./Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	2.9 (69)	0 (69)	0.0	1.4 (138)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BIOCREDIT Malaria Ag Pf/Pan (HRPII)(pLDH)	C32RHA25	RapiGEN Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	1.4	0.0	0.0	0.7	2.9	0.0	0.0	0.0	2.9	0.0	2.9	0.0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0.0	1.4	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Is It... Malaria Pf PAN	MPPFAN050	Medsource Ozone Biomedicals Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	4.3 (69)	2.9	0.0	3.6 (139)	5.7	2.9	0.0	0.0	5.7	2.9	4.3	0.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table A4.4 (continued)

Product	Product code	Manufacturer	200 parasites/μl False positive Pf infection ^a (%)			2000 parasites/μl False positive Pf infection ^a (%)		
			<i>P. vivax</i> samples (n=35)					
			Lot 1 (n=70)	Lot 2 (n=70)	Overall (n=140)	Lot 1 (n=35)	Lot 2 (n=35)	Overall (n=70)
Pf and Pv								
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0.0	0.0	0.0	0.0	2.9 (34)	1.4 (69)
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	0.0 (69)	0.0	0.0 (139)	0.0	3.0 (33)	1.5 (68)
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0.0	0.0	0.0	0.0	0.0 (34)	0.0 (69)
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	0.0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf/Pv Rapid Test	GCMAL(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf/PAN Test	PROPMPALPFV001	Real World Diagnostics	7.1	1.4	4.3	8.6	5.7	7.1
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	1.4	0.0	0.7	2.9	0.0	1.4
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	0.0	0.0	0.0	0.0	0.0	0.0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Truline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0
Pf, Pv and Pan								
PALUTOP +4 optima®	5499	ALDIAG SA	0.0	1.4	0.7	0.0	0.0	0.0

Pf, *Plasmodium falciparum*; Pv, *Plasmodium vivax*; pan, *Plasmodium* species^a Pf positive line indicates a false-positive *P. falciparum* infection

Table A4.5: Phase 2 pan (or *P. vivax*) test line false-positive rate for non-*P. falciparum* infection on phase 2 wild-type *P. falciparum* samples at low (200) and high (2000) parasite density (parasites/μl)

Product	Product code	Manufacturer	P. falciparum samples (n=100)					
			200 parasites/µl			2000 ^a parasites/µl		
			False positive non-Pf infection (%)		Overall (n=400)	False positive non-Pf infection (%)		Overall (n=200)
Lot 1 (n=200)	Lot 2 (n=200)	Overall (n=400)	Lot 1 (n=100)	Lot 2 (n=100)	Overall (n=200)			
Pf and Pan								
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Adv Chemical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60AL-40	Alere Medical Private Limited	2.5	0.0	1.3	1.0	1.0	1.0
AlITest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	1.0	1.5	1.3	2.0	2.0	2.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0.5	0.5 (199)	0.5 (399)	1.0	1.0	1.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0.0 (199)	0.5	0.3 (399)	2.0	0.0	1.0
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C32RHA25	RapiGEN Inc.	0.0	0.0	0.0	0.0	1.0	0.5
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	1.0	0.5	0.8	1.0	0.0	0.5
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	1.0	1.5	1.3	1.0	0.0	0.5
ICT MALARIA DUAL TEST	MLO3	ICT INTERNATIONAL	0.0	0.5	0.3	1.0	1.0	1.0
Is It... Malaria Pf PAN	MPFPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	1.0	3.0	2.0	1.0	0.0	0.5
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	0.5	1.0 (199)	0.8 (399)	1.0	1.0	1.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-PfPan-CAS/25	Hema Diagnostic Systems	0.0	0.0	0.0	0.0	0.0	0.0
Pf and Pv								
ADVANCED QUALITY™ ONE STEP Malaria (pf/pv.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	1.5	0.5	1.0	1.0	1.0	1.0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	1.0 (199)	1.0	1.0 (399)	1.0 (99)	1.0	1.0 (199)
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-05072	Access Bio, Inc.	1.5	2.0	1.8	2.0	2.0	2.0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0	0.0	0.0 (99)	1.0	0.5 (199)
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	21.5	23.0	22.3	92.0	93.0	92.5
One Step Malaria HRP2/pLDH (P-F/Pv.) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0.5	0.0	0.3	1.0	1.0	1.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	1.0	0.0	0.5	0.0	0.0	0.0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	45.0	34.5	39.8	24.0	31.0	27.5
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0
Pf, Pv and Pan								
PALUTOP +4 optima® - Pv-pLDH band	5499	ALLDIAG SA	0.0	1.0	0.5	0.0	0.0	0.0
PALUTOP +4 optima® - Pan-pLDH band			1.0	0.5	0.8	1.0	0.0	0.5

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species

^a 3 (3%) of the 100 *P. falciparum* high parasite density dilution samples were at 5000 parasites/μl rather than 2000

Table A4.6: Phase-2 false-positive rate for *P. falciparum* test line results on all malaria-negative samples

Product	Product code	Manufacturer	Percentage of false positive Pf test lines on clean ^a negative samples			Percentage of false positive Pf test lines on samples containing non- <i>Plasmodium</i> spp. infectious agents ^b			Percentage of false positive Pf test lines on samples containing immunological factors ^c		
			Lot 1 (n=116)	Lot 2 (n=116)	Overall (n=232)	Lot 1 (n=30)	Lot 2 (n=30)	Overall (n=60)	Lot 1 (n=54)	Lot 2 (n=54)	Overall (n=108)
Pf only											
Adv Dx [™] Malaria Pf Rapid Malaria Antigen Detection Test	RKMAL017	Advvy Chemical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	3.7	5.6	4.6
ADVANCED QUALITY [™] ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	0.9	0.0	0.4	0.0	0.0	0.0	0.0	1.9	0.9
Alere [™] Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	1.7 (115)	0.0	0.9 (231)	0.0	0.0	0.0	0.0	0.0	0.0
Aspen [®] Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	2.6	0.0	1.3	0.0	0.0	0.0	14.8	14.8	14.8
BioTracer [™] Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart [™] Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	0.0	0.9	0.4	0.0	0.0	0.0	3.7	5.6	4.6
CareStart [™] Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - HRP2 band			0.9	0.0	0.4	0.0	0.0	0.0	3.7	3.7	3.7
CareStart [™] Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - Pf-pLDH band	RMSM-05071	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
careUS [™] Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	1.7	0.0	0.9	0.0	3.3	1.7	3.7	3.7	3.7
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	0.0	0.0	0.0	0.0	0.0	0.0	1.9	1.9	1.9
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	1.7	1.7	1.7	6.7	0.0	3.3	11.1	9.3	10.2
KHB [®] Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf Rapid Test	GCMAL(p.f)-402a	Zhejiang Orient Gene Biotech Co. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	0.9	0.0 (115)	0.4 (231)	3.3	3.3	3.3	3.7	5.6	4.6
One Step Malaria HRP2 (P.f) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	7.4	7.4	7.4
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	0.0	0.0	0.0	0.0	3.3	1.7	0.0	1.9	0.9
PALUTOP + pf [®]	5531	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Parahit [®] Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	0.0	0.0	0.0	0.0	0.0	0.0	11.1	18.5	14.8
Parahit [®] F Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	0.0	0.0	0.0	0.0	0.0	0.0	14.8	14.8	14.8
SD BIOLINE Malaria Ag P.f. (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	0.0 (115)	0.0	0.0 (231)	0.0	0.0	0.0	5.6	3.7	4.6
Pf and Pan											
Adv Dx [™] Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advvy Chemical Private Limited	0.0	0.0	0.0	3.3	0.0	1.7	0.0	0.0	0.0
Alere Trueline [™] - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	05FK60AL-40	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	1.9
AllTest [™] Malaria P.f./Pan Rapid Test Cassette	IMPAN-402	Hangzhou AllTest Biotech Co. Ltd.	0.9	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0
Asan Easy Test [®] Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0.9	1.7	1.3	3.3	0.0	1.7	1.9	3.7	2.8
Aspen [®] Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	1.7 (115)	0.9	1.3 (231)	0.0	0.0	0.0	3.7	3.7	3.7
BIOCREDIT Malaria Ag Pf/Pan (HRPII)(pLDH)	C32RHA25	RapiGEN Inc.	0.0	0.0	0.0	3.3	0.0	1.7	0.0	1.9	0.9
Biosynex [®] Malaria Pf/Pan	0584_K25	Biosynex	0.0	0.0	0.0	0.0	3.3	1.7	1.9	3.7	2.8
BioTracer [™] Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0.9	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.0
CareStart [™] Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0.0	0.9	0.4	0.0	0.0	0.0	3.7	5.6	4.6
CareStart [™] Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0.0 (115)	0.0	0.0 (231)	0.0	0.0	0.0	3.7	5.6	4.6
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	1.7	0.0	0.9	0.0	3.3	1.7	5.6	5.6	5.6
Is It... Malaria Pf PAN	MPPFAN050	Medsorce Ozone Biomedicals Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table A4.6 (continued)

Product	Product code	Manufacturer	Percentage of false positive Pf test lines on clean ^a negative samples			Percentage of false positive Pf test lines on samples containing non- <i>Plasmodium</i> spp. infectious agents ^b			Percentage of false positive Pf test lines on samples containing immunological factors ^c		
			Lot 1 (n=116)	Lot 2 (n=116)	Overall (n=232)	Lot 1 (n=30)	Lot 2 (n=30)	Overall (n=60)	Lot 1 (n=54)	Lot 2 (n=54)	Overall (n=108)
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	6.0	1.7	3.9	10.0	13.3	11.7	22.2	24.1	23.1
Rapid 1-2-3 HEWA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0.0	0.9	0.4	0.0	0.0	0.0	1.9	3.7	2.8
Pf and Pv											
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	1.9	3.7	2.8
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	0.0 (114)	0.0	0.0 (230)	3.3	0.0	1.7	0.0	0.0	0.0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0.0 (115)	0.0 (114)	0.0 (229)	3.3	0.0	1.7	1.9	5.6	3.7
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0.0	0.0	0.0	0.0	0.0	0.0	3.7	1.9	2.8
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	0.0	0.0 (115)	0.0 (231)	0.0	0.0	0.0	1.9	1.9	1.9
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0.0	0.0	0.0	0.0	6.7	3.3	1.9	3.7	2.8
Malaria Pf/Pv Rapid Test	GCWAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0 (115)	0.0 (231)	0.0 (28)	0.0	0.0 (58)	1.9	0.0	0.9
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	6.0	4.3	5.2	6.7	0.0	3.3	13.0	11.1	12.0
One Step Malaria HRP2/pLDH (P-f/P-v) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0.0	0.0	0.0	0.0	3.3	1.7	1.9	0.0	0.9
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	0.0	0.9 (115)	0.4 (231)	0.0	0.0	0.0	3.7	3.7	3.7
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	1.9
Pf, Pv and Pan											
PALLUTOP +4 optima®	5499	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* spp.^a Blood samples from healthy volunteers with no known current illness or blood abnormality^b See Table A4.7 for details^c See Table A4.8 for details

Table A4.7: Phase 2 false-positive rate for *P. falciparum* in samples containing specific non-malarial infectious pathogens

Product	Product code	Manufacturer	Percentage of false positives for <i>Plasmodium</i> spp. by infectious pathogen										
			Chagas		Dengue		Leishmaniasis		Schistosomiasis				
			Lot 1 (n=4)	Lot 2 (n=4)	Lot 1 (n=14)	Lot 2 (n=14)	Lot 1 (n=8)	Lot 2 (n=8)	Lot 1 (n=4)	Lot 2 (n=4)			
Pf only													
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA1017	Advy Chemical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria P.f Rapid Card	17912	Bio Focus Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line – HRP2 band	RM5M-05071	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - Pf-pLDH band			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	0.0	0.0	0.0	0.0	0.0	0.0	12.5	0.0	0.0	0.0	0.0
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ICT MALARIA P.F. CASSETTE TEST	MLO1	ICT INTERNATIONAL	25.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf Rapid Test	GCMAL(p.f)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	25.0	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.0	0.0
MERISCREEN Malaria Pf HRP-II Ag													
PALUTOP + pf®	5531	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Parahit® Ver 1.0 – Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Parahit® f Ver 1.0 – Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD BIOLINE Malaria Ag P.f. (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pf and Pan													
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Advy Chemical Private Limited	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FK60A1-40	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AllTest™ Malaria P.f./Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co, Ltd	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BIOCREDIT Malaria Ag Pf/Pan (HRP2)(pLDH)	C32RHA25	RapiGEN Inc.	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ICT MALARIA DUAL TEST	MLO3	ICT INTERNATIONAL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Is It... Malaria Pf PAN	MPFPAN050	Medsourse Ozone Biomedicals Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	25.0	25.0	7.1	21.4	12.5	0.0	0.0	0.0	0.0	0.0	0.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table A4.7 (continued)

Product	Product code	Manufacturer	Percentage of false positives for <i>Plasmodium</i> spp. by infectious pathogen							
			Chagas		Dengue		Leishmaniasis		Schistosomiasis	
			Lot 1 (n=4)	Lot 2 (n=4)	Lot 1 (n=14)	Lot 2 (n=14)	Lot 1 (n=8)	Lot 2 (n=8)	Lot 1 (n=4)	Lot 2 (n=4)
Pf and Pv										
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-05072	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0.0	0.0	0.0	0.0	0.0	25.0	0.0	0.0
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0 (3)	0.0	0.0 (13)	0.0	0.0	0.0	0.0	0.0
Malaria Pf/PAN Test	PROFMALPFV001	Real World Diagnostics	25.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0
One Step Malaria HRP2/pLDH (P.f/P.v) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	12.5	0.0	0.0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pf, Pv and Pan										
PALUTOP +4 optima®	5499	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pf, <i>Plasmodium falciparum</i> Pv, <i>Plasmodium vivax</i> pan, <i>Plasmodium</i> species										

Table A4.8: Phase 2 false-positive rate for *P. falciparum* in samples containing potentially cross-reacting blood immunological factors

Product	Product code	Manufacturer	Percentage of false positives for <i>Plasmodium</i> spp. by blood immunological factor											
			Anti-mouse antibodies		Anti-nuclear antibodies		Rheumatoid factor		Rapid plasma reagin (RPR) positive					
			Lot 1 (n=6)	Lot 2 (n=6)	Lot 1 (n=24)	Lot 2 (n=24)	Lot 1 (n=12)	Lot 2 (n=12)	Lot 1 (n=12)	Lot 2 (n=12)				
PF only														
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA1017	Advv Chemical Private Limited	33.3	33.3	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002- TC25	InTec Products, Inc.	0.0	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	66.7	66.7	0.0	0.0	33.3	33.3	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	33.3	33.3	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - HRP2 band	RMSM-05071	Access Bio, Inc.	33.3	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - Pf-pLDH band			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	33.3	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DIAQUICK Malaria Pf. Cassette	W06200	DIALAB	16.7	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	50.0	50.0	8.3	0.0	8.3	0.0	0.0	0.0	0.0	0.0	16.7	0.0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf Rapid Test	GCMAL(pf)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	33.3	33.3	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	33.3	33.3	0.0	0.0	0.0	16.7	16.7	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	0.0	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MERISCREEN Malaria Pf HRP-II Ag														
PALUTOP + pf®	5531	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	16.7	66.7	0.0	0.0	0.0	41.7	50.0	0.0	0.0	0.0	0.0	0.0
Parahit® f Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	33.3	33.3	0.0	0.0	0.0	50.0	50.0	0.0	0.0	0.0	0.0	0.0
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	50.0	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PF and Pan														
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Advv Chemical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II(pLDH)	05FK60AI-40	Alere Medical Private Limited	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AllTest™ Malaria P.f./Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0.0	16.7	4.2	0.0	0.0	0.0	8.3	0.0	0.0	0.0	0.0	0.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0.0	33.3	0.0	0.0	0.0	16.7	0.0	0.0	0.0	0.0	0.0	0.0
BIOCREDIT Malaria Ag Pf/Pan (HRP-II(pLDH)	C32RHA25	RapiGEN Inc.	0.0	0.0	0.0	0.0	0.0	0.0	8.3	0.0	0.0	0.0	0.0	0.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	16.7	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0.0	0.0	0.0	0.0	0.0	16.7	25.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0.0	33.3	0.0	0.0	0.0	16.7	8.3	0.0	0.0	0.0	0.0	0.0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	50.0	33.3	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Is It... Malaria Pf PAN	MPPFAN050	Medsource Ozone Biomedicals Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	33.3	16.7	33.3	25.0	8.3	25.0	8.3	25.0	0.0	8.3	25.0	0.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-PF/Pan-OAS/25	Hema Diagnostic Systems	16.7	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table A4.8 (continued)

Product	Product code	Manufacturer	Percentage of false positives for <i>Plasmodium</i> spp. by blood immunological factor							
			Anti-mouse antibodies		Anti-nuclear antibodies		Rheumatoid factor		Rapid plasma reagin (RPR) positive	
			Lot 1 (n=6)	Lot 2 (n=6)	Lot 1 (n=24)	Lot 2 (n=24)	Lot 1 (n=12)	Lot 2 (n=12)	Lot 1 (n=12)	Lot 2 (n=12)
Pf and Pv										
ADVANCED QUALITY™ ONE STEP Malaria (p.f(p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0.0	33.3	0.0	0.0	0.0	0.0	8.3	0.0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	16.7	33.3	0.0	4.2	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2(pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	33.3	16.7	0.0	0.0	0.0	0.0	0.0	0.0
CareStart™ Malaria Pf/Pv (HRP2(pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	16.7	16.7	0.0	0.0	0.0	0.0	0.0	0.0
careUS™ Malaria Combo Pf/Pv (HRP2(pLDH) Ag	RMV-M05082	WELLS BIO, INC	16.7	33.3	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Malaria Pf/PAN Test	PROPMAIPFPV001	Real World Diagnostics	16.7	0.0	12.5	16.7	25.0	0.0	0.0	16.7
One Step Malaria HRP2/pLDH (P.f(P.v.) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	33.3	33.3	0.0	0.0	0.0	0.0	0.0	0.0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pf, Pv and Pan										
PALUTOP +4 optima®	5499	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pf, <i>Plasmodium falciparum</i>	Pv, <i>Plasmodium vivax</i>	pan, <i>Plasmodium</i> species								

Table A4.9: Phase 2 false-positive rate of pan or *P. vivax* test line results on all malaria-negative samples

Product	Product code	Manufacturer	Percentage of false positive pan test lines on "clean" ^a negative samples			Percentage of false positive non-Pf <i>Plasmodium</i> spp. infectious agents ^b			Percentage of false positive non-Pf test lines on samples containing immunological factors ^c		
			Lot 1 (n=116)	Lot 2 (n=116)	Overall (n=232)	Lot 1 (n=30)	Lot 2 (n=30)	Overall (n=60)	Lot 1 (n=54)	Lot 2 (n=54)	Overall (n=108)
Pf and Pan											
Adv Dx [™] Malaria Pan/Pf Rapid Test Detection Kit (HRP-II/pLDH) – Rapid test kit for Malaria Ag Pf/Pan AllTest [™] Malaria P.f./Pan Rapid Test Cassette Asan Easy Test [®] Malaria Pf/Pan Ag Aspen [®] Malaria Ag Pf/Pv BIOCREDIT Malaria Ag Pf/Pan (HRP1/pLDH) Biosynex [™] Malaria Pf/Pan BioTracer [™] Malaria P.f./PAN Rapid Card CareStart [™] Malaria Pf/PAN (pLDH) Ag RDT CareStart [™] Malaria Screen RDT ICT MALARIA DUAL TEST Is It... Malaria Pf PAN NG-Test MALARIA Pf/Pan (pLDH) Rapid 1–2–3 HEMA [®] CASSETTE MALARIA Pf/PAN	RKMAL016	Advv Chemical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	05FK60AI-40	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0.0	0.9	0.4	0.0	0.0	0.0	0.0	1.9	0.9
	AM4650-K	ASAN Pharmaceutical Co., Ltd	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.9
	AS0060	Aspen Laboratories Pvt. Ltd.	0.0 (115)	0.9	0.4 (231)	0.0	0.0	0.0	5.6	1.9	3.7
	C32RHA25	RapiGEN Inc.	4.3	3.4	3.9	0.0	0.0	0.0	0.0	1.9	0.9
	0584_K25	Biosynex	0.0	0.0	0.0	0.0	0.0	0.0	3.7	3.7	3.7
	17012	Bio Focus Co., Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	RMLM-05071	Access Bio, Inc.	1.7	0.9	1.3	3.3	0.0	1.7	13.0	14.8	13.9
	RMAM-05071	Access Bio, Inc.	0.0 (115)	0.0	0.0 (231)	0.0	0.0	0.0	5.6	9.3	7.4
	MLO3	ICT INTERNATIONAL	0.9	0.0	0.4	3.3	3.3	3.3	20.4	18.5	19.4
	MPPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	3.4	4.3	3.9	16.7	3.3	10.0	5.6	9.3	7.4
	NGB-MAL-W23-005	NG Biotech	37.9	27.6	32.8	46.7	46.7	46.7	68.5	81.5	75.0
	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0.0	0.0	0.0	0.0	0.0	0.0	7.4	7.4	7.4
Pf and Pv											
ADVANCED QUALITY [™] ONE STEP Malaria (pf/p.v.) Tri-line Test BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) Biosynex [™] Malaria Pf/Pv CareStart [™] Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT CareStart [™] Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT careUS [™] Malaria Combo Pf/Pv (HRP2/pLDH) Ag Malaria Pf/Pv Rapid Test Malaria Pf/PAN Test One Step Malaria HRP2/pLDH (Pf/Pv) Test One-Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag QuickProfile [™] Malaria Pf/Pv Antigen Test Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	ITP11003-TC25	InTec Products, Inc.	0.9	0.0	0.4	0.0	0.0	0.0	16.7	14.8	15.7
C60RHA25	RapiGEN Inc.	0.0 (114)	0.0	0.0 (230)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
0581_K25	Biosynex	0.0 (115)	0.0 (114)	0.0 (229)	0.0	0.0	0.0	3.7	3.7	3.7	
RMVM-03091	Access Bio Ethiopia	0.0	0.0	0.0	0.0	0.0	0.0	5.6	3.7	4.6	
RMVM-05072	Access Bio, Inc.	0.0	0.0 (115)	0.0 (231)	0.0	0.0	0.0	11.1	11.1	11.1	
RMV-M05082	WELLS BIO, INC	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.9	
GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0.0	0.0 (115)	0.0 (231)	0.0 (28)	0.0	0.0 (58)	1.9	1.9	1.9	
PROPWALPFV001	Real World Diagnostics	19.0	21.6	20.3	20.0	16.7	18.3	37.0	46.3	41.7	
W056-C	Guangzhou Wondfo Biotech Co., Ltd.	1.7	0.9	1.3	0.0	0.0	0.0	0.0	0.0	0.0	
MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
71050	Lumiquick Diagnostics Inc.	23.3	22.6 (115)	22.9 (231)	53.3	36.7	45.0	64.8	61.1	63.0	
11108191040	Alere Medical Private Limited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Pf, Pv and Pan											
PALUTOP +4 optima [®] - Pv-pLDH band	5499	ALLDIAG SA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PALUTOP +4 optima [®] - Pan-pLDH band			0.0	0.0	0.0	0.0	0.0	3.7	3.7	3.7	

NA, not applicable

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species

^a Blood samples from healthy volunteers with no known current illness or blood abnormality

^b See Table A4.7 for details

^c See Table A4.8 for details

Table A4.10: Heat stability testing results for *P. falciparum* test line on a *P. falciparum* sample at low parasite density (200 parasites/ μ l). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing						35°C						45°C						Room temperature								
			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)					
			No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid
Pf only																													
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA1017	Advx Chemical Private Limited	15	0	3.0	15	0	3.0	15	0	2.9	15	0	2.1	15	0	3.0	15	0	3.0	15	0	2.5	15	0	2.9	15	0	3.0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP1002-TC25	InTec Products, Inc.	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	2.9	15	0	3.1	15	0	3.0
Alere™ Malaria Ag Pf	05FK140-40-0	Standard Diagnostics, Inc.	15	0	3.9	15	0	4.0	15	0	3.7	15	0	3.6	15	0	3.4	15	0	3.4	15	0	3.6	15	0	3.9	15	0	3.7
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	15	0	3.0	15	0	3.0	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	2.9	15	0	3.0
BioTrace™ Malaria Pf Rapid Card	17912	Bio Focus Co., Ltd.	15	0	3.1	15	0	3.3	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.1
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	15	0	3.9	15	0	3.5	15	0	3.9	15	0	3.6	15	0	3.4	15	0	3.4	15	0	3.4	15	0	3.9	15	0	3.5
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - HRP2 band	RMSM-05071	Access Bio, Inc.	15	0	2.9	15	0	3.6	15	0	3.0	15	0	3.0	15	0	3.1	15	0	3.1	15	0	3.0	15	0	4.0	15	0	3.1
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - Pf-pLDH band			15	0	1.8	15	0	1.0	15	0	1.2	15	0	1.1	15	0	1.4	15	0	1.4	15	0	1.1	15	0	1.8	15	0	1.1
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	15	0	3.8	15	0	3.4	15	0	4.0	15	0	3.5	15	0	3.6	15	0	3.6	15	0	3.1	15	0	3.9	15	0	3.4
DIAQUICK Malaria Pf. Cassette	W06200	DIALAB	15	0	2.8	15	0	3.0	15	0	2.0	15	0	2.0	15	0	1.6	15	0	1.6	15	0	2.0	15	0	3.0	15	0	3.0
ICT MALARIA PF CASSETTE TEST	MI01	ICT INTERNATIONAL	15	0	3.3	15	0	3.9	15	0	3.5	15	0	3.0	15	0	3.5	15	0	3.5	15	0	3.1	15	0	3.9	15	0	2.9
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	15	0	3.0	15	0	3.0	15	0	2.9	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0
Malaria Pf Rapid Test	GCMAL(pf)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	15	0	3.0	15	0	3.3	15	0	3.0	15	0	3.0	15	0	3.0	14	1	2.9	15	0	3.0	15	0	3.2	15	0	3.0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostics (Pty) Ltd	15	0	2.8	15	0	3.4	15	0	3.4	15	0	2.9	15	0	2.8	15	0	2.8	15	0	3.0	15	0	3.4	15	0	3.0
One Step Malaria HRP2 (Pf) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	15	0	3.0	15	0	3.0	15	0	2.9	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.2	15	0	2.9
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	15	0	2.3	15	0	2.9	15	0	2.2	15	0	2.0	15	0	2.0	15	0	2.0	15	0	2.0	15	0	2.4	15	0	2.4
PALUTOP + pf®	5531	ALLDIAG SA	15	0	3.0	15	0	3.0	15	0	3.6	15	0	3.0	15	0	3.8	15	0	3.8	15	0	3.1	15	0	4.0	15	0	3.0
Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	15	0	1.5	15	0	2.0	15	0	1.9	15	0	2.0	14	1	2.3	15	0	2.0	15	0	2.0	15	0	2.5	15	0	2.0
Parahit® f Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	15	0	2.0	15	0	2.4	15	0	2.0	15	0	2.0	15	0	2.2	15	0	2.2	15	0	2.0	15	0	2.1	15	0	2.0
SD BIOLINE Malaria Ag Pf. (HRP2/pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	15	0	2.8	15	0	3.0	15	0	3.0	15	0	2.7	15	0	2.9	15	0	2.9	15	0	3.0	15	0	2.9	15	0	2.9
Pf and Pan																													
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Advx Chemical Private Limited	15	0	2.0	15	0	2.4	15	0	2.0	15	0	1.9	15	0	2.0	15	0	2.0	15	0	1.9	14	0	2.1	15	0	1.9
Alere Trueline™ -Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FKG0AL-40	Alere Medical Private Limited	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0
AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	15	0	2.0	15	0	2.0	15	0	2.0	15	0	2.1	15	0	2.3	15	0	2.3	15	0	2.0	15	0	2.0	15	0	2.1
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co, Ltd	15	0	2.9	15	0	2.9	15	0	2.9	15	0	2.9	15	0	2.9	15	0	2.7	15	0	2.9	15	0	3.1	15	0	3.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	15	0	2.8	15	0	3.0	15	0	2.7	15	0	3.0	15	0	3.0	15	0	3.0	15	0	2.9	15	0	2.7	15	0	3.0
BIOCREDIT Malaria Ag Pf/Pan (HRP1/pLDH)	C32RHA25	RapiGEN Inc.	15	0	3.0	15	0	3.0	15	0	3.1	15	0	3.0	15	0	3.3	15	0	3.3	15	0	3.1	15	0	3.3	15	0	3.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	15	0	3.0	15	0	2.9	15	0	2.9	15	0	2.0	15	0	2.0	14	0	2.0	15	0	3.0	15	0	3.0	15	0	3.0
BioTrace™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	15	0	3.0	15	0	3.4	15	0	3.0	15	0	3.0	15	0	2.9	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.0
CareStart™ Malaria Pf/PAN Rapid Card	RMLM-05071	Access Bio, Inc.	15	0	1.4	15	0	1.5	15	0	1.3	14	0	1.4	15	0	1.3	13	0	1.4	15	0	1.4	15	0	1.4	15	0	1.6
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	15	0	3.0	15	0	3.6	15	0	3.1	15	0	3.0	15	0	3.1	15	0	3.1	15	0	3.0	15	0	3.9	15	0	3.0
ICT MALARIA DUAL TEST	MI03	ICT INTERNATIONAL	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	2.9
Is It... Malaria Pf PAN	MPFPAN050	Medsourse Ozone Biomedicals Pvt. Ltd.	15	0	2.9	15	0	2.9	15	0	3.0	13	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.7	15	0	2.9
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	15	0	3.1	15	0	3.1	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.3	15	0	3.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-PfPan-CAS/25	Hema Diagnostic Systems	15	0	3.5	15	0	3.7	15	0	3.0	15	0	3.0	15	0	3.1	15	0	3.1	15	0	3.0	15	0	3.5	15	0	3.0
Pf and Pv																													
ADVANCED QUALITY™ ONE STEP Malaria (p.f.p.v.) Tri-line Test	ITP1003-TC25	InTec Products, Inc.	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	G6ORHA25	RapiGEN Inc.	13	0	1.0	15	0	1.0	15	0	1.0	11	0	1.0	4	1	1.0	13	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	15	0	3.0	15	0	3.0	15	0	3.0	15	0	2.0	15	0	2.0	15	0	2.0	15	0	1.8	15	0	3.0	15	0	3.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	15	0	3.0	15	0	3.0	15	0	3.7	15	0	3.0	15	0	2.9	15	0	2.9	15	0	3.0	15	0	3.6	15	0	2.9
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	15	0	2.6	15	0	3.1	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.7	15	0	2.9
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	15	0	3.0	15	0	3.1	15	0	3.9	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.7	15	0	3.0

Table A4.10 (continued)

Product	Product code	Manufacturer	Baseline testing						35°C						45°C						Room temperature					
			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)		
			No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid
Malaria Pf/Pv Rapid Test	GCMAL(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	15	0	3.1	15	0	3.1	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.1	15	0	3.0
Malaria Pf/PAN Test	PROPMALPFPV001	Real World Diagnostics	15	0	3.1	15	0	3.9	15	0	3.4	15	0	3.0	15	0	3.1	15	0	3.0	15	0	3.6	15	0	3.1
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	15	0	3.0	15	0	3.0	15	0	3.0	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.4	15	0	2.9
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	15	0	2.7	15	0	3.0	15	0	2.7	15	0	2.1	15	0	2.1	15	0	2.0	15	0	2.7	15	0	2.9
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	15	0	2.9	15	0	2.9	15	0	3.0	15	0	2.0	15	0	2.9	15	0	2.9	15	0	2.7	15	0	3.0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trucline Malaria Ag Pf/Pv	11T08191040	Alere Medical Private Limited	15	0	3.0	15	0	2.9	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.0	15	0	3.2	15	0	3.0
Pf, Pv and Pan																										
PALUTOP + 4 optima®	5499	ALLDIAG SA	15	0	3.0	15	0	3.2	15	0	3.2	15	0	2.9	15	0	3.1	15	0	3.0	15	0	3.9	15	0	3.0

ND, not determined

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species

Table A4.10a: Heat stability testing results for pan test line of combination RDTs on a *P. falciparum* sample at low parasite density (200 parasites/μl). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing						35°C						45°C						Room temperature					
			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)		
			No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid
Pf and Pan																										
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Advy Chemical Private Limited	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	0	ND
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FKG0A1-40	Alere Medical Private Limited	14	0	1.0	0	ND	15	0	1.0	6	0	1.0	0	1.0	0	1.0	0	ND	7	0	1.0	4	0	1.0	1.0
AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPAN-402	Hangzhou AllTest Biotech Co. Ltd.	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	ND	5	0	1.0	3	0	1.0	0	0	ND	ND
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	10	0	1.0	13	0	1.0	8	0	1.0	7	0	1.0	0	0	ND	3	0	1.0	11	0	1.0	15	0	1.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0	0	ND	15	0	1.0	12	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0	10	0	1.0	15	0	1.0
BiOCREDIT Malaria Ag Pf/Pan (HRP-II/pLDH)	C32RHA25	RapiGEN Inc.	12	0	1.0	12	0	1.0	7	0	1.0	1	0	1.0	0	0	ND	2	0	1.0	8	0	1.0	10	0	1.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	0	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	ND	0	0	ND
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	15	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0	14	0	1.0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0	0	ND	0	0	ND	1	0	1.0	1	0	1.0	0	0	ND	0	0	ND	0	0	ND	0	0	ND
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	15	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0	15	0	1.0	13	0	1.0	15	0	1.0
ICT MALARIA DUAL TEST	MILO3	ICT INTERNATIONAL	1	0	1.0	0	0	ND	0	0	ND	1	0	1.0	2	0	1.0	2	0	1.0	0	0	ND	0	0	ND
Is It... Malaria PF PAN	MPFPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	14	0	1.0	14	0	1.0	15	0	1.0	13	0	1.0	13	0	1.0	15	0	1.0	14	0	1.0	15	0	1.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	6	0	1.0	10	0	1.1	13	0	1.4	13	0	1.2	10	0	1.4	10	0	1.2	4	0	1.3	11	0	1.3
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0	0	ND	0	0	ND	0	0	ND	0	0	ND	1	0	1.0	9	0	1.0	5	0	1.0	0	0	ND
Pf, Pv and Pan																										
PALUTOP + 4 optima®	5499	ALLDIAG SA	15	0	1.9	15	0	1.0	15	0	1.6	15	0	1.0	15	0	1.8	15	0	1.0	15	0	2.0	15	0	1.0

ND, not determined

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species

Table A4.11: Heat stability testing results for *P. falciparum* sample at high parasite density (2000 parasites/ μ l). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing						35°C						45°C						Room temperature								
			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)					
			No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity			
Pf only																													
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA1017	Advx Chemical Private Limited	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
BioTracer™ Malaria P.f Rapid Card	17912	Bio Focus Co., Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMDM-03091	Access Bio Ethiopia	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - HRP2 band	RMSM-05071	Access Bio, Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - Pf-pLDH band			5	0	2.0	5	0	2.0	5	0	2.0	5	0	1.6	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	3.8	5	0	3.8	5	0	4.0	5	0	4.0	5	0	4.0
ICT MALARIA P.f. CASSETTE TEST	MI01	ICT INTERNATIONAL	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Malaria Pf Rapid Test	GCMAL(pfr)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
One Step Malaria HRP2 (P.f) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Merril Diagnostics Pvt. Ltd.	5	0	4.0	5	0	3.8	5	0	4.0	5	0	4.0	5	0	4.0	5	0	3.8	5	0	4.0	5	0	4.0	5	0	4.0
PALUTOP + p®	5531	ALLDIAG SA	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Parahit® f Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Pf and Pan																													
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Advx Chemical Private Limited	5	0	4.0	5	0	4.0	5	0	4.0	5	0	3.8	5	0	4.0	5	0	3.8	5	0	4.0	5	0	4.0	5	0	4.0
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FKG0A1-40	Alere Medical Private Limited	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
AllTest™ Malaria P.f/Pan Rapid Test Cassette	IMPNI-402	Hangzhou AllTest Biotech Co. Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	3.2	5	0	4.0	5	0	4.0	5	0	4.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	Asan Pharmaceutical Co., Ltd	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	5	0	4.0	5	0	4.0	5	0	3.6	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C32RHA25	RapiGEN Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
BioTrace™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	5	0	2.6	5	0	2.8	5	0	3.0	5	0	3.2	5	0	2.8	5	0	3.2	5	0	2.8	5	0	3.0	5	0	3.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
ICT MALARIA DUAL TEST	MI03	ICT INTERNATIONAL	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Is It... Malaria Pf PAN	MPFPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Rapid 1+2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
Pf and Pv																													
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMMV-03091	Access Bio Ethiopia	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMMV-05072	Access Bio, Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0

Table A4.11 (continued)

Product	Product code	Manufacturer	Baseline testing						35°C						45°C						Room temperature							
			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)				
			No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0		
Malaria Pf/Pv Rapid Test	GCMA(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	3.8	5	0	4.0	5	0	4.0	5	0	4.0		
Malaria Pf/PAN Test	PROPMA(pfpv)001	Rea World Diagnostics	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	3.8	5	0	4.0		
One Step Malaria HRP2/pLDH (P: Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0		
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0		
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0		
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Truline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	5	0	4.0	5	0	4.0	5	0	4.0	5	0	4.0	4	1	4.0	5	0	4.0	5	0	4.0	5	0	4.0		
Pf, Pv and Pan																												
PALUTOP +4 optima®																												
5499			ALLDIAG SA																									
Pf, Plasmodium falciparum	Pan, Plasmodium vivax		Pan, Plasmodium species																									

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* speciesTable A4.11a: Heat stability testing results for pan test line of combination RDTs on a *P. falciparum* sample at high parasite density (2000 parasites/μl). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing						35°C						45°C						Room temperature					
			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)			Lot 1 (n=5)			Lot 2 (n=5)		
			No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	
Pf and Pan																										
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Advx Chemical Private Limited	5	0	1.0	5	0	1.0	5	0	1.0	5	0	1.0	5	0	1.0	5	0	1.0	5	0	1.0	5	0	1.0
Alere Trueline™ –Rapid test kit for Malaria Ag Pf/Pan (HRP-1/pLDH)	05FKG0AL-40	Alere Medical Private Limited	5	0	2.2	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0
AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPIN-402	Hangzhou AllTest Biotech Co. Ltd.	4	0	1.0	5	0	1.0	5	0	1.6	5	0	2.0	5	0	2.0	5	0	1.2	5	0	2.0	5	0	2.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	Asan Pharmaceutical Co., Ltd	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	1.6	5	0	2.0	5	0	2.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0
BIOCREDIT Malaria Ag Pf/Pan (HRP1/pLDH)	C32RHA25	RapiGEN Inc.	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	1.6	5	0	2.0	5	0	2.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	5	0	1.6	5	0	2.0	5	0	1.8	5	0	1.8	5	0	1.0	5	0	2.0	5	0	1.8	5	0	1.8
BioTrace™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	5	0	1.8	5	0	1.0	5	0	1.0	5	0	1.0	5	0	1.0	5	0	1.0	5	0	1.2	4	0	1.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	5	0	2.0	5	0	3.0	5	0	2.4	5	0	2.0	5	0	3.0	5	0	2.0	5	0	2.0	5	0	2.0
ICT MALARIA DUAL TEST	MLO3	ICT INTERNATIONAL	4	0	1.0	5	0	1.6	5	0	1.2	5	0	1.4	5	0	2.0	5	0	1.8	5	0	1.0	5	0	1.0
Is It... Malaria Pf PAN	MPPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	5	0	1.2	5	0	1.6	5	0	1.8	5	0	1.0	5	0	2.0	5	0	1.6	5	0	1.0	5	0	1.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0	5	0	2.0
Pf, Pv and Pan																										
PALUTOP +4 optima®	5499	ALLDIAG SA	5	0	2.8	5	0	2.0	5	0	3.0	5	0	2.0	5	0	3.0	5	0	2.4	5	0	3.0	5	0	2.0
Pf, Plasmodium falciparum	Pf, Plasmodium vivax	Pf, Plasmodium species																								

Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species

Table A4.12: Heat stability testing results for *P. falciparum* test line on parasite-negative samples. Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)	
			No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid
Pf only																		
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA017	Adv Chemical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Alere™ Malaria Ag P.f	O5FK140-40-0	Standard Diagnostics, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BioTrace™ Malaria P.f Rapid Card	17912	Bio Focus Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - HRP2 band	RMOM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - Pf-pLDH band	RMOM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2) Ag	RMOM-05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Pf (HRP2) Ag	RMOM-05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	0	0	0	0	0	2	0	0	0	1	0	0	3	0	0	0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Malaria Pf Rapid Test	GCMAL(p.f)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Malaria HRP2 (P.f) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALUTOP + pf®	5531	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Parahit® F Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SD BIOLINE Malaria Ag P.f. (HRP2)(pLDH) 2 Lines	O5FK130-40-0	Standard Diagnostics, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf and Pan																		
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA016	Adv Chemical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	O5FK60A1-40	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
AllTest™ Malaria Pf./Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pan (HRPII)(pLDH)	C32RHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Biosynex® Malaria Pf/Pan	O584_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BioTrace™ Malaria P.f/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Is It... Malaria Pf PAN	MPFPAN050	Medsources Ozone Biomedicals Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	0	0	0	0	2	0	0	0	1	0	1	0	1	0	0	0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Table A4.12 (continued)

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=4)	No. positive	No. invalid	Lot 2 (n=4)	No. positive	No. invalid	Lot 1 (n=4)	No. positive	No. invalid	Lot 2 (n=4)	No. positive	No. invalid	Lot 1 (n=4)	No. positive	No. invalid	Lot 2 (n=4)
Pf and Pv																		
ADVANCED QUALITY™ ONE STEP Malaria (p.f(p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMV/M-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag, Combo RDT	RMV/M-05072	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/Pv Rapid Test	GCMA(p.f/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, Pv and Pan																		
PALUTOP +4 optima®	5499	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, <i>Plasmodium falciparum</i>	Pv, <i>Plasmodium vivax</i>	pan, <i>Plasmodium</i> species																

Table A4.12a: Heat stability testing results for pan or *P. vivax* test line of combination RDTs on parasite-negative samples. Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)	
			No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid
Pf and Pan																		
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA016	Advv Chemical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	O5FK60A1-40	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
AllTest™ Malaria Pf/Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C32RHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Biosynex® Malaria Pf/Pan	O584_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	0	0	0	0	1	0	0	0	0	0	3	0	0	0	0	0
Is It... Malaria Pf PAN	MPPFAN050	Medsorce Ozone Biomedicals Pvt. Ltd.	0	0	0	0	2	0	0	0	0	0	1	0	0	0	1	0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	4	0	2	0	4	0	4	0	3	0	3	1	3	0	3	0
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf and Pv																		
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Biosynex® Malaria Pf/Pv	O581_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag, Combo RDT	RMVM-05072	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/Pv Rapid Test	GCMAL(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/PAN Test	PROPMALPPV001	Real World Diagnostics	2	0	1	0	2	0	3	0	3	0	2	0	1	0	3	0
One Step Malaria HRP2/pLDH (P.f/P.v.) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	2	0	1	0	1	0	4	0	4	0	3	0	3	0	3	0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, Pv and Pan																		
PALUTOP +4 optima® - Pv-pLDH band	5499	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALUTOP +4 optima® - Pan-pLDH band			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, Plasmodium falciparum Pv, Plasmodium vivax pan, Plasmodium species																		

Table A4.13: Heat stability testing results for *P. falciparum* test line on *P. vivax* samples at low parasite density (200 parasites/ μ l). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)	
			No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid
Pf only																		
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA017	Adv Chemical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BioTracer™ Malaria P.f Rapid Card	17912	Bio Focus Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - HRP2 band			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - Pf-pLDH band	RMSM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf Rapid Test	GCMAL(pf)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Malaria HRP2 (P.f) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Meril Diagnostics Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALUTOP + pf®	5531	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Parahit® Ver 1.0 - Dipstick	55IC103-50	ARKRAY Healthcare Pvt Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Parahit® F Ver 1.0 - Device	55IC104-50	ARKRAY Healthcare Pvt Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SD BIOLINE Malaria Ag P.f. (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf and Pan																		
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA016	Adv Chemical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	05FK60AI-40	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
AllTest™ Malaria P.f./Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pan (HRPII)(pLDH)	C32RHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BioTracer™ Malaria P.f/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
CareStart™ Malaria P.f/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Is It... Malaria Pf PAN	MPFPAN050	Medsorce Ozone Biomedicals Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

(continued)

Table A4.13: Heat stability testing results for *P. falciparum* test line on *P. vivax* samples at low parasite density (200 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C (continued)

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)		Lot 1 (n=4)		Lot 2 (n=4)	
			No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Herna Diagnostic Systems	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf and Pv																		
ADVANCED QUALITY™ ONE STEP Malaria (p.f.p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C6QRHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/Pv Rapid Test	GCMAL(p7/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meri Diagnostics Pvt. Ltd.	0	0	0	0	0	0	0	0	4	0	2	0	0	0	0	0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, Pv and Pan																		
PALLTOP +4 optima®	5499	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, <i>Plasmodium falciparum</i>	Pv, <i>Plasmodium vivax</i>	pan, <i>Plasmodium</i> species																

Table A4.14: Heat stability testing results for *P. falciparum* test line on *P. vivax* samples at high parasite density (2000 parasites/μl). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=2)		Lot 2 (n=2)		Lot 1 (n=2)		Lot 2 (n=2)		Lot 1 (n=2)		Lot 2 (n=2)		Lot 1 (n=2)		Lot 2 (n=2)	
			No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid
Pf only																		
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test	RKMA017	Adv Chemical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test	ITP11002-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Alere™ Malaria Ag P.f	05FK140-40-0	Standard Diagnostics, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Aspen® Malaria Ag Pf	AS0015	Aspen Laboratories Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BioTracer™ Malaria P.f Rapid Card	17912	Bio Focus Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2) Ag RDT	RMOM-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - HRP2 band			0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf (HRP2)(pLDH) Ag Combo 3-Line - Pf- pLDH band	RMSM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Pf (HRP2) Ag	RMO-M05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIAQUICK Malaria P.f. Cassette	W06200	DIALAB	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ICT MALARIA P.F. CASSETTE TEST	ML01	ICT INTERNATIONAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
KHB® Malaria Ag (HRP2) Pf Rapid Test	R-409-50-C	Shanghai Kehua Bio-engineering Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf Rapid Test	GCMAL(p.f)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GMD Malaria Pf test	GMDMALPF001	Medical Diagnostech (Pty) Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Malaria HRP2 (P.f) Test	W37-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag	MPHRPD-01	Merit Diagnostics Pvt. Ltd.	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
PALUTOP + pf®	5531	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Parahit f® Ver 1.0 - Dipstick	55(C)03-50	ARKRAY Healthcare Pvt Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Parahit® f Ver 1.0 - Device	55(C)04-50	ARKRAY Healthcare Pvt Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SD BIOLINE Malaria Ag P.f. (HRP2)(pLDH) 2 Lines	05FK130-40-0	Standard Diagnostics, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf and Pan																		
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA016	Adv Chemical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II)(pLDH)	05FK60AI-40	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
AllTest™ Malaria P.f./Pan Rapid Test Cassette	IMPN-402	Hangzhou AllTest Biotech Co. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co., Ltd	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pan (HRPII)(pLDH)	C32RHA25	RapIGEN Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BioTracer™ Malaria P.f/PAN Rapid Card	17012	Bio Focus Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Is It... Malaria Pf PAN	MPFPAN050	Medsorce Ozone Biomedicals Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

(continued)

Table A4.14: Heat stability testing results for *P. falciparum* test line on *P. vivax* samples at high parasite density (2000 parasites/ μ L). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C (continued)

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=2)		Lot 2 (n=2)		Lot 1 (n=2)		Lot 2 (n=2)		Lot 1 (n=2)		Lot 2 (n=2)		Lot 1 (n=2)		Lot 2 (n=2)	
			No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Herna Diagnostic Systems	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf and Pv																		
ADVANCED QUALITY™ ONE STEP Malaria (p.f.p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C6QRHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meri Diagnostics Pvt. Ltd.	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, Pv and Pan																		
PALLTOP +4 optima®	5499	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, <i>Plasmodium falciparum</i>	Pv, <i>Plasmodium vivax</i>	pan, <i>Plasmodium</i> species																

Table A4.15: Heat stability testing results for *P. vivax* test line on *P. falciparum* samples at low parasite density (200 parasites/ μ L). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=15)		Lot 2 (n=15)		Lot 1 (n=15)		Lot 2 (n=15)		Lot 1 (n=15)		Lot 2 (n=15)		Lot 1 (n=15)		Lot 2 (n=15)	
			No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid
Pf and Pv																		
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	1	0	3	0	4	0	8	0	3	0	4	0	1	0	0	0
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	6	0	5	0	9	0	13	0	10	0	11	0	6	0	8	0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, Pv and Pan																		
PALUTOP + 4 optima®	5499	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, Plasmodium falciparum	Pv, Plasmodium vivax	pan, Plasmodium species																

Table A4.16: Heat stability testing results for *P. vivax* test line on *P. falciparum* samples at high parasite density (2000 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing				35°C				45°C				Room temperature			
			Lot 1 (n=5)		Lot 2 (n=5)		Lot 1 (n=5)		Lot 2 (n=5)		Lot 1 (n=5)		Lot 2 (n=5)		Lot 1 (n=5)		Lot 2 (n=5)	
			No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid	No. positive	No. invalid
Pf and Pv																		
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/Pv Rapid Test	GCMAL(pf/pv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malaria Pf/PAN Test	PROPMALPFV001	Real World Diagnostics	3	0	4	0	5	0	5	0	5	0	5	0	5	0	5	0
One Step Malaria HRP2/pLDH (Pf/Pv) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	0	0	0	0	1	0	2	0	2	0	0	0	0	0	0	0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Pf, Pv and Pan																		
PALUTOP +4 optima®	5499	ALLDIAG SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pf, <i>Plasmodium falciparum</i>	Pv, <i>Plasmodium vivax</i>	pan, <i>Plasmodium</i> species																

Table A4.17: Heat stability testing results for pan or *P. vivax* sample at low parasite density (200 parasites/μl). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing						35°C						45°C						Room temperature								
			Lot 1 (n=4)			Lot 2 (n=4)			Lot 1 (n=4)			Lot 2 (n=4)			Lot 1 (n=4)			Lot 2 (n=4)			Lot 1 (n=4)			Lot 2 (n=4)					
			No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity	No. positive	No. invalid	Mean band intensity			
Pf and Pan																													
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMAL016	Advx Chemical Private Limited	4	0	1.0	4	0	1.0	4	0	0.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	3	0	1.0	4	0	1.0
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FKG0A1-40	Alere Medical Private Limited	4	0	2.0	4	0	1.5	4	0	2.0	4	0	1.5	4	0	2.0	4	0	1.5	4	0	1.8	4	0	1.8	4	0	1.3
AllTest™ Malaria Pf./Pan Rapid Test Cassette	IMPNI-402	Hangzhou AllTest Biotech Co. Ltd.	3	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	3	0	1.0	3	0	1.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	ASAN Pharmaceutical Co, Ltd	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	1.8	4	0	1.3	4	0	2.0	4	0	2.0	4	0	2.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	3	0	2.0	3	0	1.7	4	0	2.0	4	0	2.0	4	0	1.8
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C32RHA25	RapiGEN Inc.	4	0	1.8	4	0	1.0	4	0	2.0	4	0	1.3	4	0	1.0	4	0	1.0	4	0	2.5	4	0	2.5	4	0	1.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	4	0	2.0	4	0	1.5	4	0	1.0	4	0	1.8	4	0	1.0	4	0	1.0	4	0	1.5	4	0	1.5	4	0	1.0
BioTrace™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	0	0	0.0	2	0	1.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.5	4	0	2.5	4	0	2.5	4	0	2.5	4	0	2.0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	3	0	1.0	4	0	1.0
Is It... Malaria Pf/PAN	MPPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	4	0	1.3	4	0	1.5	3	0	1.0	4	0	1.0	1	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	4	0	1.5	4	0	2.0	4	0	2.0	4	0	2.0	4	0	1.8	4	0	1.8	4	0	1.5	4	0	1.5	4	0	2.0
Pf and Pv																													
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test	ITP11003-TC25	InTec Products, Inc.	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	G60RHA25	RapiGEN Inc.	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	4	0	2.0	4	0	1.0	4	0	2.0	4	0	1.3	4	0	1.0	4	0	1.0	4	0	2.0	4	0	2.0	4	0	1.8
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	4	0	2.0	4	0	1.8	4	0	2.0	4	0	1.3	4	0	2.0	4	0	1.5	4	0	2.0	4	0	2.0	4	0	2.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.3	4	0	2.0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	4	0	2.0	4	0	1.5	4	0	2.0	4	0	1.3	4	0	1.5	4	0	1.0	4	0	2.0	4	0	2.0	4	0	1.8
Malaria Pf/Pv Rapid Test	GCMAL(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	4	0	1.3	4	0	2.0	4	0	1.8	4	0	1.0	4	0	1.5	4	0	1.3	4	0	1.0	4	0	1.0	4	0	1.0
Malaria Pf/PAN Test	PROPMALEFPV001	Real World Diagnostics	0	0	0.0	0	0	0.0	0	0	0.0	1	0	1.0	0	0	0.0	3	0	1.0	0	0	0.0	0	0	0.0	0	0	0.0
One Step Malaria HRP2/pLDH (Pf/Pv.v) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.8	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	4	0	1.5	4	0	2.0	4	0	1.8	4	0	1.0	4	0	1.3	4	0	1.0	4	0	2.0	4	0	2.0	4	0	1.3
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	4	0	1.0	4	0	1.0	4	0	1.8	4	0	1.0	4	0	2.0	4	0	1.0	4	0	1.0	4	0	1.0	4	0	1.0
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	4	0	2.0	4	0	1.8	4	0	2.0	3	0	1.0	4	0	2.0	4	0	1.5	4	0	1.8	4	0	1.8	4	0	1.0
Pf, Pv and Pan																													
PALUTOP +4 optima® - Pv-pLDH band	5499	ALLDIAG SA	4	0	2.0	4	0	1.8	4	0	2.0	4	0	1.0	4	0	1.3	4	0	1.8	4	0	2.0	4	0	2.0	4	0	1.0
PALUTOP +4 optima® - Pan-pLDH band			4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.0	4	0	2.8	4	0	2.8	4	0	2.0

ND, not determined
Pf, *Plasmodium falciparum* Pv, *Plasmodium vivax* pan, *Plasmodium* species

Table A4.18: Heat stability testing results for pan or *P. vivax* sample at high parasite density (2000 parasites/μL). Positivity rate at baseline (room temperature) and after 60 days incubation at room temperature, 35°C and 45°C

Product	Product code	Manufacturer	Baseline testing						35°C						45°C						Room temperature					
			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)			Lot 1 (n=15)			Lot 2 (n=15)		
			No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid	No. positive	Mean band intensity	No. invalid
Pf and Pan																										
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit	RKMA1016	Advx Chemical Private Limited	2	0	3.0	2	0	2.5	2	0	2.5	2	0	2.0	2	0	2.5	2	0	3.0	2	0	2.5	2	0	2.0
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH)	05FKG0A1-40	Alere Medical Private Limited	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	4.0	2	0	3.0	2	0	3.5	2	0	3.0
AllTest™ Malaria Pf./Pan Rapid Test Cassette	IMPIN-402	Hangzhou AllTest Biotech Co. Ltd.	2	0	2.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0
Asan Easy Test® Malaria Pf/Pan Ag	AM4650-K	Asan Pharmaceutical Co., Ltd	2	0	4.0	2	0	3.5	2	0	3.5	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0
Aspen® Malaria Ag Pf/Pv	AS0060	Aspen Laboratories Pvt. Ltd.	2	0	4.0	2	0	4.0	2	0	3.5	2	0	3.0	2	0	4.0	2	0	3.0	2	0	4.0	2	0	3.0
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)	C32RHA25	RapiGEN Inc.	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	2.0	2	0	3.0	1	0	3.0	2	0	3.0
Biosynex® Malaria Pf/Pan	0584_K25	Biosynex	2	0	3.0	2	0	3.0	2	0	3.5	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0
BioTracer™ Malaria Pf/PAN Rapid Card	17012	Bio Focus Co., Ltd.	2	0	4.0	2	0	4.0	2	0	4.0	2	0	2.0	2	0	3.5	2	0	3.0	2	0	3.5	2	0	4.0
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	RMLM-05071	Access Bio, Inc.	1	0	1.0	2	0	1.0	2	0	1.0	2	0	1.0	1	0	1.0	1	0	1.0	0	0	0.0	1	0	1.0
CareStart™ Malaria Screen RDT	RMAM-05071	Access Bio, Inc.	2	0	4.0	2	0	4.0	2	0	4.0	2	0	3.5	2	0	4.0	2	0	4.0	2	0	4.0	2	0	4.0
ICT MALARIA DUAL TEST	ML03	ICT INTERNATIONAL	2	0	3.0	2	0	2.0	2	0	3.0	2	0	2.0	2	0	2.0	2	0	2.0	2	0	3.0	2	0	2.0
Is It... Malaria Pf PAN	MPFPAN050	Medsource Ozone Biomedicals Pvt. Ltd.	2	0	3.5	2	0	4.0	2	0	3.5	2	0	2.5	2	0	3.5	2	0	3.5	2	0	4.0	2	0	4.0
NG-Test MALARIA Pf/Pan (pLDH)	NGB-MAL-W23-005	NG Biotech	2	0	2.5	2	0	3.0	2	0	2.5	2	0	2.0	2	0	2.0	2	0	2.0	2	0	2.0	2	0	2.0
Rapid 1-2-3 HEMA® CASSETTE MALARIA Pf/PAN	MAL-Pf/Pan-CAS/25	Hema Diagnostic Systems	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0
Pf and Pv																										
ADVANCED QUALITY™ ONE STEP Malaria (p.f.p.v.) Tri-line Test	ITP11003-TC25	Intec Products, Inc.	2	0	4.0	2	0	3.5	2	0	4.0	2	0	3.5	2	0	3.5	2	0	3.0	2	0	4.0	2	0	3.5
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	C60RHA25	RapiGEN Inc.	2	0	4.0	2	0	4.0	2	0	4.0	2	0	4.0	1	1	4.0	2	0	4.0	2	0	4.0	2	0	3.5
Biosynex® Malaria Pf/Pv	0581_K25	Biosynex	2	0	3.0	2	0	3.0	2	0	3.5	2	0	2.5	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT	RMVM-03091	Access Bio Ethiopia	2	0	4.0	2	0	3.0	2	0	3.5	2	0	3.0	2	0	3.0	2	0	3.0	2	0	2.0	2	0	3.0
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT	RMVM-05072	Access Bio, Inc.	2	0	4.0	2	0	4.0	2	0	4.0	2	0	3.5	2	0	4.0	2	0	4.0	2	0	4.0	2	0	4.0
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag	RMV-M05082	WELLS BIO, INC	2	0	4.0	2	0	3.0	2	0	3.5	2	0	2.5	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0
Malaria Pf/Pv Rapid Test	GCMA1(pfpv)-402a	Zhejiang Orient Gene Biotech Co., Ltd.	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	1	1	2.0	2	0	3.0	2	0	3.0
Malaria Pf/PAN Test	PROPMALPPFV001	Real World Diagnostics	0	0	0.0	0	0	0.0	0	0	0.0	1	0	1.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
One Step Malaria HRP2/pLDH (P.f.P.v.) Test	W056-C	Guangzhou Wondfo Biotech Co., Ltd.	2	0	3.0	2	0	3.0	2	0	2.5	2	0	2.5	2	0	3.0	2	0	3.0	2	0	3.0	2	0	2.5
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag	MFLRPD-02	Meril Diagnostics Pvt. Ltd.	2	0	3.0	2	0	3.5	2	0	3.0	2	0	3.0	2	0	2.5	2	0	2.0	2	0	3.5	2	0	3.0
QuickProfile™ Malaria Pf/Pv Antigen Test	71050	Lumiquick Diagnostics Inc.	2	0	3.0	2	0	3.0	2	0	3.0	2	0	2.0	2	0	2.5	2	0	3.0	2	0	3.0	2	0	2.5
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv	11108191040	Alere Medical Private Limited	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.5	2	0	3.0	2	0	3.0	2	0	3.0
Pf, Pv and Pan																										
PALUTOP +4 optima® – Pv-pLDH band	5499	ALLDIAG SA	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	3.0	2	0	4.0	2	0	3.0
PALUTOP +4 optima® – Pan-pLDH band			2	0	3.0	2	0	4.0	2	0	3.0	2	0	4.0	2	0	4.0	2	0	4.0	2	0	4.0	2	0	4.0
Pf, Plasmodium falciparum Pv, Plasmodium vivax pan, Plasmodium species																										

Annex 5: Introducing RDT-based malaria diagnosis into national programmes

Introduction of parasite-based diagnosis at small clinics and at village level for case management poses many challenges, not only of logistics but also in managing the health-seeking and health-providing behaviour of patients and health workers. These can be addressed by a clear, time-bound strategic plan covering planning, implementation, monitoring and evaluation of the diagnosis programme, which must begin well before RDTs are procured. Furthermore, funding for the programme must include a significant component for planning and coordination, sensitization, information, education and communication, training, quality assurance, monitoring, supervision and logistics, in addition to procurement. In the absence of such funding, much of the expenditure on RDTs will be wasted, and loss of confidence in RDT-based

diagnosis can hinder strengthening of appropriate malaria case management. A focal person or persons should be available to coordinate the overall implementation plan and to ensure that the various agencies involved understand the process and their own roles.

Examples of successful wide-scale introduction of malaria RDTs by various national programmes and comprehensive technical guidance on achieving universal access to malaria diagnostic testing have been reported (14–15). Figures A5.1 and A5.2 give examples of the steps and timelines for RDT implementation and budget components for a malaria diagnosis programme, respectively. These will have to be modified considerably for each programme.

Key challenges

Changing past thinking that “fever equals malaria unless proven otherwise”.

Introducing RDTs will disprove this statement. To have an impact on malaria diagnosis and treatment, RDTs must be seen to provide an accurate diagnosis by both health workers and patients, that is, they must be as good or better than those relied on previously. A health worker requires a good alternative to antimalarial medicines for the management of parasite-negative febrile patients. To achieve and maintain confidence in RDT-based diagnosis, a good quality assurance system must be in place. There must be satisfactory education of health workers and widespread community sensitization. Health workers should have understanding of other causes of fever in order to devise appropriate management algorithms for parasite-negative cases.

Changing and enforcing regulatory requirements

At the national level, regulation might be required to control the importation and use of malaria RDTs, and new procedures for storage, distribution and inventory management, such as those used for medicines, might be necessary.

Figure A5.1. Example of malaria RDT implementation steps and timeline^a

RDT IMPLEMENTATION TIMELINE									
Coordinating group									
Appoint malaria diagnosis coordinator(s)									
Policy recommendations								MoH endorsement	
Programme planning									
Guidelines ^b									
Case management of fever of unknown origin								MoH endorsement	
Case management of malaria									
RDT (and microscopy) quality assurance									
RDT transport and storage									
Decide districts for initial / phased implementation									
Fever management algorithm						Written			
Community sensitization									
General health care providers' education								MoH endorsement	
Determine / designate transport and storage methods									
Regulatory issues									
Define collaborative roles (NMP and regulatory body)									
Write/adopt regulatory guidelines									
Create RDT registry for reference									
Disseminate regulatory criteria									
Product selection, supply chain management									
Select several products									
Samples for ease-of-use assessment									
Final decision on RDT									
Negotiate specifications with manufacturer									
Competitive bidding and procurement								Dependent on registration process	
Receive first batch (of staggered delivery)									
Distribution to field									
Procure gloves									
Procure sharps boxes									
Procure other associated materials									
RDT quality control									
Write sentinel site SOP									
Set up/engage field-based quality control monitoring sites									
Decide on lot-testing site								Determine site	
Post-marketing surveillance ^c									Commence testing

Figure A5.1 (continued)

Training											
Conduct case management training for fever											
Modify RDT instructions and training manual											
Field-test modified training/instructions											
Training of trainers and supervisors											
Health worker training											
Advocacy, communication, social mobilization											
Engaging civil society organizations											
Community sensitization											
Engaging opinion leaders											
General health care education											
Monitoring and evaluation											
Develop/adopt appropriate record forms											
Define methods for capturing different indicators											
Integrate RDTs into the routine health information management system											
Plan for a post-introduction programme review											

MoH, ministry of health; NMP, national malaria programme

^a Adapted with permission from FIND and Uganda National Malaria Control Programme

^b May already be in place

^c Sentinel site microscopy, possibly positive control wells in future

Figure A5.2. Components of the budget for a malaria diagnosis programme^a

Component	Activities specific to microscopy	Activities specific to RDTs	Activities for management of malaria and non-malaria fevers
Preparation of technical guidelines, standard operating procedures and checklists			
Guidelines	Laboratory supervision ^b	RDT transport and storage	Fever management algorithm
Standard operating procedures for diagnostic testing	Microscopy performance	RDT performance	Other tests used at primary care level
Other standard operating procedures	Proficiency testing, validation of routine slide results	RDT storage	
Training material	Training manual for microscopy	Training manual for RDTs	Training manuals for integrated management of fevers
Checklists for supervision	Laboratory visits ^b	Health facility visits	
Procurement and supply of commodities			
Diagnostic tests	Microscopes and related supplies	RDT kits	Urine dipsticks, haemoglobin meter, haematocrit meter, glucometer
Medicines	Artemisinin-based combination therapy		Antibiotics, zinc, inhaled salbutamol, rehydration salts
Other commodities	Gloves, lancets, alcohol, cotton-wool, timers, sharps boxes		
Distribution of commodities to the field	All items listed above		
Quality management system			
Pre-shipment testing		Lot-testing	
Training of focal people	Quality management system for focal people		
Monitoring the quality management system	Quality monitoring supervision visits and compilation of health information management data		
Training of health workers			
Training of tutors	Expert microscopists	Tutors for RDT performance outside laboratories and clinical management of fever cases	
Training of health workers	Microscopists	Health workers	Clinicians
Training of supervisors	Laboratory supervisors ^b	Clinical supervisors	
Supervision			
Supervisory visits	Laboratory visits ^b	Health facility visits	
Advocacy, communication and social mobilization			
Design of strategies and material	Communication on the need for malaria testing		Communication on other causes of fever
Dissemination of key messages	Through each delivery channel		
Monitoring and evaluation			
Updating the health information management system	Add row for RDTs in laboratory report and column for malaria test results in clinicians' book		Column for other test results in clinicians' book
Train health workers in the new health information management system	Training of person in charge or focal person for reporting on health information management in health facilities		

^a Adapted with permission (14)

^b For simplicity, activities specific to laboratories are listed under 'Microscopy', although both microscopy and RDT are generally performed in laboratories.

References

1. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large proportion of *P. falciparum* isolates in the Amazon region of Peru lack *pfhrp2* and *pfhrp3*: implications for malaria rapid diagnostic tests. *PLoS One*, 2010;5:e8091.
2. Bharti PK, Chandel HS, Ahmad A, Krishna S, Udhayakumar V, Singh N. Prevalence of *pfhrp2* and/or *pfhrp3* gene deletion in *Plasmodium falciparum* population in eight highly endemic states in India. *PLoS One* 2016;11:e0157949.
3. Berhane A, Mihreteab S, Mohammed S, Embaye G, Hagos F, Zehaie A, et al. *PfHRP2* detecting malaria RDTs: alarming false negative results in Eritrea. Poster 879. In: 65th annual meeting of the American Society for Tropical Medicine and Hygiene. Oakbrook Terrace, IL; 2016.
4. Cheng Q, Gatton M, Barnwell J, Chiodini P, McCarthy J, Bell D, et al. *Plasmodium falciparum* parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting. *Malaria J* 2014;13:283.
5. Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. *Pfhrp2*-deleted *Plasmodium falciparum* parasites in the Democratic Republic of Congo: a national cross-sectional survey. *J Infect Dis*. 2016;. doi:10.1093/infdis/jiw538
6. Amoah LE, Abankwa J, Oppong A. *Plasmodium falciparum* histidine rich protein-2 diversity and the implications for *PfHRP 2*: based malaria rapid diagnostic tests in Ghana. *Malaria Journal*. 2016;15:101. doi:10.1186/s12936-016-1159-z.
7. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 1 (2008)*. Geneva: World Health Organization; 2009.
8. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 2 (2009)*. Geneva: World Health Organization; 2010.
9. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 3 (2010–11)*. Geneva: World Health Organization; 2011.
10. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 4 (2012)*. Geneva: World Health Organization; 2012.
11. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 5 (2013)*. Geneva: World Health Organization; 2014.
12. *Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 6 (2014–2015)*. Geneva: World Health Organization; 2015.
13. *Recommended selection criteria for procurement of malaria rapid diagnostic tests*. Geneva: World Health Organization; 2016.
14. *Universal access to malaria diagnostic testing: an operational manual*. Geneva: World Health Organization; 2011.
15. Thiam S, Thior M, Faye B, Ndiop M, Diouf ML, Diouf MB, et al. Major reduction in anti-malarial drug consumption in Senegal after nation-wide introduction of malaria rapid diagnostic tests. *PLoS One* 2011;6:e18419.

NOTES



Global Malaria Programme
World Health Organization
20, Avenue Appia
1211 Geneva 27
Switzerland

infogmp@who.int
www.who.int/malaria

FIND

Campus Biotech
Building B2, Level 0
9, Chemin des Mines
1202 Geneva, Switzerland
P.O. Box 87
CH - 1211 Geneva 20

T: + 41 (22) 710 05 90
info@finddiagnostics.org
www.finddiagnostics.org

ISBN 978 92 4 151268 8



9 789241 512688